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ABSTRACT 
This Thesis examines the benefits and usefulness of a National Drug Policy (NDP) 
for the developing of the Health Care System in Kuwait. The NDP is one of the 
most important structures of the Health System  which can lead to improved health 
services by establishing guidelines, proposals and directives to organize, structure 
and regulate health legislation; it is of help to ensure the availability of quality, 
safety and efficacy in using medicines and it can reduce the irrational use of 
medicines. The NDP is a frame work between the government, schools and 
universities, media, health professionals, pharmaceutical industries and companies 
and public. It is cooperation between the public and private sectors to achieve the 
goal of access to good quality medicines for all. However there are many key 
factors which need to be examined before the National Drug Policy is introduced 
and these are considered the baseline for establishing a good policy, and includes; 
selection of essential drugs, affordability of drugs, drug financing, supply 
management, drug regulation, rational use of drugs, drugs registration, purchasing 
of drugs, health research and human resource development. During this research 
study from 2012 – 2015 several visits to the public and private health areas, were 
undertaken. At this time there were discussions with 121 health professionals and 
data was collected and this indicated that in Kuwait there are no such policies. This 
is despite the availability of financial means, specialized human resources and the 
existence of the ministerial decisions and regulations governing the health sector in 
both public and private, whether hospitals, health centers, pharmacies and health 
departments. In addition it is suggested that the process of a good NDP should be 
built around 3 main components which includes: 1.Development, 2. Implementation 
and 3. Monitoring and Evaluation. Therefore the establishing of a NDP without 
implementation and monitoring is not enough and does not achieve the desired 
results. The aim of this Thesis is to establish a NDP in the State of Kuwait. This 
policy is necessary for the State of Kuwait to ensure development an improvement 
of the Health Care System and ensure better health for population. 
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Chapter 1.0: Introduction 
 
Drugs are biochemicals used to combat the effect of diseases, their prevention and 
cure or diagnosis or treatment or improvement of physical or mental health. They 
are also known as ‘medicines’ when used for cure and are taken by mouth or 
injected to blood directly or applied over to the surface of the body (WHO, 2011). 
 
Drugs play an important role in protecting and maintaining human life and health, 
for that reason many countries governments, pharmaceutical companies and 
international organizations, whether they are based in developed or developing 
countries allocate very large amounts of money to scientific research and studies 
that contribute to the discovery, development and ensuring quality of medicines 
which can provide support when encountering and dealing with diseases and 
epidemics throughout the world.  
 
In addition the Ministries of Health in countries and other agencies try to ensure 
drug access to the largest number of people in a country, which helps to decrease 
the mortality and morbidity.  
 
It has been suggested that ‘health and access to essential drugs’ are considered 
fundamental human rights (WHO, 2003; MSH, 2001).  However, access and use of 
essential drugs worldwide is still far from optimal for a large proportion of the 
human population (WHO, 2003; MSH, 2001).   
 
It is estimated that 25-50% of the people living in developing countries and a small 
number from developed countries do not have access to essential medicines. It is 
proposed that this is influenced by a series of factors such as political, economic 
and social conditions which can vary between different countries and that there is 
an inverse correlation between drug development/production and availability to the 
population. Reasons for this are lack of availability of drugs in certain areas of the 
world, high prices of essential drugs, absence of sufficient trained professionals 
and infrastructure to support the delivery of essential drugs to populations in need 
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wherever appropriate . Moreover additional challenges such as the increase of 
incidence of chronic disease, caused by the increase in human life-expectancy, the 
emergence of new serious diseases such as AIDS, the development of drug 
resistance of previously known and managed life-threatening conditions (such as 
malaria, tuberculosis), can add more pressure on a health authorities ability to 
meet the increasing health demands (WHO, 2003; MSH, 2001).   
 
As indicated above the provision of health support is very expensive and covers a 
very large area. The organization of pharmaceutical services should not only 
emphasize the availability of drugs, but cover a range of aspects to include 
services that deal with the quality of medicines, availability of health-care support, 
which will assist in ensuring the reduction of the spread of disease and sustainable 
development for health in the long-term.  
 
There also has to be taken into account the very many country-wide and local 
problems and difficulties facing a health organization and the local communities in 
supply and organization of medicines, including: availability, affordability, access to 
the medication, rational use, counterfeiting, storage and distribution, pricing, 
ensuring quality, safety and efficacy of the drugs and other problems related to the 
medicines, which in turn lead to difficulty in the face of disease and lead to a 
reduction in the level of health care system. 
 
For these reasons the World Health Organization (WHO) (prompted by the World 
Health Assembly) through initial discussions in 1970 introduced the dialogue which 
was designed to develop a basis for the availability of the right medicines, which 
were cost effective and could assist in the choice and access issues, mentioned 
above.  Initially the WHO in the discussions suggested that certain drugs could be 
assembled in a list, which was later referred to as the Essential Drug List (EDL) (it 
was proposed that such lists could be different from country to country, dependent 
on the individual countries requirements). These proposals were adopted and 
since the initial introduction of an initial Essential Medicines List in 1975-1977 the 
WHO have continued to regularly (every 2 years) update the list, based on 
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evidence based decisions. Alongside the EDL the World Health Assembly agreed 
that the WHO should extend their work into organization issues and provide 
assistance in organizational structure which would bring together a number of 
management structural aspects for improved efficient pharmaceutical services in a 
country. The first of these was to set out the initial outline of the areas which could 
be considered to form the basis of a well-organized pharmaceutical policy which 
could cover the majority of areas associated with the pharmaceutical structure to 
the government and the public, through what would eventually be called a National 
Drug Policy (NDP), (WHO, 2001). 
 
These proposals included discussion of responsible monitoring, evaluation and 
development of drug policies. A NDP would assume responsibility for all issues 
regarding essential drugs and their use. It was suggested this mechanism could 
also be responsible for setting training standards for the health professional 
workforce in order to ensure the appropriate use of medicines at safe and efficient 
dosage by introducing a NDP (WHO, 2001).  
 
Its implementation would also provide a framework of clearly defined and 
thoroughly researched legislation and regulatory standards to ensure the 
appropriate access, quality and distribution of the Essential Drugs (WHO, 2001). In 
addition it was proposed that implementation of a NDP could offer important 
financial and political benefits through the regulation of the pharmaceutical market 
thus reducing financial speculation and individual gain against the common good 
for a country. 
 
This research study focuses on discussing the importance and need for a NDP for 
Kuwait and how it can help in supporting development of the healthcare system in 
the country. Furthermore, it has been shown in this study that there are a number 
of areas where the introduction of a NDP could lead to improvements in the 
operation and control of the Kuwait regulations and processes. The rapid rise in the 
cost of medicines in the country year on year is also of concern. It is proposed 
through the evidence gathered in this study that Kuwait could benefit substantially 
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in terms of improvements in healthcare and control of quality, safety and efficacy of 
medicines if Kuwait was to introduce a national drug policy.  It is also shown that 
there could be better control of financial outlay on medicines Presently, Kuwait 
does not have a NDP and the content of this thesis is promoting the importance of 
the development and introduction of a NDP. 
 
In this study, Chapter 2 begins with a description of a NDP: its definition, 
composition, general goals and objectives, also the major components, formulation 
and structure. Furthermore, in this chapter some examples of NDPs in other 
developing countries are given and the resultant benefits from implementation. In 
Chapter 3, the aim, objectives, methodology and methods of the thesis are 
developed. Chapter 4 presents the analysis of interview data and results. The 
pharmaceutical sector in Kuwait is presented in Chapter 5, and in Chapter 6, the 
discussion of the study results from the interviews and the observations from the 
visits to the facilities; and in Chapter 7 a number of recommendations are made. 
Finally, a further proposal for the introduction of a Kuwaiti NDP is presented in 
Chapter 8.  
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Chapter 2.0: Background 
2.1 Understanding the concept of a National Drug Policy: 
2.1.1 The definition of a NDP 
In the proposal the precise definition for a National Drug Policy is suggested to 
depend on the regulatory needs, priorities for the health care system, various goals 
and objectives for each country. But the common definition for the National Drug 
Policy which was proposed, is “It is an authorized written statement set by the 
government, giving information, guidelines, goals and responsibilities for the 
pharmaceutical sector, whether public sector or private sector which plays as a 
guide for action and a commitment to a goal" (Brudon, et al., 1997). Therefore it 
presents a common frame work to set and identify the main strategies for the 
pharmaceutical field to reach and realize the health for all, and it should be 
developed throughout time.  (Brudon, et al., 1997) 
 
In addition Burdon and co-workers suggested that the NDP is able to assign roles 
and responsibilities to various parties involved in the medicines provision process 
thus giving the opportunity to improve efficiency. In this respect it is possible to 
ensure that all aspects of access to Essential Medicines can be effectively 
monitored and regulated (WHO, 2003). It was also proposed that a NDP could go 
hand in hand with a general National Health-care System. 
These two organisational structures (NPD and a Health-care System) are 
considered to influence each other since a NDP requires an established National 
Health-care System in which to function, while a Health-care System can 
experience significant improvements by the strict and organised legislation and 
regulatory structures of a NDP. 
 
An NDP is thus suggested to be a guideline or set of principles which can be used 
as an organisational reference text for health professionals in matters of drug 
usage and preventing any possible harm from improper use of drugs.  An NDP can 
be a wide ranging organisational proposal which could include within the system 
medically/pharmaceutically based laws, specified courses of action, regulatory 
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measures relating to usage and financial priorities regarding drugs which are 
published or regulated by any government agency or their representatives 
(Kilpatrick, 2000). It was considered that the essential parts of a NDP would 
comprise of: Recognition of therapeutic requirements; Priority selection of essential 
drugs; Assurance of medicines quality; Drug supply and a distribution system; 
Effective legislation and regulation; Human resource development; and 
Dissemination of drug-related material (Gerald, 1991). 
2.1.2 Composition of a NDP 
An NDP is normally an official government statement (developed by the Ministry of 
Health) in presentable form which acts as a formal document for Aims, Decisions 
and Commitments regarding medicines. It can be suggested that in the absence of 
such a policy it is unlikely that there will be a general overview for the actions 
required leading the chance of conflicts among various government guidelines, due 
to unavailability of clear definition of goals, guidelines and their correct 
interpretation. (Hoebert et al., 2013)  
Apart from the organizational aspects of the NDP, the Policy is normally based 
around the choices resulting from countries Essential Medicines List and the 
development of access to these medicines which can result in them being utilized 
to their highest potential. By deciding to have in place a list of Essential Medicines 
it forms a major part of health care, through medicines availability, affordability and 
cost effectiveness and other associated issues. It is known that the cost of 
medicines forms the main expense of the health budget within the pharmaceutical 
field. Part of the expense however can results from the initial purchase of poor 
quality of the medicines, inappropriate or irrational use of the medicines, and lack 
of access to essential medicines and wastage of medicines. It is also suggested 
that a NDP document is required to develop a platform for the discussions on the 
topics relating to drugs and pharmaceuticals (Hoebert et al., 2013). 
It is possible to abbreviate the main needs of the NDP into: 
 
• Presenting a record of aspirations, aims, value, and decisions of 
Government commitments; 
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• Defining National goals, objectives and priorities for the pharmaceutical 
sector, 
• Identifying strategies to meet the objectives and identify the various factors 
responsible for implementing policy components; 
• Providing a forum for discussions. 
 
2.1.3 Main Goals and Objectives of a National Drug Policy 
From these abbreviations, the goals and objectives of a NDP as proposed by the 
WHO are:    
● To ensure the availability, affordability and accessibility of the essential drugs for 
the largest number of patient at all times.   
● To promote the rational use of medicines.  
● To make available and to use drugs which have quality, are safe and effective. 
 
This leads onto the meeting of other national goals such as; improving national 
health, drugs manufacturing and handling at an economic level which effects 
directly nationwide services, and develops improved professionalism of the work 
(Reuter and Caulkins, 1995).  But as indicated earlier a NDP revolves around the 
essential drugs concept which suggests that there should be consideration of a 
limited number of clinically recommended drugs which can thus lead to improve 
rational use, distribution and cost (Strang et al., 2012). The simplicity of dealing 
with fewer therapeutic agents can also facilitate easier training of health 
professionals, better quality assurance, procurement, storage and distribution.  
But as indicated above in establishing the common goals and objectives of a NDP 
there will be differences from one country to another according to the needs, 
elements and requirements of each country.  But even though the actual medicines 
will vary in respect of the needs of a country, in introducing an NDP the major 
objectives are to provide availability of the designated essential drugs to the 
population at affordable cost and without any discrimination and at the same time 
addressing quality, and safe and efficient use of all the medicines. As a result it 
focuses on implementing the practices for therapeutic levels and cost effective 
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medicines usage by patients and health service providers resulting generally in 
reduced numbers of medicines prescribed (WHO, 2001). 
 
However in establishing the common goals and objectives of a NDP, it is accepted 
in the WHO guidelines that there will be differences from one country to another 
according to the needs, elements and requirements of each country. Based on the 
information above, it is proposed that the Kuwaiti Government should set the main 
goals and objectives of a NDP according to their needs before establishment of the 
organization.   
 
Major components of a NDP with respect to the objectives attained are listed below 
in Table 2.1 which shows that most of the components are not restricted to one 
objective only (WHO, 2001). 
 
It can be proposed that the most important objectives of a NDP are: 
 
 Access: equitable access and affordability of essential medicines; 
 Quality: quality, efficacy and safety of all medicines; 
 Rational use: therapeutically sound and cost-effective use of the medicines 
by health care professionals and consumers.  
Although the specific goals and objectives of a policy will depend heavily on the 
situation of a country, political priorities should be aligned to the National Health 
Policy.  
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Table 2.1 Components of a NDP, linked to key policy objectives (WHO, 2001) 
 
 
 
2.1.4 The structure and basis of a NDP 
The WHO (WHO, 2001) has suggested that the structure of a NDP can be 
considered to be tree like, consisting of roots, trunk and fruits. Initially when they 
are available, a strong and well-established roots system would consist of such as: 
the stakeholders of the government, media, consumer, health professionals, 
schools and universities and pharmaceutical industries. This can then lead to a 
strong broad trunk that consists of fundamental major points such as: monitoring 
and evaluation, human resources development, economic strategies for drugs, 
rational drug use, quality assurance, supply management, selection of drugs and 
legislation and regulation. It is then proposed that if the roots and trunk are good 
the tree will bear effective and mature fruits such as medicines needs for patients, 
which are safe and effective, rationally prescribed and dispensed, provide value for 
money, be affordable essential drugs and thus provide better health for all (WHO, 
2001). The tree structure of a NDP suggested by the WHO is summarised in 
Figure2.1. 
 
Therefore overall it can be strongly suggested that having a NDP in place is very 
important to a country, in terms of providing appropriate cost effective quality 
medicines when the patient needs them. But in producing an efficiently run system 
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with an NDP there is a dependence on many factors to be effective (Gerald, 1991). 
The requirements involved in setting up an NDP are therefore various in each 
country, and concerns the circumstances of the country, the political priorities, the 
economic situation, the level of health services and the extent to which there is 
government support for health care. As indicated above there are many reasons 
for needing the NDP, of which the most important include it: 
 
 Provides official documentation on aims, objectives, decisions, 
responsibilities and ambitions which provides an insightful outlook for the 
government. 
 Helps the global and local pharmaceutical sectors to know the main goals 
and objectives of a country. 
 Identifies the strategies and studies needed to meet these objectives and 
identifies the various factors responsible for implementing the policy. 
 Enables the pharmaceutical sector to ensure the availability and affordability 
of appropriate essential drugs. 
 Provides a national forum for discussion and gives the opportunity to look 
for the problems which relates to pharmaceutical sectors, the public and the 
private sector (Gerald, 1991). 
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Figure 2.1 National Drug Policies - A Tree That Bears Fruit (WHO, 2001) 
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2.2 The formulation of an NDP 
 
The process by which a NDP comes into being should be based around three 
major parts namely: the ‘development process, implementation and monitoring’  
(Reuter and Caulkins, 1995). 
 
The ‘development process’ is normally the first step taken and it aims to formulate 
the actual content of the NDP. This process is then followed by implementation of 
the policy aiming to achieve the objectives defined earlier through appropriate 
actions. The stage also includes the design of a long-term implementation plan, 
which typically could take between 3-5 years, and aims to ensure the steady 
progress of the policy implementation over time. In this plan the roles and 
responsibilities of all parties involved can be generally defined. These may include 
other government/association branches such as authoritative committees 
concerned with educational, trading and industrial development. In addition this 
stage would also involve health care professionals, pharmaceutical industry 
representatives, higher education/academic institutions, non-governmental 
organizations (NGOs); insurance companies associated with health care coverage 
and consumer committees. In bringing all these groups together it is considered 
very important to have a high degree of consultation and cooperation within these 
aspects in order to ensure that all sectors involved remain unaffected by the 
reforms necessary and that their concerns and their needs are met. This process 
has been shown to be extremely helpful in minimizing opposition to the significant 
alterations that the introduction of a NDP brings. In the final stage, the 
effectiveness of the measures taken and the results of the process should be 
monitored to ensure successful policy implementation and to correct any 
discrepancies (WHO, 2001). These major stages in the formulation of a NDP are 
summarised in Table 2.2. 
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Table 2.2 Formulation stages of National Drug Policy (adapted from WHO, 
2001) 
 
 
1. Policy process 
organization 
 
Appropriate national authorities initiate the development process 
identifying the policy objective and priorities as well as the parties 
involved and the resources to be used. Consultation with the WHO 
at this stage of the process is important. 
 
 
2. Problem identification 
 
A team of experts with prior experience in formulating drug 
policies at an international level perform an examination of the 
situation to identify the problems that implementation of a drug 
policy might be faced with and make appropriate 
recommendations to overcome these obstacles. 
 
 
3. Situation analysis 
 
Following problem identification, a thorough situation analysis has 
to take place in order to diagnose the cause of these limitations 
and identify appropriate strategies to guarantee the successful 
implementation of the drug policy. 
 
4. Definition of priorities to 
achieve goals and 
objectives of NDP 
Based on the situation analysis, priorities and strategies are set 
and decisions are made to deal with the most important problems.  
 
 
5. Preparation of NDP 
 
Having decided on the priorities and approaches towards tackling 
the major problems, the official policy document is drafted to 
clearly and formally introduce the principles, objectives and 
strategies of the NDP.  
 
 
6. Revision of NDP 
 
The policy document is subsequently subjected to a thorough 
revision with the participation of representatives from all sectors 
and authorities involved and corrections/improvements are carried 
out leading to a finalized version of the NDP document.  
 
 
7. Formal endorsement of  
NDP 
 
The completed NDP document should then be formally endorsed 
by the local authorities/government. This is of crucial importance 
in order to demonstrate the political will and commitment to the 
implementation of the drug policy.  
 
8. Launch of NDP 
Success of the policy depends widely on the commitment of the 
parties involved to the policy objectives and also on the promotion 
of the policy and education of the consumers/general population. 
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2.3 The major components of NDP 
2.3.1 NDP components 
As has been indicated above a NPD is comprised of a wide range of components, 
all of which can be considered to possess important roles in achieving the principal 
objectives of the policy. The main components are proposed to be: selection of 
essential drugs, affordability, drug financing, supply systems, regulation and quality 
assurance, rational use, research & development, human resources development 
and finally monitoring and evaluation (Webb, 1999). 
2.3.2 Selection of Essential Drugs   
In choosing drugs which can appear in the Essential Drugs List for a country, it is 
important to determine in the Government Policy, established by the Ministry of 
Health, priorities for both the public sector and the private sector, and specify the 
appropriate need of the drugs and their adoption for the essential list. Also, it is 
important to define the procedural requirements for defining a drug and its 
formulation in the Essential Drugs List and the basis of the selection criteria for 
traditional and herbal medicines (Hogerzeil, 2004; Laing, 1991). 
 
Initially, one of the main aspects which should be considered is the importance of 
the Essential Drugs List. In all countries which have introduced a NDP the 
importance of considering the basis and differences in the origins of the 
populations should be taken into account, for aspects such as indigenous health 
issues, their immigration status,  and their rights to access to medicines, based 
upon the rules of a country.  Different population requirements and resources are 
likely to place different demands on the healthcare system, and may have a 
bearing on the procurement choice in the initial decision stages of medicines 
choice are most important. Accordingly, the Essential Drugs List can help to set 
priorities in the NDP and promotes equity in that a small number of well-
established drugs (and associated dosing regimens) can form a central position in 
the policy. These are the medicines that are most commonly required in the 
population and can be the most cost-effective way to treat pathologies of 
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relevance. Having a smaller list of essential drugs can also be important for 
physicians and patients who want to have a clear understanding of what is being 
done and what is available (Morgan et al., 2008).   
These common – essential – drugs tend to be present in many or in all countries 
NDPs and assist in ensuring a reliable, low-cost supply is always available both 
locally and globally. The WHO argues that buying large numbers of drugs in 
purchase orders results in better price competition and economies of scale 
(Morgan et al., 2008). Quality assurance, purchasing, storage, distribution and 
legislation can all be simpler when a smaller number of drugs is involved, further 
demonstrating the importance of an Essential Drugs List (Who, 2003). In this 
respect, maintaining an Essential Drugs List can save money for the country when 
it comes to medicines procurement and ensures a steady supply of medicine.  
However, the Essential Drugs list is only one aspect of a NDP, albeit an important 
one. The availability of drugs is not much use without the correct and safe means 
by which to use them. In fact, their incorrect use can be fatal, and appropriate 
safeguards need to be in place to prevent inappropriate use. It is therefore 
essential that drugs have to be regulated to ensure patients receive a benefit and 
not a problem; this is a central aim of a NDP.  
In short, the availability of an Essential Drug List in Kuwait is likely to support the 
Kuwaiti Government in determining the appropriate need of drugs, reducing the 
number of expired drugs in the Central Medical Store and savings of the general 
budget. This is especially as the government purchases around 1100 to 1350 
pharmaceutical products (drugs, injections and medical consumables) yearly 
(KMOH, 2016), and the establishment of an Essential Drug List would support the 
vision for a long term programme for the specific needs of these products. 
Furthermore, the introduction of an Essential Drug List as part of the NDP could 
contribute to the promotion of the rational use of medicines and ensure that the 
procured drugs meet the needs of the health care system in Kuwait. 
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2.3.3 Affordability 
The important factors in establishing the drug affordability are the commitments of 
the government, to: pricing policies; tariffs and distribution margins; reduced drug 
tax rates; multi-source product promotions for increasing the competition in generic 
goods; promoting generic policies for product exchange which should entail good 
procurement practices; the therapeutic replacement for a single source product; 
price negotiations; the position of Trade–Related Intellectual Property Rights 
(TRIPS), to include the introduction of  complaint measures, the recognition of the 
basis for patented drugs and their compulsory licensing should be discussed in the 
documents (Morgan et al., 2008). 
2.3.4 Drug financing 
Appropriate medicines financing aims at ensuring efficiency in medicines use with 
limited wastage, where the financing should include special privileges for the needy 
patients, and address increased funding requirements for priority diseases as 
proposed by the Ministry, and from government (WHO, 2001). 
 
The Kuwaiti Government has given considerable financial support, (as will be 
shown later in the Thesis), to its healthcare system and it is keen to increase the 
volume of spending in this area in order to keep pace with population growth in the 
country and to prevent any shortage in the level of healthcare, whether in hospitals, 
health centres, medical equipment and medicines. But it also has acknowledged 
that there needs to be some form of overall control of expenditure which is 
increasing considerably year on year.  This is illustrated in Table 2.3, the annual 
health budget allocated to the Ministry of Health from 2004 to 2015 is shown. 
   
Through an analytical study which examined the budgets of the last five years, it 
has been shown that the budget is increasing and will reach 1.548 billion USD in 
2019/2020. However, it was proposed that part of the increase in the budget in this 
sector is related to the increase in the population, and the incremental needs to 
cover the increase of medicines and increase in related medical materials prices. 
See Table 2.4. 
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Table 2.3.The general budget of the Kuwaiti Ministry of Health from 2004 to 
2015 (KMOH, 2015 a) 
 
 
Fiscal 
Year 
 
Lab. Materials 
(Million USD) 
Medical 
Consumables 
(Million USD) 
 
Drugs 
(Million USD) 
 
Total Amount 
(Million USD) 
 
2003/2004 
 
28,290  
 
42,438  
 
131,356 
 
202 
 
2004/2005 
 
27,647 
 
41 
 
133,462 
 
202,215 
 
2005/2006 
 
37,400 
 
44  
 
166  
 
247,400  
 
2006/2007 
 
43,350  
 
59,231  
 
176  
 
278,500  
 
2007/2008 
 
48,851  
 
61  
 
184,856  
 
294,693  
 
2008/2009 
 
74,594  
 
77,400  
 
250,300  
 
402,253  
 
2009/2010 
 
63  
 
86,314  
 
315,835  
 
465  
 
2010/2011 
 
65  
 
88,552  
 
325,233  
 
478,733  
 
2011/2012 
 
93  
 
119,332  
 
507  
 
719  
 
2012/2013 
 
86,933  
 
125,958  
 
465,131  
 
677,873  
 
2013/2014 
 
89,618  
 
152,267  
 
606,471  
 
848,358  
 
2014/2015 
 
113  
 
200,676  
 
697,907  
 
1 Billion  
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Table 2.4 Five years forecasting for the health budget in Kuwait by using time 
series analysis 
 
Fiscal 
Year 
 
Lab.Materials 
 
% 
 
Medical 
Consumables 
 
% 
 
Drugs 
 
% 
 
Total 
Amount 
 
2015/2016 
 
169,689 Million 
USD 
 
15% 
 
218,817 Million 
USD 
 
19% 
 
744.991 
Million 
USD 
 
66% 
 
1,135 
Billion 
USD 
 
2016.2017 
 
185 Million 
USD 
 
15% 
 
238,534 Million 
USD 
 
19% 
 
812,122 
Million 
USD 
 
66% 
 
1.237 
Billion 
USD 
 
2017/2018 
 
201 Million 
USD 
 
15% 
 
258,718 Million 
USD 
 
19% 
 
880,142 
Million 
USD 
 
66% 
 
1,339 
Billion 
USD 
 
2018/2019 
 
216 Million 
USD 
 
15% 
 
279,144 Million 
USD 
 
19% 
 
948,170 
Million 
USD 
 
66% 
 
1,443 
Billion 
USD 
 
2019/2020 
 
231 Million 
USD 
 
15% 
 
300 Million USD 
 
19% 
 
1,017 
Billion 
USD 
 
66% 
 
1,548 
Billion 
USD 
Based on last 5 years experience 
In Table 2.3, the increasing amount from the budget which is allocated for the 
purchase of medicines, medical consumables and the associated laboratory 
materials in each year shows that the Ministry of Health is keen to provide the 
necessary medicines and medical supplies and has taken into account the medical 
cost of the increase in the population and the numerous modern developments in 
medical and pharmaceutical services. 
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2.3.5 Supply systems 
In establishing an efficient NDP, an efficient medicines procurement scheme and a 
reliable supply system is an important factor for access to Essential Medicines as it 
can provide a balance between the country’s needs, over and under supply, 
efficient procurement practices and having medicines available at the appropriate 
time in a yearly cycle.  It can also provide a balance in the private and public 
system in supply and distribution structures. Associated with these processes it 
can lead to preventative actions for theft control and corruption, improved inventory 
control and prescribing methods for waste or expired drug disposal and measures 
for meeting acute emergencies (Yusuff and Tayo, 2004). In terms of the 
organizational structure, the establishment of a NDP in Kuwait could also assist in 
giving an improve structural basis on which the KMOH can examine whether 
changes are required in the procurement system for medicines brought into Kuwait 
and the associated supply management system. By closer identification of the 
appropriate selection of drugs this could lead to providing a possible improved cost 
effectiveness and overall reductions in expenditure within the national budget. 
2.3.6 Regulation and quality assurance 
It is normally the case that part of the function of the Ministry of Health’s Drug 
Regulatory body is to establish and enforce legislation and policies on the 
pharmaceutical sector (which includes many aspects of provision, adverse drug 
reactions of medicines and supply of medicines to the patients of a county). The 
Drug Regulatory Authority (DRA) is the agency appointed by a government to 
ensure that the research, manufacture, procurement, import/export, distribution, 
supply, marketing and sale of drugs adhere to specified and strict standards (Ray 
and Stein, 2006). 
Also it is to ensure there are records which provide accurate information about 
quality matters related to products, which can guarantee their authenticity (to 
include being free from counterfeiting) and safety.  It is normally suggested that the 
groups involved in medicines provision (agents, wholesalers and manufacturers) 
should be transparent and independent in their working and their relations with 
Ministry of Health and should not be biased. It is suggested to be the case that a 
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NDP will clearly state the measures which should be taken to define the processing 
steps for drug registration and evaluation.  
 
Normally the Ministry of Health within the Government should ensure an efficient 
legal framework for regulation and adequate manpower and financial support. The 
DRA in the regulations associated with the Health Policy would normally provide 
the written basis for commitment to medicines procurement from: outside a country 
to include good written or inspection processes; and where medicines 
manufacturing occurs good manufacturing practices (GMP) approaches. The 
Policy should also state the basis of law enforcement; drug control facilities; and 
regulated drug promotion methods, also make reference to working guidelines for 
herbal and traditional medicines. As the NDP develops it is likely that checks for 
effective pharmacovigilance would be developed for monitoring for possible 
adverse reactions from drugs and that there would be a joining with International 
Databases which deal with promotion of international exchange of drug related 
information (Ray and Stein, 2006). 
. 
Therefore Drug Regulation is an important component of a NDP. As a result much 
attention is often paid in a country to developing an efficient system and to 
providing adequate regulation.  
It is proposed that the DRA should operate independently and with a transparency 
in order to provide an unbiased support service. The agency should have access to 
steady funding, be in regular contact and working in cooperation with external 
experts and international organisations. It should also have quality control facilities 
at its disposal and a reliable system of law enforcement (WHO, 2001). In carrying 
out their work, one of the key functions of the DRA is to establish drug registration. 
The main stages of the drug registration process are shown in Table 2.5. 
 
This current study will discuss later (in Chapter 6) the effects of a NDP on 
medicines and organizational quality assurance in Kuwait, namely how to 
investigate the basis of regulations and legislations and the potential for introducing 
Quality Assurance Departments in the MOH Administrations and Hospitals, and 
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whether there would be an advantage in establishing a Pharmacovigilance Centre 
in Kuwait.   
 
Table 2.5 Stage of drug registration (adapted from WHO, 2001)   
 
 
1. Notification procedure 
 
The procedure does not examine the safety, 
efficacy and quality standards, but instead focuses 
on providing standard information about all the 
drugs available in the country.  
 
 
2. Basic authorization procedure 
Licensing of drugs through assessment of efficacy, 
safety and quality, by the DRA itself or based on the 
WHO Certification Scheme on the Quality of 
Pharmaceutical Products Moving in International 
Commerce.     
 
 
3. Full registration 
 
Evaluation of the data regarding a pharmaceutical 
product prior to marketing authorization and 
determination whether this product would be 
branded as a prescription drug. At this level the 
drug registration should be reviewed regularly. 
 
 
4. Re-evaluation of older drugs 
 
Reassessment of already available products and 
renewal or revocation of license according to clinical 
guideline updates. NDPs usually impose a limited 
registration period (~5 years). At the end of this 
period drug registrations and licenses have to be re-
submitted and re-evaluated. 
 
2.3.7 Rational use of Drugs 
In terms of prescribing a medicine for a patient it is implied that suitable drugs 
should be in the correct dosage, for the clinical needs of the patients and that this 
is addressed in an efficient manner and at the right time and lowest possible cost 
to meet the health issues. However in practice, many aspects can affect the 
rational prescribing of drugs.  These can include the wrong drugs for the patient 
condition, the wrong formulation or strength, drug-drug interactions, inappropriate 
dosage for the patient (e.g. children) Common problems in prescribing 
inappropriate drugs can be overcome by strict regulatory interventions and 
promotion of rational drugs use. To achieve these objectives there is a need to 
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bring into operation ‘evidence based guidelines’ to assess the value of a particular 
medicine for clinical activities as a first step towards training, utilization reviews, 
and supply of drugs. (Ratanawijitrasin et al., 2001; Song et al., 2014) 
 
There is also the need of training programs for informal drug sellers and provision 
of unbiased drug information, educating consumers and provision of control and 
monitor of Ministry of Health (MOH) over the health professionals who working in 
private sector and implementation of managerial strategies. All of which are key 
issues to enhance rational drug use (Ratanawijitrasin et al., 2001; Song et al., 
2014). (This aspect is discussed more fully. later in Chapter 6, Page 300) 
2.3.8 Research 
Operational research is generally considered in many fields to be an important 
mechanism for assessing the policy impact on national systems, and in this field it 
is useful to determine the economics of medicines, prescribing practices and the 
methods of dispensing drugs, in both the work and socio-cultural environment 
(WHO, 2001). It is suggested to be of help in evaluating various drug related 
scenarios and monitoring and implementation of policy developments for drugs. It 
has also been used in the field of clinical drug research (WHO, 2001). 
 
2.3.9 Human resources development 
In a successful health system fully trained staff is extremely important to provide an 
efficient functioning facility and for this reason HR policies are regularly designed 
around addressing issues which relate to ensuring the availability of trained, skilled 
and motivated individuals for health policy implementation and to avoid failure of 
the proposed policy objectives. It is agreed that in the health field that governments 
(through the MOH) are liable for overseeing and planning for the emerging needs 
of training the manpower for the pharmaceutical/health sector in a country. Career 
plans and team building activities are often central to this training and 
pharmaceutical/health staff across the many disciplines is normally employed after 
fulfilling the minimum qualification and training requirements in the specific 
category (Schneider et al., 2006). 
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The possible need for human resource development and training programmes for 
health professionals in Kuwait are discussed in detail in Chapter 6. In addition, 
there is discussion of studies on whether the NDP can lead to possible changes in 
personnel development, training and the development of job satisfaction and work 
performance.  If these aspects were to be examined, then it is proposed that there 
may be an increase in professionalism and efficiency of the health service 
workforce.   
 
2.3.10 Monitoring and evaluation 
In any of these developments there is a need to monitor the success of outcomes 
of human resource development and in the monitoring and evaluation of the 
pharmaceutical/health sector developments. As a result it is proposed in the WHO 
documents that there should be some form of compulsory commitment from the 
MOH regulatory authorities for drug monitoring and evaluation using some form of 
assessment, such as, standard indicator-based surveys and their evaluation for 
impact analysis on whole health system and effectively the economy (Abdollahiasl 
et al., 2014). 
 
2.4 World Health Organization and NDP 
 
As has been suggested above it was proposed at the World Assembly meeting that 
every human being has the fundamental right of the highest standard of health 
without any discrimination of religion, race, political view, economic condition or 
social status. In this respect the access to Essential Medicines plays a crucial role 
in increasing the standard of living of the individual along with food, clothing, 
housing, and what could be considered necessary social services. As has been 
indicated earlier, in developing countries drug costs account for a very large share 
of the total health budget, but the outcome of spending such large sums does not 
guarantee that the appropriate medicines will be available for all of the population. 
In addition the problems for a developing country in providing treatment for its 
people is accentuated by the inability to provide appropriate and sufficient 
 
 
24 
 
medicines to deal with traditional diseases like tuberculosis and malaria and other 
tropical diseases alongside newer diseases, such as diabetes, heart disease 
through obesity and AIDS and increasing drug resistance for the important 
antibiotics which has all led to increased pressure on health resources and 
increased spending on drugs.  
 
Over the last 40 years, pharmaceuticals have played a vital role in reducing global 
morbidity and mortality. But, just as medicines are one of the highest government 
budget costs, they are also very high in household expenditure in many developing 
countries. The WHO has estimated that one-third of the world’s population needs 
access to essential drugs (WHO, 2001). Over these 40yr the WHO has worked 
with numerous countries to try to achieve the aim of access to essential drugs and 
medicines, and in improving quality and safety of medicines and to work with 
countries and other agencies to improve the rational use of medicines.  
 
In order to achieve these improvements it is considered essential in the advice 
given by the WHO and other agencies that all countries should formulate and 
implement a suitable NDP (WHO, 2001).  
 
 
Table No 2.6: National drug policy components related to the key policy 
objectives 
Components:                          Objectives 
Access Quality Rational use 
Selection of essential medicines √ (√) √ 
Affordability √   
Financing options √   
Supply systems √  (√) 
Regulation and quality assurance  √ √ 
Rational use   √ 
Research √ √ √ 
Human resources √ √ √ 
Monitoring and evaluation √ √ √ 
√ = direct link; (√) = indirect link 
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National Drug Policy: 
 
As has been shown in earlier sections the WHO have had a major part in 
proposing the basis for an NDP. The initial function of the WHO, when established 
back in the 1970s was to provide considerable attention to ensuring the saving of 
lives by improving health in all regions of the world. This is carried out through 
advising on procedures and the establishing of structures which can assist in the 
improvement in access to drugs, which was followed up by a request to suggest 
the basis for an initiative in Essential Medicines/Drugs. In addition advice was 
developed in providing the basic outlines on how to improve the quality of drugs. 
As the portfolio grew the rational use of drugs became an important area for the 
WHO and their involvement has grown into advice in Developing Policy and into 
Pharmacovigilance. Because of the basis of the development of the WHO is 
through the World Health Assembly the organization is keen on establishing 
international norms and standards for pharmaceutical products, through 
encouraging and supporting the WHO member countries to establish develop and 
implementation medicines policies and in particular an NDP. (WHO, 2001)  
 
The establishment of a NDP is however considered to depend mainly on the will of 
a National Government to provide the support and assistance, which will involve 
financial or administrative support. In this respect the Government with the MOH 
will play the most important part in the process by cooperating with several 
Government agencies including the MOH, the Ministry of Finance, the Ministry of 
Trade and Industry, Universities and other government bodies.  In addition in 
establishing a NDP there should be involvement of the private and public sectors to 
include pharmaceutical industries, associations, companies and pharmaceutical 
agents and notification to all other agencies which are related to Medicines. In 
order to assess the success of the NDP developments the WHO and MOH have 
shown that they could sight clear results which demonstrated the advantages to 
health and the organization of the function of obtaining and using medicines linked 
into a developing NDP framework between all the partners and by the end of 1999, 
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over 100 countries had NDP in place or under development, see Figure 2.2. 
(WHO, 2000)  
 
 
Figure 2.2. By the end of 1999 over 100 countries had National Drug Policies 
in place or under development 
 
Typical examples of the support work done by the WHO in this area was 
demonstrated by the establishment in the late 1990s of a program designed to help 
its member states, in the Eastern Mediterranean regions to develop, implement, 
monitor and to evaluate their National Drug Policies. The core concept for this 
program was to attempt to solve the pharmaceutical issues, by training staff in the 
MOH in following the WHO guidelines on each step of the policy process through 
consultative meetings between the WHO and the countries involved. 
The first meeting was in September 1998, in Alexandria, in Egypt which focused on 
drug policy development, priority setting, implementation strategies and indicators 
for evaluation. 
The second meeting was in Tehran, in the Islamic Republic of Iran, in December 
1999, and concerned rational drug use. 
 
 
27 
 
Throughout the biennium between “1998-1999” the WHO project assisted 23 
countries including Angola, Oman and India to develop their NDP’s. Other 
countries including Slovakia, Czech Republic, Romania and Uzbekistan also 
initiated the first stages of the process, and other countries like Kenya took 
advantage from these projects in moving from their theoretical policy forward to a 
practical policy by which their NDP is now implemented. The results of these 
efforts have also impacted on improving access, quality and rational use in these 
countries. See Figure 2.3. (WHO, 1999)  
 
 
 
Figure 2.3 Improvement access, quality and rational use - National Drug 
Policy 1999 
 
2.5 NDP process, implementation and regulation - Role of the WHO 
 
As has been indicated above however, the development of a NDP is a complex 
process involving formulation of policy, implementation of strategic activities aimed 
at achieving policy objectives and monitoring. In order to organize and prioritize 
requires careful planning involving all the parties along with political dynamics is 
needed in order to achieve a successful National Drug Policy (WHO, 2002). 
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2.5.1 Planning 
Prior to policy adoption, an implementation plan is required. The implementation 
plan defines action points, division of responsibility, estimates the required budget 
and gives indicative time frame (WHO, 2002).  The plan and the process leading to 
the expected outcome make a NDP meaningful. The strategic plan used to develop 
the policy should specify various steps in the development process.  
 
2.5.2 Involving all parties 
As indicated it is important for consultation and negotiations to take place with all 
interested groups which would normally involve government bodies, non-
governmental organizations (NGOs), professional associations, academia, 
international pharmaceutical industries, drug sellers, doctors, pharmacists, nurses 
and consumer groups and their involvement is regularly necessary throughout the 
policy process. In addition, consultation with the Drug Regulatory Administration 
(DRA), district and provincial medical and administrative personnel, traditional and 
herbal drugs practitioners and sometimes insurance companies would be involved. 
Also it may be appropriate to involve media and international organizations can 
also be of help in implementing the policy (WHO, 2002). 
 
2.5.3 Political dynamics 
As has been stated the formulation and implementation of a policy needs to have 
political authority and the participation because the aim of a policy is to achieve 
access to basic health care and development of a NDP is likely to require funding 
and changes in the regulatory framework. These changes transmitted within 
governmental areas will have to be proposed and a clear advantaged expressed to 
the other government officials outside of Health.  Such advantages could be 
expressed by indicating that the pharmaceutical sector is likely to be more efficient 
and responsive to health needs. Strong political direction and sustained devolution 
are vital for the formulation and effective implementation of a national drug policy 
(WHO, 2002).  
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2.6 The steps of NDP process 
 
Since the WHO established the proposal of a NDP, it has been promoted on the 
basis of having in place processes to ensure its effectiveness. The process of a 
good national drug policy should be built around the 3 main components of: 1). 
Development, 2). Implementation and 3). Monitoring and Evaluation (Chowdhury et 
al., 2006). 
 
2.6.1 National Drug Policy Development   
The majority of countries have formulated and subsequently updated their NDP. In 
a number of countries an emergency or an important political change involving 
developments such as the expansion of local industry or the implementation of a 
global trade agreement has often created an opportunity to start the process of 
formulating or adjusting a policy. The WHO has proposed a process for 
development of a NDP to support countries in identifying the work procedure of this 
project. But the development process suggested by the WHO is not channeled 
directly at countries, where, as mentioned before each state has its own priorities, 
needs, specificity and factors that determine the mapping of work on their project 
(WHO, 2001). The development process can include; 
 
Step 1: Organization of policy process 
It is suggested that the Ministry of Health would normally lead the process of 
formulating a NDP and organize the process of taking forward the development of 
the policy structure, its objectives and its priority components. An important part is 
to Identify the interested parties, necessary resources, donors, assistance from 
other support agencies, and outside agencies such as the WHO and to make 
contact if appropriate with countries who had relevant experience’ 
 
Step 2: Identify the main problems 
To set realistic objectives an understanding and methodical analysis of the 
problems in the pharmaceutical sector is generally required. It is proposed that 
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expertise and knowledge is developed from gathering knowledge from experience 
gained from other countries and knowledgeable professionals. Also from other 
disciplines and backgrounds which, are gathered to examine the situation 
systematically, to identify the main problems which the country faces and make 
recommendations to overcome these issues. It is proposed that these issues and 
recommendations can be discussed at multidisciplinary workshops which help in 
formulating consolidated advice to the government 
 
Step 3: Situation analysis 
It is considered important to carry out detailed analysis of the situation in 
pharmaceutical sector before moving forward and then to undertake an analysis of 
the source of problems in order to identify potential solutions, and to choose and 
set appropriate strategies.  
 
Step 4: Setting goals and objectives  
After the identification of the main problems, goals can be set and priority 
objectives identified. This can start with discussions among key policy-makers and 
involve interested parties.. From these developments the discussion can become 
more detailed and can include more careful deliberation of the variations of interest 
and structural limitations within the existing system from which is important to set 
objectives and strategies which are attainable. 
 
Step 5: Drafting the policy 
After situation analysis and reference to NDP’s from other countries the completion 
of the outline of the main goals, objectives and approaches can be addressed.  At 
this stage small groups of professionals from different areas of the MOH and Drugs 
Regulation and other interested parties can be brought in and can be involved 
during earlier stages of the process and generally draft the policy. 
 
Step 6: Circulating and revising the draft 
The Draft Policy should then be circulated for comments from members of the 
Ministry of Health, and other Government Ministries and Departments, also 
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relevant institutions, and those considered having an interest in the private and 
academic sectors. Based on the comments received, after circulating the draft 
policy document, a further iteration of the NDP can be revised and finalized. Once 
a further draft is development, it is time for early discussion which will hopefully 
lead to in principle authorization by the government sectors responsible for 
planning, finance and education which is so important for successful 
implementation of the policy.  However one aspect which is unlikely to be agreed at 
this time is the agreement of the budget at this stage.   
 
Step 7: Securing formal endorsement  
Once these stages are decided it is important that the Development of the 
Regulations is proposed and that only the enabling components of the policy are 
included into law.   Without the operational details agreed as it may become 
difficult for future adjustment.  
 
Step 8: Launching NDP 
The next stage should be to launch the NDP which is one of the most important 
steps as it is important because the success of the policy depends on an early 
understanding by different sections of society and their support for the policy 
objectives. To assist with success the implication and benefits for all the interested 
parties should be clearly highlighted. In this respect knowledgeable professionals 
and opinion leaders can help endorse and promote the policy through a well-
designed campaign. To ensure public understanding and support for the policy the 
media and a variety of other channels can play a major role in publicizing and 
making the policy availability to different target groups, (WHO,2001). 
2.6.2. NDP Implementation  
In order to attain success from the 8 stages above it is suggested that a carefully 
formulated policy is insignificant if it is not implemented through a “Master Plan”, 
which includes the main structural plan for establishing the NDP through identifying 
the main issues, requirement and needs of the health care system. Every 
component of a policy requires a detailed strategy and specific action plans.  
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2.6.2.1 Priorities for implementation 
However although the Steps above can be discussed within each country who 
consider the introduction of a NDP the priorities of each country can vary and 
hence the priorities of implementing the policy differ. For instance rational use and 
cost of medicines could be of concern in countries having broad health care 
coverage with no access issues. Therefore, implementation of a drug policy would 
normally be focused on regulating the market and the cost without affecting 
sustainable access and equity. In contrast the focus of the policy in least 
developed countries may be on increasing access to Essential Medicines. 
Prioritization of implementation in both cases could be decided by the severity of 
problems under consideration and the potential of achieving the objective with 
available resources and making a meaningful impact (Chowdhury et al., 2006).  
 
2.6.2.2 Master plan and work plans 
From the NDP it is likely that there will be generation of an implementation plan 
which can illustrate the development structure for each component of the policy 
and indicates what needs to be done and who is responsible. At this stage it is 
possible to obtain some ideas about the required budget and a rough time frame 
associated with development and implementation, although overall the introduction 
of a fully operating NDP has in other countries taken around 5yr. By having an 
outline Master Plan it helps in instigation, operation, what should be communicated 
and monitored by all parties involved. It is suggested for proper execution, of the 
master plan that is should be divided into periods such as annual action and work 
plans then developed accordingly with the various agencies involved in its 
implementation. Approaches for each component, such as identifying the 
responsibility, the major tasks, and defining the target output, the time frame and 
the outline budget would normally be outlined in the plan (Chowdhury et al., 2006). 
2.6.2.3 Responsibilities in implementation 
It is proposed that a co-ordination body designated by the Ministry of Health should 
supervise and coordinate all activities. They should monitor the implementation 
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process and the targets to be achieved. It is also considered to be important for 
national consultative forum to be created to maintain countrywide support, and to 
ensure that the major stakeholders are consulted and involved (Chowdhury et al., 
2006). 
 
2.6.2.4 Financial resources 
The matching of strategies and action plans with available financial resources is 
also important. Also it is indicated that it should be made clear what allocations will 
come from government funds, the contributions from international and local donors 
and the revenue generated from drug registrations and fees comprise the usual 
funding sources (WHO, 2001). 
 
2.6.2.5 Regional cooperation 
In implementation of drug policies, it is also considered important that there are 
regional cooperation, skills, expertise and facilities in different countries, and what 
support can be given by institutions and organizations. It has been reported that 
cooperation between countries on a regional basis is increasing on a wide variety 
of policy and economic issues. It is proposed the greater harmonization in drug 
regulatory standards could results in a more economical use of resources.  
A typical example of regional partnerships: are the Association of South-East Asian 
Nations (ASEAN), the European Union (EU) and the Organization of African Unity 
(OAU). (WHO, 2001) 
 
2.6.2.6 Technical cooperation with WHO 
In addition to the support provided the countries and associations listed above, the 
WHO has previously provided an information exchange forum and further promote 
a cooperation through training courses and research projects. They have for some 
time helped to form professional networks, and provides training and research 
through collaborating centers, and also helped developing NDP’s by providing 
technical information and key documents.  
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In addition to all of these support areas there is regularly, the International 
Conference of Drug Regulatory Authorities (ICDRA) and also training courses 
which are conducted to discuss drug regulatory matters and drug policy issues 
(WHO, 2001). 
 
2.6.3 National Drug Policy Monitoring and Evaluation   
Once in place it is suggested that Monitoring and Evaluation is essential to ensure 
the program is progressing satisfactorily.  This can occur through various methods 
such as: 
 
     1. Organization of the data collection. 
     2. Data collection procedure. 
     3. Analysis and reporting of the obtained findings. 
     4. Survey implementation. 
     5. Determination of the cost of the most important drugs. 
The supervisory visits and routine and sentinel reporting which can be used for 
monitoring and reviewing the implementation of planned activities. The Monitoring 
and evaluation of a system is a constructive management tool that allows a 
continuous assessment of progress and also provides transparency creating a 
standard in comparison with other countries (Carr et al., 2007). 
 
2.6.3.1 Indicators for monitoring  
Initially in carrying out the above it is important to determine the progress achieved 
and to set realistic and achievable performance standards or targets. Once that is 
completed indicators to measure changes can be selected and used to compare 
and assess whether the targets are being achieved. These indicators are required 
to be measurable, clear, valid and reliable. 
Categories of policy indicators include: structural indicators, background 
information, process indicators and the outcome indicators. These indicators 
should be highly standardized so that trends can be identified.  
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Some of the important main indicators can cover the following aspects: 
■ Having access to Essential Drugs, and other indicators on medicine financing 
schemes, and on public supply management; which can provide information on 
access to essential drugs;  
■ Ensuring the function and efficiency of the quality control laboratory, regulatory 
authority, and handling of drugs to maintain the quality provide information about 
drug quality; 
■ Evaluating the prescribing and dispensing of drugs should be done using a list of 
essential drugs and the clinical guidelines, which should provide drug use 
information patterns. 
It is suggested that by using an indicator-based method of evaluating the 
pharmaceutical situation it can be useful for all parties involved in the 
pharmaceutical field. These studies and its results can provide clarity of the 
problems in the country so that Policy-makers, implementers and managers can 
reassess their strategies and priorities.  
The results can also be useful to international agencies and donors to focus on the 
areas that require support and to determine the significance of investing resources 
in the areas in order to achieve best impact  (Abdollahiasl et al., 2014). 
 
2.6.3.2 Multi-country comparative evaluations 
It is also helpful during overall evaluation to include other multi-country studies, and 
international collaborations on policy issues which can assist national policymakers 
in learning about innovative approaches (WHO, 2001). 
 
2.6.3.3 Periodic evaluations  
Finally after the NPD has been introduced and been in operation for a period of 
time, it is suggested that its working within the country should be evaluated 
periodically by professionals either from the country or from other countries or 
other agencies to monitor its continued development and also to suggest any 
improvements if appropriate  (Abdollahiasl et al., 2014). 
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2.7 Examples of National Drug Policies in Operation in other Developing 
Countries 
2.7.1 The introduction of a NDP in Developing Countries 
Based on the previous sections, it is already clear that NDPs can be extremely 
useful for countries in the developing world in order to help them control drug use 
and improve healthcare conditions and public welfare. Assistance is also available 
to these countries from a number of sources and as an example the UK 
Government in recent years has taken steps towards collaborating with 
governments of the developing world.  This included sending out a message of 
commitment to assist in improving access to essential medicines in countries of the 
developing world (DFID-UK, 2004). In this section, a few examples of countries 
that have benefited from the implementation of NDPs are mentioned below.   
 
The perception of the importance of the NDP in the development of a 
pharmaceutical healthcare system has encouraged many developing countries to 
organize and structure the basis for their own NDP, such as recently in Sri Lanka 
(2015) and as a result, many Ministries of Health have established a belief in the 
importance of a NDP in developing the medical and pharmaceutical healthcare 
fields in both the public sector and private sector.   
2.7.2 National Drug Policy of Ghana 
There are now many Developing Countries that have establishing their NDP, and 
have used it in developing its overall health system.  When doing this they have 
made efforts to deal with problem areas and found solutions, which can alleviate 
the problem areas.  Once in place these countries have generally followed these 
up by continuously developing the NDP organization. It is proposed that the State 
of Kuwait should take note of the benefits reported from these examples and 
analyze these examples, especially where the country has discussed issues in 
these countries that are very similar to those issues in Kuwait.  From this 
information the difference in aim, objectives, nature of work, factors and the 
specificity of each country has been taken into account.   
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As an example of recent discussions of NDPs’, In Africa, Ghana had significant 
gaps in access to medicines despite the implementation of a NDP in 1999. 
Problems were related particularly to affordability of products and quality of service 
in rural areas. As a result of a re-examination a revised edition was undertaken and 
the NDP was passed and adopted in 2004 by implementing significant changes in 
order to improve the current situation (GNDP, 2004). The objectives of the Ghana 
NDP are to ensure rational drug availability for all the users including the 
consumers, dispensers and the prescribers and to enable easy access and equity 
in health care, and it is this which is proposed could be examined in Kuwait 
alongside ensuring continuity for the Health System for the future by allowing 
access to essential drugs by all users irrespective of any financial detriments 
applied. The Ghanaian National Drug Policy (GNDP) also suggests that it would 
employ and educate more man power in the health sector which was expected to 
lead to improvements in quality and quantity of usage of pharmaceuticals at all 
levels, and it is suggested that State of Kuwait should also take forward this point 
and develop training programs for Kuwait health professionals to improve their 
health education and to develop their experiences, to ensure durability of the work 
in the health services field. On the operational safety side increased training is 
likely to lead to reductions in medical and administrative errors in the hospitals, 
health clinics and administrations and therefore increase patient safety. This action 
is expected to bring into place more efficient drug management by rationalisation of 
drug procurement and to lead to streamlining supplies and improving drug 
distribution and other health care delivery systems at all levels,  
By studying these examples it is likely to help the senior staff in Kuwait to avoid 
such issues and problems with reliability in drug procurement through having a well 
organised system in place centred on establishing an Essential Drug List which 
could save huge amounts of money and lead to procurement of only the needs of 
patients and appropriate drugs for the Health Service. Returning to Ghana, in order 
to have control over public and private sales and the distribution sector, the 
Ministry of Ghana applied more quality assurance measures for secure and 
effective drug supplies (Ministry of Health Ghana, 2004). 
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It is reported that in order to achieve a successful Policy, various strategies were 
formulated and applied to achieve these objectives such as cost sharing and 
allocation of examination of resources to areas where people had low access; by 
enhancing the amount allocated in the drug budget. New procedures were also put 
into place for improving the drug supply, its procurement and to encourage local 
production; The Ghanaian Ministry of Health also suggested a flexible approach 
towards future developments and variations, including keeping the vision for 
achieving and accommodating the future needs and ensuring a healthy 
environment for the public of Ghana (Ministry of Health Ghana, 2004). 
These are also matters for Kuwait and with the outline of a NPD in place they 
should be expected to be working towards covering all health aspects and 
disciplines. 
Returning to Ghana, in order to ensure the success of these objectives, the Ghana 
Authorities have taken certain steps such as providing funding through the Food 
and Drug Board and the Pharmacy Council and also the formation of a National 
Pharmacovigilance Centre. The State of Kuwait also suffers from a lack of a 
Pharmacovigilance Centre and this issue effects generally positively on the health 
care system where it has been introduced and its absence should be resolved 
through the establishment of a Kuwaiti NDP.  
In the Ghana Public sector, it is the State’s procurements methods which prevail, 
so for effectiveness of procedures an operative procurement unit has been formed 
in Ghana for health purposes. Ghana’s Pharmaceutical Procurement System has 
become more cost effective by application of an internationally competitive bidding 
procedure. Through the government’s free market policy and through withdrawing 
the tax exemptions for raw materials used in medicines production it has helped in 
reducing the local manufacture to a large extent. In addition Health Services have 
been decentralised and a Revolving Drug Fund Concept has been adopted to 
improve the drug distribution system.  
The Central Medical Stores have also been updated to include increased 
responsibilities regarding the supply mechanism (Ministry of Health Ghana, 2004). 
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Added to all these initiatives was the formation of a clinical pharmacy training 
programme, the introduction of workshops for health professionals and special 
training for chemical sellers. All these developments have provided the steps to 
achieve improved Rational Drug usage by guiding the health professionals towards 
their effective role. In order to provide reliable and unbiased drug information, an 
Information Resource Centre has been formed both for clients and health 
providers. However it was found that these developments required improved 
financial management and adequate drug financing and as a result there was a 
need to introduce increased economic developments, which included 
developments in health insurance plans and generic prescribing.  
From these developments there is evidence that indicate that healthcare in Ghana 
is continuing to improve and that the development of the NDP has had 
considerable influence on this and remains an important area of focus for the 
Government, with the list of essential medicines continually being updated by the 
administrating Food and Drugs Authority Ghana (Food and Drugs Authority, 2015).   
As with many other African Nations, the major focus of concern for the Ghanaians 
when drafting the NDP was the prevention of the diseases of HIV/AIDS, 
tuberculosis and malaria. However the trends in these diseases over recent years 
has been downwards.  For instance TB cases show there to be a continual 
reduction since the introduction of the NDP, with a concomitant decrease in 
mortality, suggesting that better prevention and treatment strategies are now in 
place (WHO, 2015); indeed, it is proposed that treatment success rates are now 
commonly greater than 80% of the cases identified. Driven on by the success in 
tackling TB, Ghana has recently increased the budget allocated to eradicate the 
disease, which now totals $80 million dollars annually (WHO, 2015). Likewise, HIV 
rates plateaued around the year 2000 due to increased awareness and medical 
treatments. In this respect it should also be noted that, in providing treatments for 
HIV victims, there has also been a spread of knowledge through communities 
where HIV has been widely found and by dealing with the disease there has been 
a lifting of the stigmas which were associated with the disease.  As a result it has 
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encourages more people to have confidence to visit the doctor and receive 
treatment. 
 
However, despite these best efforts relating to the development of the NDP, 
Ghana, like many countries in the developing world, it still has problems in fully 
delivering effective medication in a cost-effective manner to a large number of 
people. This is not only due to budget shortcomings but also that there are still 
concerns over the lack of a fully organized infrastructure, to serve all of the country. 
As a result it is proposed that education relating to the NDP and a division of labour 
between the private and public sectors, requires further work. Thankfully, 
assistance from international organizations, such as the Bill and Melinda Gates 
Foundation, have provided funding for initiatives which are bringing together 
private and public institutions in Ghana, with an aim of streamlining the process by 
which drugs get to patients (Miralles et al., 2003). Efforts in this initiative have 
included strengthening the drug management systems and procedures by; 
strengthening the Pharmacy Council’s Regulatory Functions; to include 
improvements in the delivery of medicines to geographically isolated populations; 
and generating an entrepreneurial spirit amongst local businessmen and women to 
improve medicines trading, and thus, reduce medicines costs and improve 
healthcare. 
In Ghana one initiatives was the until now the problems of medicines abuses 
arising after the government introduced exemptions for the low income people at 
public health institutions and although these abuses have not been completely 
resolved. The additional establishment of a National Health Insurance Fund (NHIF) 
in Ghana has helped through drug management and decentralisation of health 
related services.  
 
As regards the position in Ghana for development of controls in Traditional and 
Alternate Medicines, a Directorate of the Ghana Health Service has been formed to 
describe the importance of traditional medicines in the health sector. In this area 
the Ghanaian efforts have been focussed in providing a platform for all Traditional 
 
 
41 
 
Medicine Practitioners under one national organisation. From this they have 
developed guidelines for standards of practice and ethics, and a training manual 
for the development of a professional approach in this sector. 
 
With these initiatives there has also been a number of developments in effective 
monitoring and evaluation, and to assess these initiatives research was conducted 
through a baseline study of the pharmaceutical sector which has covered issues 
relating to rational drug use, procurement and financing of drugs. In addition there 
has been a link to a Group which is involved in the study of Knowledge, Attitudes, 
Beliefs and Practices (KABP) in Ghana. The NDP has also addressed the 
intellectual property rights which are covered under Trade Related Aspects of the 
Intellectual Property Rights agreement (TRIPS). The NDP also provides guidelines 
for the local manufacture of antiretroviral drugs for HIV/AIDS and their significance 
in assisting the combating of the disease in the country (Ministry of Health Ghana, 
2004). 
 
It is from the experiences of countries such as Ghana that Kuwait can learn many 
lessons and within this research program the researcher has already started to 
work on the study of their health status, by finding the main issues and preparing 
solutions, but in doing so has not neglecting the experiences of other developing 
countries.  
 
2.7.3 National Drug Policy of Namibia 
As a further example Namibia has gone through many stages of achieving an 
operational NDP. The Namibian NDP was established some years ago and initially 
introduced in August 1998. At that time the foremost objectives were to: meet the 
pharmaceutical needs of the Namibian public by looking at information on disease 
identification of health problems specific to the country.  This led to a basis of 
prevention of illnesses wherever possible and to provide effective cures, by 
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ensuring a supply of good quality medicines for the common diseases at the 
cheapest possible rates. 
Prior to the introduction of the NDP in Ghana, which had been developed along 
similar lines to other Developing Countries, who had started the NDP route at that 
time, and had taken information and advice from different agencies of which the 
WHO was just one, Namibia had put into place several different laws and 
guidelines to regulate the passage and use of drugs, which formed the basis of 
their NDP.  The most important of these in Namibia was the Medicines and Related 
Substances Control Act. In order to create a working system the government at the 
time of introduction of this Act also attempted to integrate a new NDP with this and 
existing legislation.  In addition it also created the Namibia National Pharmaceutical 
Master Plan which they proposed was designed to meet the aim of delivering 
overall improved standards of care to Namibians by the year 2000.  One of the 
major aims of these developments (in-keeping with other NDP's developed around 
the same time) was to develop more fully the major requirements that medicines 
should be safe, rationally used, efficacious and cost-effective. (Stiftung, 2012) 
However in establishing the NDP Namibia, as a relatively poor developing country, 
had to try to address a great many challenges when it came to acquiring and 
delivering medicines. These included the relatively low life expectancy in the 
country which was approximately 64 years of age, which had links to many 
communities living in relative poverty, in isolation and some distance from major 
urban centres and therefore not having easy access to medical services. 
Furthermore, more than 85% of the population was dependent on public health 
services (Stiftung, 2012), and there was only limited public access to private 
services.  This was despite Namibia having a very large private healthcare sector, 
one which was similar to South Africa, in which richer individual’s pooled money 
together in trust funds to help cover their medical expenses.  But access was 
limited to the vast majority of the population which could not afford the private 
healthcare membership fees. This had created a two-tier system in which the large 
number of government-dependent individuals had a much-reduced access to 
health care.   
 
 
43 
 
Accordingly, Namibia Health Administrators had to try to deal with the problem of 
relative isolation from their Health Services of many of its people. Through the 
organization associated with the development of the NDP they firstly had to find 
funding to meet the human resource cost associated with access difficulties in the 
communities. In addition in terms of delivering the access to health services as a 
priority of the NDP, very few pharmacists were registered in the country (<150), 
and most were based in the main cities therefore the issue of deliver of medicines, 
had to be addressed.  It was the case that  pharmacists from adjacent countries 
were often the ones serving Namibian residents (Ministry of Health and Social 
Services, Namibian Government 1998). The Pharmacy Council of Namibia were 
however at the forefront in the early years of the NDP and they strived to improve 
the standards and to increase the numbers of properly trained practitioners in the 
country, although in these early years the actual number of registered members 
and fully trained pharmacists was unknown. 
Added to this position there was also a low number of doctors per head of 
population at the time of planning and introducing the NDP and at the same time 
there were financial constraints on the range of medicines which could be 
purchased.  From this information, it was therefore apparent that Namibia faced 
many pressing issues pertinent to health. Not the least of these was that the 
Namibian healthcare budget for drugs was only $550 million, and to give a 
comparison aggregate figure, healthcare costs in the USA totaled $3.0 trillion at 
that time (CDC, USA 2015). To give another degree of comparison when one 
considers that most drugs are/were developed and first marketed in the developed 
countries such as the USA and Europe, where the salaries and funding is generally 
many times that of the African Countries generally, the economic disparity between 
the 2 areas made it almost impossible for the developing world to reach very high 
improvement levels of health. It is therefore the case that unless the global 
economic model is altered and existing debts erased, countries like Namibia will 
generally always lag far behind.   
It was suggested in establishing the NDP that it would act as a guideline for 
workforce planning and training, and more effective management of the 
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pharmaceutical sector, and would bring about legislative reforms in the 
procurement and handling of medicines. The NDP was also aimed at ensuring a 
continuous drug supply, with equitable access to all its citizens at affordable prices 
both in the public and private sectors (Ministry for Health and Social Services, 
1998). A review of the Namibia’s successful experience in the establishment of the 
NDP indicates that it would help the State of Kuwait by considering the stated 
advantages of the benefits of this process and could contribute to the successful 
introduction of a NDP in Kuwait.    
In order to achieve these objectives in Namibia, the Ministry of Health and Social 
Services increased the regulatory and managerial powers of the Medicines Control 
Council (MCC). One of the main developments in constructing the NDP was to 
develop sets of guidelines which provided for the registration of medicines, health 
practitioners, private hospitals, other health facilities and the enhancement of 
quality assurance systems. They also introduced registration requirements for 
generic products which emphasised the importance of GMP and product quality. 
Through the NDP the MCC provided a fast track procedure for Essential Drug 
Registration and computerisation of this process and it was claimed that this 
computerisation ensured information exchange with regulatory authorities, while 
maintaining confidentiality. The NDP was also reported to have maintained 
internationally acceptable standards for medical devices and disposable medical 
items (Ministry for Health and Social Services, 1998). 
As a part of the NDP an Essential Drug List committee was formed for determining 
the priority drugs required for prevention and cure of prevailing diseases and steps 
were taken to incorporate the priority drugs into the Namibia Essential Drugs List 
(Nedlist). This list was designed to ensure that the drugs which were included are 
based on their international non-proprietary name (INN) or generic name.  With the 
Nedlist in place it was decided it should be reviewed and updated periodically for 
efficient monitoring. In order to ensure availability of Essential Drugs in the required 
quantity for the whole population, the NDP imposed limitations on drug 
procurement of only registered drugs for sole use through Namibian companies, 
after receiving permission from the Ministry of Health/MCC.  
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In the NDP the emphasis was also on trying to introduce the rational use of drugs 
by health professionals as well as educating the population at large by providing 
strict guidelines for sanction of authority to professionals and dispensers in 
prescribing and dispensing Essential Medicines. In the NDP there is also a section 
on introducing the promotion of specialised training and education updates for 
health professionals and the community.  The method of approach was to suggest 
the development of a systematic and team approach to patient care management, 
and it was planned to introduce effective control measures to release information 
which was accurate and to make information available to the public. In addition it 
was also planned in the NDP to emphasise generic medicines, the rationalisation 
of the pricing system and its effective monitoring and to negotiate for a cost 
effective drug supply (Ministry for Health and Social Services, 1998).   
It was also the intention of the Namibian Ministry of Health to have a NDP that 
worked with high standards of control of advertising and promotion of medicines to 
try to prevent the public from poor quality and counterfeit medicines images by 
setting National Ethical Criteria for drug promotion. It was agreed that 
advertisements should be evidenced by scientific proof and they should educate 
the health professionals (rather than public) as medicines were to be considered 
sensitive commodities for use mainly by medical prescription. The NDP also 
provided guidelines for the minimum information recommended about the use of 
medicines and side effects and the extent of the material presented on the 
information label/packaging insert.  
In Namibia prior to introduction of the NDP, and in the early years of its 
introduction, the education of the health professionals was introduced to help to 
bring the NDP into action, and for pharmacists training programs were developed 
and the staffing requirements were analysed in both the public and private sectors. 
To assist in this development there was to be an effective association with 
professional bodies and training involvement through the universities to actively 
design the pharmacist’s curriculum, in tune with the NDP (Ministry for Health and 
Social Services, 1998). Again these points above and particularly the training are 
aspects which can be considered in the State of Kuwait.  
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Another positive aspect of the Namibia NDP which could be introduced once the 
Kuwait NDP is in place, is the formation of multi-disciplinary research and training 
of the research professionals to measure the impact of policy and its actions, and 
this could also be considered in Kuwait.  
Added to all of these requirements and guidelines there is also provision for secure 
and effective use of traditional medicines.  This area was also to be strengthened 
by technical collaboration and harmonisation with other nations. It was suggested 
that sufficient funds should be allocated to the pharmaceutical sector through the 
Finance Policy of Namibia for mobilising sustainable National Drug needs.  
However overall, the Namibia NDP has appeared to have a beneficial effect in 
some areas, such as on the number of HIV/AIDs cases in the country. Prior to 
2002, the number of HIV-infected individuals was increasing year on year, rising 
from 2.5% of adults infected in 1992 to 15.8% in 2002. However, since then the 
frequency has dramatically decreased, something again attributable to increased 
disease awareness and increased condom usage amongst sexually-active males 
(Africa Health Observatory, 2017), which was brought about due to increased 
publicity and health planning. Better management of the condition has also been 
observed in the country since the implementation of the NDP, although there is still 
marked room for improvement: 59% of infected females were under anti-retroviral 
(ART) at public-health facilities in 2011, whereas only 31% of affected males were 
(Africa Health Observatory, 2017). 
Taking the cases of African HIV/AIDs viewed as a whole, it does appear that 
concerted international efforts to reduce disease burden started around the turn of 
the millennium and included NDP-directed efforts (by agencies including the WHO) 
and also efforts by ‘big pharma’ to make their products more available to the 
developing countries.     
Since 2000, Namibia has also seen a remarkable drop in the number of malaria 
infections and cases, something which is accredited to accessibility and improved 
use of repellents, anti-malarial medication and increased public awareness through 
the efforts associated with the NDP. In terms of the actual number of cases in the 
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country they are reported to have fallen by 99 percent between 2001-2012 (Africa 
Health Observatory, 2017). However, the impact of global warming on diverse 
aspects of mosquito and malarial parasite physiology cannot be ruled out as a co-
factor in this reduction.  
As indicated in earlier sections, one aspect which assists a country in bringing new 
important medicines to the patients is the speed with which new drugs can be 
registered, with medicines regulatory bodies. The Namibian health organization 
have tried out various procedures, as have other countries, in order to try 
streamline the process of getting new drugs into the clinic. One of the most 
important criteria for registering a new drug is the checking that the clinical effects 
of medicines, is carried out thoroughly. Unless this takes place, it is possible that 
less-efficacious and even dangerous medicines can be allowed through to the 
patients.  In assessing clinical effectiveness clinical trials are the main checking 
procedure.  Carrying out extensive trials in a developing country is however 
difficult. Where short term trials can be carried out the outcome assessment is also 
difficult and the best results are not usually obtained without long-term 
assessments in patient groups to establish safety and efficacy for any medication.  
An example where this could have been the case was demonstrated by Vioxx, 
produced by Merck and Co. Ltd., where there were increased deaths due to 
cardiovascular disease in significant numbers of patients which was not picked up 
in short-term trials (Krumholz et al., 2007).   
There are however many studies which are presently undertaken which can give a 
better indicator of clinical effectiveness against determining the level of side effect. 
Future disease incidence trends will be particularly useful for establishing further 
the efficacy of the Namibian NDP and how it might be improved. 
 
2.7.4 National Drug Policy of Kenya 
In addition to the experiences of the countries mentioned above, Kenya has 
provided a number of indicators which were used for the development of their 
NDP, when it was first established 21 years ago (July 1994). Kenya’s NDP was 
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developed; where one of the main objectives of the Policy was to ensure equitable 
access to Essential Medicines through the public, faith-based, NGO and private 
providers.  
In setting up of the NDP and it was described as a continuous operation where the 
Ministry of Health has continued to promote the objectives below: 
 Ensure continuous availability of safe and effective medicines in the public 
sector. 
 Ensure that the medicines provided to patients are of good quality, are safe 
and efficacious both for use in humans and in animals and up to 
international standards. 
 Encourage whenever possible local manufacture of essential medicines and 
promotion of growth in pharmaceutical exports. 
 Promote good prescribing and dispensing and appropriate use. 
 Encourage development of traditional, alternative and herbal medicines. 
 Continue to provide adequate resources to meet the needs of the 
pharmaceutical sector. 
 Increase and strengthen institutional, technical and human resource 
capacity for effective pharmaceutical services. 
 Promote and regulate pharmaceutical research to make medicines and 
health technologies more effective, safer and more affordable. (The Kenya 
National Drug Policy, 1994). 
 
It can be seen by looking at these objectives for Kenya that establishing a NDP in 
the Developing Countries is of high importance and it is suggested that the Ministry 
of Health in Kuwait can learn from the experiences of other countries by comparing 
the starting points and the achievements of the health care system in Kuwait with 
these countries, and developing and adjusting the NDP by taking into account the 
appropriate needs and requirements of Kuwait.   
 
If a NDP is to be introduced in Kuwait, it is important that the experiences of 
countries such as those above are assessed and the important issues considered. 
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The questions which should be asked are how was the NDP developed for these 
countries and what have been the benefits for these countries since their 
implementation?   
Firstly, a key aim of the Kenyan NDP was to generate a list of essential medicines 
(based on the advice of the WHO and others) and to ensure that their procurement 
received priority. While this practice makes financial sense (and drugs were 
procured through competitive tender) and ensured that common ailments could be 
dealt with pharmaceutically (as discussed below), it meant that the Kenyan system 
faced the same pressures as elsewhere, namely that medicines used to treat less 
common diseases were seldom available, meaning diverse patient groups still had 
limited access to pharmaceuticals from the developed world (where it is 
increasingly a problem); their high cost (associated with research and development 
expenses and free-market economics) is still a barrier to their acquisition. 
However, in Kenya's case they also consider life-expectancy. As an example in the 
mid-1980s, the life expectancy of Kenyan males reached 60 years of age, although 
this also coincided with the highest prevalence of HIV in the country; which has 
been mentioned a number of times in earlier section of the Thesis. It is a 
notoriously insidious disease which is likely to have been circulating in humans in 
places such as Kinshasa since the 1920s (Sharp and Hahn, 2011). In the absence 
of treatment, HIV+ Kenyan patients progressed to AIDs in vast numbers, with the 
disease being a major contributor to the reduced life expectancy seen by 2000 
(Warungo, 2013). However, by 2002 this trend had been reversed, thanks largely 
to the increasing availability of ART drugs, antibiotics and anti-inflammatory 
medication. These reached Kenyan patients reasonably efficiently through the 
organizational structures set up by the MOH. Indeed, ART drugs has recently been 
scaled-up to meet WHO guidelines for HIV/AIDS; and ART drugs have now been 
reported as being available to 61% of affected individuals, which is up from 29% in 
2007, where it is estimated that up to 214,000 people still had not received any 
treatment at all (Odhiambo et al., 2014). In light of this it can be suggested that this 
is one area where the NDP was a success, and it can be suggested that an earlier 
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implementation may have curtailed major loss of life if available to greater numbers 
earlier. 
As regards the introduction of a NDP and the benefits that can be gained, they are 
often 'held-up' by financial constraints and organizational agreements to implement  
which are more-often-than-not the determining factor when it comes to public 
healthcare systems and their functions – in the developed or developing world.  
There is overall in countries health development a constant demand for access to 
new treatments and longevity. However it can be said for countries such as Kenya, 
the NDP has generally brought with it improvements, such as the National Hospital 
Insurance Fund and the protections (and health benefits) citizens received from the 
currents systems in place. 
A NDP has also led to improvements with regard to the infrastructure required for 
the dispensing of medicines; whereas in the past a limited number of individuals 
(i.e. doctors) dispensed compounds directly to patients, now organizations tend to 
handle the dispensing, and most are now accredited and designated 
establishments (pharmacies), giving the public confidence when it comes to 
acquiring such products. The Pharmacy and Poisons Board of the Kenyan 
government (Pharmacy and Poisons Board: Registration and Enrollment. Kenya)  
oversees the training, accreditation and registration for practice in the country, 
demonstrating further advancement under the NDP.  
The Kenyan NDP has had additional benefits with regard to clinical trials and 
foreign investment. After the NDP was implemented, effectively, a framework for 
evaluating medicines was put in place. When coupled with increasing hospital 
infrastructure (including the development of specialist research units and the 
establishment of good manufacturing practices) and globalization, Kenya began to 
benefit from large-scale clinical trials being carried out in the country.  
One such example is provided by one (of many) trials run by the pharmaceutical 
company Glaxosmithkline (GSK Ltd., UK) in which an Advanced Market 
Commitment Scheme was used to fund the development and clinical evaluation of 
a pneumococcal vaccine, which was later introduced into Kenya’s national 
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immunization programme in 2011 (Green, 2013). Although MOH have accepted 
that clinical trials come with risks, they will allow a cohort of patients to be treated 
(with many patients being treated for the first time), and allow foreign investment 
(by large pharmaceutical companies) which can generate local jobs and facilities, 
and help develop academic clinical medicine training in the country. Without a 
NDP, it is unlikely such advancements would have been possible. GSK recently 
committed to a £130 million investment in Africa (GSK, 2014), stemming from 
successes such as the one described.  
Furthermore, increasing private investment in medical research – and in particular 
concerning HIV/AIDS (Gates, Sr., 2003) – through crowd-funding initiatives and 
non-profit groups (such as MEDS, http://www.meds.or.ke), as well as by large 
medical research charities like the Wellcome Trust, MRC and Bill and Melinda 
Gates Foundation, are bringing advanced technologies and therapies to the 
country. As humans have recently been shown to display geographically- and 
ethnically-dependent seasonal physiological differences (Dopico et al., 2015; 
Roederer et al., 2015), such studies not only help us better understand pathology 
and health in African populations, but also further afield in other countries.  
Furthermore, the addition of the passing into law of the provision of veterinary 
medicine products has been essential for improving the health and wellbeing of 
Kenyan citizens (Chema and Gathuma, 2004). As a country with a large 
agricultural population and a long history of animal health (the Kenyan Veterinary 
Association dates it formation to 1966), many in Kenya live and work in close 
contact with animals.  It is the case that animals that often suffer from the same 
diseases as humans (such as pneumonia and parasitism), and often transmit 
diseases to other species, man and between themselves – as we do. Accordingly, 
it follows that improvements in animal health (through the provision of antibiotics, 
for example) is associated with improvements in human health; as stated by the 
currently-popular ‘one health policy’ – stating that improvements in human health 
benefit animal health, and vice versa (van Helden et al., 2013). Improvements in 
animal health through education (i.e. how to safely house and care for animals) 
and the reduction in disease burden leads to reduced zoonosis risk and better food 
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product yields (indeed, nutrition is strongly associated with health and 
demonstrates one way in which the NDP has improved the health of Kenyans). 
The importance of the issue is demonstrated by the fact that the Kenyan 
government recently formed a Zoonotic Disease Unit (http://zdukenya.org/about-
zdu/).  
Importantly, the development of the NDP of Kenya has ensured the further 
exploration of ethnobotanicals, suggesting that they could be further incorporated 
into modern healthcare policy alongside modern pharmaceuticals. Indeed, further 
interest in ethnobotanicals in the country has led to wide population surveys 
concerning medicinal plant use (such as species, route of administration, 
agreement on effects and side-effects) and the establishment of conservation 
schemes to protect areas where such rare plants grow (Jeruto et al., 2008).  
The NDP of Kenya also stipulates the importance of educational and training 
programmes to facilitate efficient drug use and to seek out routes to improve 
academic medicine. Importantly, partnerships between Kenyan and Western 
institutions are in place – such as the one between University of Nairobi College of 
Health Sciences and University of Maryland Health Sciences Department (Mayo, 
2014) – these help in the transition towards the digital age that is set to become the 
norm as ‘big-data’ is likely to revolutionise biology and medicine in the future (Marx, 
2013).   
The need for further development of the NDP in Kenya is however been recently 
shown by the fact that the four biggest causes of death in the country are due to 
the treatable/manageable diseases of: pneumonia, HIV/AIDs, stroke and diarrheal 
diseases. It has been proposed however that improved patient access to 
medication, especially in rural populations and acute situations, will help reduce 
this burden. As a simple example low-dose aspirin, which benefits the 
cardiovascular system, has for some time in the western world been recommended 
for adults at risk of hypertension (from which stroke can arise) (Berger et al., 2008). 
With better developments within the NDP discussions aspirin as a cheap and easy 
to manufacture medication could be made more readily available. 
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2.7.4.1 Some examples of the successes in the policies previously implemented 
Kenya has been reasonably successful in 2 notable areas; the introduction of a 
control program for AIDS where the program is in its fifth year of the health 
development plan. In addition the Malaria eradication program has lead to a 
significant drop in the number of cases of malaria. Both of these were developed 
out of the NDP structure. 
 
Another success in Kenya has been the Expanded Program on Immunization (EPI) 
which strives to achieve and maintain high immunization coverage and reduction of 
communicable diseases in children. The immunization coverage had reached 99% 
at the national level in 2003. Added to this under the organizational structure of the 
NDP, there has been a notable improvement in the rational use of antibiotics in 
primary health care which is a goal generally of many developing countries.   
 
With the help of the WHO, the Department of Rational Drug Use in Kenya has 
conducted a publicity and national survey campaign and recognized inappropriate 
antibiotic use in the Primary Health Care (PHC) centre. With the operation of a 
study for only six months there had been a reduction of about 53% in the 
consumption of antibiotics. The aim of reducing antibiotic consumption was also 
included into the Kenya National Plan for 2003 with a view to promote the 
improved rational use of antibiotics (Williams et al, 2004).  
 
Relating this to the State of Kuwait, there is generally a large problem of Rational 
Use of Medicines which is thought primarily to revolve around a high level of self-
medication by its people. This can result in irrational (sometimes abuse) of 
antibiotics, psychotropic, slimming, sexually related drugs and herbal drugs, and it 
would be proposed that this was one area which should be addressed under the 
guidelines of pharmaceutical therapy and use in a future NDP for Kuwait. As a 
result it will be proposed that the KMOH should consider in the NDP, increasing the 
knowledge of the public by increasing health education programs for the media, in 
schools and in public areas. In addition they could encourage the establishment of 
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health education conferences and seminars which support rational use of 
medicines and describes the health disadvantages of this practice. 
 
2.7.5 National Drug Policy of Oman 
The examples above relate to African countries and in this section it is proposed to 
consider how the Gulf Country of Oman has developed and introduced a NDP.   
 
Oman has many similarities to Kuwait in terms of its size, population and 
pharmaceutical system and its organization. The Sultanate of Oman is situated on 
the east southern part of the Arabian Peninsula. Oman is classified as the upper-
middle income country, similar to Kuwait, according to the World Bank 
classification. In Oman, the public health sector is well funded and well equipped. 
95% of the total population has good access to the public Health Care System. It is 
also a member of the Gulf Cooperative Counsel (GCC). This includes Oman, Saudi 
Arabia, United Arab Emirates, Kuwait, Bahrain and Qatar. 
 
Oman published its NDP in the year 2000, and the Sultanate at the time hoped it 
would better serve the needs of its approximately 4,700,000 million citizens, of 
which nearly half are under 15 years of age and more than 70% reside in urban 
centres where infectious disease might spread more quickly than in less densely-
populated areas (Ministry of Health, Sultanate of Oman 2000). Life expectancy in 
Oman is 76 years.  
However even before the implementation of the NDP in Oman, the country had 
been making important progress towards improving the health of its citizens and 
residents. For example, a total of 24 hospitals in 1975 was surpassed by a total of 
47 hospitals in 1999; 80% of which were operated by the Ministry of Health 
(Ministry of Health, Sultanate of Oman 2000). Therefore, when the NDP came into 
effect, many infrastructures and the required for its deployment were already in 
place. In 2000, when data was last collected, there were 302 pharmacies in the 
country, helping rational dispensing and patient information. 
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In addition, right up to today the NDP supports the Ministry of Health (the Central 
Drug Committee) which sets and approves the budget for drugs and determines 
which medicines appear on the list. Currently, more than 900 drugs and 500 
chemicals are on the registry, and all of them have passed rigorous safety, efficacy 
and manufacturing standards (Ministry of Health, Sultanate of Oman 2000). 200 of 
these medicines are available only by prescription, representing a large number of 
entities that can be freely traded. It is proposed however in published literature that 
improved education on medicines would help more of these compounds to be 
appropriately used.  These include the aspect of drug-repositioning (Sirota et al., 
2011) and combination therapies which are becoming more common (Feig et al., 
2013).  
 
The general objective of the Oman NDP was to develop the potential that drugs 
have to control common diseases and reduce suffering. The policy and the 
government commitment are clearly directed in this way and in establishing the 
NDP government offices, professional organizations, academia, industry, non-
governmental organizations, patients and consumers were all involved in its 
development (Omani National Drug Policy, 2003). 
 
The policy contains a number of specific objectives which were to:  
 
 Ensure efficient operation of legislation and related regulations, which 
provide the general public with access to safe, effective, affordable 
medicines.  
  Ensure that medicines imported or manufactured in the Sultanate of 
Oman are fully evaluated for quality.  
 Ensure that there is a selection of drugs and their availability to 
communities and individuals at an appropriate level that are safe and 
effective in use. 
  Support the procurement system for cost-effective medicines with 
quality. 
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 To establish an efficient drug distribution system for constant supply of 
drugs. 
 
 To provide Pharmaceutical Quality Assurance of any drug product.  
 To establish good manufacturing practices, where manufacturing takes 
place in the country. 
 To encourage Good Pharmacy Practice (GPP). 
 
 To improve the use of drugs through rational prescribing and 
dispensing.  
 To ensure the highest degree of co-operation with other Countries and 
International Organizations to improve the supply, distribution and use 
of drugs. 
 To ensure traditional and herbal medicines are safe and effective. 
 
The NDP of Oman has also benefited from being part of the Gulf States Joint 
Tender on Medicinal Products (Khoja and Bawazir, 2005), allowing quotations to 
be evaluated and exchanged between member states, who ‘pool’ their 
requirements, which increases the leverage the countries have when it comes to 
purchasing together commonly expensive products. 
 
2.7.6 How can Kuwait benefit from such examples? 
Taking together all the points raised in the section above, Kuwait will have many 
unique challenges to face when it comes to implementing its own NDP. However, 
there are other countries NDP’s which can be used as indicators of the way 
forward.  It has been highlighted in the text above that there are several 
steps/directions that can be taken to ensure the process runs smoothly and 
benefits the highest number of people in Kuwait. Steps which could be considered 
as a means to ensure the smooth running of its implementation and success 
include: 
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 Encouraging foreign investment in health care services – this will bring with 
it not only financial incentives but also experts and businessmen able to 
share their knowledge with the local economy to establish the best practice. 
Clinical trials and non-profit research are major ways to achieve this aim. 
 Maintaining a continually updated list of essential medicines – in so doing, 
the most recent evidence concerning safety and indicated/counter-indicated 
conditions can be taken into account. New medicines should be cautiously 
added to the list. In the case of Kuwait, it may be advisable to withhold drug 
registration until efficacy has been established elsewhere (including 
regulatory approval) or the cost has fallen. 
 Joining an international drug-purchasing consortium to secure better prices 
on drugs and chemical compounds – this can save the public finances 
several million dollars per year through price negotiations and quotations 
from different suppliers. If quality can be guaranteed, generic medicines 
should be purchased to reduce costs.  
 Ensuring the infrastructure is in place to allow effective deployment of the 
new NDP – medicines, without the means to deliver them are not much use. 
Therefore, an appropriate network of distributors, pharmacists and 
physicians are required to deliver therapies to patients.   
 Perhaps often undervalued, ensuring a high level of medical education 
reaches the community and patient groups could be amongst the most 
important steps of any NDP, which should put in place the steps required to 
inform people that if they need treatment, there are medicines available. In 
the absence of proper public information dissemination, individuals will not 
visit the doctor, or if they do, comply with their instructions.  
 Kuwait should have a NDP tailored specifically to its unique requirements – 
What are the diseases present in Kuwait? How can they be treated? How 
can treatment be delivered? What are the attitudes towards health care in 
the population? 
 
In short, having reviewed the developments in establishing a NDP in the example 
countries above and highlighted some of the issues which these countries had to 
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deal with, these issues and how they have been dealt with will be considered in the 
establishment of the Kuwaiti NDP. It is proposed that the experiences of these 
countries are likely to be very helpful in the legislative developments of a NDP for 
Kuwait to ensure quality, safety and efficacy for the medicines. They can also help 
in improving the health regulation and legislation, to strengthen the control over 
medicines usage, to assist in reducing the irrational use of medicines, and improve 
the drug supply management which can lead to saving in the national budget and 
to development in the health care system. For these reasons it is suggested that 
every developing countries should have an interest in the experiences of 
establishing an NDP for their own country.    
                                                               
Overall in the draft NPD proposed here it may be suggested that the KMOH should 
re-examine the legislation related to the control of prescribing and dispensing of 
medicines.  
 
2.8 The Health Care System in Kuwait 
The State of Kuwait has focused on health since the establishment of the first 
government after independence in 1961. At that time, the government developed 
the basis of the healthcare system by establishing hospitals and health centres, 
providing funding for medical health professionals from abroad and sending its 
people on medical and pharmaceutical scholarships to countries around the world 
to gain competencies in the field of medicine, pharmacy and dentistry. In 1976, the 
Faculty of Medicine (Kuwait University) was established to provide qualified health 
professionals and to develop their knowledge and skills to improve the health 
services (Kuwait University, 1998).  
 
The healthcare system in Kuwait has passed through four different stages over the 
years: 
A) Pre-emergence of oil. Kuwait was a very poor country before the discovery of 
oil, with its economy mainly depending on maritime trade and pearl fishing, and the 
lack of adequate sources of income negatively affected the standard of healthcare. 
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It suffered from a lack of hospitals and health clinics in the cities and villages, and 
Kuwaitis were treated with folk and public medicine. Mortality was common and 
disease spread rapidly in the country and especially affected children with the 
spread of epidemics such as plague and smallpox, and also deaths during 
pregnancy and birth due to poverty, ignorance and lack of necessary health 
support (Kuwait University, 1998).   
B) Establishment of the first British Health Clinic and the American Hospital in 
Kuwait. With the arrival of the first British political mission in 1904, the High British 
Envoy advised that the State should bring in physicians to treat the Prince and 
population of Kuwait, and after that the first health clinic in Kuwait was established 
by the High British Envoy. Thereafter, in 1910 the American Mission established 
the American Hospital in Kuwait. This was the first hospital in the State and it 
started to provide health services and medical treatments. The first gynecologist 
clinic was established in this hospital which was a major step forward for the health 
services.  
C) Appearance of health care services. In 1949, the first public hospital (Al Ameri 
Hospital) in Kuwait was established. It consisted of one floor, containing 45 beds. 
In addition, it had an outpatient clinic, a laboratory and one pharmacy. In the 
beginning, the health professionals were composed of 13 male physicians and one 
female physician who specialized in gynecology. It was a major leap forward in the 
field of health services and the beginning of the organization and establishment of 
the healthcare system in Kuwait.       
D) Health services after independence. In 1961, after independence and the 
discovery of oil the State had been increasing the infrastructure of the health field 
by building general and specialized public hospitals and health clinics in all the 
areas and governorates in Kuwait. Also, the State started to provide and establish 
medical emergency service centres, a blood bank, central sterilization centre, 
central medical store and other medical and health facilities. It also began to 
develop this field in all its technical and technological aspects (Kuwait University, 
1998).  
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By looking at the history of the healthcare system in Kuwait it can be observed that 
the development of the field has continued with the passage of time. Despite the 
lack of different sources and difficult conditions in the past, the government has 
been keen to improve the healthcare system further in order to complete the 
development of this important area. 
   
Therefore, during the period leading up to this decade, Kuwait has come a long 
way in developing its health system and has put in place the medical structures 
and the trained staff to support its health needs. The MOH/Government have to be 
commended for this. However, as regards the next stage, it is recommended that 
the organizational structure for delivering the health service would benefit from 
overviewing the way in which it operates the service and how the health support, in 
particular the medicines provided to patients, are procured and organized. With this 
in mind, it is likely that through the establishment of a NDP the service provision 
and medicines delivery can be enhanced. 
 
This national project on introducing a NDP is therefore considered extremely 
important in the provision of health support to the population of Kuwait. One major 
part of achieving this will be the development, improvement and updating of all 
legislation and regulations which belong to the areas associated with medicines 
and their delivery in the health sector, where the NDP will provide support to health 
guideline for health professionals.  
 
Along with other countries with a comparable high human development index and 
small population (4.2 million in 2016), Kuwait has shown a consistently improving 
life expectancy over the past century. Currently, the average age at death in 
Kuwait is nearly 75 years, demonstrative of the good general state of health in the 
country (World Bank, 2017). Successive Kuwaiti governments have expressed an 
interest in continually improving the healthcare system and indicated that it has 
always made it a top concern and priority. Especially after the discovery of oil in 
Kuwait in 1936, the country’s economy has grown sharply and is now has the 4th 
highest per capita income worldwide. It has to be noted that the health expenditure 
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per capita in Kuwait is the third highest among the other Gulf States and is 
considerably higher than the expenditure in developing Africans countries (See 
Table 2.5). (WHO, 2014) 
 
Table 2.7 Health expenditure per capita in developing countries (current 
USD). 
(Global Health Expenditure Database, 2014) 
 
Over the past recent decades, non-communicable diseases have overtaken 
infectious diseases as the primary cause of death worldwide, and Kuwait is no 
exception. Now, the figures show that, the public is more likely to die from obesity, 
cancer or cardiovascular disease (including cardiac arrest, atherosclerosis, stroke 
and hypertension) than from a bacterial, protozoal or viral infection (Boutayeb and 
Boutayeb, 2005). Indeed, in Kuwait, between 1987 and 2000, the biggest causes 
of death (apart from those associated with hypertension) were ischemic heart 
disease, traffic accidents and cancers (El-Shazly et al., 2004; Radovanovic, 1994), 
which demonstrates the point. This change in the threat to health requires a 
fundamental shift in how we conceptualize and deal with the human condition in 
Kuwait. 
 2007 
 
2008 2009 2010 2011 2012 2013 2014 
Bahrain 651.47 730.12 725.75 741.57 756.55 1006.91 1142.49 1242.84 
Ghana 58.25 59.86 56.67 70.58 76.30 78.64 84.53 57.89 
Namibia 293.43 285.98 332.05 405.64 486.47 467.90 470.04 499.02 
Kenya 34.99 36.60 39.29 39.41 52.99 65.06 70.00 77.70 
Oman 393.60 462.07 495.79 546.64 539.86 551.58 562.89 675.043 
Qatar 1563.75 1555.81 1618.84 1483.08 1716.89 2031.81 2067.50 2106.35 
Kuwait 963.14 1052.24 1423.52 1041.02 1244.29 1309.07 1252.53 1385.78 
United Arab 
Emirates 
 
1101.01 
 
1338.93 
 
1332.63 
 
1349.45 
 
1473.34 
 
1433.11 
 
1551.35 
 
1610.80 
 
 
62 
 
There is also a stark contrast between the ratio of deaths caused by communicable 
to non-communicable diseases between the Gulf States and the Africans 
countries. Communicable diseases such as malaria or AIDS are major factors 
contributing to mortality rates in Ghana, Namibia and Kenya (WHO, 2014). On the 
other hand, the Gulf States are more affected by non-communicable diseases, 
such as cancer, cardiovascular diseases and diabetes (considering the prevalence 
of overweight and obese cases in those richer countries). See Tables below.   
Table 2.8 Diabetes prevalence (% of population ages 20 to 79) in 2015 
(International Diabetes Federation Diabetes Atlas, 2015) 
 
 
 
 
 
 
 
Table 2.9 Prevalence of overweight in developing countries (% of adults) 
(WHO's World Health Statistics, 2014)  
 
 
 
 
 
 
Bahrain 19.6 
Ghana 2.3 
Namibia 4.2 
Kenya 2.4 
Oman 14.8 
Qatar 20 
Kuwait 20 
United Arab Emirates 19.3 
 2010 2014 
Bahrain 69.4 71.7 
Ghana 30.3 33.6 
Kenya 23.9 26.2 
Kuwait 73.3 75.4 
Namibia 40 42.9 
Oman 64.7 67.4 
Qatar 75.1 78.1 
United Arab Emirates 72 74 
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Table 2.10 Mortality from Cardiovascular diseases, cancer, diabetes or 
chronic respiratory diseases between ages 30 and 70 (%) in 2014 (Global 
Health Observatory Data Repository, 2014) 
Bahrain 13 
Ghana 20 
Namibia 20 
Kenya 18 
Oman 18 
Qatar 14 
Kuwait 12 
United Arab Emirates 19 
 
The increase in non-communicable disease burden could be due to a number of 
factors. For example, people have suggested that increasing access to modern 
medicines (especially antibiotics) reduces our life-long exposure to foreign 
pathogens which over evolutionary time exerted checks and balances on our 
physiological defence mechanisms (Okada et al., 2010). Some argue that in the 
absence of such pathogenic challenges, our immune systems have developed 
abnormally and may even end up attacking our own tissues (as occurs in type 1 
diabetes) or altering our metabolism (Liston, 2008). 
In addition, it has been proposed that other triggers present in our environment 
could be pre-disposing us towards developing such diseases; as has been 
demonstrated by smoking in the case of lung cancer, and a high-fat diet and 
myocardial infarction (Boutayeb and Boutayeb, 2005) – although the triggers are 
seldom known. Thus, the role of the environment (and nature versus nurture) 
should not be overlooked, especially as the increasing burden of such non-
communicable diseases is increasing at a quicker rate than could be accounted for 
by changes in the germ-line DNA sequence; although epigenetic effects have been 
shown to modulate such phenotypes (Champagne, 2008) and require careful 
exploration to arrive at disease mechanism – something that would accelerate new 
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drug development and use. New research should focus on understanding how 
genetic and environmental factors interact and the consequences on 
pathophysiology. Along these lines, Kuwait should also, therefore, invest in the 
research and development of treatments for its own population in order to improve 
pharmacogenomics and personalized medicine interventions (Chan and Ginsburg, 
2011).  
Finally, based on the information mentioned above, it could be indicated that all 
these factors will also need to be taken into consideration before the comparisons 
and analogies might be drawn between the ways of implementation and 
development of the NDP in those countries and a possible NDP in the State of 
Kuwait. 
 
2.9 Search strategy 
In order to complete this research project, the researcher sourced peer-reviewed, 
randomized controlled trials and systematic review articles, as well as authoritative 
reports and book chapters from the following academic text databases: 
 PubMed - https://www.ncbi.nlm.nih.gov/pubmed 
 Web of Science - http://wok.mimas.ac.uk  
 Science Direct - http://www.sciencedirect.com  
 Google Scholar - https://scholar.google.com  
 
The keywords used (in search engines) for searches included: National Drug 
Policy/NDP; NDP in Developing Countries; NDP in Developed Countries; Rational 
Use of Drugs; Disease Trends; Drug Pricing; Drug Legislation and Regulation; 
Essential Medicines List; Human Resources Development; Drug Efficacy; Quality 
Assurance; Drug Counterfeiting; Drug Cost Effectiveness; Pharmacovigilance 
Center; Drug Registration; NDP Process; NDP Components; NDP Formulation; 
and NDP Implementation and Development.  
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Different keywords and databases gave a range of search hits, although commonly 
many hundreds of records were identified. Across the entire document, 220 
publications were found. Of these, 75 have been used by the author as they were 
relevant to the research study. Further exploration of the references arrived at from 
the search strategy also allowed for additional references to be found within the 
text and taken into account. In addition, personal experience and non-English 
language articles were excluded. 
 
Chapter 3.0: Research methodology 
 
From the information above, it was proposed that Kuwait should consider 
developing a NDP as a major step forward in introducing additional improvements 
in health delivery to its people. The work of this research program is therefore 
centered around showing more detail of why a NDP is needed and how it 
should/could be structured and implemented. 
 
3.1 Aim 
The overall aim of this research program was therefore to establish the basis for 
the introduction of a NDP for the pharmaceutical sector in Kuwait. This could be 
achieved by establishing the national priorities and objectives for the 
pharmaceutical sector and in doing so developing suitable structures, 
organizations, regulatory guidelines and legislation that could provide the basis to 
regulate, develop and monitor the health care system. 
 
3.2 Objectives 
The major objective in introducing a NDP was to establish the basis for 
promoting the sustainability of the Kuwaiti pharmaceutical sector and to provide 
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continuous access to reliable, affordable and cost-effective essential medicines. 
In order to achieve this, it was clear that there was a need for adjustment and 
extension of pharmaceutical regulations and legislations, and possible changes 
to certain organizations, and these should be examined in terms of the structure 
and operation of the pharmaceutical services in the Kuwait. This study intends 
to do this by: 
1. Identifying the main issues and any weakness in the current 
pharmaceutical healthcare system in Kuwait. 
2. Examining the present guidelines for the legislations and regulations 
which relate to medicines in Kuwait.  
3. Establishing the basis for introduction of a NDP. 
4. Setting goals and strategies needed for development of a NDP in 
Kuwait. 
 
3.3 Research methodology and examination of the objectives 
The research process would involve the following: 
  An outline plan of work for the research project.   
  The research programme design, which has been discussed with the 
supervisor(s) and which would lead to the setting up of an appropriate 
research structure for the project.  
  Data collection and methodology across many aspects of the 
investigation areas which were highlighted as being problematic in the 
first year studies and the assessment of the current system, which 
would include in-depth interviews with key personnel; which it was 
expected initially to take between 2 to 3 months to be completed. 
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 Organization and presentation of information for Senior Members of the 
Kuwaiti Ministry of Health (KMOH) to gain approval to continue the 
programme. 
 The methods and data analysis of the current health care system in 
Kuwait. 
 Methods and procedures for the interpretation and utilization of the 
research. 
 Publication of the findings either as an internal document to the KMOH 
and/or external publication in a suitable journal.  
In this research programme, a mixture of primary and secondary data was used. 
One of the primary data collection methodologies was through the direct 
interview contact method. For this a number of health care professionals were 
interviewed face-to-face. 
Interview questions were set and formalized; the same set of questions was asked 
of all respondents. The secondary data collection was mainly through literature 
reviews and documentary reviews. 
 
3.4 Methodology and methods 
3.4.1 Methodology 
Quantitative and qualitative methodologies form the main part of health and social 
studies. There are many ways to distinguish the quantitative and qualitative 
approach (Yilmaz, 2013). Quantitative research explains collected data statistically, 
for example, through self-reported questionnaires. In addition, it involves testing a 
theory which comprises variables and which are therefore measured with numbers 
(Gay and Airasian, 2000). The epistemology (the nature of knowledge) of the 
quantitative approach is based on objectivism (one single reality) and attempts to 
develop explanatory in health research. It therefore focuses on the measurement 
of a cause and effect relationship between variables (Denzin and Lincoln, 2005). 
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As for the qualitative approach, its nature is exploratory and it aims to achieve 
opinions, beliefs and underlying phenomena (Dingwell and Murphy, 2003). The 
qualitative method, unlike the quantitative approach, can also involve a small 
sample size, and participants can be deemed sufficient when they no longer 
generate new ideas, for example during interview.  
A qualitative approach generally uses, why and how questions in contrast to 
quantitative studies which are generally concerned with how many and how much. 
A qualitative study often does not depend on one reality but different 
interpretations. Moreover, it tends to explore the subjective meaning of the 
participants. Therefore, qualitative research is more able to understand the 
participants’ perspectives and beliefs thoroughly and produce textual data, such as 
the interviews in the current study (Green and Thorogood, 2004). 
To understand participants’ beliefs and opinions in this research study and in light 
of qualitative theory, the author conducted interviews to receive in-depth data. 
There are however a number of different types of interviews; structured interviews 
for instance involve predetermined questions which can provide limited answers. 
Un-structured interviews generate a range of data; these are generally conducted 
without the author pre-planning the questions (Green and Thorogood, 2004). In the 
current research, a semi-structured interview procedure was used, which provides 
a balance between unstructured and structured interviews. This has the benefit of 
flexibility for the interviewee to elaborate on answers. Moreover, this may support 
the author to probe and prompt the participants (Green and Thorogood, 2004). 
 
3.4.1.1 The approach used to underpin mixed methods 
Mixed methods were used in the current research. The researcher aimed to use 
both quantitative and qualitative approaches to gain enriched data and to minimize 
the shortcomings of each approach. It was expected this could enable a deep 
understanding of collected data being observed. The researcher was of the view 
that using a questionnaire alone was not enough to generate a broad data base; 
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and hence this was why the interview method was selected as an appropriate 
method for collecting data (Creswell and Clark, 2011).   
 
3.4.2 Methods 
2.4.2.1 Pilot study 
Piloting a study is a vital stage in any study as it reduces the limitations of the 
methods (Bryman, 2004). In fact, it increases the validity, reliability and feasibility of 
the research instruments (Oppenheim, 1992). All the tools in this study underwent 
piloting. The questionnaire was piloted on 15 health professionals in order to assist 
the practicality of the constructed questionnaire, and to receive feedback about the 
development of the questionnaire and experience about the study. It is important to 
note that the methods used in the pilot and main stage are similar and are 
explained as a single set of methods. It is essential to choose a sample population 
set as it results in valid research. For this reason, the researcher selected an 
approachable number set that matched the study’s aim (Punch, 2013). Therefore, 
a permission request letter was sent to the Pharmaceutical Associations 
explaining; the purpose of the study – the development of the NDP in Kuwait – and 
expressing the researcher’s need for health professionals to be involved. This was 
done by an email which was then forwarded to 200 health professionals out of 
which however only 121 accepted to take part in the study. The researcher also 
visited various hospitals, clinics, pharmaceutical administrations and health centers 
and kindly requested the Administrations to distribute questionnaires to health 
professionals in order to establish a participation set. (This is discussed in detail in 
Chapter3, Page 85). 
 
3.4.2.2 Methods of data collection used in the study 
1. Questionnaire: Establishing a National Drug Policy in Kuwait 
The researcher used questionnaires (See Appendix 1) as one of the vital data 
collection tools for the study. The questionnaire was expected to help to elicit 
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various experiences and opinions regarding the operation of health care 
professionals in different areas of the health care system in Kuwait, relating to 
Pharmaceutical Services, which served to add credibility to the findings. The items 
listed in the questionnaire of this study were constructed by talking note of four 
other questionnaires in the literature, as they were the most relevant to the 
objective of this research. For instance five questions (Q4, Q7, Q9, Q11 and Q12) 
in the constructed study questionnaire were adapted by considering the work of 
Phnouvong (2008) who conducted a study in the USA specifically relating to 
medicine quality assurance and medicine quality control activities in a 
pharmaceutical supply system. These adapted questions were selected for the 
researcher’s questionnaire due to their relevance in terms of drug control and 
monitoring, EDL, access to quality, aspects of drug safety and efficacy, and the 
establishment of a NDP. However, other items in Phnouvong’s questionnaire were 
excluded as they covered specific aspects such as product packaging and labeling, 
product delivery and transportation, defective product recall and handling, and 
rejected products. 
The designed questionnaire for this study also took note of five other items (Q1, 
Q2, Q5, Q6 and Q8) which were from the Jaffar, S. and WHO (2011) who 
undertook a study based in Oman which examined the strengths and weaknesses 
of their pharmaceutical situations relating to the health services, drug policies and 
regulations, rational use of drugs, selection of drugs and drug pricing. The 
questions from the WHO study were noted because they discussed aspects of the 
implementation of a NDP, human resources development, drug pricing policy 
issues and the irrational use of drugs. All these areas are related to the focus of 
this research.  Other areas of these studies mentioned which assisted the 
development of the questionnaire which were because they did not support the 
objectives of the research included types of disease, neonatal mortality rate, the 
prescribing policies and clinical trials. 
Furthermore, one question (Q10) from the designed questionnaire for this study 
was considered from the study of Wondemagegneha (1999) whose questionnaire 
presented a basis for studies conducted in Myanmar and Vietnam concerning the 
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assessment of counterfeit drugs and its effect on the health care system. 
Therefore, Question 10 in this study’s questionnaire focused on the importance of 
the existence of the pharmaceutical supply chain in the country and its effect on 
the access to medicines for the health care system in both the public and private 
sectors. Again, the rest of the questions in Wondemagegneha’s questionnaire were 
not considered closely relevant as they did not support the aim of the research 
such as drug imports and drug outlets.  
Finally, Question 3 in the constructed questionnaire was examined and adapted 
from Elmi (2013), who carried out a study in developing countries of East Africa as 
well as the Middle East. Elmi’s questionnaire discussed information in regards to 
the access, safety and quality of drugs in these emerging areas and how to 
increase control and evaluation over counterfeit drugs. Thus, Question 3 was 
designed to study the aspect of issues concerned with the organization of the 
pharmaceutical side of the health care system. In that respect careful consideration 
of the relevance of others work was carried out and irrelevant topics about places 
where patients purchase their medicines, questions about patient’s visits and 
discussions that take place between patients and physicians were excluded. 
 
2. Interview to assess opinions of health care professionals 
Interviews are considered a valuable means of gathering in-depth data on a large 
range of topics (Dornyei, 2007). However, Grimm (2010) claims there is a common 
concern that arises during interviews, which is the participants’ desire to reflect 
themselves in a progressive way, by giving controlled satisfactory answers rather 
than expressing their honest opinions. However, Cohen et al. (2007) states that 
such an issue should not prevent a researcher from conducting an interview if care 
is taken, as the feedback from it can be contrasted with responses from other 
collected data. For this reason, this study carried out here as part of this research 
has focused on more than one type of data collection. This section of the study 
was conducted using a semi-structured approach. It was chosen because it 
enabled flexibility for the interviewee in terms of the planning of the structured 
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questions in advance while also allowing other relevant questions to be raised, if it 
was considered necessary in order to reach the study’s objective (Pawar, 2004). 
Therefore 12 questions were constructed and the same questions were asked of 
all respondents who were taking part (See Appendix 1). 
It was also considered very important for the researcher to make various efforts not 
to impose their opinions on the participants during discussions. Overall the purpose 
of the interview was to explore participants’ understanding of the health care 
system in Kuwait and whether any suggested solutions were found towards 
enhancing it. It is important to note that the researcher conducted interviews with 
participants individually to make them feel comfortable in giving honest answers 
(Creswell, 2009). 
 
3.5 Validity and Reliability 
Establishment of a NDP in Kuwait    
3.5.1 Validity 
The extent of the success which a researcher has in assessing what they 
planned to measure is considered as validity. External validity is the ability of the 
study to be generalized to other situations and to other people (Bowling, 2014). 
However, in the current study the focus is on the qualitative approach because the 
researcher intended to understand the experience and perspectives of the 
participants. As such, however the findings in this study are hard to generalize. The 
type of analysis of this data include: Internal Consistency Validity (Validity was 
discussed in details in Chapter3, Page 84).  
3.5.2 Reliability 
Reliability is the level to which procedures are consistent when performed by 
different participants. In this case the author used the questionnaire to assess the 
objectives output of the participants (Murphy and Dingwall, 2003). 
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The questionnaire therefore was intended to evaluate the direct experience of 
health care professionals in regard to the development of the health care system 
in Kuwait. In terms of the operating system used the questionnaire was sent to 
the participants before meeting with them. The reason for this was the 
expectance that; this was more likely to make participants more comfortable 
with the questionnaire and familiar with the type of questions. 
For the meetings, to enhance the reliability, the author gave participants the 
opportunity to choose the meeting place and time which was suitable to them. In 
effect, all of the participants agreed to an interview with the author at their place 
of work (Murphy and Dingwall, 2003). 
The researcher planned to ask the participants the same questions in the same 
style to enhance the consistency of their responses. However, it was accepted that 
their experience in the health care system might vary. Moreover, the researcher did 
not guide the participants towards a certain agenda but rather tried to understand 
their opinions and recommendations, which again was considered might enhance 
the reliability of data. 
In addition, it can be said that an interview belongs to the interpretivist paradigm, 
and in order to achieve this the author used audio recording to capture the 
subjective meaning of the participants (O’Leary, 2004). 
Semi-structured Interview 
There are many types of interview for the purposes of collecting data; one of these 
methods is the semi-structured interview. This type of interview facilitates the 
participants to talk freely and encourages the researcher to understand the 
opinions and concerns of the participants. It is considered that this style of 
communication with the participants is more likely to make them comfortable 
(Ritchie et al., 2003). 
Audio recording 
Legard et al. (2003) also mentioned that the participants should agree that their 
interview with the author is recorded before they take part in the study. 
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Furthermore, using audio recording increases the reliability of data collection in 
detailed (Ritchie et al., 2003). However, some of the participants in the study 
indicated that they preferred that the interview was not recorded. Thus, the author 
documented the participants’ account and then sent this to those participants to 
enhance the reliability of the interview. The recorded interviews were transcribed 
verbatim (Murphy and Dingwall, 2003). 
In addition, in order to enhance the reliability of data the transcripts were uploaded 
to SPSS 10 software (QSR, 2014) in order to facilitate management of data. SPSS 
helps the author to code and in the retrieval function (Pope, 2006). The type of 
analysis of this data includes the Split Half Method and Spearman and Brown 
Correlation Coefficient (Reliability was discussed in details in Chapter 3, Page 89). 
3.5.3 Quantitative approach 
A positivist view (dependent on factual knowledge) assumes that the behavior of 
people can be quantified. Therefore, as Smallbone and Quinton (2004) 
suggests, the tool for the measurement of human behavior should be reliable 
and valid. 
 
3.5.4 Qualitative approach  
In the current study, an in-depth interview was used to understand the 
participants’ experiences of the health care system in Kuwait. 
 
3.6 Sampling 
A code of ethics normally guides an author who plans to conduct interviews with 
participants. In this case the sample of those interviewed also included the 
Assistant Undersecretary of Drugs and Medical Supplies Affairs in the KMOH, 
pharmacists, physicians, nurses, senior academics at Kuwait University and the 
Kuwaiti Pharmaceutical Association. In the current study, the sample was a non-
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randomized but a purposive one which it was hoped would support the author to 
generate data for the research study (Holloway and Wheeler, 2010). 
The total participants who were invited to take part in this study were 200 
different health care professionals. Of these, 120 invitations were sent to 
pharmacists, 50 to physicians and 30 to nurses. 
The respondents were health care professionals with varying levels of 
experience of the structure, regulation and organization of pharmaceutical work 
in Kuwait; generally they possessed a good degree of knowledge in their field. 
They were also selected from each division of the KMOH. As a basis for this, 
advice was taken for the WHO, for such a study, where they suggested that the 
inclusion criteria should focus on members who are responsible for the 
efficiency of the health care system. As a result, inexperienced health care 
professionals in low level positions in the health care sectors were excluded 
from the questionnaires and interviews. In addition, a number of health care 
professionals from the private sector were included in the study. 
 
3.7 Ethical considerations 
The requirements set out in the code of ethics were noted before the study was 
conducted to ensure the confidentiality and safety of all participants (See Appendix 
2). It is considered to be the responsibility of the researcher to reduce the harm 
which may result from the engagement of the participants in the study, particularly 
participants’ personal information. Another responsibility of the researcher involves 
the participants being made aware and freely deciding whether to take part in the 
study (Murphy and Dingwall, 2003). In other words, consent was sought in order to 
reduce the harm to participants. 
Ethical approval was issued and approved by KMOH (See Appendix 2 ) on the 
basis of the heading of – ‘Development of a National Drug Policy in Kuwait’, by a 
concerted interview with concerned health professionals and data would be 
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collected relating to drug regulations and legislations of the health care system in 
the country. 
In the piloting stage and second phase, the participants would receive a consent 
form and an information letter to inform them about the nature of the study 
(Appendix 1 - Consent Form). In the main method (second phase), ethical approval 
was required and the KMOH was responsible for that. 
In addition, ethical approval was obtained through the Kuwait Ethical Panel, for 
which a supporting letter from the University of Bradford (where approval was 
also achieved) was sufficient to allow clearance for data collection. It was made 
clear that the data gathered was not of human health origin and no patient 
information was gathered. 
As indicated above, written consent was obtained from all respondents after 
thorough explanation of the purpose and nature of the study. Anonymity, 
confidentiality and safety in the handling of the data gathered were explained. Each 
respondent was asked to date and sign the consent form if they were willing to take 
part in the study. 
 
3.8 Recruitment 
The recruitment of the participants in this study was undertaken over two phases: 
the piloting phase and the second phase. The former was made up of a sample 
size of 15 participants (pharmacists, physicians and a nurse). Ten pharmacists 
worked at KMOH; four worked in public health administrations (CMS, DCA, DIA, 
PSA), four worked in public hospitals; and two worked in public health clinics. Of 
the four physicians, two worked in public hospitals and two worked in public health 
clinics. The nurse worked in a public hospital. All participants were invited via email 
as the main aim was to collect initial data in order to conduct the main method of 
this study. The latter (the second phase) focused on achieving the objectives of the 
study by increasing the number of participants (121 health professionals).  
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The researcher visited a number of health locations (KMOH, Dasman Diabetes 
Institute, public and private hospitals, health clinics and pharmaceutical companies, 
and the School of Pharmacy) and explained the current study to the directors in 
order to seek assistance. Of 200 emails sent, 121 recipients expressed an interest 
in participating in the study. The researcher was satisfied with a sample size above 
100 as it was adequate to reduce the margin of error to a reasonable level 
(Grasley, 2007). Participants were interviewed in a place and time of their 
choosing. Data collection was completed within six months due to the restrictions 
of time and availability of participants. 
The places where the collection of information from Kuwait was made are shown 
below: 
A. Kuwaiti Ministry of Health 
The current structure of the pharmaceutical sector under the KMOH is divided into 
4 main administrations and includes: 
1. Pharmaceutical Services Administration (2 pharmacists interviewed). 
2. Drug Inspection Administration (2 pharmacists interviewed). 
3. Drug and Food Control Administration (8 pharmacists interviewed). 
         4. Central Medical Store Administration (5 pharmacists interviewed). 
The four Administration Units are managed through the Assistant Undersecretary 
of Drugs and Medical Supplies Affairs in the KMOH. Each of the administrations 
has its own general director and administrative structure, and is responsible for 
regulating and developing its own work and seeking to ensure appropriate services 
to consumers and improvements in the health care system under the supervision 
of the KMOH. 
B. DASMAN Diabetes Institute 
This Institute is the only Research Centre in Kuwait. During a visit to it, the 
Assistant Director of the Centre and the Head of the Diabetic Department were 
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interviewed. Data was also collected about how the Institute undertakes its 
responsibilities and operating system. 
C. Public and private hospitals, health clinics and pharmaceutical companies in 
Kuwait 
Data collected from the public and private sector is included in this work, namely 
interviews with health professionals (79 participants) and investigations to 
identify the nature of the work and knowledge of the most important 
requirements and issues in these places. 
D. Drug Release Department at Kuwait Airport 
This Department is responsible for release and control of all medicines, 
pharmaceutical products and medical devices received into Kuwait International 
Airport in cooperation with the Drug and Food Control Administration. 
The data collected from this Department included an interview with the Head of 
Department and data relating to the way the Department works, the staff and 
staffing, and any issues and requirements. 
E. School of Pharmacy at Kuwait University 
Data was collected from the School of Pharmacy of Kuwait University and 
included interviews with the Vice Dean of the School of Pharmacy and the Head 
of Quality Assurance Department of the School of Pharmacy. 
There were also some discussions with academic staff on the importance of a 
NDP and suggestions on how to solve the issues of the health care system in 
Kuwait. 
[Note It should be noted that the Assistant Undersecretary of Drugs and Medical 
Supply Affairs at KMOH, Dr. Omar AL Sayed Omar, is acting as an external 
supervisor on this research program and indicated at an early stage that he would 
provide support for data gathering and advice until the PhD thesis was completed 
(See Appendix 2). 
 
 
79 
 
3.9 Analysis of results 
3.9.1 Quantitative results 
This study therefore made use of one questionnaire to assess the experiences and 
suggestions of the participants in regards to improving the health care system and 
specifically the pharmaceutical field by identifying the main issues and weaknesses 
of the current health system, understanding the nature of work in the public and 
private sectors, finding solutions and setting out a future plan of action. 
 
As indicated above, in terms of assessing the results, the questionnaires were 
recorded manually by the researcher and then the data were uploaded to 
version 10 of SPSS. SPSS is one of the most popular statistical programs. It 
allows for the construction of complex graphs and illustrations from statistical 
data. Both forms will be used in this PhD project report (Taylor, et al., 2003). In 
addition, SPSS will assist in converting the qualitative data to quantitative data 
and analyzing the qualitative data from the interviews with the health 
professionals in Kuwait (Woods, 2011). 
In terms of the method of primary data collection (questionnaire and interview) is 
the observation method. This involves the gathering of primary data by the 
investigator's own direct observation of relevant people, actions and situations 
without directly asking questions of the respondents. The type of analysis of 
these data include: Descriptive Analysis, Chai Square Test ( ), One Way 
Analysis of Variance, T-Test and Shefe Method (were discussed in details in 
Chapter3). 
In this study, 11 questions were constructed, which were asked of all 
respondents who were taking part (See Appendix 1). 
The questionnaire used 2 types of scales: 
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1.  Questions 1, 3, 6, 8 and 9 were scored using a five Likert scale: 1 = very 
important, 2 = important, 3 = not applicable, 4 = not important, and 5 = 
useless.  
2. Questions 2, 4, 5, 7, 10 and 11 were scored using a Yes/No style system: 
1 = yes and 2 = no.  
In addition, the chosen questions of the questionnaire were determined based 
on the structure and basis of a NDP. All appropriate health aspects were 
included: monitoring and evaluation, human resources development, economic 
strategies for drugs, rational use of drugs, quality assurance, supply 
management, selections of drugs (EDL), and legislations and regulations of 
drugs (adapted from WHO, 2001). 
 
3.9.2 Qualitative results 
The nature of a qualitative study elicits participants’ experiences in an asocial 
context which is not standardizing (Murphy and Dingwall, 2003). 
The presence of the author may also affect the collected data. However, as 
stated earlier, no personal information or questions were taken from the 
participants, which made it more likely for the participants to be open with the 
author. In addition, the recruited participants were professionals and so 
potentially there was no power imbalance which would have been the case had 
the participants been patients (O’Leary, 2004). 
The overall conclusion from this chapter is that a lack of previous studies and 
data on the subject of a NDP in Kuwait forced the researcher to use relevant 
previous studies to build the questionnaire. 
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Chapter 4.0: Analysis of Interview Data 
 
4.1 Introduction 
As discussed in the previous chapter, the researcher built the questionnaire after 
reviewing the theoretical literature and previous studies related to the subject of 
current research in order to verify the psychometric properties (Validity and 
reliability) of the questionnaire on Establishing of a National Drug Policy in Kuwait. 
The questionnaire included 12 questions:  
1. How important is having a national drug policy (NDP)? 
2. Do you think we can develop and improve the health care system in Kuwait? 
3. Are there any issues of concern with the organization of the health care 
system in Kuwait? 
4. In the public and private sectors, do you think we have enough control over 
regulating the process associated with pharmaceuticals? 
5. Do you feel that the training of health professionals in the public and private 
sectors is sufficient? 
6. Do you think that the price range of medication in the private sector is 
publically acceptable? 
7. Do you think that there are any issues with access to quality, safe and 
efficacious drugs? 
8. Do you think that there is an irrational use of drugs in Kuwait? 
9. How important is having an Essential Drug List? 
10.  Do you think that Kuwait should develop its own pharmaceutical industry? 
11. Do you think it is time to establish a NDP in Kuwait? 
 
The questions were divided into two, with the first part containing 11 questions. 
The second part involved a sub-question (Appendix 1). The target of these 
questions was to direct a specific question to the research sample as shown in the 
previous questions above. The structure of the questionnaire was as follows: 
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- Questions 1 and 9 contained five responses and were arranged according 
to the following scale: Very important – Important – Not applicable – Not 
important – Useless, and each response was given scores to be analyzed 
by using SPSS, as the following: Very important with 5 scores, Important 
with 4 scores, Not applicable with 3 scores, Not important with 2 scores and 
Useless with 1 score. 
- Questions 3, 6 and 8 contained five responses and were arranged on the 
following scale: Strongly agree – Agree – Not applicable – Disagree – 
Strongly disagree, and each response was given scores as the following: 
Strongly agree given 5 scores, Agree given 4 scores, Not applicable given 3 
scores, Disagree given 2 scores and Strongly disagree given 1 score. 
- Questions (2, 4, 5, 7, 10, and 11), contained two responses and arranged as 
(Yes – No), and each response was given scores as the following: Yes 
given 2 scores and No given 1 score. Table 4.1 shows description of the 
questions from the first part of the questionnaire, its responses and scores. 
 
Table 4.1 Questions from the first part of the questionnaire, its responses 
and scores. 
Question No Responses Scores Max Score Min Score 
1 and 9 Very important – 
Important - Not 
applicable - Not 
important - Useless 
From 5 
to 1 
5 1 
2, 4, 5, 7, 10 and 
11 
Yes – No From 2 
to 1 
2 1 
3, 6 and 8 Strongly agree – Agree – 
Not applicable – 
Disagree – Strongly 
disagree 
From 5 
to 1 
5 1 
Total   37 11 
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While the second part of the questionnaire involved 12 interpretive questions, and 
each question from the second part was focused on directing an interpretive 
question to the research sample following each question of part one as mentioned 
in Table 4.2. In addition, it was observed that the responses of research samples 
differed from one question to another in the second part (interview), as mentioned 
in Table 4.3.  
 
Table 4.2 The number of questions from the second part of the questionnaire  
No. of 
Question 
Question 
1, 3, 5, 6 and 11 Please explain? 
2, 7, 8 and 9 How? 
4 If No, please explain? 
10 Explain how can we develop? 
12 If yes, do you think it will influence the health care system in Kuwait?   
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Table 4.3 Responses to questions from the second part (interview) of the 
questionnaire 
Question No Responses No of Responses 
1 A-B-C-D-E 5 
2 A-B-C-D-E 5 
3 A-B-C-D-E-F-G-H 8 
4 A-B-C-D-E-F 6 
5 A-B-C-D 4 
6 A-B-C-D 4 
7 A-B-C-D 4 
8 A-B-C-D-E 5 
9 A-B-C-D-E 5 
10 A-B-C-D-E 5 
11 A-B-C 3 
12 A-B-C-D-E 5 
 
4.2 Validity of Questionnaire 
Validity is a research method that is used to describe whether the results obtained 
from the study meet all of the requirements of scientific research method and 
whether the research study measures what intends to measure (Csikszentmihalyi, 
et al., 2014). Two main type of validity are available: internal and external validity 
(Bolarinwa, 2015). Internal validity refers to the validity of the measurement and 
test itself, whereas external validity refers to the ability to generalise findings to the 
target population (Bolarinwa, 2015). 
The researcher has resorted two types of validity checking: Specialists Validity and 
Internal Consistency Validity. 
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4.2.1 Specialists Validity 
After preparation of the questionnaire, it was presented to a group of faculty 
members in the Kuwait Pharmaceutical Faculty (Vice Dean of Pharmaceutical 
Faculty and Head of Pharmaceutical Department of the Faculty) and was also 
presented to Assistant Under Secretary for Drug and Medical Supplies of KMOH. 
Then, the researcher asked them to modify the questions that need to be amended 
in the area of the procedural definition of what is measured by the questionnaire; to 
edit responses that were in need of amendment; and to judge the appropriateness 
of the questions when measured by the concept. This resulted in analysis by the 
researcher of the modifications of these arbitrators in order to arrive at the 
strongest possible version.  
 
4.2.2 Internal Consistency Validity 
This refers to a measure of consistency based upon the amount of correlation 
between different data points within the same dataset (Bentler, 2009). In other 
words, it monitors whether two (or more) different data points which might be 
expected to have similar values really do have similar values. 
Initially the questionnaire was conducted on a pilot sample of health professionals 
working in Kuwait, which amounted to a sample size of 15 participants 
(pharmacists, physicians and a nurse). The correlation coefficient between pilot 
sample scores on each question and the total score for the two parts of the 
questionnaire (parts 1 and 2) was calculated. The same calculation was done for 
each part separately (the results are given in the following tables). 
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Table 4.4 Correlation coefficient between the pilot sample scores on each 
question from the first part of the questionnaire and the total score 
Question No. Correlation Coefficient (R)  
1 0.280** 
2 0.286** 
3 0.279** 
4 0.366* 
5 0.291** 
6 0.370* 
7 0.412* 
8 0.561* 
9 0.282** 
10 0.571* 
11 0.511* 
* R (48, 0.01)=0.354              ** R (48, 0.05)=0.273 
 
This table shows that all the questions from the first part of the questionnaire were 
correlated with the total score of this part and the correlated significance was at the 
level of (0, 05) and (0, 01). This result indicates that the questions in the first part 
were closely correlated to the questionnaire. 
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Table 4.5 Correlation coefficient between the pilot sample scores on each 
question from the second part of the questionnaire and the total score 
Question No Correlation Coefficient (R)  
1 0.467* 
2 0.523* 
3 0.290** 
4 0.486* 
5 0.572* 
6 0.291** 
7 0.290** 
8 0.527* 
9 0.462* 
10 0.581* 
11 0.279** 
12 0.529* 
* R (48, 0.01)=0.354              ** R (48, 0.05)=0.273 
 
This table shows that all the questions from the second part of the questionnaire 
were correlated with the total score of this part and the correlated significance was 
at the level of (0, 05) and (0, 01). This result indicates that the questions in the 
second part were closely correlated to the questionnaire. 
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Table 4.6 Correlation coefficient between the pilot sample scores of the 
questions from the first part of the questionnaire. 
Ques 
No 
1 2 3 4 5 6 7 8 9 10 11 
1 ـــــــــــــ  
 
          
2 0.361 ـــــــــــــ  
 
         
3 0.422 0.321 ــــــــــــ  
 
        
4 0.567 0.566 0.496 ــــــــــــ  
 
       
5 0.511 0.511 0.522 0.467 ــــــــــــ  
 
      
6 0.481 0.311 0.297 0.521 0.411 ــــــــــــ  
 
     
7 0.281 0.290 0.316 0.531 0.528 0.416 ــــــــــــ  
 
    
8 0.311 0.571 0.481 0.518 0.469 0.592 0.413 ــــــــــــ  
 
   
9 0.322 0.486 0.567 0.281 0.327 0.517 0.528 0.582 ــــــــــــ  
 
  
10 0.561 0.523 0.528 0.469 0.288 0.316 0.565 0.513 0.568 ــــــــــــ  
 
 
11 0.527 0.416 0.316 0.590 0.519 0.528 0.534 0.586 0.481 0.312 ـــــــــ  
 
* R (48, 0.01)=0.354              ** R (48, 0.05)=0.273 
This table shows that the questions from the first part of the questionnaire were 
correlated with each other and the correlated significance was at the level of (0, 05) 
and (0, 01). This result indicates that the questions in the first part were closely 
correlated to each other. 
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This table shows that the questions from the second part of the questionnaire were 
correlated with each other and the correlated significance was at the level of (0, 05) 
and (0, 01). This result indicates that the questions in the second part were closely 
correlated to each other. 
The overall conclusion from this section of the study is that the information 
presented above indicates that the validity of questionnaire was closely acceptable. 
 
4.3 Reliability of Questionnaire 
In addition to the above, to increase the reliability of the questionnaire, a split-half 
method was used. The questionnaire was piloted with 15 participants (pharmacists, 
physicians and a nurse) in the pharmaceutical sector. A correlation coefficient was 
calculated between the pilot sample scores of the questions in the first part of the 
questionnaire, which revealed a consistency of (0.480). Therefore, to strengthen 
the reliability and credibility of the score, the Spearman-Brown formula (This non-
parametric measure of correlation assesses how well a relationship between two 
points can be described using a monotonic function, and is a rank correlation 
method) (Sedgwick, 2014) was applied which indicated a correlation number of 
(0.649), which is significant at level (0.01). Moreover, a calculation of the 
correlation coefficient between pilot sample scores of the second part of the 
questionnaire (interview) was also conducted, and showed a significance of 
(0.461). Hence, (0.631) at level (0.01) in the Spearman-Brown formula, which 
indicates a high level of reliability. The questionnaire therefore fulfills psychometric 
characteristics, which makes it possible to be used with the research pilot sample. 
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4.4 The interview procedure and examination of the data generated by the 
interviews of senior staff 
 
121 health professionals were interviewed from both the public and private sector 
in Kuwait in the period February 2012 to June 2013. As indicated in the earlier 
section these professionals included pharmacists, physicians and nurses. 
4.4.1 Interviews in public sector 
- The interviews in the public sector were carried out in 19 health locations 
distributed across public health administrations, public general hospitals, public 
specialized hospitals, public health clinics, Dasman Diabetic Institute, public 
military hospital, Public National Guards Clinic and the University Pharmaceutical 
Faculty. The interviews were conducted with 101 health professionals from the 
following institutions: 
1. Kuwait Food and Drug Control Administration, (8 pharmacists). 
2. Kuwaiti Central Medical Store Administration, (5 pharmacists). 
3. Kuwaiti Pharmaceutical Services Administration, (2 pharmacists). 
4. Kuwaiti Drug Inspection Administration, (2 pharmacists). 
5. Mubarak Hospital (General Hospital), (7 physicians). 
6. Al Amiri Hospital (General Hospital), (3 pharmacists and 2 nurses). 
7. AL Sabah Hospital (General Hospital), (14 pharmacists,1 physician and 3 
nurses).  
8. Qortoba Clinic (Public Health Clinic), (10 physicians). 
9. Shaikhan Al Farisi Hospital (Endocrine Hospital), (3 pharmacists and 3 
physicians). 
10. NBK Hospital (Pediatric Hospital), (4 pharmacists). 
11. Medicine Hospital (Internal Hospital), (8 pharmacists and 4 physicians). 
12. Ibin Sina Hospital (Neurological Hospital), (6 pharmacists). 
13. Al Bahar HospitalL (Ophthalmology Hospital), (1 pharmacist and 1 
physician). 
14. Dasman Diabetic Institute (Diabetic Research Center), (2 physicians). 
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15.  Hamed AL Essa Hospital (Renal and Organism Transplantation Hospital), 
(2 pharmacists). 
16. Military Hospital (General Hospital), (2 pharmacists). 
17. National Guards Clinic (Health Clinic), (1 pharmacist). 
18. Pharmaceutical Faculty (Kuwait University), (2 pharmacists). 
19. Assad Al Hamad Hospital (Dermatology Hospital), (4 pharmacists). 
 
 
 
 
93 
 
 
Figure 4.1 The Public Health Areas visited during the Interviews   
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-  In addition to the health professionals, a number of very senior staff working in 
different places in the public health sector was interviewed as listed below: 
1. Assistant Under Secretary for Drug and Medical Supplies of KMOH. 
2. Director of Drug Inspection Administration. 
3. Director of Drug and Food Control Administration. 
4. Director of Central Medical Stores. 
5. Director of Pharmaceutical Services Administration. 
6. Director Assistant of Dasman Diabetic Institute. 
7. Supervisor of Registration and Release of Drug and Food Control 
Administration. 
8. Supervisor of Disposable Department of Central Medical Stores. 
9. Supervisor of Drug Department of Central Medical Store.  
10. Supervisor of Pharmaceutical Services Administration. 
11. Head of Tablet Department of Central Medical Stores. 
12. Head of Pharmaceutical services in Al Sabah Area. 
13. Head of Drug Registration Department of Drug and Food Control 
Administration. 
14. Head of Public Drug Inspection of Drug Inspection Administration. 
15. Head of Pharmaceutical Services in Capital Area. 
16. Head of Nurse Department in Al Sabah Hospital. 
17. Head of Pharmacy in NBK Hospital. 
18. Head of Imported Drug Release Department in Kuwait International Airport. 
19. Head of Medicine Wards in Al Sabah Hospital. 
20. Head of Pharmacy in Medicine Hospital. 
21. Head of Pharmacy in Dermatology Hospital. 
22. Head of Special Order Department in Central Medical Store. 
23. Head of Diabetic Department in Dasman Diabetic Institute.  
24. Vice Dean of Kuwait Pharmaceutical Faculty. 
25. Head of Pharmaceutical Department of Kuwait Pharmaceutical Faculty. 
26. Head of Pharmacy in Military Hospital. 
27. Head of Pharmacy in Kuwaiti National Guard Clinic 
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As indicated the total number of senior staff interviewed were 27 from the 101 
interviewed health professionals in the public sector (see the Table below, which 
shows the number of interviewed senior staff and their positions).  
 
Table 4.8: Number of Interviewed Senior Staff in Public Health Sector. 
 
Senior Staff Positions  
 
No 
Assistant Under Secretary for Drug and 
Medical  
Supplies of KMOH  
 
1 
Directors of Public Heath Administrations 5 
Supervisors of Public Heath Administrations 4 
Head of Public Departments  16 
Vice Dean of Kuwait Pharmaceutical 
Faculty 
 
1 
Total  27 
 
 
4.4.2 Interviews in the private sector 
 
- In addition to the public sector, a number of senior managers in the private sector 
were interviewed in 10 pharmaceuticals companies and one private hospital:  
1. Astra Zeneca Drug Company (Their Branch in Kuwait). 
2. Merik Sharb and Domin – Al Humaizi Drug Company. 
3. Sandos Drug Company (Their Branch in Kuwait). 
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4. Mohamed Naser Al Hajri Drug Company. 
5. Pfizer – Safwan Drug Company. 
6. Yiaco Drug Company. 
7. Abbot – Al Mojil Drug Company. 
8. Dunia Medical Drug Company. 
9. Al Wazan Drug Company. 
10. Boshehri Drug Company. 
11. Royal Hayat Hospital (Private Hospital). 
 
- The interviews also included a number of senior staff working in different places 
in the private sector.  
The total interviewed senior staff was 16 from the 21 interviewed health 
professionals in the private sector, as listed below: 
1. The Board Member of Royal Hayat Hospital (Private Hospital).  
2. Regional Sales Manager in Yiaco Drug Company. 
3. Key Account Manager in Yiaco Drug Company. 
4. Sales Manager in Abbot – Al Mojil Drug Company. 
5. OM Regional Manager Lower Gulf Countries in Al Wazan Drug Company. 
6. District Sales Manager in Kuwait, Bahrain and Qatar. 
7. Pharma Manager in Safwan Drug Company. 
8. Sales Manager in Al Humaizi Drug Company. 
9. Business Development Manager in Yiaco Drug Company. 
10. Key Account Manager in Pfizer – Safwan Drug Company. 
11. DRA Drug Regulatory Manager in MNHS Drug Company. 
12. Area Sales Manager in all GCC countries in Astra Zenica. 
13. Pharmacy Manager in Yiaco Drug Company. 
14. Sales Supervisor Pharma Division in Boshehri Drug Company. 
15. Field Force Supervisor. 
16. Head of Sales Department in GCC for Sandoz Drug Company.   
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4.5 Descriptive Analysis 
 
The work on the establishment of the National Drug Policy in Kuwait requires many 
areas of study and development. One of the important factors is the knowledge 
about the access to necessary information and data generation which can show 
the level of operation of the health care system. This would include the medical 
and pharmaceutical services and the health regulations and legislations in Kuwait. 
As indicated in the last section, it was important to take into account the views of 
the health care professionals and this was carried out in this study by building an 
information database from the questionnaire and interview procedure to take 
advantage of their experiences, opinions and recommendations. The results 
obtained are presented and discussed below. 
The gender of the respondents is shown in Table 4.9, where the majority of the 
respondents were male (57.9%) and the rest (42.1%) female, but this does not 
reflect the health professionals’ population where most managerial level staff is 
male. It was also easier to meet a male pharmacist because most female 
pharmacists refused to participate in the interview for matters relating to customs 
and traditions of Arab society and modesty. 
 
Table 4.9 
                                        Gender 
  Frequency Percent 
Male 70 57.9 
Female 51 42.1 
Total 121 100.0 
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  Figure 4.2 
 
In selecting the interviewees, both the public and private sectors were considered 
but the bias was to the public sector; where there were 101 interviewees from the 
public sector and 20 from the private sector (See Table 4.10). The largest numbers 
of interviewees were chosen from the public sector because it contains the largest 
range of health professionals (pharmaceutical administration, pharmacies, 
hospitals, health clinics, health areas, research centres and the Kuwaiti 
Pharmaceutical Faculty). 
 
Table 4.10 
Sector 
  Frequency Percent 
Public Sector 101 83.5 
Private Sector 20 16.5 
Total 121 100.0 
Gender
Male
58%
Female
42%
Male Female
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  Figure 4.3 
 
The professions of the interviewees’ were: 88 pharmacists, 28 physicians and 5 
nurses from 121 interviewees. From the 88 pharmacists, there were 2 pharmacists 
who had PhDs in the Pharmaceutical Sciences (Assistant Under-Secretary for 
Drug and Medical Supplies of KMOH and Vice Dean of Kuwait Pharmaceutical 
Faculty), and 1 professor of pharmaceutics (Head of Pharmaceutical Department 
of Kuwait Pharmaceutical Faculty). The largest number of interviewees chosen 
were pharmacists because they are mainly concerned with the issues, factors, 
nature and works of a future national drug policy (see Table 4.11 below). 
The interviewees were distributed across different functions, including hospitals, 
health administration, drug companies, health clinics, research center and 
pharmaceutical faculty (see Table 4.12). This range was to take advantage of all 
the expertise and get the bulk of the information and requirements needed for the 
research project.  
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Public Sector
83%
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17%
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Table 4.11 
Profession 
 Frequency Percent 
Pharmacist 88 72.7 
Physician 28 23.1 
Nurse 5 4.1 
Total 121 100.0 
 
 
 
 
  Figure 4.4 
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  Table 4.12 
Place 
 
 
 
 
 
 
 
 
 
 
 
  Figure 4.5 
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  Frequency Percent 
Hospital 69 57.0 
Health 
Administration 
18 14.9 
Drug Company 20 16.5 
Clinic 10 8.3 
Research Center 2 1.7 
University 2 1.7 
Total 121 100.0 
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4.6 Questions asked at the interviews and the outcomes 
 
The interview consisted of 12 questions which were related to the research project 
and covered all the parts of the health care system in Kuwait. The questions were 
designed to find out the main issues related to the health care system, to discuss 
these issues and then find possible suitable solutions for the issues and their 
requirements which could help in establishing a Kuwaiti National Drug Policy on 
valid grounds. Also they were designed to try to provide the viewpoints of senior 
health professionals so that the Kuwaiti Ministry of Health (KMOH) may consider 
establishing a NDP.  
Question 1: “How important is having a NDP?” 
All the 121 interviewees agreed that it is important that a NDP is developed as this 
would improve the health care system and is likely to establish an on-line system of 
regulations and legislation (see Table 4.13 below). 
Question 1 included 5 answers which were divided into: Very Important, Important, 
Not Applicable, Not Important and Useless, to cover all the interviewees opinions’ 
and contentment with the point. From the 5 possible answers which could be 
chosen, all the health professionals gave the first 2 answers. This indicates that all 
the interviewees were convinced of the importance of having a National Drug 
Policy (See Appendix 1). 
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Table 4.13 Question 1: How important is having a national 
drug policy?                                                                                  
  Frequency Percent 
Very Important 107 88.4 
Important 14 11.6 
Total 121 100.0 
 
 
Figure 4.6 Question 1:  How important is having a national drug policy?      
 
- Question 2: “Do you think we can develop and improve the health care system in 
Kuwait?" 
95.9% of the 121 interviewees answered that the health care system could be 
improved by establishing a NDP, and suggested that education for health 
professionals on all relevant regulatory affairs should be introduced. This should be 
done by improving the training programs. They also indicated that improving the 
software programs and establishing an electronic link between the administration, 
1 . How important is having a national drug policy? 
Very Important 
88% 
Important 
12% 
Very Important Important 
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hospitals and health clinics of the KMOH would improve the system and that 
further research centers should be established as well as an Essential Drug List. 
However 4.1% said that such development was not possible because of the lack of 
guidelines for the health sector and the unwillingness to make the decisions to 
improve the system (see Table 4.14 below). 
 
Table 4.14 Question 2: Do you think we can develop and improve the 
health care system in Kuwait? 
 
  Frequency Percent 
Yes 116 95.9 
No 5 4.1 
Total 121 100.0 
 
 
 
Figure 4.7 Question 2: Do you think we can develop and improve the health 
care system in Kuwait? 
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- Question 3:” Are there any issues of concern with the organization of the Health 
Care System in Kuwait?” 
82.6% of the 121 interviewees indicated that Kuwait has issues in the health care 
system and provided the follow comments:  
 Lack of knowledge of MOH regulators on the economics related to the 
system. 
 Delays in the decision making process from regulators. 
 Lack of centralization. 
 Inadequate strict penalties for counterfeit drugs. 
 A need for more hospitals and additional beds. 
 The need for an increase in the number of health staff, particularly 
pharmacists and nurses. 
 The need for an increase in information technology facilities in the KMOH.  
 The need for more research centers because there is currently only one 
(Dasman Diabetes Institute). 
 Lack of training programs and conferences for health professionals. 
 The need for greater cooperation between the KMOH and Kuwait University 
to take advantage of their science research.  
 Improve the Drug Release Department in Kuwait Airport by providing 
suitable staff to organize an electronic link system with the Kuwait Drug and 
Food Control Administration. 
Only 7.4% of the 121 interviewees answered that there are no issues with the 
system, and in 9.9% of cases the answers were not considered applicable (see 
Table 4.15 below.)  
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Table 4.15 Question 3: Are there any issues of concern with the organization 
of the health care system in Kuwait? 
  Frequency Percent 
Strongly Agree 35 28.9 
Agree 65 53.7 
Not Applicable 12 9.9 
Disagree 5 4.1 
Strongly Disagree 4 3.3 
Total 121 100.0 
 
 
 
 
Figure 4.8 Question 3: 
Are there any issues of concern with the organization with the health care 
system in Kuwait? 
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- Question 4: “In the public and private sectors, do you think we have enough 
control over regulation of the process associated with pharmaceuticals?” 
55.4% of the 121 interviewees thought that in Kuwait there was enough control 
over the registration of pharmaceutical products and over their secondary control 
after licensing. They also suggested that there was enough inspection and 
administration being carried out which covers the auditing and monitoring of public 
and private pharmacies, medical stores and medical companies. The remaining 
44.6% disagreed, indicating there is a lack of control over private pharmacies. This 
is because they think there are pharmacists in the private sector who are 
dispensing drugs without prescription or unregistered drugs for the patients and 
there are counterfeit drugs in the market place (see Table 4.16 below). 
 
 
Table 4.16 Question 4: 
In the public and private sector, do you think we have enough control over 
regulation of the process associated with pharmaceuticals? 
  Frequency Percent 
Yes 67 55.4 
No 54 44.6 
Total 121 100.0 
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Figure 4.9  Question 4: 
In the public and private sector, do you think we have enough control over 
regulation of the process associated with pharmaceuticals? 
 
 
- Question 5: “Do you feel that the training of health professionals in the public and 
private sector is sufficient?” 
 64.5% of the 121 interviewees answered ‘No’ to this question and gave the reason 
that there is a lack of training programs for health professionals, especially after 
graduation from university. In addition there is a lack of new knowledge introduced 
through local and national health conferences and training programs. In this 
respect, since 1992 (after the Gulf War) the pharmaceutical training programs have 
no longer been running. However, it should be noted that in 2011 the KMOH 
started to cooperate with the Kuwaiti Pharmaceutical Faculty to prepare new 
training programs and to establish a new Department for training called the Clinical 
Pharmacy Department. 
The other 35.5% of the 121 interviewees indicated that there is enough training 
programs (see Table 4.17). 
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Table 4.17 Question 5: 
Do you feel that the training of health professionals in the public and private 
sector is sufficient? 
  Frequency Percent 
Yes 43 35.5 
No 78 64.5 
Total 121 100.0 
 
 
 
Figure 4.10 Question 5: 
Do you feel that the training of health professionals in the public and private 
sector is sufficient? 
 
- Question 6: “Do you think that the price range of medication in the private sector 
is publically acceptable?” 
51.2% of the 121 interviewees disagreed and strongly disagreed that the price of 
medications in the private sector is acceptable when compared to other Gulf 
countries, e.g., in the Kingdom of Saudi Arabia (KSA). The prices in Kuwait are 
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three times higher. They also thought that the Pricing Department is not strict 
enough with the drug prices in the private sector. On the other hand, 35.6% said 
the prices are acceptable when compared to the prices in KSA. Although the prices 
are higher, this is related to a number of factors such as the larger population in 
KSA which makes bulk ordering medicines cheaper. In addition there is no 
pharmaceutical industry in Kuwait whereas there are many pharmaceutical 
companies in KSA and therefore competition exists and again the market size is 
much larger. Also, they mentioned that medicine costs are calculated against the 
USD and every six months the Pricing Department recalculates the drug prices 
according to the value of the USD. This controls and regulates the pricing better. 
On the other figures, 13.2% answered that the question was not applicable to them 
as they had no idea about the price range of medication in the private market (see 
Table 4.18 below). 
 
Table 4.18 Question 6: 
Do you think that the price range of medication in the private sector is 
publically acceptable? 
  Frequency Percent 
Strongly Agree 10 8.3 
Agree 33 27.3 
Not Applicable 16 13.2 
Disagree 34 28.1 
Strongly Disagree 28 23.1 
Total 121 100.0 
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Figure 4.11 Question 6: 
Do you think that the price range of medication in the private sector is 
publically acceptable? 
 
- Question 7: “Do you think that there are any issues with access to quality, safety 
and efficacy of drugs?” 
53.6% of the 121 interviewees answered that there are no issues with access to 
good quality, safe and efficacious drugs. The reasons given included that they 
thought the drugs procured in the public sector are of the best quality and 
medication is free for the citizens and residents. Other comments included that in 
the private market all the medicines are controlled by the KMOH as they must be 
registered and licensed by the Drug and Food Control Administration before they 
are sold in the open market. However 46.3% of the 121 interviewees suggested 
that there are issues and there should be improvements. The reasons given 
included that in the private sector there is a lack of control of non-prescription 
medicines, which includes antibiotics and sexual medicines (see Table 4.19 
below). 
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Table 4.19 Question 7: 
Do you think that there are any issues with the access to quality, safe and 
effective drugs? 
  Frequency Percent 
Yes 56 46.3 
No 65 53.7 
Total 121 100.0 
 
 
 
Figure 4.12 Question 7: 
Do you think that there are any issues with access to quality, safe and 
effective drugs? 
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- Question 8: “Do you think that there is irrational use of drugs in Kuwait?”  
86% of the 121 interviewees felt that there is a problem with irrational drug 
prescribing and use in Kuwait. This was suggested to occur mostly through self-
medication, an example is the usage of an antibiotic without prescription and usage 
of sexual drugs without consultation with a physician. In addition, they suggested 
that compliance of patients is very low in Kuwait due to the weak health education, 
especially with the older patients (see Table 4.20 below). 
 
 
Table 4.20 Question 8: 
Do you think that there is irrational use of drugs in Kuwait? 
  Frequency Percent 
Strongly Agree 55 45.5 
Agree 49 40.5 
Not Applicable 6 5.0 
Disagree 8 6.6 
Strongly Disagree 3 2.5 
Total 121 100.0 
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Figure 4.13 Question 8: 
Do you think that there is irrational use of drugs in Kuwait? 
 
- Question 9: “How important is having an Essential Drug List?” 
95% of the 121 interviewees suggested that Kuwait should establish an Essential 
Drug List which would be based upon the needs of the state. The majority thought 
that an Essential Drug List would lead to savings in the national budget and 
reductions in the numbers of expired drugs held in the stores. Also, it could lead to 
better ways of determining the appropriate drug needs for the long term and also 
reduce any costs associated with adverse reactions, severe side effects and legal 
complications (see Table 4.21 below). 
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Table 4.21 Question 9: 
How important is having an Essential Drug List? 
  Frequency Percent 
Very Important 84 69.4 
Important 31 25.6 
Not Applicable 5 4.1 
Not Important 1 .8 
Total 121 100.0 
 
Figure 4.14 Question 9: How important is having an Essential Drug List? 
 
- Question 10: “Do you think that Kuwait should develop its own pharmaceutical 
industry?” 
82.6% of the 121 interviewees were in favour of developing a Kuwaiti 
pharmaceutical industry. One of the main reasons given was that it would secure 
the country’s medicines resources by providing availability during emergencies and 
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war. Also it increases and improves the national sources of income and develops 
the pharmaceutical technologies.  
However, 17.4% of the interviewers were against the proposal because they 
thought that Kuwait has too small a market to have many pharmaceutical 
companies and as well as the world is fairly small each country should do what 
they are good at. Also, a pharmaceutical industry needs high level technology, 
research centers and trained staff to ensure the production of quality drugs but all 
these are absent in Kuwait (see Table 4.22). 
 
Table 4.22 Question 10:  
Do you think that Kuwait should develop its own pharmaceutical industry? 
  Frequency Percent 
Yes 100 82.6 
No 21 17.4 
Total 121 100.0 
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Figure 4.15 Question 10:  
Do you think that Kuwait should develop its own pharmaceutical industry? 
 
- Question 11:  “Do you think it is time to establish a NDP in Kuwait?” 
95% of the 121 interviewees agreed that it would be beneficial to establish a NDP 
in Kuwait. It was suggested that it is likely to improve the health system and 
develop the health services in Kuwait. Only 5% of the interviewees disagreed, 
stating that the KMOH did not have enough power, and neither would they be able 
to make the decisions and manage such a major development as establishing a 
NDP in Kuwait at this moment (See Table 4.23 below). 
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Table 4.23 Question 11: 
Do you think it is time to establish a national drug policy in Kuwait? 
  Frequency Percent 
Yes 115 95.0 
No 6 5.0 
Total 121 100.0 
 
 
Figure 4.16 Question 11: 
Do you think it is time to establish a national drug policy in Kuwait? 
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4.7 Methods of evaluating the Data:  Cross Tabulation 
 
4.7.1 Quantitative Analysis 
In this analysis, 5 hypotheses were used to analyze the collected data from the 
questionnaire. These are described below.  
 
Results of the first hypothesis 
This hypothesis provided that no statistically significant differences were present 
between the sample responses to the questions in the questionnaire: 
1. How important is having a NDP? 
2. Do you think we can develop and improve the health care system in Kuwait? 
3. Are there any issues of concern with the organization of the health care 
system in Kuwait? 
4. In the public and private sectors, do you think we have enough control over 
regulating the process associated with pharmaceuticals? 
5. Do you feel that the training of health professionals in the public and private 
sector is sufficient? 
6. Do you think that the price range of medication in the private sector is 
publically acceptable? 
7. Do you think that there are any issues with access to quality, safe and 
effective drugs? 
8. Do you think that there is irrational use of drugs in Kuwait? 
9. How important is having an Essential Drug List? 
10. Do you think that Kuwait should develop its own pharmaceutical industry? 
11. Do you think it is time to establish a NDP in Kuwait?  
 
To validate this hypothesis, the Chi-Square Test ( ) was used (this is a widely 
used non-parametric statistical test that describes the magnitude of discrepancy 
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between the observed data and the data expected to be obtained with a specific 
hypothesis) to identify the significance of the differences between the obtained 
frequencies from the research sample on the responses of the questions of the 
questionnaire. A chi-squared test is constructed through sample variance or from 
the sum of squared errors in a data set, and refers to any statistical hypothesis test 
where the sampling distribution of a test statistic follows a chi-square distribution 
when the null is true (Zibran, 2015). It is a common non-parametric statistical 
method used when data consists of counts, or a frequency, and where the 
probability of association between independent facts is sought.  
Again, chi-square tests rely upon the assumption that data is normally distributed. 
These tests can be useful for analysing variance in a normal population or for the 
analysis of categorical data. For example, imagine a study analysing the survival 
times of patients suffering from four different types of blood cancer, and how it was 
related to four categorical variables, such as the level of household income, or the 
number of cigarettes smoked per day in a smoking cohort. Here, the chi-squared 
test can be used to identify the most likely correlates amongst the data, and is 
useful for stratifying the patient cohort (Zibran, 2015). The result is set out in the 
table below (Page 120, 121 and 122).  
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Table 4.24 The Result of the use of Chi-Square Test ( ) to identify the 
significant difference between the frequency of the research sample 
responses to the questions of the questionnaire 
Ques 
No 
Responses  
Frequency and 
Percentage 
 
Chi square  
 
Level of 
significan
ce 
1. 
Very Important  107 
88.4 
71.48 0.01* 
Important 14 
11.6 
2. 
Yes 116 
95.9 
101.82 0.01* 
No 5 
4.1 
3. 
Strongly Agree 35 
28.9 
66.61 0.01** 
Agree 65 
53.7 
Not Applicable 12 
9.9 
Disagree 9 
7.4 
4. 
Yes 67 
55.4 
1.40 0.30* 
No 54 
44.6 
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Follow Table 4.24 The Result of the use of Chi-Square Test ( ) to 
identify the significant difference between the frequency of the research 
sample responses to the questions of the questionnaire 
Ques 
No 
Responses  
Frequency and 
Percentage 
 
Chi square  
 
Level of 
significan
ce 
5. 
Yes 43 
35.5 
10.12 0.01* 
No 78 
64.5 
6. 
Strongly Agree 
10 
8.3 
20.98 0.01*** 
Agree 
33 
27.3 
Not Applicable 
16 
13.2 
Disagree 
34 
28.1 
Strongly Disagree 
28 
23.1 
 
 
 
7. 
 
 
 
Yes 
56 
46.3 
0.66 0.50** 
No 
65 
53.7 
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Follow Table 4.24 The Result of the use of Chi-Square Test ( ) to identify the 
significant difference between the frequency of the research sample responses 
to the questions of the questionnaire 
Ques 
No 
Responses  
Frequency and 
Percentage 
Chi square  
 
Level of 
significan
ce 
8. 
Strongly Agree 
55 
45.5 
63.56 0.01** 
Agree 
49 
40.5 
Not Applicable 
6 
5.0 
Disagree 
11 
9.1 
9. 
Very Important 
84 
69.4 
78.67 0.01**** Important 
31 
25.6 
Not Applicable 
6 
4.9 
10. 
Yes 
100 
82.6 
51.58 0.01* 
No 
21 
17.4 
11. 
Yes 
115 
95.0 
98.20 0.01* 
No 
6 
5.0 
 * (1,0.01)=6.635                         (3,0.01)= 11.345                              (4,0.01)= 13.277   
(2,0.01)=9.210                  (1,0.30)=1.074                                   (1,0.50)=0.455 
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This table shows the following: 
1. There was a significant difference at the level (0.01) between the responses 
of the research sample to question 1 with highest frequency given to “very 
important”, and this means that the research sample indicated that the 
existence of a NDP in Kuwait is very important. In addition the proportion of 
total confidence in the outcome of question 1 reached 99% (0.01). 
2. There was a significant difference at the level (0.01) between the responses 
of the research sample to question 2 with highest frequency given to 
response “yes”, and this means that the research sample indicated that the 
health care system in Kuwait could be developed and improved. In addition, 
the proportion of total confidence in the outcome of question 2 reached 99% 
(0.01). 
3. There was a significant difference at the level (0.01) between the responses 
of the research sample to question 3 with highest frequency given to the 
response “agree”, and this means that the research sample indicated that 
there are issues of concern with the health care system in Kuwait. In 
addition, the proportion of total confidence in the outcome of question 3 
reached 99% (0.01). 
4. There was a significant difference at the level (0.30) between the responses 
of the research sample to question 4 with highest frequency given to the 
response “yes”, and this means that the research sample suggested that 
there is enough control over public and private pharmaceutical sectors in 
Kuwait. In addition, the proportion of total confidence in the outcome of 
question 4 reached only 70% (0.30). 
5. There was a significant difference at the level (0.01) between the responses 
of the research sample to question 5 with highest frequency given to the 
response “no”, and this means that the research sample indicated that the 
number of training programs for health professionals (physicians, 
pharmacists and nurses) in the public and private sector is insufficient. In 
addition the proportion of total confidence in the outcome of the question 5 
reached 99% (0.01). 
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6. There was a significant difference at the level (0.01) between the responses 
of the research sample to question 6 in with highest frequency given to the 
response “strongly disagree”, and this means that the research sample 
agreed that the price range of medication in the private sector is not 
acceptable and exaggerated. In addition, the proportion of total confidence 
in the outcome of question 6 reached 99% (0.01). 
7. There was a significant difference at the level (0.50) between the responses 
of the research sample to question 7 with highest frequency given to the 
response “no”, and this means that the research sample accepted that there 
are no issues with access to good quality, safe and efficacious drugs. In 
addition, the proportion of total confidence in the outcome of question 7 
reached only 50% (0.50). 
8. There was a significant difference at the level (0.01) between the responses 
of the research sample to question 8 with highest frequency given to the 
response “strongly agree”, and this means that the research sample agreed 
that there is irrational use of drugs in the state. In addition, the proportion of 
total confidence in the outcome of question 8 reached 99% (0.01). 
9. There was a significant difference at the level (0.01) between the responses 
of the research sample to question 9 with highest frequency given to the 
response “very important”, and this means that the research sample 
indicated that the existence of an Essential Drug List is very important. In 
addition, the proportion of total confidence in the outcome of question 9 
reached 99% (0.01). 
10.  There was a significant difference at the level (0.01) between the responses 
of the research sample to question 10 in with highest frequency given to the 
response “yes”, and this means that the research sample indicated that 
Kuwait could develop its own pharmaceutical industry. In addition, the 
proportion of total confidence in the outcome of question 10 reached 99% 
(0.01). 
11.  There was a significant difference at the level (0.01) between the responses 
of the research sample to question 11 with highest frequency given to the 
response “yes”, and this means that the research sample suggested that the 
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establishment of a NDP in the country would be useful at the current stage. 
In addition, the proportion of total confidence in the outcome of question 11 
reached 99% (0.01). 
 
Based on the information above, it can be summarized that in question 4 the level 
of confidence in the outcome of the question reached 70%, while in question 7 the 
level of confidence reached 50%; with the rest of the questions (1, 2, 3, 5, 6, 8, 9, 
10 and 11) it reached 99%. As such, the results indicate that all the research 
sample responses were not subjected to chance, but it were deliberately, in which 
the responses showed cognition, understanding and awareness.  
 
Results of the second hypothesis 
This hypothesis provided that there is no statistically significant difference between 
the sample responses to the questions in the questionnaire based on gender.  To 
validate this hypothesis, the One Way Analysis of Variance method was used in 
relation to the degrees obtained by the male and female participants in the 
questionnaire. This test is commonly used to compare differences between three 
(or more) groups of unrelated values, although it can also be used on two data sets 
(Daya, 2003).The result is observed in the table below (Page 126, 127 and 128). 
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Table 4.25 Result of the use of One Way Analysis of Variance method to the 
degrees obtained by the male and female participants to the questions of the 
questionnaire  
Ques 
No 
Source of 
Variation  
Sum of 
squares 
Degrees of 
Freedom 
Average 
Squares 
F   Value 
Level of 
significance 
1. 
Between Groups 35.68 1 35.68 
1.61 
No 
significance 
Within Groups 
(error) 
2637.04 119 22.16 
Total 2672.72 120  
2. 
Between Groups 35.65 1 35.65 
1.14 
No 
significance 
Within Groups 
(error) 
3721.13 119 31.27 
Total 3756.78 120  
   3. Between Groups 36.51 1 36.51 
1.00 
No 
significance 
Within Groups 
(error) 
4344.69 119 36.51 
Total 4381.20 120  
   4. Between Groups 19.13 1 19.13 
0.95 
No 
significance 
Within Groups 
(error) 
2396.66 119 20.14 
Total 2415.79 120  
   5. Between Groups 20.36 1 20.36 
1.06 
No 
significance 
Within Groups 
(error) 
2285.99 119 19.21 
Total 2306.35 120  
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Follow Table 4.25 Result of the use of One Way Analysis of Variance 
method to the degrees obtained by the male and female participants to the 
questions of the questionnaire 
Ques 
No 
Source of 
Variation 
Sum of 
squares 
Degrees of 
Freedom 
Average 
Squares 
F   Value 
Level of 
significance 
6. 
Between Groups 30.99 1 30.99 
1.21 
No 
significance 
Within Groups 
(error) 
3047.59 119 25.61 
Total 3078.58 120  
7. 
Between Groups 24.30 1 24.30 
0.72 
No 
significance 
Within Groups 
(error) 
4016.25 119 33.75 
Total 4040.55 120  
8. 
Between Groups 11.96 1 11.96 
0.61 
No 
significance 
Within Groups 
(error) 
2332.40 119 19.60 
Total 2344.36 120  
9. 
Between Groups 15.79 1 15.79 
0.86 
No 
significance 
Within Groups 
(error) 
2184.84 119 18.36 
Total 2200.63 120  
 
 
10. 
 
 
Between Groups 60.97 1 60.97 
2.30 
No 
significance 
Within Groups 
(error) 
3154.69 119 26.51 
Total 3215.66 120  
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Follow Table 4.25 Result of the use of One Way Analysis of Variance 
method to the degrees obtained by the male and female participants to the 
questions of the questionnaire 
Ques 
No 
Source of 
Variation 
Sum of 
squares 
Degrees of 
Freedom 
Average 
Squares 
F   Value 
Level of 
significance 
  11. Between Groups 44.02 1 44.02 
2.01 
No 
significance 
Within Groups 
(error) 
2606.10 119 21.90 
Total 2650.12 120  
All 
Ques. 
Between Groups 97.59 1 97.59 
2.11 
No 
significance 
Within Groups 
(error) 
5503.75 119 46.25 
Total 5601.34 120    
 F(1,119,0.05)=3.92. 
 
It can be seen from the table above that there is no significant difference between 
the responses of the research sample to the questions in the questionnaire or on 
its total degrees due to gender.  
 
Results of the third hypothesis 
This hypothesis provided the indication that there is no statistically significant 
difference between the sample responses to the questions in the questionnaire due 
to sector differences (public and private).   
To validate this hypothesis, the One Way Analysis of Variance method was used to 
examine the degrees obtained by the public and private sector participants to the 
questions in the Questionnaire. The result can be observed in the table below 
(Page 129, 130 and 131).  
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Table 4.26 Results of the use of One Way Analysis of Variance method to the 
degrees obtained by the public and private sector participants to the 
questions in the questionnaire  
Ques 
No 
Source of Variation  
Sum of 
squares 
Degrees of 
Freedom 
Average 
Squares 
F   Value 
Level of 
significance 
1. 
Between Groups 38.09 1 38.09 
1.12 No significance 
Within Groups 
(error) 
4047.19 119 34.01 
Total 4085.28 120  
2. 
Between Groups 83.46 1 83.46 
1.98 No significance 
Within Groups 
(error) 
5015.85 119 42.15 
Total 5099.31 120  
3. 
Between Groups 137.03 1 137.03 
4.12 0.05* 
Within Groups 
(error) 
3957.94 119 33.26 
Total 4094.97 120  
4. 
Between Groups 93.91 1 93.91 
2.10 No significance 
Within Groups 
(error) 
5321.68 119 44.72 
Total 5415.59 120  
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Follow Table 4.26 Results of the use of One Way Analysis of Variance 
method to the degrees obtained by the public and private sector 
participants to the questions in the questionnaire  
Ques 
No 
Source of Variation  
Sum of 
squares 
Degrees of 
Freedom 
Average 
Squares 
F   Value 
Level of 
significance 
5. 
Between Groups 47.78 1 47.78 
1.68 No significance 
Within Groups 
(error) 
3384.36 119 28.44 
Total 3432.14 120  
6. 
Between Groups 96.91 1 96.91 
2.12 No significance 
Within Groups 
(error) 
5439.49 119 45.71 
Total 5536.40 120  
7. 
Between Groups 51.43 1 51.43 
1.82 No significance 
Within Groups 
(error) 
3362.94 119 28.26 
Total 3414037 120  
8. 
Between Groups 136.19 1 136.19 
4.28 No significance 
Within Groups 
(error) 
3786.58 119 31.82 
Total 3922.77 120  
 
 
9. 
 
 
Between Groups 37.90 1 37.90 
1.66 No significance 
Within Groups 
(error) 
2716.77 119 22.83 
Total 2754.07 120  
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Follow Table 4.26 Results of the use of One Way Analysis of Variance 
method to the degrees obtained by the public and private sector 
participants to the questions in the questionnaire 
Ques 
No 
Source of Variation  
Sum of 
squares 
Degrees of 
Freedom 
Average 
Squares 
F   Value 
Level of 
significance 
10. 
Between Groups 56.51 1 56.51 
1.79 No significance 
Within Groups 
(error) 
3756.83 119 31.57 
Total 3813.34 120  
11. 
Between Groups 56.22 1 56.22 
2.12 No significance 
Within Groups 
(error) 
3155.88 119 26.52 
Total 3212.10 120  
All 
Ques. 
Between Groups 54.51 1 54.51 
1.31 No significance Within Groups 
(error) 
4951.59 119 41.61 
Total 5006.10 120    
 F(1,119,0.05)=3.92. 
 
It can be seen from the table above that there is no significant difference between 
the responses of the research sample to the questions (1, 2, 4, 5, 6, 7, 9, 10 and 
11) or on its total degrees due to sector (in which the participants work) 
differences. However, statistically significant differences were present between the 
responses of the research sample to questions (3 and 8) based on sector 
difference. In order to identify the significant differences between sector medians 
for questions 3 and 8, the T. Test was used to determine whether two sets of 
(normally distributed) data are different from each other (or have different average 
values), and therefore, is central to basic research applications (Kim, 2015). T-tests 
are widely applied, and many variations of the test exist, each designed to deal 
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with different dataset features and hypothesis testing scenarios. In essence they 
compare means between different data sets, and can compare data to 
hypothesised values (one-sample tests) or other data sets (in two-sample tests).  
More specifically, t-tests refer to any statistical hypotheses where the test statistic 
follows a student’s t-distribution under conditions of the null hypothesis; data falling 
into a non-normal distribution will lead to test inaccuracy (Main and Ogaz, 2016). 
(See table below). 
Table 4.27 Results from the use of T. Test, and the significant differences 
between the means of the public and private sector on questions 3 and 8.  
No. 0f 
Ques. 
Public  
N(101) 
Private  
N(20) T   Value 
Level of 
significance 
M ST M ST 
3 4.07 0.16 3.60 0.24 6.91 0. 01* 
8 4.27 0.25 3.65 0.28 12.40 0.01* 
T(119,0.01)=2.60 
 
This table shows that there were significant differences at the level (0.01) in the 
response to questions 3 and 8 of the questionnaire. These were that:  
- The health care system in Kuwait suffers from issues in both the public and 
private sectors but the interviewees (health professionals) from the public 
sector indicated and agreed about the existence of health issues in the 
country more than the interviewees from the private sector. In Question 3, 
the mean degree (M) of the public sector (4.07) was higher than the M of the 
private sector (3.60). 
- There is a problem with irrational drug prescribing and use in Kuwait. The 
responses of the interviewees from the public sector which indicated the 
existence of this issue in question 8 were greater than the responses in the 
private sector –the M of the public sector (4.27) was also greater than the M 
of the private sector (3.65).  
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Results of the fourth hypothesis 
This hypothesis indicated that there is no statistically significant difference between 
the sample responses to the questions in the Questionnaire due to the different 
profession of the interviewees (pharmacists, physicians and nurses).   
To validate this hypothesis, the One Way Analysis of Variance method was used to 
examine the degrees of the pharmacists, physicians and nurses participants. The 
result can be observed in the table below (page 133, 134 and 135).  
Table 4.28 Results of the use of One Way Analysis of Variance method to the 
degrees of the participants (pharmacists, physicians and nurses) to the 
questions in the questionnaire  
Ques 
No 
Source of Variation  
Sum of 
squares 
Degrees of 
Freedom 
Average 
Squares 
F   Value 
Level of 
significance 
1. 
Between Groups 53.42 2 26.71 
2.40 
No 
significance 
Within Groups 
(error) 
1313.34 118 11.13 
Total 1366.76 120  
2. 
Between Groups 12.86 2 6.43 
3.20 0.05** 
Within Groups 
(error) 
237.18 118 2.01 
Total 250.04 120  
 
 
3. 
 
 
Between Groups 35.90 2 17.95 
5.61 0.01* 
Within Groups 
(error) 
661.98 118 3.2 
Total 697.88 120  
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Follow Table 4.28 Results of the use of One Way Analysis of Variance 
method to the degrees of the participants (pharmacists, physicians and 
nurses) to the questions in the questionnaire 
Ques 
No 
Source of Variation  
Sum of 
squares 
Degrees of 
Freedom 
Average 
Squares 
F   Value 
Level of 
significance 
   4. 
Between Groups 10.24 2 5.12 
3.20 0.05** 
Within Groups 
(error) 
188.80 118 1.60 
Total 199.04 120  
5. 
Between Groups 31.42 2 15.71 
2.61 
No 
significance 
Within Groups 
(error) 
710.36 118 6.02 
Total 741.78 120  
6. 
Between Groups 23.46 2 11.73 
2.20 
No 
significance 
Within Groups 
(error) 
628.94 118 5.33 
Total 652.40 120  
7. 
Between Groups 18.54 2 9.27 
2.01 
No 
significance 
Within Groups 
(error) 
543.98 118 4.61 
Total 562.52 120  
 
 
8. 
 
 
Between Groups 25.42 2 12.71 
4.89 0.01** 
Within Groups 
(error) 
306.80 118 2.6 
Total 332.22 120  
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Follow Table 4.28 Results of the use of One Way Analysis of Variance 
method to the degrees of the participants (pharmacists, physicians and 
nurses) to the questions in the questionnaire 
Ques 
No 
Source of Variation  
Sum of 
squares 
Degrees of 
Freedom 
Average 
Squares 
F   Value 
Level of 
significance 
9. 
Between Groups 25.68 2 12.84 
2.21 
No 
significance 
Within Groups 
(error) 
685.58 118 5.81 
Total 711.26 120  
10. 
Between Groups 10.66 2 5.33 
3.81 0.05** 
Within Groups 
(error) 
165.20 118 1.40 
Total 175.86 120  
11. 
Between Groups 13.60 2 6.80 
1.89 
No 
significance 
Within Groups 
(error) 
435.42 118 3.69 
Total 449.02 120  
All 
Ques. 
Between Groups 7.74 2 3.87 
3.20 0.05** 
Within Groups 
(error) 
142.78 118 1.21 
Total 150.52 120  
F( 2,118,0.01)= 4.78 
 F (2,118,0.05)= 3.07 
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This table shows that: 
1. There were significant differences at the level (0.01) between the responses 
of the research sample to the questions (3 and 8) due to the different 
professions of the interviewees.   
2. There were significant differences at the level (0.05) between the responses 
of the research sample to the questions (2, 4 and 10) and the total degrees 
of the questionnaire due to the different professions of the interviewees.   
3. There were no significant differences between the responses of the 
research sample to the questions (1, 5, 6, 7, 9 and 11) and the total degrees 
of the questionnaire due to the different professions of the interviewees. In 
addition, and to identify the significant differences between median degrees 
(for pharmacists, physicians and nurses) for questions (1, 5, 6, 7, 9 and 11), 
the Scheffe Method was used (see table below). The Scheffe test is a post-
hoc test used in the analysis of variance (Curtis, et al., 2015). It is a test that 
usually used after running ANOVA test and got a significant statistical result 
(rejected null hypothesis) to find out which pairs of means are significant 
(Williams and Abdi, 2010). The Scheffe test is the most flexible three mean 
comparisons test, however, it has the lowest statistical power (Williams and 
Abdi, 2010). 
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Table 4.29 Results of the use of the Scheffe Method and its significant 
differences between the means of interviewees (pharmacists, physicians and 
nurses) in question 2 of the questionnaire.  
Question No Profession Pharmacist Physician Nurse 
2 
Pharmacist 
M(1.97) 
--   
Physician 
M(1.93) 
0.05 --  
Nurse 
M(0.36) 
1.61 1.63 -- 
Scheffe Range = 0.992 
 
The previous table shows that: 
1. There were no significant differences between the participants (pharmacists 
and physicians) as to whether the health care system in Kuwait could be 
developed and improved. 
2. There were significant differences at the level (0.05) between the 
participants (pharmacists and nurses) over agreement that the health care 
system in Kuwait could be developed and improved. However, the result 
was in favour of pharmacists.  
3. There were significant differences at the level (0.05) between the 
participants (physicians and nurses) in agreeing that the health care system 
in Kuwait could be developed and improved.  
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Table 4.30 Results of the use of Scheffe Method and its significant 
differences between the means of interviewees (pharmacists, physicians and 
nurses) on question 3 of the questionnaire.  
Question No Profession Pharmacist Physician Nurse 
3 
Pharmacist 
M(3.92) 
--   
Physician 
M(4.32) 
0.04 --  
Nurse 
M(0.64) 
3.28 3.68 -- 
Scheffe Range = 1.580 
 
This table shows that: 
1. There were no significant differences between the participants (Pharmacists 
and Physicians) on whether Kuwait has issues in the health care system. 
2. There were significant differences at the level (0.01) between the 
participants (pharmacists and nurses) in agreeing that Kuwait has issues in 
the health care system. However, the result was in favour of pharmacists.  
3. There were significant differences at the level (0.01) between the 
participants (physicians and nurses) in agreeing that the Kuwait has issues 
in the health care system. However, the result was in favour of physicians.  
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Table 4.31 Result of the use of the Scheffe Method and its significant 
differences between the means of interviewees (pharmacists, physicians and 
nurses) on question 4 of the questionnaire. 
Question No Profession Pharmacist Physician Nurse 
4 
Pharmacist 
M(1.61) 
--   
Physician 
M(1.29) 
0.32 --  
Nurse 
M(0.36) 
1.25 0.93 -- 
Scheffe Range = 0.893 
 
This table shows that: 
1. There were no significant differences between the participants (pharmacists 
and physicians) who both thought that in Kuwait there was enough control 
over the pharmaceutical sector. 
2. There were significant differences at the level (0.05) between the 
participants (pharmacists and nurses) in agreeing that in Kuwait there was 
enough control over the pharmaceutical sector. However the result was in 
favour of pharmacists.  
3. There were significant differences at the level (0.05) between the 
participants (physicians and nurses) in agreeing that in Kuwait there was 
enough control over the pharmaceutical sector. However the result was in 
favour of physicians.  
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Table 4.32 Results from use of the Scheffe Method and its significant 
differences between the means of interviewees (pharmacists, physicians and 
nurses) on question 8 of the questionnaire. 
Question No Profession Pharmacist Physician Nurse 
8 
Pharmacist 
M(4.17) 
--   
Physician 
M(4.25) 
0.08 --  
Nurse 
M(0.64) 
3.53 3.61 -- 
Scheffe Range = 1.421 
 
This table shows that: 
1. There were no significant differences between the participants (pharmacists 
and physicians) and suggested that Kuwait should establish an Essential 
Drug List which would be based upon the needs of the state.   
2. There were significant differences at the level (0.01) between the 
participants (pharmacists and nurses) in agreeing that Kuwait should 
establish an Essential Drug List which would be based upon the needs of 
the state. However, the result was in favour of pharmacists.  
3. There were significant differences at the level (0.01) between the 
participants (physicians and nurses) in agreeing that Kuwait should 
establish an Essential Drug List which would be based upon the needs of 
the state. However, the result was in favour of physicians.  
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Table 4.33 Results from the use of the Scheffe Method, and the significant 
differences between the means of interviewees (pharmacists, physicians and 
nurses) on question 10 of the questionnaire. 
Question No Profession Pharmacist Physician Nurse 
10 
Pharmacist 
M(1.78) 
--   
Physician 
M(1.79) 
0.01 --  
Nurse 
M(0.36) 
1.42 1.43 -- 
Scheffe Range = 0.818 
 
This table shows that: 
1. There were no significant differences between the participants (pharmacists 
and physicians) in thought that the development of the pharmaceutical 
industries in Kuwait ought to improve.  
2. There were significant differences at the level (0.05) between the 
participants (pharmacists and nurses) in agreeing that development of the 
pharmaceutical industries in Kuwait should substantially improve. However 
pharmacists’ responses were closest to support the findings.  
3. There were significant differences at the level (0.05) between the 
participants (physicians and nurses) in agreeing that development of the 
pharmaceutical industry in Kuwait should substantially improve. However 
physicians’ responses were closest to support the findings.  
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Table 4.34 Results from use of the Scheffe Method and the significant 
differences between the means of interviewees (pharmacists, physicians and 
nurses) on the total degree of the questionnaire. 
Question No Profession Pharmacist Physician Nurse 
All 
Questions 
Pharmacist 
M(2.77) 
--   
Physician 
M(2.76) 
0.01 --  
Nurse 
M(1.61) 
1.16 1.15 -- 
Scheffe Range = 0.744 
 
This table shows that: 
1. There were no significant differences between the participants (pharmacists 
and physicians) in the responses to the questionnaire as a whole. 
2. There were significant differences at the level (0.05) between the 
participants (pharmacists and nurses) in the responses to the questionnaire 
as a whole. However, the result was in favour of the pharmacists.  
3. There were significant differences at the level (0.05) between the 
participants (physicians and nurses) in the responses to the questionnaire 
as a whole. However, the result was in favour of physicians.  
 
Results of the fifth hypothesis 
This hypothesis indicated that there is no statistically significant difference between 
the sample responses to the questions in the questionnaire due to the different 
workplaces of participants (hospitals, health administrations, drug companies, 
health clinics, research center and pharmaceutical faculty).   
 
 
144 
 
To validate this hypothesis, the One Way Analysis of Variance method was used to 
examine the degrees of the workplaces of participants to the questions of the 
questionnaire. The result can be observed in the table below (page 143, 144 and 
155).   
Table 4.35 Results of the use of the One Way Analysis of Variance method to 
examine the degrees of the participants working in different health places  
 Ques 
No 
Source of 
Variation  
Sum of 
squares 
Degrees of 
Freedom 
Average 
Squares 
F   Value 
Level of 
significance 
1. 
Between Groups 38.30 5 7.66 
2.11 
No 
significance 
Within Groups 
(error) 
417.45 115 3.63 
Total 455.75 120  
2. 
Between Groups 17.70 5 3.54 
1.60 
No 
significance 
Within Groups 
(error) 
254.15 115 2.21 
Total 271.85 120  
3. 
Between Groups 46.00 5 9.20 
2.00 
No 
significance 
Within Groups 
(error) 
529.00 115 4.60 
Total 575.00 120  
 
 
4. 
 
 
 
Between Groups 24.20 5 4.84 
2.01 
No 
significance 
Within Groups 
(error) 
277.15 115 2.41 
Total 301.35 120  
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Follow Table 4.35 Results of the use of the One Way Analysis of Variance 
method to examine the degrees of the participants working in different 
health places  
No. 0f 
Ques. 
Source of 
Variation  
Sum of 
squares 
Degrees of 
Freedom 
Average 
Squares 
F   Value 
Level of 
significance 
5. 
Between Groups 16.10 5 3.22 
1.73 
No 
significance 
Within Groups 
(error) 
213.90 115 1.86 
Total 230.00 120  
6. 
Between Groups 19.90 5 3.98 
2.30 
No 
significance 
Within Groups 
(error) 
198.95 115 1.73 
Total 218.85 120  
7. 
Between Groups 13.05 5 2.61 
2.16 
No 
significance 
Within Groups 
(error) 
139.15 
115 
1.21 
Total 152.20 120  
8. 
Between Groups 16.15 5 3.23 
2.21 
No 
significance 
Within Groups 
(error) 
167.90 
115 
1.46 
Total 184.05 120  
 
 
9. 
 
 
Between Groups 18.10 5 3.62 
1.31 
No 
significance 
Within Groups 
(error) 
317.40 
115 
2.76 
Total 335.50 
120 
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Follow Table 4.35 Results of the use of the One Way Analysis of Variance 
method to examine the degrees of the participants working in different 
health places 
No. 0f 
Ques. 
Source of 
Variation  
Sum of 
squares 
Degrees of 
Freedom 
Average 
Squares 
F   Value 
Level of 
significance 
10. 
Between Groups 16.50 5 3.30 
2.31 
No 
significance 
Within Groups 
(error) 
164.45 
115 
1.43 
Total 180.95 120  
11. 
Between Groups 20.25 5 4.05 
1.66 
No 
significance 
Within Groups 
(error) 
280.60 
115 
2.44 
Total 300.85 120  
All 
Ques. 
Between Groups 15.50 5 3.10 
2.20 
No 
significance 
Within Groups 
(error) 
162.15 
115 
1.41 
Total 177.65 120  
F(5,115,0.05)= 2.44 
 
It can be seen from this table that there is no significant difference between the 
responses of the research sample to the questions in the questionnaire or on its 
total degrees.  
4.7.2 Qualitative Analysis 
In this analysis, the hypothesis provided that there were no statistically significant 
differences between the research samples in their responses regarding the 
reasons for their responses to the questions in the interview. 
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To validate this hypothesis, the frequency of responses giving reasons were 
calculated, and this was then given as a percentage. In addition, the Chi-Square 
Test was used to identify the significance of the differences between the 
frequencies of responses of research samples to the reasons for answering the 
interview questions. The result is observed in the table below.  
 
Table 4.36 Results of the use of the Chi-Square Test ( ) to identify the 
significant differences between the frequency of responses of research 
samples to the reasons for answering Question 1 of the interview.  
 
 
 
 
The responses of the interviewees to question 1 included: 
- Response (A): To develop and improve the health care system and 
reregulate the legislations and regulations of the pharmaceutical sector. 
- Response (B): To ensure access to safe, effective and quality drugs. 
- Response (C): To reduce the issues related to drugs and setting up 
necessary health organizations (for example, quality assurance department, 
Essential Drug List and pharmacovigilance center).  
Level of Significance 
Chi square 
 
Frequency and 
Percentage 
Responses Ques No 
No significance* 1.93 
21 
17.4 
A 
1 
23 
19.0 
B 
30 
24.8 
C 
24 
19.8 
D 
23 
19.0 
E 
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- Response (D): To apply better control over traded drugs, improve the 
rational use of drugs and ensure availability of drugs in the country with 
good cost-effectiveness. 
- Response (E): To provide guidelines and protocol for the health 
professionals. 
 
It can be seen from the table above that there were no significant differences 
between the mentioned responses of research sample to question1 in the 
interview. This means that the listed responses occurred by chance. For this 
reason, the researcher believes that a lack of an NDP in Kuwait impacted on 
participants’ responses and on their understanding and knowledge of the 
importance of this policy.  
 
Table 4.37 Results of the use of the Chi-Square Test ( ) to identify the 
significant differences between the frequency of responses of research 
samples to the reasons for answering Question 2 of the interview.  
  
 
In addition to the information above, the responses of the interviewees to the 
Question 2 included: 
Level of Significance 
Chi square 
 
Frequency and 
Percent 
Responses 
No. 0f 
Ques. 
0.01* 35.24 
23 
19.0 
A 
2 
29 
24.0 
B 
19 
15.7 
C 
45 
37.2 
D 
5 
4.1 
E 
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- Response (A): The health care system can be improved by increasing 
control and monitoring over drugs and strengthening the penalties.  
- Response (B): The health care system can be improved by developing the 
training programs for health professionals (pharmacists, physicians and 
nurses) and by improving their health education level. 
- Response (C):  The health care system can be improved by providing 
software programs and electronic link system between health places of the 
KMOH.  
- Response (D): The health care system can be improved by establishing 
further research centers, pharmacovigilance center, quality assurance 
departments, Essential Drug List and a NDP in Kuwait. 
- Response (E): The health care system cannot be developed because of the 
lack of guidelines which regulate the health sector and the absence of 
decisions to improve the health system. 
 
This table shows that there were significant differences at level (0.01) between the 
mentioned responses of the research sample to question 2 with highest frequency 
emphasized by response D as it involved the largest number of participants 
(N=45). 
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Table 4.38 Results of the use of the Chi-Square Test ( ) to identify the 
significant differences between the frequency of responses of research 
samples to the reasons for answering Question 3 of the interview.  
Level of Significance 
Chi square 
 
Frequency and 
Percentage 
Responses Ques No 
0.05* 15.10 
15 
13.6 
A 
3 
12 
9.9 
B 
12 
9.9 
C 
19 
15.7 
D 
8 
6.6 
E 
24 
19.8 
F 
9 
7.4 
G 
12 
9.9 
H 
  
 
The responses of the interviewees to question 3 included: 
- Response (A): Absence of knowledge on the economics related to the 
system from the MOH regulators such as drug cost effectiveness and supply 
management. 
- Response (B): Delays in the decision-making process from KMOH 
regulators and lack of centralization. 
- Response (C): Need for more hospitals and medical beds and weakness in 
control over the traded drugs in the private market (for example, the 
increase in counterfeit and unlicensed drugs).   
- Response (D): Lack of sufficient training programs and conferences for 
health professionals. 
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- Response (E): The need to have more research centers in the state 
because there is only one research center (Dasman Diabetes Institute). 
- Response (F): Absence of cooperation between KMOH administrations, 
hospitals and health clinics due to lack of an IT link system. 
- Response (G): The health care system in Kuwait is well-structured and there 
are no clear issues. 
- Response (H): The question was not considered applicable. 
 
This table shows that there were significant differences at level (0.05) between the 
mentioned responses of the research sample to question 3 with highest frequency 
emphasized by response F as it included the largest number of participants 
(N=24). 
 
Table 4.39 Results of the use of the Chi-Square Test ( ) to identify the 
significant differences between the frequency of responses of research 
samples to the reasons for answering Question 4 of the interview.  
Level of Significance 
Chi square 
 
Frequency and 
Percentage 
Responses Ques No 
0.01* 33.29 
36 
29.8 
A 
4 
27 
22.3 
B 
13 
10.7 
C 
20 
16.5 
D 
11 
9.0 
E 
14 
11.6 
F 
  
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The responses of the interviewees to question 4 included: 
- Response (A): There is enough control over drug registration and over 
secondary control after licensing. 
- Response (B): There is sufficient inspection and monitoring over public and 
private pharmacies, drug stores and pharmaceutical companies. 
- Response (C): There is insufficient control over the private market due to 
the presence of counterfeit and unregistered drugs. 
- Response (D): There is not enough control over the private sector, with the 
dispensing of prescribed drugs without prescription (for example, 
antibiotics). 
- Response (E): The issue of not having enough control because of the lack 
of a pharmacovigilance center in Kuwait. 
- Response (F): Weakness of penalties for the irregularities is the main 
reason for the absence of sufficient control over the pharmaceutical sector.    
 
This table shows that there were significant differences at level (0.01) between the 
mentioned responses of the research sample to question 4 with highest frequency 
given for response A, as it included the largest number of participants (N=36). 
Table 4.40 Results of the use of the Chi-Square Test ( ) to identify the 
significant differences between the frequency of responses of research 
samples to the reasons for answering Question 5 of the interview.   
  
Level of Significance 
Chi square 
 
Frequency and 
Percentage 
Responses Ques No 
0.05* 10.21 
38 
31.4 
A 
5 
21 
17.4 
B 
40 
33.1 
C 
22 
18.2 
D 
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The responses of the interviewees to question 5 included: 
- Response (A): There is a lack of training programs (for example, in clinical, 
ethical, communication and medical skills programs) for health 
professionals, specifically for newly-graduated staff. 
- Response (B): The pharmacists training programs are insufficient and there 
is an absence of any training programs for the inspectors and staff of the 
pharmaceutical administrations in the public sector (drug control, central 
medical store and drug inspection administrations). 
- Response (C): There were enough and appropriate training programs for 
health professionals due to the existence of a one year training rotation 
course for the newly-recruited staff. 
- Response (D): There are not enough training programs for physicians and 
nurses in the public sector, in addition, there is an absence of medical 
conferences, seminars, lectures and workshops for nurses. 
 
This table shows that there were significant differences at level (0.05) between the 
mentioned responses of research sample to question 5 with highest frequency 
given to response C because it included the largest number of participants (N=40). 
However, the total number of interviewees who answered that the training 
programs in Kuwait are insufficient were 81, and their answers were distributed 
across the other responses (A, B and D).    
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Table 4.41 Results of the use of the Chi-Square Test ( ) to identify the 
significant differences between the frequency of responses of research 
samples to the reasons for answering Question 6 of the interview.   
Level of Significance 
Chi square 
 
Frequency 
and 
Percentage 
Responses Ques No 
0.01* 19.13 
43 
35.5 
A 
6 
22 
18.2 
B 
41 
33.9 
C 
15 
12.4 
D 
          
 
 
The responses of the interviewees to question 6 included: 
- Response (A): The price range of medication in the private sector is not 
acceptable when compared to the prices in other Gulf countries (for 
example, KSA), where the drugs prices in Kuwait are three times more 
expensive. 
- Response (B): The price range of medication in the private sector is not 
acceptable as the Pricing Department of the Drug and Food Control 
Administration is not qualified and strict enough in dealing with the private 
drugs prices and specifically the prices of generic drugs. 
Response (C): The price range of medication in the private sector is acceptable 
even when compared to the prices in KSA because the drugs prices are related to 
a number of factors such as the population of KSA is the largest in the Gulf area so 
ordering in bulk makes it cheaper than Kuwait. In addition, there is an absence of a 
pharmaceutical industry in Kuwait whereas affected negatively in increasing the 
needs for the imported drugs and cause an increase in the price range of the 
drugs. 
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- Response (D): The answer was not applicable due to the interviewees not 
knowing information about the price range of medication in the private 
sector. 
This table shows that there were significant differences at level (0.01) between the 
mentioned responses of research sample to question 6 with highest frequency 
given to response A, because it included the largest number of participants (N=43). 
 
Table 4.42 Results of the use of the Chi-Square Test ( ) to identify the 
significant differences between the frequency of responses of research 
samples to the reasons for answering Question 7 of the interview.   
 
 
  
 
The responses of the interviewees to question 7 included: 
- Response (A): There were no issues with access to quality, safe and 
effective drugs because the available drugs in the public sector are of the 
best quality and the medications are available for free for the citizens and 
residents in the State. 
- Response (B): There were no issues with access to quality, safe and 
effective drugs because all the drugs in the private market are under the 
Level of Significance 
Chi square 
 
Frequency and 
Percentage 
Responses Ques No 
No significance* 2.21 
29 
24.0 
A 
7 
37 
20.6 
B 
26 
21.5 
C 
29 
24.0 
D 
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control of the KMOH, where drugs should be registered and licensed by the 
Drug and Food Control Administration before they are sold in the market. 
- Response (C): There are issues in this respect because there is not enough 
control and there is weakness in the inspection of drugs sales in the private 
sector, specifically in the sale of non-prescription drugs. 
- Response (D): The main issues related to this aspect are the lack of a 
pharmacovigilance center and drug information center in Kuwait. 
It can be seen from the table above that there are no significant differences 
between the mentioned responses of the research sample to question 7 in the 
interview, which means that the listed responses were the result of chance.   
Table 4.43 Results of the use of the Chi-Square Test ( ) to identify the 
significant differences between the frequency of responses of research 
samples to the reasons for answering Question 8 of the interview.   
Level of Significant 
Chai square 
 
Frequency and 
Percent 
Responses 
No. 0f 
Ques. 
0.01* 63.90 
56 
46.3 
A 
8 
26 
21.5 
B 
23 
19.0 
C 
6 D 
 
 
157 
 
 
 
 (4,0-01)=13,277 
 
The responses of the interviewees to question 8 included: 
- Response (A): There is a problem with irrational use of prescription drugs in 
Kuwait, specifically usage of antibiotics, sexual products and hormones.  
- Response (B): There is an increase in the irrational use of drugs in the 
country due to the issue of self-medication among the public. 
- Response (C): There is issue with irrational use of drugs due to weak health 
education of patients and specifically the elderly, as well as the low 
education of some physicians in prescribing inappropriate medications to 
patients. 
- Response (D): The answers were not applicable because the interviewees 
did not have enough information about the irrational use of drugs in Kuwait 
and they could not take a decision in this question. 
-  Response (E): There is no irrational use of drugs in both the public and 
private sector in Kuwait. 
This table shows that there are significant differences at level (0.01) between the 
mentioned responses of the research sample to question 8 with the highest 
frequency given from response A, because it included the largest number of 
participants (N=56). 
 
Table 4.44 Results of the use of the Chi-Square Test ( ) to identify the 
significant differences between the frequency of responses of research 
samples to the reasons for answering Question 9 of the interview.   
5.0 
10 
8.3 
E 
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  
 
  
Level of Significance Chi square 
 
Frequency and 
Percentage 
Responses Ques No 
0.01* 40.14 
24 
19.8 
A 
9 
49 
40.5 
B 
20 
16.5 
C 
22 
18.2 
D 
6 
5.0 E 
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The responses of the interviewees to question 9 included: 
- Response (A): Kuwait should establish an Essential Drug List based upon 
the appropriate needs of the country for the medications to ensure 
availability and affordability of the main drugs. 
- Response (B): The Essential Drug List is very important to the State and it 
would lead to savings to the national budget. 
- Response (C): The Essential Drug List is important for determining the 
appropriate needs of drugs for the long term for both the public and private 
sector. 
- Response (D): The Essential Drug List would help to reduce any costs 
associated with adverse reactions and ensure drug effectiveness. 
- Response (E): The question is not applicable because the interviewees do 
not know enough about it. 
- Response (F): There is no reason to have an Essential Drug List in Kuwait.   
 
This table shows that there were significant differences at level (0.01) between the 
mentioned responses of the research sample to question 9 with highest frequency 
given by response B, because it included the largest number of participants 
(N=49). 
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Table 4.45 Results of the use of the Chi-Square Test ( ) to identify the 
significant differences between the frequency of responses of research 
samples to the reasons for answering Question 10 of the interview.  
  
 
 
  
 
The responses of the interviewees to question 10 included: 
- Response (A): The presence of a pharmaceutical industry would secure the 
country’s medicines resources and reduce the monopoly of international 
drugs companies.  
- Response (B): The pharmaceutical industries would help availability of 
drugs during emergencies and wars. 
- Response (C): It would increase and improve the national sources of 
income and improve the pharmaceutical technologies. 
- Response (D): There is no benefit to having a pharmaceutical industry in 
Kuwait because it will cost more than purchasing imported drugs and 
specifically generic drugs. 
- Response (E): In Kuwait there is a lack of certain factors that would lead to 
success in drug production, such as a high level of technologies, quality 
trained staff and research centers.  
 
Level of Significance 
Chi square 
 
Frequency and 
Percentage 
Responses Ques No 
0.01* 40.14 
24 
19.8 
A 
10 
49 
40.5 
B 
20 
16.5 
C 
22 
18.2 
D 
6 
5.0 
E 
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Table 4.46 Results of the use of the Chi-Square Test ( ) to identify the 
significant differences between the frequency of responses of research 
samples to the reasons for answering Question 11 of the interview.   
 
 (1,0.01)=9.210 
 
This table shows that there were significant differences at level (0.01) between the 
mentioned responses of the research sample to question10 with highest frequency 
given from response C, because it included the largest number of participants 
(N=47). 
 
 
 
The responses of the interviewees to question 11 included: 
- Response (A): It is a suitable time to establish a NDP in Kuwait and the 
KMOH had all the necessary factors and the base structure to work on this 
action plan. 
- Response (B): The KMOH should start working on the establishment of a 
NDP but first it should provide and improve appropriate factors to complete 
this action successfully.  
- Response (C): The KMOH does not have sufficient capacity, is unable to 
take the decisions and cannot successfully produce a NDP in the country at 
this current time.  
Level of Significance 
Chi square 
 
Frequency and 
Percentage 
Responses Ques No. 
0.01* 137.33 
13 
10.7 
A 
11 101 
8.5 
B 
7 
5.8 
C 
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This table shows that there were significant differences at level (0.01) between the 
mentioned responses of the research sample to question 11 with highest frequency 
given from response B because it included the largest number of participants 
(N=101). 
 
Table 4.47 Results of the use of the Chi-Square Test ( ) to identify the 
significant differences between the frequency of responses of research 
samples to the reasons for answering Question 12 of the interview. 
 
* (4,0.01)=13.272 
 
The responses of the interviewees to question 12 included: 
- Response (A): It would develop and strengthen the present guidelines for 
the legislations and regulations related to drugs. 
- Response (B): It can help to improve the level of the pharmaceutical sector, 
such as drug registration, inspection, supply management, procurement, 
dispensing, control and monitoring and ensure availability of safe and effect 
drugs in the State. 
Level of Significance 
Chi square 
 
Frequency and 
Percentage 
Responses Ques No 
0.01* 28.38 
17 
14.0 
A 
12 
25 
20.7 
B 
12 
9.9 
C 
46 
38.0 
D 
21 
17.4 
E 
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- Response (C): It would support the establishment and existence of 
necessary health departments and organizations such as quality assurance, 
pharmaovigilance and research centers. 
- Response (D): It could improve the health care system by solving many 
issues such as the lack of an Essential Drug List, IT link system and training 
programs, as well as reduce the spread of counterfeit drugs in the private 
market and increase the rational use of drugs. 
- Response (E): It would develop the cooperation between the health 
organizations, administrations, hospitals, associations and university 
through a discussion forum to define goals and objectives of the health care 
system and set priorities.   
 
This table shows that there were significant differences at level (0.01) between the 
mentioned responses of the research sample to question 12 with highest frequency 
given from response D because it included the largest number of participants 
(N=46). 
 
4.8 Limitations of the study 
During the undertaking of the study the researcher was faced with some limitations 
and problems. First, the researcher wanted to apply a different method of interview, 
namely one with a focus on discussions between participants. However, it was 
difficult to arrange a meeting between the groups of participants due to time 
restrictions. Second, participants (pharmacists) were the largest sample size which 
potentially indicates their interest in participating. This meant there was a smaller 
sample size of other participants such as physicians and nurses as it was hard to 
access them and also because of the time pressure which prevented them from 
taking part in the study. In fact, some physicians were extremely disinterested and 
unwilling to participate, to the point that they expressed it verbally. In addition, a 
lack of an IT-link system between health areas of KMOH created more work and 
consumed more time for the researcher at the data collection stage. 
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4.9 Strength of the study 
Lack of previous studies, finding sufficient research resources and statistics related 
to the development of a NDP in Kuwait were some of the difficulties but the 
researcher found in these difficulties a unique challenge as it was necessary to 
take action to establish the initial ground for development of a NDP in the State. In 
addition, the study combined quantitative and qualitative approaches in order to 
improve its robustness and to facilitate exploration through the opinions of 
participants. Moreover, the validity and reliability of the questionnaire increased 
when these two different methods were used (quantitative and qualitative 
methods). 
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Chapter 5.0: The Pharmaceutical Sector in State of Kuwait 
 
The pharmaceutical sector is one of the most important areas for the Health Care 
System in Kuwait. It includes all the pharmaceutical services in the public and 
private sectors in the country, also it ensures the access, affordability and 
availability of the drugs for the patients and is responsible for ensuring the quality, 
safety and efficiency of the medicines which are used.  
It is proposed that the establishment of a Kuwaiti NDP should support an increase 
in the development and improvement of the pharmaceutical sector by introducing, 
organizing, operating and reviewing the policies which would be introduced and 
could be built upon in the future. In addition such developments would be expected 
to lead to reregulation of the pharmaceutical legislations and regulations and work 
towards updating to keep pace with the requirements and needs for the future.  
It is proposed that the major outcome and analysed data from the structured 
interviews (presented in Chapter 4) provides an understanding of the current 
position of the pharmaceutical sector in Kuwait.  In this Chapter the present 
pharmaceutical services in the public and private sectors in Kuwait are further 
identified, studied and discussed, in order to understand the nature of the 
pharmaceutical operation in Kuwait, and how legislations and regulations are used.  
Also the issues and requirements of this sector are identified and procedures are 
discussed with proposals and solutions which could help accommodate the 
establishment of a NDP.     
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5.1 The Public Sector 
The public pharmaceutical sector in the State of Kuwait includes all the 
pharmaceutical administrations of the Kuwaiti Ministry of Health (KMOH). These 
administrations are divided into 4 main areas which are the: 
1. Pharmaceutical Services Administration. 
2. Drug and Food Control Administration. 
3. Central Medical Store Administration. 
4. Drug Inspection Administration. 
The four administration units are managed through the Assistant Undersecretary of 
Drugs and Medical Supplies Affairs in KMOH (Dr. Omar, the third supervisor). 
Each of the administrations has their own general Director, administrative 
structure, and health professional staff and is responsible for regulating and 
developing their own work and they seek to ensure appropriate services to the 
consumers and improvements in the health care system under the supervision of 
the Ministry of Health. See Figure 5.1 (KMOH, 2011 a) (Alali, 2011). 
 
Figure 5.1.The structure of pharmaceutical sector for the KMOH (KMOH, 2011 
a) 
5.1.1 Pharmaceutical Services Administration. 
In the 1980’s the KMOH wanted to develop further the pharmaceutical services in 
line with the health situation in the country, and it was decided to established the 
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pharmaceutical services administration in 1985 (Ministerial Decree.166, which was 
amended by the Ministerial Decree.67 and 151 in the year 1986). (KMOH, 2011 b) 
The Pharmaceutical Services Administration is responsible for many duties, such 
as: 
1. Participation in the development of the general plan on the regulation of 
pharmaceutical services and in the follow-up and implementation of these 
regulations after adoption. 
2. Carrying out all the work and tasks related to the provision of pharmaceutical 
services in accordance with the general plan of the MOH. 
3. Supervising the preparation of pharmaceutical patient leaflets and moderating 
periodically and developing services in coordination with the concerned authorities.  
4. Coordination with regional and international institutions in the field of 
pharmaceutical services.  
5. Coordination and technical supervision of the pharmacists in the public 
hospitals, health clinics and health centers. 
6. Preparing annual reports on the activities of pharmaceutical services in the 
health areas, hospitals and health centers. 
7. Preparing the annual needs of health professionals and the necessary 
equipment for the pharmaceutical services in coordination with the concerned 
authorities in this field. 
8. Regulating and monitoring the pharmaceutical services in all Governmental 
hospitals and health clinics in the State of Kuwait, which covers 6 provinces, and 
it’s responsible for the work of pharmacists and technicians and for their training, 
developing, evaluation and distribution of medicines and devices to public 
pharmacies. It is the largest administration of the MOH that deals with patients. 
See Figure 5.2. (KMOH, 2011 c)  
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Figure 5.2 Organization Structure of Pharmaceutical Services Administration 
(KMOH, 2011 c) (MSc, 2011) 
 
- The structure of the Pharmaceutical Services Administration: 
This administration consists of two supervisions, the:  
1. Planning and training supervision. 
2. Coordination and follow-up supervision. 
 
As was mentioned above, this administration is responsible for introducing training 
courses for the pharmacists and technicians. But there is only one training program 
for the new pharmacists working in KMOH. The period of this training course is 1 
year and includes: working 2 months in a Public Health Center, 6 months in Public 
General Hospital and 4 months in a Private Hospital. Through this rotation training 
course the pharmacist will work in many units to identify and learn the work in a 
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central pharmacy unit, medicine manufacturing unit, intravenous nutrition unit, unit 
of drug and mental effects, emergency unit, outpatient unit and medical storage 
unit. 
After completion of this training course, the Administration distributes the 
pharmacists to the pharmacies which belong to the MOH.  But after this training 
there is no any training course to update, improve and evaluate the pharmacist’s 
scientific or practical level. (KMOH, 2014 a) 
 
5.1.1.1 The Review of the Pharmaceutical Services Administration for this Study 
The Administration was visited during the PhD program (during the structured 
interviews and informal visits) discussions were undertaken with the staff at a 
number of levels (Further details of these discussions and number of staff involved 
can be found in chapter 4, page 90 - 94); From these studies, it was found that 
there were a number of concerns in the working system, and these included:   
1. The lack of further training programs for the pharmacists and technicians.  
2. Absence of updating courses and training studies for the senior staff. 
3. The regrading system for pharmacists is generally not based on capability, but 
depends on the number of years in the workplace. 
4. The shortage of access to internal and external professional conferences and 
symposia to which health professionals can attend and in some cases present at.    
 
It was suggested in the structured interviews (in Chapter4) that the KMOH should 
be resolving these problems which it was felt would improve the professionalism of 
the Health Services and reflect positively in the health care system and with 
patients and this development should be introduced into an established NDP in the 
State.  
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5.1.2 Drug and Food Control Administration 
The KMOH established the Drug and Food Control Administration in 1990, 
according to the Ministerial Decree.8.3 (KMOH, 2011 d). The reason for 
establishing this Administration was because it was considered very highly 
important as the main unit for controlling legislation in the pharmaceutical sector.  
In this respect it is responsible for many areas related to the quality and delivery of 
medicines, available to the population, and its function includes: 
1. Responsibility for the registration of herbal and pharmaceuticals, cosmetic 
products, veterinary drugs, unclassified and medical devices products and 
food supplement products which are entering the country and control 
according to the Kuwaiti MOH rules and conditions.  
2. Responsibility for the licensing of pharmaceutical products the other health 
products and for regulating their release into the pharmaceutical areas. 
3. To carry out studies and develop statistics for the registered products and to 
classify them into defined categories. 
4. To insure the co-operation with all local and international agencies which 
are concerned concern with the importation and distribution of medicines in 
Kuwait. 
5. To ensure efficient medicines processing and drug control. 
6. To ensure that all the legislations and pharmaceutical guidelines and 
controls are adhered to which confirm the quality and safety of the 
medicines and health products. 
7. Responsibility for the registration of the drug companies in conducting 
business in the pharmaceutical field. 
8. To provide guarantees that all imported and exported drugs are under GMP 
conditions before releasing them to the market. 
9. Controls over the price of the drugs in the private market. 
 
From examination of the information above it can be proposed that a successful 
establishment of a NDP is likely to depend to a large extent on the efficiency of the 
Drug and Food Control Administration, and there is a suggestion for the KMOH to 
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support the Administration and help in establishing a NDP, and the KMOH should 
develop and improve this Administration, solve any issue in its system and 
contribute to improving the level of health professional staff to ensure the continuity 
of the success of the work on developing the NDP in Kuwait (KMOH, 2015 b). 
 
The organization structures of the Drug and Food Control Administration, consists 
of two main supervision units and three individual Departments: 
1. Registration Supervision. 
2. Laboratories Supervision.  
3. Drug Pricing Department. 
4. Drug Release Department in Kuwait International Airport. 
5. Quality Assurance Department. (KMOH, 2015 b) 
 
 
Figure 5.3 Organization Structure of Drug and Food Control Administration 
(KMOH, 2015 b) 
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5.1.2.1 The Registration and Release Supervision 
This Supervision is concerned with the registration, licensing and releasing of the 
pharmaceutical, herbal, veterinary, cosmetics, food supplements and non-
classified medicines and products. 
 
- The objectives of Drug/Product registrations and release are to: 
1. Ensure that all medicines and pharmaceutical products which imported or 
manufactured in the country are evaluated and registered by Drug and Food 
Control Administration. 
2. Ensure the quality, safety and efficacy of all the imported/ used drugs. 
3. Obtain the benefit from the particular product accompanied by the appropriate 
professional advice. 
4. Ensure that all the drug companies are registered and licensed under the rules 
of the Administration and to regulate and follow them through the process of 
dispensing to the patient. (KMOH, 2015 c) 
 
- The advantages which could be developed from Drug Registrations are: (From 
direct experience of working in this area during 7 years and from observation and 
discussion with a supervisor of this area during the structured interviews):  
1. Some of the revenue from Registration Fees could be used by the MOH to 
develop this Department. 
2. As the reporting of adverse drug reactions is not commonly carried out it should 
be further supported and promoted.  
3. To ensure that all the Branded and Generics Medicines meet quality standards 
and are under the required control. 
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- Types of registrations, which are under the Drug and Food Control 
Administration: 
1. Pharmaceutical Products (capsules, injections, serums and tablets). 
2. Herbal Products. 
3. Food Supplement Registration. 
4. Cosmetic Products. 
5. Unclassified and Medical Devices Registration. 
6. Veterinary Products. 
7. Pharmaceutical Companies and Agencies Registration. 
8. Drug Stores and Warehouses Registration. (KMOH, 2015 c) 
 
- This is one area which may benefit from an examination of its operation.  For 
instance to register a new product with the Kuwaiti Drug Control Department could 
take three months for each application, if all the requirements are submitted 
appropriately.  This could be considered a convenient approval time at three 
months, when compared with a number of other countries.  For instance in:  
Algeria (registration time=7 months), Nigeria (registration time=4 months) and 
Uruguay (registration time=5 months). But in other developing countries the 
registration time is shorter, such as in Costa Rica the registration’s time is six 
weeks. This is one area where the KMOH could examine the operation to ensure 
that the assessment of the drug registration period is as efficient as it could be and 
reduce it if possible in order to provide faster access of drugs to the public. (Kaplan 
and Laing, 2003).  
        
In addition the license certificate lasts for 2 years and can be renewed.  It is a 
requirement that all the drugs/medicines to include: imported - exported drugs 
stored and sold medicines and locally produced medicines should be registered 
before it reaches the consumer or patient. 
The Registration and Release Supervision consists of eight departments to 
include: 
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- Pharmaceutical registration department. 
- Herbal registration department. 
- Veterinary registration department. 
- Unclassified and medical devices registration department. 
- Invoice release department. 
- Food supplements registration department. 
- Cosmetics registration department. 
- Training department. 
 
 
 
Figure 5.4.The Organization Structure of the Registration and Release 
Supervision (KMOH, 2015 c) 
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a) Pharmaceutical Registration Department:   
which specializes in: 
1. Registration of imported and local manufactured medicines according to the 
registration rules. 
2. Giving the first and final release for imported medicines after ensuring the 
accompanying paperwork, invoices and checks that the items are 
registered. 
3. Taking control of the entire drug invoices and medicines parcels and 
ensuring that the paperwork obeys the regulatory rules. 
4. Giving licenses for the approved registered drugs. 
5. Giving licenses for the pharmaceutical companies and agencies. 
6. Giving licenses for the drug/medicines storage and warehousing. 
 
In order to receive the licenses the Drug Companies should follow the rules and 
conditions of the Drug and Food Control Administration, which are clearly stated 
below. 
a1) Requirements for registration of pharmaceutical products, includes:  
1. Provision of samples including: packaging, patient leaflet in Arabic or English 
language and the written information on the medicine e.g. storage conditions, the 
brand or generic name, active ingredient and shelf life. 
2. Certificate of Pharmaceutical Products (CPP), and it should be original and 
legalized from the Kuwaiti Embassy in the country of origin.  
3. Original and legalized Good Manufacture Practice (GMP) Certificate. 
4. Any clinical studies for the pharmaceutical product under registration. 
5. Stability studies (long term study and accelerated study). 
6. Provision of Bioequivalent study (only for the generic products). 
7. Pricing certificate for the pharmaceutical product under registration. 
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8. Drug Analysis Certificate. 
9. Certificate shows if the product was registered in other countries. 
b). Herbal Registration Department:  
It specializes in: 
1. Registration of the imported and local manufactured herbal products 
according to the registration rules. 
2. Giving the first and final releases for the imported herbal products after 
insuring the invoices and checking that the items were registered. 
3. Checking of the entire herbal product invoices and herbal parcels and insure 
that they are under the rules. 
4. Provision of licensing for the approved registered herbal products. 
 
c). Veterinary Registration Department: 
 It is specializes in: 
1. Registration the imported and local manufactured veterinary drugs 
according to the registration rules. 
2. Giving the first and final releases for the imported veterinary drugs after 
insuring the invoices and checking that the items were registered. 
3. Making control for the entire veterinary drugs invoices and veterinary drugs 
parcels and insure that it was under the rules. 
4. Giving licensing for the approved registered veterinary drugs. 
 
c1) - There is a list of requirements for registering a veterinary company, such as: 
1. Legalized and original manufacturing license. 
2. Legalized and original letter of appointment issued by the mother (original) 
company. 
3. Legalized and original GMP certificate. 
4. The company profile. 
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c2) - There are list of basic requirements for registering a veterinary product for 
non-consumption animals (Pets, horses and birds), such as: 
1. Finished product sample. 
2. Legalized and original price certificate. 
3. Legalized and original Free Sale Certificate or CPP. 
4. Finished product specifications. 
5. Certificate of Analysis Product (with the same batch number of the sample 
submitted).  
 
c3) - The basic requirements for the registration of a veterinary product for human 
consumption animals are: 
1. Finished product sample. 
2. Legalized and original price certificate. 
3. Legalized and original Free Sale Certificate or CPP. 
4. Finished product specifications. 
5. Certificate of Analysis Product (with the same batch number of the sample 
submitted).  
6. Summary of product characteristics. 
7. Source of supply of active ingredients. 
8. List of countries where the product is registered with registration dates. 
9. Raw material specifications. 
10. Stability studies. 
11. Clinical studies. 
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12. Toxicological and residue studies. 
13. Certificate of drug residue and withdrawal period. 
 
d). Unclassified and Medical Devices Registration Department: 
It specializes in: 
1. Registration the imported and local manufactured unclassified and medical 
devices products according to the registration rules. 
2. Giving the first and final releases for the imported unclassified and medical 
devices products after insuring the invoices and checking that the items 
were registered. 
3. Making control for the entire unclassified and medical devices products 
invoices and unclassified and medical devices products parcels and insure 
that it was under the rules. 
4. Giving licensing for the approved registered unclassified and medical 
devices products. 
 
e). Drug Release Department: 
It specializes in: 
1. Co-operating with Kuwait’s marine, air and land ports, and regulates the 
coordination between them and the Drug Control Administration.  
2. Monitoring all imported drugs, pharmaceuticals products, herbal, veterinary, 
medical devices, food supplement and cosmetic shipments and parcels, and 
matches finance to the imported products. 
3. Supervising the re-export (rejection of) pharmaceutical products and food 
supplements which are not allowed to be used in the country.  
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e1)  The Drug Release Department includes the following offices and sections to 
include the: 
1. Release Office in Kuwait International Airport. 
2. Release Office in AL Shuwaikh Port. 
3. Land Customs office. 
4. Kefan Post office. 
 
f). Food Supplement Registration Department: 
It specializes in: 
1. Registration of imported and locally manufactured food supplements 
products according to the registration rules. 
2. Giving the first and final releases for the imported food supplement products 
after ensuring the authenticity of invoices and the checking that the items 
were registered. 
3. Control of the entire food supplement product invoices and food supplement 
parcels and insuring that they come under the rules. 
4. Giving licensing for the approved registered food supplement products. 
5. Researching and studying chronic diseases for different age groups and 
finding good solutions for these health issues. 
6. Developing and carrying out training programs for health professionals to 
increase their efficiency in their work.  
 
g). Cosmetic Registration Department: 
It specializes in: 
1. Registration of imported and locally manufactured cosmetic products 
according to the registration rules. 
2. Giving the first and final release for the imported cosmetic products after 
insuring the invoices and checking that the items were registered. 
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3. Controlling of the entire cosmetic product invoices and cosmetic parcels and 
insuring that they are under the rules. 
4. Giving licenses for the approved registered cosmetic products.    
 
h). Training Department: 
It specializes in: 
1. Developing training programs and courses in drug control and drug 
registration for the health professionals in the administration. 
2. Monitoring and regulating the visits of medical and pharmaceutical students 
to the administration.  
 
All these points appear to be appropriate however during the fieldwork for this PhD 
research study, the basis and how these operations are carried out was 
investigated further.  From this the main issues found in the Registration System 
were obtained through informal visits in this administration (in 2015) as well as the 
structured interviews with the staff (in 2014) (Further details of these visits, 
discussions and number of staff involved was discussed in chapter 4), However the 
main points were that: 
1. The staff needs more training course and experience in the following: 
               A. Bioequivalence test study. 
               B. Stability Studies. 
               C. GMP training courses. 
               D. Clinical test studies. 
The structured interviews which were carried out were conducted with four senior 
staff: the Assistant Under Secretary for Drug and Medical Supplies of the KMOH, 
Director and Supervisor of registration and release of drugs; and Head of the drug 
registration department of Drug and Food Control Administration, who were each 
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interviewed. The main points that they raised were that the staff needed more 
training programs in the aspects mentioned above. These comments were also 
backed up in the informal discussions with other staff in the same administration 
who also stated that there was a lack, generally of training programs for health 
professionals; but especially in the areas mentioned above.  They also indicated 
that there should be programs of a practical nature in their field in order to increase 
their skills and reduce their work errors.       
      
2. Another area which was mentioned and should be given priority is that there 
should be more computerization of the evaluation system as the present system 
does not easily support working and receiving applications manually.3. 
Prioritization of registration should be based on need. 
4. There should be provision of a link system between all the departments to save 
effort and time. 
5. There should be a listing of normal procedures and standards for registration of 
medical devices. 
6. It is important to have a link system with the Central Medical Store. 
7. That a drug index system for the Drug Control Administration would help the 
staff, health professionals and the agencies to know which are the registered drugs 
in Kuwait and this index should be update yearly. 
8. A need to increase the co-operation with other local or international agencies. 
9. To have an official web site for the Administration.  
 
5.1.2.2 The Laboratories Supervision 
This Supervision includes the following Departments: 
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1. Chemical Analysis Laboratory Department: which is concerned with the process 
of analysis of all imported drugs and pharmaceuticals to the State of Kuwait for 
both public and private sectors. 
Chemical Analysis Laboratory Department which works on physicals tests 
(hardiness, dissolution and pH) and chemicals test (to include HPLC and UV). 
(KMOH, 2011 e) (MSc, 2011) 
 
2. Pharmacology Laboratory Department: the functions of this Department are to 
conduct tests to ensure the safety of intravenous fluids and other similar 
medications, e.g. those which are used for diabetes, such as injecting insulin, for 
work using experimental animals and other tests for analyzing drugs. 
Pharmacology Laboratory Department also carries out sterility and pyrogen tests. 
This Laboratory was renewed in 2011, and the methods changed from animal 
testing to HPLC and other tests to increase efficiency, reduce the cost and time 
consumed for animal care. 
3. Microbiological Laboratory Department: which, is concerned with the process of 
laboratory experiments, which test stability, sterility, and includes an effectiveness 
test for the drugs, injections and medical devices. This Laboratory was renewed in 
2011, and the methods also updated e.g. a dark room for the sample was built, and 
the air flow system was renewed and an enhanced disposal system for toxic waste 
was introduced. (KMOH, 2011 e) (MSc, 2011) 
 
The issues were found in the laboratory system, when carrying out informal visits 
to this Administration in 2014-2015 (during PhD study).  The informal discussions 
with the staff included mention of: 
1. Insufficient numbers of Laboratory equipment for medicines analysis and 
assessment (e.g. dissolution baskets) which increases the time of the work 
and also lack of HPLC columns. 
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2. The need to expand the work areas in the Laboratories and to allow for the 
provision of space for writing up of the Laboratory results.  
3. Overall there is the need for more equipment for pharmaceutical and 
biomedical analysis. (e.g. only one HPLC is currently available) 
4. The needed to implement the latest GLP and SOPs procedures in the 
Laboratory. 
5. Overall there should be assessments to try to reduce the overall time of 
analysis procedures. 
 
 
5.1.2.3 The Drug Pricing Department 
This Department operates directly under the control of the Assistant 
Undersecretary of Drugs and Medical Supply Affaires in Kuwaiti, which is managed 
by the Ministry of Health. Three pharmacists are working in this Department. 
 Its function is to: 
1. Control and regulate the drug pricing for the private sector. 
2. To make sure that the approved prices by the Ministry of Health are followed. 
(KMOH, 2011 f)  
It is clear that these functions would become very important in the future 
development of a NDP. (KMOH, 2014 b) 
 
During the studies it was proposed that when pricing the medicines, the Kuwaiti 
Government should take into account two important factors, 1) the balance 
between ensuring equal access and the make of the medicine affordable to the 
public, and at the same time still allowing drug companies to make profits which 
are essential for the return on their investment. The pharmaceutical companies 
argue that charging the current prices allows them to continue investing in research 
and development and producing the next generation of drugs (Moynihan et al., 
2002). However, the National Governments and country collaborations e.g. Gulf 
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States (and particularly those with large cash reserves and population-size 
leverage) still have a major influence on the cost of medicines as they can put 
pressure on the companies as in the public sector they are responsible for the 
health of their residents and citizens.  As a result particularly when countries come 
together they can, purchase medicines in bulk in their required amounts. Thus, the 
prices of drugs are generally determined as a compromise between both by what 
major governments are willing to pay, and what the companies believe is a overall 
product costs. For example, in the United Kingdom, the NHS is the country’s 
largest buyer of pharmaceutical products and approaches companies to negotiate 
prices with them directly (House of Parliament, UK Government, 2010).  
However this can be a confusing economic and healthcare web, and governments 
(Ministries of Health) have an important responsibility towards development of the 
drug sector. For instance, presently, the NHS was predicted to save £2.7 billion 
annually when it started buying generic versions of drugs that had come off patent 
(House of Parliament, UK Government, 2010). It can be suggested that is great 
news both for the government budgets and for the UK tax payer, but the question 
which can be asked is – ‘what happens to the companies who may be losing out’?  
It may be suggested that often, it is the Generic Drug companies (along with the 
people of the country) who benefit.  However the down side is that Generic 
Companies do not invest as heavily in R&D as do traditional Pharmaceutical 
Companies, meaning essentially, that generic companies do not develop new 
drugs – that task is still left to ‘Big Pharma’. Ultimately, it can be said that if the 
R&D money dries up, fewer drugs may make it to market; which is especially 
concerning in certain areas such as where resistance is being felt; - given the rapid 
rise of antibiotic resistance and increasing autoimmunity and cancer incidence 
worldwide. Such problems are exacerbated at the present time by the fact that 
many developed economies are passing through a decade of stagnant growth (and 
even negative equity), driving steep budget cuts in health care and social services, 
and the lowering of drug prices (House of Parliament, UK Government, 2010).  
However, faced with falling sales in certain areas, if ‘Big Pharma’ increases the 
price of new drugs then there becomes a vicious circle with no winner – such as 
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limited next-generation drugs able to cure modern ailments and known conditions 
more effectively – making them less available. Therefore, it is suggested that the 
governments have a responsibility to pharmaceutical companies and the wider 
economy (and nation’s health) to ensure that fair prices are paid to the drug 
companies. As an example in the UK, separate government agencies decide upon 
which drugs they want, and how much they should cost, helping more objective, 
population-level statistical analyses to be made, and fairer prices reached, 
wherever possible – which is better for both sides in the long-term.  
 
In this case, towards a productive end for both sides have tried to evade a trade 
war, the UK government and various pharmaceutical companies have entered into 
a voluntary agreement, called the Pharmaceutical Price Regulatory Scheme, which 
regulates the profits that companies can make from NHS sales (currently capped 
at nearly 30%); although in practice it is very difficult to determine which profits 
arose from the UK activities of very large companies, and creative accounting may 
mask any intended benefit. Within the agreement, pharmaceutical companies are 
also allowed to change the prices of drugs if new evidence concerning their use 
comes to light. However, as a sweetener for the government, the scheme also 
ensures that the price of each drug falls by 5% each year of continual use (House 
of Parliament, UK Government, 2010). Through such schemes, the public and 
private sectors might work together better for the benefit of taxpayers and patients. 
Finally, central to most successful drug purchases (and negotiations) are metrics of 
value-based pricing; i.e. what the particular drug is worth to that population at the 
time. In addition, recently, the new President of the USA (2016), suggested that big 
pharmaceutical companies would be made more accountable to the patients and 
public, stating that drug prices should be reduced to affordable levels (Landers, 
2017). 
 
Drug pricing however raises many ethical issues, as discussed (Green, 2008). 
Chief amongst these is the provision of drugs to the developing world. Classically, 
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pharmaceutical companies were not interested in selling drugs cheaply to less-
developed nations as it did little to help their market capitalization.  But this lead to 
deteriorating health conditions, epidemics and increased morbidity that could have 
been avoided for millions of people. The ‘blind eye’ turned by Big Pharma to the 
developing world over the last century can be said to be, ‘amongst the greatest 
crimes for humanity’. In the last few years, however, major drug companies have 
thankfully begun selling drugs to low-income economies at reduced rates (mostly 
due to activist pressure and public opinion going against them), helping the drugs 
enter the healthcare systems where they are most needed (Gottlieb, 2000).  
 
Overall unfortunately however, and perhaps unsurprisingly, the pharmaceutical 
industry is not remarkably transparent, and it is difficult to determine who paid 
‘what, when and for how much’. The amount a developing country has to pay for a 
drug can be a major determinant of morbidity. It is suggested however that in the 
future, drug transactions could be publically-listed for all interested parties to 
peruse (although this is very unlikely in the current capitalist climate worldwide), 
allowing for increased competition in the marketplace and fairer pricing across the 
board.   
 
In the ideal world, any individual, at any given time, should have access to proper 
health care, as stated in numerous international declarations on human rights. This 
should be the determining principle when it comes to obtaining drugs, although the 
economic models generally do not allow for such a situation at present. The 
Kuwaiti Government should study and analyses the mentioned factors to achieve a 
suitable prices for both consumers and companies. 
 
5.1.2.4 The Quality Assurance (QA) Department 
The Quality Assurance Department is part of the Drug and Food Control 
Administration, and   belongs as part of the Drug Control Supervision. The links in 
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this way however do cause problems, because of conflict of interest and this is 
suggested to be a large issue.  As a result it was proposed in the discussions with 
the staff (in informal visits to the Department during the PhD study), that the QA 
Department would be best located as an individual department because of the 
overlap which results from its duty to control, monitor and evaluate the other 
Supervisions and Departments. (KMOH, 2014 c) 
The functions of this department are: 
1. Working on insuring the quality, safety and efficacy of the drugs.  
2. To ensure that the drugs/medicines entering the country are registered 
drugs and insure that there are not any recent adverse effects from them.  
3. Controlling and Monitoring the registration and laboratories supervisions and 
working towards having in place an efficient Post Marketing Surveillance 
system. 
4. Carrying out inspections and reporting on suspect counterfeiting drugs in 
Kuwait’s marketplace.  
5. Reviewing studies for the safety of food supplement products according to 
WHO conditions. 
6. Ensuring that the working of the laboratories is under GLP conditions. 
(KMOH, 2014 c) 
 
The issues found in this department are: 
1. Lack in the number of health staff, for instance the number of working staff of the 
Quality  
     Assurance Department is only two pharmacists.  
2. Shortage in the provision of training programs in quality assurance, 
management and safety     
    studies for the health professional staff. 
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3. The Department should be independent and divided from Quality Control 
Supervision. 
4. The KMOH should be providing greater powers of authorization to the 
Department to insure there is enough control over the Quality Control and 
Laboratories. (The Quality Assurance was discussed in details in Chapter 6, page 
255.) 
 
5.1.2.5 Drug Release Office in Kuwait International Airport 
This office is responsible for releasing all the imported drugs which arrived in 
Kuwait Airport. It releases products for both public and private sectors, but not for 
the products of the Central Medical Store because they have their own office in the 
airport. This office is responsible therefore for release for the shipments and 
parcels (KMOH, 2014 d).  
 
The issues found in visiting this Department by the structured interview are: 
1. There is not enough staff, as there is only: 1 pharmacist and 4 technicians 
working in the Department. 
2.  There is only one store and it is not large enough for all the storage 
requirements and the store is not under the GMP condition. 
3. Insufficient facilities of IT connection between the Office and the Drug 
Control Administration. 
4. They should have their individual department for personal parcels. 
As a Summary to the information above; it can be suggested that by amending the 
problem issues in the system of the Drug and Food Control Administration it is 
likely it will result in an increase and improvements in the quality and efficiency of 
the work in this administration, and it will help to reduce the errors in the work. It is 
likely that the development of the Administration will accelerate once there a 
completion of work on the establishment of the NDP in the right way.  
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5.1.3 Drug Inspection Administration 
As mentioned above the KMOH issued a Ministerial Decree No.166, for the 
establishment of the Drug Inspection Administration in 1985, to ensure enough 
control over the pharmaceutical sector (KMOH, 2011 f). The main function of this 
Administration is to inspect and monitor all the public and private health areas 
(pharmacies, drug stores, industries and drug companies) and other places where 
the medicines are traded with the population, to ensure that the medicines used 
are safe for human use and are registered under the full conditions of the KMOH 
rules.    
The organization structure of a Drug Inspection Administration is divided into two 
Supervisors:  
1. Inspection supervision. 
2. The supervision of licensed materials, narcotics and psychotropic 
substances.  
 
5.1.3.1 Inspection supervision 
Consists of four departments which include: 
a). Department of Public Inspection: 
 whose duty is to supervise the inspection and observation all the pharmacies and 
medicines stores which are linked to the KMOH and the work of their regulatory 
staff, as well as having control of the annual inventory of drugs and ensuring the 
validity of the data and results. 
Also it is their responsibility to inspect the public pharmacies in the public hospitals 
and wards, health clinics, the pharmacies of the Military Hospital, pharmacies of 
the Internal Forces Health Clinic, pharmacies for the elderly and disabled people 
which belong to the Ministry of Social Affairs and the pharmacy for diabetics in the 
Dasman Diabetic Institution.  
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The number of inspectors working in this Department are only 6 Pharmacists and 
they are responsible for inspecting 316 public pharmacies which are registered 
under the KMOH, also the medicines drug store of the CMS and in addition they 
have a large commitment to keeping the paper and office work under control, 
where electronic records are still not in place in this section of the KMOH. The 
average number of inspections which are required for each public pharmacy is 4-5 
times yearly, which can be greater than this number where there are requirements 
for addition more inspection visits in cases where there are complaints from the 
consumers (KMOH, 2014 e). 
 
b). Department of Private Inspection: 
It is responsible for monitoring the private pharmacies to ensure that the drugs are 
registered and approved by the Kuwaiti Drug and Food Control Administration, this 
action has the effect of prevention of the spread of counterfeiting drugs to the 
population.  It also can ensure that the pharmacies have a license and that their 
employees are registered with the MOH.  They also ensure that the medicines are 
purchased under the ministerial pricing controls and the dispensed drugs are sold 
in relation to medical prescription. Also this Department is responsible for 
inspection of the local pharmaceutical industries and the private medical stores to 
ensure that they operate under Good Manufacturing Practice (GMP) and under the 
ministerial roles (KMOH, 2011 g) (MSC, 2011). 
It is also the responsibility of this section to inspect all the private pharmacies in 
private hospitals, health clinics, drug companies, private drug warehouses and 
drug industries. The numbers of inspectors in this department are only 9 
pharmacists, and there are 3 inspection teams working in the morning, afternoon 
and evening and their work includes: 450 pharmacies, 40 warehouses and 20 
hospitals (KMOH, 2015 e).  
Each team normally consists of 2-3 inspectors and the average number of 
inspections for each private pharmacy is 4-5 times yearly. In addition there can be 
more inspection visit for private pharmacies where there are complaints from the 
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consumers. For example the total number of all inspections for the private sector in 
2013 was 2123 inspection visits, as detailed in the Table 5.1. 
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Table 5.1 The total number of all inspection visits to the private pharmacies 
(and Public/Private stores in 2013 was 2123 as broken down below (KMOH, 
2013 a). 
 
Governorate 
Capital 
Health 
Area 
Hawalli 
Health 
Area 
AL 
Ahmadi 
Health 
Area 
AL Jahra 
Health 
Area 
AL 
Farwaniya 
Health 
Area 
Public/ 
Private 
Stores 
Total 
 
Jan 
 
27 
 
76 
 
26 
 
15 
 
57 
 
10 
 
209 
 
Feb 
 
16 
 
36 
 
42 
 
15 
 
10 
 
8 
 
127 
 
March 
 
28 
 
59 
 
41 
 
16 
 
52 
 
- 
 
196 
 
April 
 
24 
 
93 
 
43 
 
37 
 
40 
 
20 
 
244 
 
May 
 
30 
 
70 
 
26 
 
21 
 
40 
 
13 
 
197 
 
June 
 
20 
 
56 
 
34 
 
23 
 
26 
 
22 
 
181 
 
July 
 
15 
 
67 
 
26 
 
9 
 
37 
 
12 
 
166 
 
Aug 
 
13 
 
38 
 
16 
 
5 
 
24 
 
12 
 
108 
 
Sep 
 
17 
 
68 
 
34 
 
29 
 
48 
 
3 
 
199 
 
Oct 
 
23 
 
61 
 
28 
 
9 
 
33 
 
12 
 
166 
 
Nov 
 
17 
 
50 
 
28 
 
14 
 
34 
 
7 
 
150 
 
Dec 
 
13 
 
74 
 
38 
 
13 
 
35 
 
7 
 
180 
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These inspections should cover technical workings e.g. lighting, temperature and 
hygiene control. Also they check the Pharmacy License, the employment license, 
the storage conditions, prices of the purchased drugs and compare them with the 
prices on the MOH list.  The inspectorate also examines medical preparations such 
as creams and drops which are prepared in the pharmacy.  Overall they insure that 
all the purchased drugs are under the control and are registered with the MOH.     
 
c). The Department of Herbal and Veterinary Inspection: is working to control, 
regulate and monitor all the herbal and veterinary products which are available in 
the private hospitals and the private veterinary clinics, to ensure that the herbal and 
veterinary drugs are under the regulation, qualifications of registration and 
requirements of KMOH and to adjust and confirm that the licenses are valid to 
practice the Profession of Pharmacy in the areas of veterinary medicine. 
This Department is relatively new and was established in 2005, and the work 
effectively started in 2011, the number of Pharmacist health professionals is 4. 
(KMOH, 2011 h) (MSc, 2011)  
 
d). Department of Statistics follows up and filing. (KMOH, 2011 l)  
 
5.1.3.2 The supervision of licensed materials, narcotics and psychotropic 
substances 
This Section is answerable for regulation, follow up and monitoring for illegal and 
unregistered dispensing of narcotics and psychotropic drugs in the private sector. 
This supervision consists of two departments: 
1. The licensing department of materials and products of psychotropic substances. 
2. The Licensing Department of Narcotics Substances and Preparations. (KMOH, 
2011 i)   
 
 
194 
 
This administration was visited during the PhD study and structured discussions 
(interviews) were carried out with the Pharmacist staff (Further details of these 
discussions and number of staff involved can be found in chapter 4); and it was 
found that there were a number of issues in the working system, these included:   
1. There is a lack of an electronic system in the Drug Inspection 
Administration, where there is a limited link between this Administration and 
the Drug and Food Control Administration.  Because of this a large number 
correspondences had to be carried out by manual means which is very time 
consuming, to establish new registered drugs and to update the existing 
data.   
2. The lack of a full internal IT system (e.g. laptop or simply i-pads) for easy 
communication within the administration which can extend the time taken to 
carry out an inspection, because of the lack of all the required information 
during an inspection. 
3. Insufficient number of inspectors and staff, there are only 25 inspectors in 
total in the Administrations and they are responsible to inspect and carry out 
checks on the controls for all the public and private pharmacies.  These 
inspectors also carry out a large number of inspections for each pharmacy 
or related unit each year, which is higher generally than in other countries. 
4. It was also mentioned that the inspectors did not generally have access to 
training and update training programs for the staff.  This is especially true for 
access to GMP assessment courses.  
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Figure 5.5 Organization structure of Drug Inspection Administration (KMOH, 
2011 i) (MSC, 2011). 
 
5.1.4 The Central Medical Stores Administration 
The Central Medical Stores Administration (CMS) was established in 1985, 
according to the Ministerial Decree .166, and it was regulated in 2005, according to 
the Ministerial Decree 287. 
This Administration specialized in the regulation of tasks relating to the Affairs of 
Medicines, Medical Consumables and Laboratory Materials, and work related to 
 
 
196 
 
the distribution of these products to all public hospitals, health clinics and health 
centers in the State of Kuwait (KMOH, 2013 m). 
The duties and functions of this Administration are to: 
1. Ensure the access needs of the State are provided for through medicines 
requirements and by implementing programs that ensure supply in accord with the 
drug policy. 
2. Apply the KMOH plans for provision of medicines and that sufficient are in 
storage to deal with the needs of the population at any one time and to ensure the 
availability of the medicines at all the times. 
3. Implementation of Drug Procurement and Purchasing Policies in order to ensure 
the availability and affordability of a range of several kinds of medicines to treat 
conditions. 
4. Ensuring an adequate supply of essential medicines, especially for possible 
emergency cases and to have in place strategies which can deal with any shortage 
of drugs. 
5. The provision of suitable storage areas, which operate under the documented 
storage polices, standards and conditions to ensure the safety of stored drugs and 
to implement, control and monitor these stores.   
6. Limitation the annual needs of the Ministry to the medicines, medical supplies 
and laboratory supplies.   
7. Preparing the required and necessary annual budget to meet the health needs 
of the population within Kuwait and exercising control over the overall medicines 
expenditure within the financial restrictions of the KMOH and for the medical and 
pharmaceutical products, materials and equipment.  
8. Preparing Procurement tenders for medicines, medical supplies and laboratory 
material and concluding medical contracts in accordance with the Kuwaiti rules and 
regulations. 
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9. Preparing the suitable programs for purchasing, storage and distribution of the 
medicines, medical supplies and lab materials. 
10. Preparing a special record of accepted supplies companies and local agents 
for the approved multinational and international drug companies. 
11. Working with the application instructions of the Ministry of Finance on the 
contract for the supply of medical materials, which is divided into:  
        a). Buying directly (Requirement), if the price is below 15000 USD. 
        b). Buying indirectly (Contracts), if the price is more than 15000 USD. 
12. To prepare inventory assets of drugs, medical supplies and laboratory 
materials in all the public hospitals and clinics, which is normally carried out without 
prior notice, at least once a year through the inventory drugs committees.  
13. Supervision of suppliers records and collection of all required data about the 
medicines and companies, which is then categorized to include observations of 
any future savings and for the updating of archive data. 
14. Reviewing and following-up the provision of the special drug orders and noting 
of unavailable medical supplies in the State of Kuwait. 
15. Preparing the documents associated with the donation of drugs and medical 
supplies to support stricken states, based on the recommendations of the Kuwait 
Cabinet. (KMOH, 2013 b) 
 
According to the Ministerial Decree No. 287 of 2005 which examined the 
reorganization of the CMS, the administration should be based upon five 
supervisions (KMOH, 2014 f), which includes: 
1. The Drug Supervision. 
2. The Medical Supplies Supervision. 
3. The Laboratory Supplies Supervision. 
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4. The Store Supervision. 
5. The Finance Supervision. 
 
5.1.4.1 The Drug Supervision 
The mission of this supervision is to provide the medicines for all public hospitals 
and public health clinics, and to ensure the validation of the drugs before receipt, 
storage and distribution (KMOH, 2011 i ) (MSc, 2011).  
The Drug Supervision is further divided into five departments: 
1. Injection Department. 
2. Drug Department. 
3. Medical and Pharmaceutical preparations Department. 
4. Kidney and Vaccine Department. 
5. Narcotics Department. 
 
The Departments of this supervision have specialized knowledge in: 
a) Provision in the needs of the hospitals and health centers for specific drugs 
which ensure the continuous regularity of availability, by following-up of 
dispensing rates and drug validity.  
 
b) Requesting prices and offers from pharmaceutical manufacturing companies or 
from local agencies. 
c) Following-up storage and supply of medicines according to the approved 
systems. 
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d) Preparation of annual requirements related to the medicines needs of the 
KMOH. 
e) Follow-up drug inventory rates. (KMOH, 2014 g) 
5.1.4.2 The Medical Supplies Supervision 
This supervision is concerned with ensuring the provision of consumables and 
medical devices, such as ligament surgery, rubber products, sutures, x-ray films, 
materials for sterilization, syringes and intravenous needles and other 
consumables (KMOH, 2011 j) (MSc, 2011).  
The Medical Supplies Supervision is divided into three departments: 
1. Medical Disposal Department. 
2. Ligament Surgery Department. 
3. Dentist Products Department. 
 
The Departments of this supervision are specialized in: 
a) Ensuring the required specifications are addressed for medical consumers, 
ligament surgical, dental materials and medical supplies. 
b) That the needs of the hospitals and health centers are provided for in terms of 
the medical consumers and to ensure that there is a continuous regularity of 
availability, with follow-up dispensing rates and drug validity.  
c) Preparation of annual drugs requirements in line with the needs of the KMOH. 
(KMOH, 2014 m) 
  
5.1.4.3 The Laboratory Supplies Supervision 
Has a remit to provide the laboratory products as required by the public hospitals 
and health clinics (KMOH, 2014 h). 
The Laboratory Supplies Supervision is divided into two departments: 
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1. Laboratory Disposal Department. 
2. The Solutions and Laboratory Materials Department. 
5.1.4.4 The Store Supervision 
This supervision regulates all the received, stored and distributed products (KMOH, 
2013 b). 
The Store Supervision is divided into three departments, as: 
1. Receiving Department. 
2. Storage and Distribution Department.  
3. Follow-Up Contracts Department. 
 
The departments of this supervision are specialized in: 
a) Supervising the work of the receipt, storage and distribution of all the lists of 
materials. 
b) Verifying the integrity of the examination procedures of the imported materials 
and compliance with specifications and technical conditions in the contracts. 
c) Verification of the safety of stored materials by appropriate conditions. 
d) Participation in the work of the inventory in the CMS. (KMOH, 2013 b) 
   
5.1.4.5 The Finance Supervision 
Its divide into four departments: 
1. Accounting and Auditing Department. 
2. The Budget Department. 
3. Contracts and Purchase Order Department. 
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4. Tenders Department. (KMOH, 2011 k) 
 
The Departments of this supervision are specialized in: 
a) Preparation of the draft budget for the administration jointly with concerned 
authorities, and sending it to the competent authorities and following-up of the 
implementation of the budget. 
b) Ensuring the application of laws, regulations and the financial system. 
c) Implementation of purchase orders and contracts concluded between the CMS 
and suppliers. 
d) Preparation periodic reports on the annual requirements of the materials and 
labor to be provided. 
 e) Preparation of final and periodic statement accounts and processing of different 
management activities. (KMOH, 2014 i) 
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Figure 5.6 Organization Structure of Central Medical Stores (KMOH, 2011) 
(MSc, 2011 l) 
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- The main functions of the CMS are: 
1. Purchasing the drugs. 
2. Storage the drugs. 
3. Distribution the drugs. 
 
1. The purchasing of the drugs:  is the activity which provides the needs of the 
drugs, medical supplies and lab materials for the MOH at the best quality and 
price. 
The purchased products were divided into two parts: 
a) The Regular Materials, where the stock is normally more than 8 months and 
must be available on a permanent basis, in the appropriate amount and 
exist in the items catalogue. It also includes all current deemed drugs as the 
essential medicines. 
b) The Irregular Materials, which should be available every year according to 
the requirement of the Medical Boards. It had private specifications such as: 
shelf life, quantity of the materials, usage and re-request. (KMOH, 2015 f) 
 
The purchasing of irregular materials can be done through: 
1. Special orders, through the Special Order Department in CMS. The function 
of the Department is to order and purchase medicines for patients if the 
medicines are not available in both public sector and private sector in State 
of Kuwait (This however can be a very expensive method of obtaining 
medicines which are often purchased for a small number of patients e.g. for 
some cancer diseases and when the drugs are not registered in any local 
companies in Kuwait). There are two offices for the special orders one in 
London and one in Washington.    
 
2. New item orders.  
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The purchasing cycle for the regular materials should be based on: (1) The 
integrated database and (2) study the optimal use of resources (KMOH, 2015 f). 
 The integrated database includes: 
- Statistical material. 
- Current inventory. 
- Existing orders. 
- Demands rate. 
- Usage rate. 
- Cost prior. 
- Suppliers who are available. 
- Shelf life of the material. 
- Fluctuations in the pattern of consumption. There is no justification? 
 
In the system of the purchasing cycle for the irregular materials, there is no prior 
integrated database but it is started as an integrated database after the first 
purchase order.  
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Figure 5.7 The Purchasing Drug Cycle in the CMS (KMOH, 2015 f).  
 
2. The storage cycle of the drugs: there is only one store in the CMS for the 
storage of the drugs and it is under the GMP conditions. 
In Kuwait Airport there is a Drug Release Office which belongs to the CMS, and is 
responsible for release of all the drug shipments from Airport Customs Department 
and which then transfers the medical materials to the CMS (KMOH, 2015 g). 
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There is tender storage every 3 years in the CMS where specialized storage 
companies, compete with each other to provide the best offer for the CMS, and the 
company which acquired storage tender will be responsible for arranging the drugs 
storage in the warehouse of the CMS, and its functions supervising of the: 
1. Arranging the drugs storage in the CMS.   
2. Providing the necessary employments and IT electronic system only for the 
work of storage drugs/medicines, medical consumables and laboratory 
materials in the warehouse of the CMS (without any electronic link system 
with other internal or external health areas). 
3. Classifying the storage drugs according to their usage, efficacy and type. 
4. All the drugs should be stored under the GMP conditions. 
5. Preparing the orders for the distribution. (KMOH, 2015 g)    
 
The temperatures in the storage areas are set up so that drugs can be stored at 
their optimum temperatures and the temperature variation are in 5 forms. 
1. – 15 c. 
2. 2-8 c. 
3. 14 c. 
4. 18 c. 
5. 21 c. 
 
The types of storage are: 
a) Steel Pallet for storage the bulk items. 
b) Containers for medium bulk items and volume items, because of their size 
can be move on the basis of bulk picking which can allow relatively easy 
transfer of materials to outside the store. It can be: 
- Gliding Containers (CG): used to storage the bulk items and can contain up 
to 7 containers with same shelf life and barcode for the same material. 
- Container Rack (CR): used to storage the bulk items and it contain only one 
container. 
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c) Gliding Boxes can contain 10 boxes in each area and it has the same shelf 
life and barcode for the same material. It is used for transferring bulk loads. 
d) Small multiple shelves are also used for storage the small materials. 
e) Drawer Cabinet (Modular Steel Cabinet) used to store the micro materials 
and small sized (KMOH, 2015 h). This information suggests that a full range 
of storage facilities is available in CMS. 
 
Figure 5.8 The Storage Drug Cycle in the CMS (KMOH, 2015 g).  
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3. The Distribution of Drugs: 
The CMS administration is responsible for distributing of medicines to the public 
general hospitals and clinics: 
1. Six General Hospitals. 
2. Nine Specialized Hospitals. 
3. Thirteen Specialized Clinics. 
4.  Ninety three General Medical Clinics (Additional information in chapter 
4, page 12-14) (KMOH, 2015 i). 
 
There are 2 types of Drug Distribution: 
1. Normal distribution, where the drugs are distributing every 2 weeks to the 
public pharmacies in hospitals and clinics. 
2. Urgent distribution, which is for urgent orders and can be used every day for 
only for 3 items or less. 
 
There are also other distribution procedures for: 
1. Medical gases and they are transported every week. 
2. Narcotic drugs and psychotropic substances are distributed according to 
need. 
All the medicines are distributed by the refrigerated trucks which belong to the 
CMS (KMOH, 2015 i). 
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Figure 5.9 The Distribution Drug Cycle in the CMS (KMOH, 2015 i).  
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Injections, oncology medications, specialties products, nutrition products, vaccines, 
tablets, diabetic drugs, respiratory drugs, neurology drugs, chemicals products, 
psychiatric drugs and kidney department products), was 644 million US dollars. 
This expenditure is very large when compared with countries of equivalent size to 
population in Kuwait (for example, Bahrain and Qatar) and its indicated that the 
KMOH spent high amounts of money. One major way to save on the State budget 
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In addition it was found that there was a large wastage of medicines and it was 
found that the total amount of the expired drugs in the CMS from 01/01/2013 to 
31/12/2013 was estimated to have reached 5,75 million $  (See Table 5.2), and this 
is a great amount of loss on the State budget, which could otherwise be used in 
other health projects and the MOH can take benefit from it (KMOH, 2013 c)   
The main reasons for the occurrence of expired drugs in the CMS were: 
- Lack of Essential Drug List in the CMS. 
- The short shelf life of the most ordered tenders. 
- The physicians and consultants in the public hospitals ordered products and after 
short time they changed their order and asking for different drugs. (KMOH, 2013 c) 
 
According to the collected data, informal visits and discussions (structured 
interviews) with the health professional staff of the CMS administration during the 
PhD course (Further details of these visits, discussions and number of staff 
involved can be found in Chapter 4, page), the researcher was alerted to the 
existence of some problems, needs and requirements (see below) that don’t help 
in the work in the Administration and could cause hindrance for the implementation 
of a NDP. The problems found and needs in the CMS included: 
1. The policy of the government puts pressure on the CMS to purchase 
generic drugs from non-qualified manufacturers especially from GCC 
countries. 
2. All the items were stored in one store, since 1982 the CMS didn’t increase 
the number of stores. 
3. The need for more staff especially pharmacists. 
4. The need of more training programs for the staff. 
5. Establishing Essential Drug List to better use the budget and determine 
appropriate needs of medicines. 
6. Need for an IT electronic link between the CMS and Drug Control 
Administration and the pharmacies in public hospitals and clinics. 
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7. To have more centralization in the work.  
8. To establish a Cost Effectiveness Department. 
9. To have an official electronic information web page. 
In order for to solve these issues, meet all the necessary requirements and give 
support to improve the efficiency of the work it is proposed that the KMOH should 
develop the administration system, because it could reflect positively in the 
establishment of a NDP and the development of the Health Care System.   
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Table 5.2 The cost of expired drugs in CMS from 01/01/2013 to 31/12/2013 
(KMOH, 2013 c).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2 The Private Sector  
As mentioned in the previous chapter (Chapter 3), the private sector is very 
important part of the health services in Kuwait and it’s complementary to the 
mission of the public sector. To get high standard level of a NDP in the future and 
to ensure success of the establishment of this organization in Kuwait, the KMOH 
should  give attention to the private sector and involved it in the work of 
 
Expired 
Product 
 
Cost in US Dollars 
 
Expired 
Product 
 
Cost in US Dollars 
 
1. Injections 
 
537 thousand $ 
 
7. Diabetic 
Drugs 
 
2,744 $ 
 
2. Oncology 
medications 
 
303,5 thousand $ 
 
8. Respiratory 
Drugs 
 
293,6 thousand $ 
 
3. specialties 
Products 
 
3 million $ 
 
9. Neurology 
Drugs 
 
89 thousand $ 
 
4. Nutrition 
products 
 
111 thousand $ 
 
10. Chemical 
Products 
 
2,135 $ 
 
5. Vaccines 
 
2,600 $ 
 
11. Psychiatric 
Drugs 
 
232,8 thousand $ 
 
6. Tablet 
 
963 thousand $ 
12. Kidney 
Department 
Products 
 
 
139,6 thousand $ 
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implementation a NDP to take benefits and advantages of their experiences, 
suggestions, advice and views of health professionals in this sector. Also the 
KMOH should listen to their needs, concerns and requirements which are often 
related to the regulations and legislations set out by the KMOH, and to developed 
and improved the health services in both public and private sectors.  This section 
will explain the private sector in Kuwait and focus on the most important weakness 
points to help support, understand and find solutions for the issues of this sector in 
the future. 
In 2015 the number of the private pharmacies in Kuwait was 450 (KMOH, 2015 h), 
where they were distributed around all the governorates of the country (See Table 
5.3) and divided into 3 groups, includes; 
1. Private pharmacy belongs to the individual persons or private companies, 
and it was reached to 365 pharmacies. 
2. Private pharmacy belongs to cooperatives societies, where it’s up to 66 
pharmacies. 
3. Private pharmacy belongs to the private hospitals, where it was reached to 
19 pharmacies. 
 
The growth of the population, the needs of medicines and increasing use of 
patients of treatment in the private hospitals and clinics is likely to lead to an 
increase the number of the private pharmacies in Kuwait, to meet the needs of 
consumers and follow the development of the health investment of this sector.  
According to a study which projected the future by the KMOH it is likely that there 
will be an increase of the number of private pharmacies every year, for the next 
five years (KMOH, 2015 i). Table 5.4 shows the expected number of the private 
pharmacies in Kuwait. 
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Table 5.3.The number of private pharmacies in State of Kuwait to 2015 
(KMOH, 2015 i) 
 
 
Governorate 
 
No of 
Private 
Pharmacies 
 
NO of Private 
Pharmacies 
Belong to 
Cooperative 
Societies 
 
No of Private 
Pharmacies 
Belong to Private 
Hospitals 
 
 
Totally 
 
Capital 
 
28 
 
18 
 
2 
 
48 
 
Hawalli 
 
147 
 
13 
 
6 
 
156 
 
AL Farwaniya 
 
84 
 
11 
 
1 
 
86 
 
AL Jahra 
 
37 
 
10 
 
1 
 
42 
 
AL Ahmadi 
 
69 
 
14 
 
9 
 
82 
 
Totally 
 
365 
 
66 
 
19 
 
450 
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Table 5.4 The expected number of the private pharmacies in Kuwait (KMOH, 
2015) 
Year  Expected NO. Of Pharmacy 
Year 2016 465 
Year 2017 480 
Year 2018 495 
Year 2019 510 
Year 2020 525 
 
 
5.2.1 Registration and licensing of the private drug companies in State of Kuwait 
Before the private pharmaceutical companies and agents start working in the 
private market and dealing with drug trade in Kuwait, they should apply for a 
license from the KMOH. The Drug and Food Control Administration is responsible 
to give registration and licensing for the private drug companies in State of Kuwait. 
The objectives of this aspect are to regulate the private sector, ensure that the drug 
distributors are under the conditions of KMOH, and ensure that all the drugs in the 
private market are quality and safe for the users and its support to be the private 
sector under control and monitor of the KMOH.   
 
The Registration Requirements for the licensing of the private pharmaceutical 
companies in State of Kuwait includes: 
1. Company name and country of origin. 
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2. Letter of appointment, it should be original and legalized from Kuwait 
Embassy in the country of origin. 
3. Pharmaceutical Manufacturing License, it should be original and legalized 
from Kuwait Embassy in the country of origin. 
4. GMP certificate, it should be original and legalized from Kuwait Embassy in 
the country of origin. 
5. Date of establishment, registered capital and company turnover for the last 
3 years. 
6. Number of manufacturing sites owned by the company (Name and address 
of manufacturing sites to be registered). 
7. Number of employees and their qualification. 
8. Site Master File. 
9. Type of activities (Researcher, Developing, Manufacturing and packaging). 
10.  Manufacturing lines to be registered (solid dosage forms, semisolid dosage 
form, ophthalmic/nasal products, biotech products, liquid dosage form, 
parental, aerosol dosage form or other). 
11. List of product marketed. 
12. List of countries where its products are marketed. 
13. Layout and flow diagrams of manufacturing lines. 
14. If the company is centrally registered in GCC (Required GCC Central 
Registration Certificate). 
15. The company is FDA approved (Required Evidence of FDA approval). 
16. The company is EMEA approved (Required Evidence of EMEA approval). 
17. The company is MHRA approved (Required Evidence of MHRA approval). 
18. Any inspection visit reports. 
 
- The conditions for the pharmacy license in the State of Kuwait: 
1. The owner of the pharmacy should be a Kuwaiti pharmacist. 
2. The pharmacist should be registered in the Kuwaiti Drug Association. 
3. The pharmacist should have at least 5 years experience. (This was changed 
in the last 3 years as it was 2years before this time). 
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4. The pharmacist should pass a license exam from The MOH to get a private 
pharmacists license. 
5.2.2 The Property Rights for the private pharmaceutical companies in State of 
Kuwait  
In 1994, at the Uruguay Round of the General Agreement on Tariffs and Trade 
(GATT) the Trade – Related Intellectual Property Rights (TRIPS) agreement was 
established. The TRIPS agreement is an integral part of the World Trade 
Organization (WTO) Agreements and became the most comprehensive 
international Instrument on International Property Rights (IPRS). 
 The TRIPS agreement includes: 
- Geographical indications. 
- Copyrights and related rights. 
- Trade marks. 
- Patents. 
- Industrial Designs. 
- Layout designs of integrated circuits. ( William, 2001 ) 
 
These regulations have been issued to regulate and organize the drug market and 
to protect the property rights of the pharmaceutical companies and industries. 
According to the Ministerial Degree No.675, for Year 1998, which is based on the 
agreements of the State of Kuwait with GATT, WTO and TRIPS, and also based 
on the development of adequate standards and principles to protect the Property 
Rights of the pharmaceutical products, companies and local agents, the KMOH 
decided to: 
 
1. Prevent any drug registration if it contains the same chemical composition 
and therapeutic effects with another drug, still under the period of Property 
Rights. 
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2. If the local agents want to register any pharmaceutical product under the 
Property Rights, they should submit a: 
- CPP Certificate which shows the registration date, the scientific name 
and trade name of the pharmaceutical product, and needs to mention 
the remaining period of product Property Rights in the country of 
origin. (This should be the original document and should be legalized 
from the Kuwait Embassy in the country of origin). 
3. The KMOH have the right to except the registration of some products under 
the Property Rights and import the product in special cases such as: 
A. If the KMOH can prove the exploitation of some pharmaceutical companies 
of the product Property Rights to increase the product price in Kuwait when 
compared with the prices in other countries, especially in GCC countries. 
B. If the KMOH can prove that the product under the Property Rights is not in 
conformity with the international standards and non-suitability for use. 
C. If the KMOH can prove that the pharmaceutical company that owns the 
Property Rights of the drug is not committed to supply contracts for both 
public sector and private sector, or not committed to the required conditions 
of the MOH contracts. 
D. If the pharmaceutical product under property rights is needed for the 
country in emergency cases, wars and in accordance with the public 
requirements.      
 
 The KMOH property rights regulations have emerged from the recent TRIPS 
agreement, which were issued to assist the developing countries, for example:  
- On November 2001 during the WTOs Fourth Ministerial Meeting at the Doha 
declaration, TRIPS Agreement it was approved to have safeguards which can 
protect developing countries, such as:  
- Compulsory licensing which allows the production and sale of generic drugs 
before expiry of the patent, in emergencies. 
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- Polar provision which allows testing and regulatory approvals of generic 
drugs before the patent expires so that the drug is ready for production and 
sale. 
- Parallel importation allows a country/pharmacy unit to shop around for a 
good price to increase competition. 
 
- On August 2003, The TRIPS meeting in Thailand agreed to give permission to 
Brazil, Thailand and South Africa to have a full authorize of providing HIV patented 
drug by their own companies. This is to get the medication to the largest number of 
people at the earliest time (Subramanian, 2004).  
 
- On 6 April 2004- The Global Fund, The World Bank, UNICEF and Clinton 
foundation meeting announced that the developing countries will have guarantees 
of payment to support purchasing HIV medicines at lowest prices at more than 
50% less than its available price and to ensure the security of drug distribution 
(UNICEF, 2004). 
 
- On 2002 The Trade Promotion Authority (TPA) recommended that new trade 
agreements negotiated by the USA shall respect the Doha declaration on TRIPS 
and Public Health (WHO, 2004). 
 
5.2.3 The trade penalties for the private sector 
The KMOH has issued a number of trade penalties in order to prevent or reduce 
the excesses and misuse of the systems in the private sector, also to protect the 
consumers from greed of some companies and to ensure control over the private 
drug market and private sector in the country (KMOH, 2012 a).   
The trade penalties for the private sector in Kuwait, includes that there shall be 
punishment:  
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1. By imprisonment for a period not exceeding two years or fine not exceeding 
three thousands KD (10,600 USD) or by both of them if: 
 - A practicing profession pharmacy operates without a license from MOH or 
obtains a license through an incorrect way. 
-   Establishment of private pharmacy, warehouse, pharmaceutical industry or 
research centre without a license from MOH or obtained through an incorrect way. 
2. There shall be punished by imprisonment for a period not exceeding two years 
or a fine not exceeding two thousands KD (7000 USD) or by both of them if: 
- There is a violation of drug pricing decisions. 
- The licensed premises are used for other purposes. 
3. Shall be punished by fine not exceeding two thousands KD (7000 USD) if: 
- There is violation of advertising and promotion decisions of the pharmaceutical 
products. 
4. Shall be punished by giving a warning, suspension from work for a period not to 
exceed one year, cancellation of the license to practice the profession, closure of 
the premises not exceeding six months if: 
- There is violation of the rules regulating the registration process of the 
pharmaceutical products and the medical devices. 
- The pharmacy sale of any pharmaceutical product is not from a source which is a 
registered local agency in Kuwait. 
- Sale of any pharmaceutical product which is not-registered in a Kuwaiti Drug 
Control Administration for the private market. 
5. Shall be punished by imprisonment for a period not exceeding 15 years or fine 
not exceeding 15 thousand KD (55,000 thousand USD) or by both of them if: 
- Private pharmacy, company or store, sells non-registered narcotics and 
psychotropic substances. 
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- Private pharmacy, company or store dispenses non-prescribed narcotics and 
psychotropic substances. 
-There is manufacturing or import non-registered narcotics and psychotropic 
substances. 
5.2.4 The issues, problems and needs of the Private Sector in Kuwait  
There have been frequent visits (during structured interviews) to the private 
pharmacies and pharmaceutical companies during the PhD study from 2012 to 
2014, and during the discussion with the senior and junior staff who were working 
in this sector.  During these visits it was found that the private sector needs to 
investigate many updating requirements and suffers from number of issues, such 
as:  
1. Lack of pharmaceutical industries in Kuwait, and there should be 
talks to allow the international pharmaceutical industries to have 
licenses in Kuwait and also give them the opportunity to develop all 
the facilities to allow them to work and produce medicines in Kuwait. 
2. There is a major need to establish a Kuwait Essential Drug List which 
helps the Local Medicine Companies to determine their purchases 
and to have a clear vision about choosing the appropriate medicines 
needs for the country. 
3. Reduce the numbers of routine operations in the KMOH 
Administrations especially in: Drug Control, Drug Inspection and 
Central Medical Store, to speed up the work and give them more time 
to carry out additional work with more authority  
4. To establish clear guidelines for the private sector work especially for 
drug registration, licensing and pharmacy and store conditions. 
5. The delay in registration of new drug, where it takes 3 months or 
longer.  
6. Delay in the decision making process from Regulators. 
7. The need to deal with the Drug Counterfeiting problems and the need 
to strengthen the penalties. 
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8. Lack of economical knowledge from regulators on the industry and 
marketing. 
9. The non-availability of a pharmacovigilance center in Kuwait. 
10. Lack of a NDP in Kuwait. 
11. There is shortage of a Drug Information Center and lack of national 
program for the increasing of people awareness 
12. There is no strong control over the unlicensed drug advertising and 
fake drug companies. 
13. The need for greater support for health investment in the State of 
Kuwait by  
providing information on official legislation, regulations and data 
concerning the health services 
14. A proposal to link a system between all the administrative sections of 
the  
Ministry of Health which can lead to improved and increased 
collaboration within the health framework. 
15. Also to establish an official electronic access site for the 
pharmaceutical administration to reduce the number of visits to 
these areas and to speed up the work by completing the required 
work electronically.  
 
It is proposed that the work on providing requirements and solving issues related to 
the private sector will be a key supporter and will help the KMOH in implementing a 
NDP in Kuwait.    
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Chapter 6.0: Discussion of the study results from the interviews 
and the visits to the facilities 
 
From the research carried out there is effectively three main parts to the research 
study:- 
● The examination of current operation of pharmaceutical supply and services, 
rules and regulations in Kuwait;   
●  A large number of interviews were carried with a wide range of health 
professionals in Kuwait to assess their views on the structure and delivery of 
pharmaceutical services. 
● Visits to the main operational ‘hubs’ related to pharmaceutical delivery in Kuwait 
 
The major outcome of the interviews (presented in Chapter 4) was the 100 percent 
response in favour of Kuwait developing and implementing a NDP.  This result is a 
very important step for Kuwait and gives a lead for the MOH in convincing the 
government and with agreement for the country to start the continuous 
development of the Health Care System through the NDP, which should include 
both the public and private sectors.  The responses provided in the study indicated, 
the NDP would strengthen, improve and encourage the health legislations and 
regulations to be more effective. They also clearly believed that a NDP can be act 
as a guideline for health professionals, which could facilitate better work practices. 
 
The analysis of the interview results, suggested that there are a number of areas 
where there are concerns. One of main issues, which are discussed in greater 
detail in this Chapter, was the need for legislations and regulations changes and 
some of these are indicated below;  
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1. Weakness of some legislation and regulations in the Health Care System, in 
particular: 
a) Drug registration in the Drug and Food Control Administration. 
b) Weakness in control over the pharmaceuticals process (drug selections, 
drug cost effectiveness and high prices of drugs in the market) in both public 
and private       sectors.  
c) Issue with access to quality, safe and efficacious medicines in the State of 
Kuwait. 
d) That the penalties for not adhering to the regulations and rules are weak in 
some areas and there is a need to strengthen penalties, in order to restrain 
the spread of rule breaking, such as the increasing numbers of counterfeit 
and unregistered drugs in the market.  
e) That although Drug Procurement does follow a yearly cycle for many drugs, 
the open legislation on ordering of medicines by senior medical 
professionals does lead to  budget imbalances and reductions in the overall 
drug cost/budget effectiveness. 
f) The high price range and cost variability of medications in the private sector 
in the State of Kuwait. 
2. The limited control in the selection of drugs and particularly the lack of an 
Essential Drug List. 
3. The limited use of clinical guidelines in the choice of medicines supplied to 
patient and the increase in irrational prescribing and use of drugs in the State of 
Kuwait. 
4. Insufficient training programmes and update sessions for health professionals. 
5. Limited checking of Quality Assurance in the Drug and Food Control 
Administration.  
6. Lack of a Pharmacovigilance Centre to gather world-wide data and reporting of 
problems/ patient response to medicines. 
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7. Major communication problems across the Pharmaceutical services resulting 
from a lack of IT/electronic systems linking the health areas of the KMOH. 
8. Lack of a pharmaceutical industry in the State of Kuwait, which in its most basic 
form could produce Generic/ Natural Product Medicines to supplement those 
obtained from outside the country. 
 
6.1 Improvement Legislation and Regulations of Health Care System in 
Kuwait 
 
The Legislations and Regulations is the first step to establish a NDP in State of 
Kuwait, and it is necessary to developing, improving and strengthen the Legislation 
and Regulations of the Health Care System and the Pharmaceutical sector to 
ensure the primary ground for the NDP in the State, in addition to make it 
appropriate for future strategies plans.    
 
In this section was discussed the following areas, includes: 
1. Importance of Drug Legislation and Regulations. 
2. Aim and main objectives of Drug Legislation and Regulations. 
3. Drug Legislations and Regulations in State of Kuwait 
 
6.1.1 Importance of Drug Legislation and Regulations  
A NDP involves the control, coordination and procurement of pharmaceutical 
products, and as such there are area within which there is a potential for abuse 
and wrong use. Furthermore, a NDP provide a framework which can be used to 
allow the control of aspects such as import and export of pharmaceutical products, 
 
 
226 
 
their manufacture, marketing, prescribing and dispensing practices, distribution, 
and an overall enforcement of such laws and regulations (WHO, 2001). 
For this reason, there is a need for development, improvement and updating the 
Drug Legislations and Regulations in Kuwait to support and control implementation 
of a NDP, where it is needed to implement and enforce the components of the 
NDP, where discussed in Chapter 1 and Chapter 6. 
. 
In addition, Legislation and Regulations regarding drugs provides absolute 
recognition of the objectives and values of the drug policy and guarantees full 
support against activities carried out by individuals and organisations from the 
public or private sectors aiming to act outside of the stated policy framework. In 
these cases the DRAs are able to impose legal sanctions as a penalty for activities 
of this kind.  Specific Legislation and Regulations should be passed aiming to 
define legal rights and responsibilities of the parties involved (health professionals, 
public health areas and private sector) and establish legal-binding standards for 
the control of  health services activities (WHO, 2001).  
 
Once defined the set of Legislation and Regulations should provide the regulatory 
authorities with control over premises, persons and practices involved in all 
aspects of research (clinical trials), manufacture, importation, licensing (patents), 
distribution, procurement, supply, marketing (promotion, advertising) and sale of 
drugs. Also it should be considered that a law is generally passed by a legislation 
body of a government, and are made as to meet the current and future needs that 
the country may have. Regulations on the other hand allow the authorities of the 
government to identify and define how the laws are implemented and enforced in 
terms of their interpretation (WHO, 2003). 
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6.1.2 Aim and main objectives of Drug Legislation and Regulations 
- The aim of Drug Legislation and Regulations is to ensure that all the medicines 
reaching patients are quality, safety and efficacious (WHO, 2001). 
 
- The main objectives are to ensure that all drug legislations and related 
regulations are up-to-date and meet the approved standards by: 
1. Strengthen the medicines control. 
2. Developing Drug Registration System. 
3. Promoting the QA (Quality Assurance). 
4. Enhancing the inspectorate and laboratory functions.  
5. Providing strict penalties to prevent or reduce the excesses and misuse of 
the systems in the public and private sectors. 
6. Improving purchasing of drugs. 
 
6.1.3 Drug Legislations and Regulations in State of Kuwait 
The interview results indicate that there are a number of areas of concern with the 
Drug Legislations and Regulations of the Health Care System in Kuwait, these 
include: 
1. Issues with the Drug Registration and Licensing Process in the Drug and 
Food Control Administration. 
2. Limits of authorization and power for the Quality Assurance Department in 
Drug and Food Control Administration   . 
3. Weakness in the penalties given out for irregularities in carrying out the 
regulations in  private pharmacies, hospitals, health clinics, medical stores, 
medical companies, local agencies and pharmaceutical industries. 
4. High price range of medications in the private sector where price controls 
should operate. 
5. Limitation in the adherence of the legislation control of pharmaceuticals in 
both the public and private sectors. 
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6. Poor use of Pharmaco-economics controls in providing drug cost 
effectiveness expertise in public sector. 
 
In introducing the NDP, the KMOH should look closely at the present Regulations 
and Legislation and possibly look at a major overhaul of the current rules, 
guidelines and legislation and consider how these areas can be better controlled.  
With the introduction of an Essential Medicines Programme, the present rules on 
medicines procurement and access will need to be reconsidered and the 
necessary legislation put into place. The legislation should be broad in its scope in 
order to address all the main problems and be flexible enough to make the 
legislation specific to difficult areas. 
Therefore the drafting or revising of current Drug Regulations and Legislation 
should be a priority in both the drafting of the NDP and in the work that follows.  
This can be done by making a full inventory of existing laws and regulations, and 
carefully deciding what type of Legislation is required. Then, legal experts (from 
Kuwaiti Government) should collaborate closely with health professionals (KMOH) 
and other stakeholders in drafting the new text to ensure that all drafted 
Legislations do not conflict with the States laws. After drafting, a wide consultative 
process is needed to inform interested parties (Private sector, Pharmaceutical 
Association, Medical Association and Kuwait University) and to enable them to 
comment and express their concerns. At this time it is important to ensure that 
there is political support for the proposed changes and that this support is 
maintained throughout the process. 
When writing the law, the practicalities of future enforcement should be kept in 
mind. In addition if there are no strategies, facilities and resources for 
implementation and enforcement, legislation on its own is likely to achieve negative 
results. In carrying through these discussions and drafting of policy it is important 
to balance the aims and objectives to ensure that that these can be properly 
enforced and not to be too ambitious by introducing policy that cannot be 
implemented and enforced. (WHO, 2001) 
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The following are a listing of areas and There are some suggestions  (listed below) 
can be useful to support KMOH in development , updating and revising the existing 
drug Legislations and Regulations in Kuwait, includes:     
 
1. Overall to improve the enforcement and strengthen procedures (seizures), 
penal provisions and administrative penalties, for areas of the current 
Legislation and Regulation in the Health and Pharmaceutical field. 
2. Issuing adjusted and improved Legislations and Regulations for 
establishment of; 
      a). Management Organisation relating to the quality of pharmaceutical 
services in the  
           CMS Administration and public hospitals. 
      b). Develop and introduce and Essential Medicines List for use in the 
procurement  
            system. 
      c). Develop and introduce a Pharmacovigilance Center in the State. 
      d). Under the heading of an EML to establish a Medicines Cost 
Effectiveness  
           Department in the CMS Administration. 
      e). To establish an Electronic link system throughout the public health areas 
in Kuwait. 
      f).  To bring all this together under a Pharmaceutical and Health Services 
NDP and efficiently introduce this NDP in Kuwait.  
3.  To provide and strengthen authorization and power for the QA Department 
of Drug and Food Control Administration to ensure enough control and ability to 
monitor drug registration, testing and licensing. 
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4. Strengthen penalties to encourage the private sector to reduce irregularities 
in the health field. 
5. Development the requirements which requires a certain level of academic 
attainment and attendance at training programs for public health professionals. 
6. Overall the KMOH should work towards reviewing and updating most of the 
health and Drug/Medicines Legislations and Regulations because the majority 
of the Legislation and Regulations were issued in the eighties and nineties of 
last century, where they were created in accordance with conditions and needs 
of that period and before the conflicts in Kuwait.   
 
6.2 Weaknesses in the Drug Registration system in Kuwait 
 
Drug Regulation covers various areas, to include estimation of the quality, safety 
and effectiveness of a drug, compliance of manufacturers/suppliers through the 
processes relating to GMP standards i.e. good manufacturing standards, pre 
marketing evaluation, thorough examination of various stages of drug supply chain. 
Drug regulation activities also include maintaining the register of available 
medicines and their post marketing survey results. For medicines currently it 
involves undertaking random sampling for quality checks and controls and 
pharmacovigilance reporting of registered drugs (DFID, 2004). 
 
Registration of Drugs/Medicines is an important component of drug regulation. 
Drug Registration is the interaction and a relationship between the various parties 
involved in pharmaceutical sector. It can form a bridge between Legislations and 
the Sciences or it connects the pharmaceutical manufacturers with the regulatory 
authorities along with allowing comments and inputs from the medical 
professionals and the patients. The Regulatory Authority is also interconnected 
with many other authorities in the MOH and other protection agencies and law 
enforcement agencies, such as the customs authority. When discussing Drug 
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registration is however an overarching terminology for a groups of administrations 
and includes product licensing or marketing authorization, medicines inspection 
and quality assurance (Boxtel et al., 2008). 
 
In addition, the Drug Registration Authority can undertake various advertisements 
for promoting and disseminating drug information. Dependent on the origins of the 
medicine the drug registration process can involve various steps including the 
medicine/drug evaluation and consideration of pharmaceutical quality data, 
evaluation of; animal preclinical toxicology studies, human clinical trials and 
product information documents (DFID, 2004).  
 
During the fieldwork for this PhD research study, the main issues found in the Drug 
Registration System during informal visits to this Administration (in 2014, Chapter 
5) and structured discussions with many of the senior management staff (in 
Chapter4), were; absence of training of staff in stability, clinical, bioequivalence 
and GMP studies and other issues were mentioned in Chapter 5. 
Based on this information, it is clear that the Registration of Drugs/Medicines in 
Kuwait suffers from a number of weakness and it is proposed that the KMOH 
should concerned about these present issues because drug registration is such a 
necessary operation for developing health services in Kuwait. The following section 
discusses the importance of Drug Registration and its affects on Health Care 
System. 
 
6.2.1 Importance of Drug Registration     
Drugs are complicated chemical substances whose effect cannot be determined by 
a ordinary consumer therefore it is important in a well organised health system to 
make the consumers aware of information to help them understand both the value 
and the side effects of the medicines and to take the correct decision on matters 
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relating to which medicines to use, how to use them, when to use and to consider 
the positive benefit against the side effects of the drugs as no medicine can be 
regarded as completely safe for human health. Drug Registration is required to 
determine the secure drug for consumption but due to complexity of compounds 
even healthcare professionals are not fully informed and safe decisions on possible 
effects of the drug without having been well trained in studies of drug registration. 
As an example; clinical pharmacology involves the most complicated clinical 
aspects of medicinal quality, effectiveness and safety. For this the training program 
in clinical, stability, GMP and bioequivalence studies is necessary for staff of 
Pharmaceutical, Veterinary, Food Supplements, Cosmetic and Herbal Registration 
departments in Kuwait because they normally approve the final licences for 
imported and manufactured medicines for both the public and private sectors and 
they provide the final clearance on quality and safety of a medicine before it 
reaches the patient (Boxtel et al., 2008). 
In addition, the scientific matters related to medicines are very sensitive as 
consumption of inappropriate, poor quality; harmful or adverse drugs can cause 
therapeutic failure, exaggeration of illness, insensitiveness to drugs or even death 
so normal medical trainings are not sufficient to understand the correct nature of 
drug and its effects to ensure safety. Failure to fulfil the responsibility in regard to 
the medicines quality and safety can result in lowering of the faith in the health 
system, and in the health professionals and manufacturers and distributors of 
medicines. It can tragically lead to loss of life as well as wealth both for the 
consumers and also for the manufacturers and government, and for this reason it 
is the duty of the KMOH to work for safeguarding the health and safety of its 
population in Kuwait by development and improvement the drug registration 
system (Boxtel et al., 2008) 
 
6.2.2 Development of Drug Registration System in Kuwait 
The overall conclusion from these studies are that the KMOH should re-examine 
the  registration of drugs policy to regain benefits in ensuring high quality and safe 
medications for use of its population and should follow these steps: 
 
 
233 
 
1. Provide staff needs of training programs specifically in stability, GMP, 
clinical and bioequivalence studies. 
2.  Update the list of required procedures and standards for registration of 
drugs/medicines and medical devices.  
3. Establish an e-link system between the Supervision of Pharmaceutical 
Registration and Release and Supervision of Laboratories to develop a 
more appropriate chain of authority to ensure that medicines release is 
based upon the correct basis of medicines quality and safety. 
4.  Increase the co-operation with other local or international agencies to 
ensure availability of recent and appropriate data for the drug and its quality 
and safety profile. 
5. Provide a drug index system from the Drug and Food Control Administration 
which would act as a reference for interested persons and agencies. 
 
6.3 The need to strengthen penalties, in order to restrain the spread of 
counterfeit and unregistered drugs in the Kuwait medicines market. 
 
The majority of interviewees (82.6%) of the 121 (in Chapter 4) indicated that 
Kuwait has weakness in the Health Care System for sanctioning and endorsing 
penalties for wrong doing in terms of the legislation and regulation of medicines.  It 
was indicated by the interviewees that in a number of areas it does not carry 
through the penalties or they are of a low level against the infringements incurred.  
The specific area mentioned were; for irregularities in the  private sector, limited 
control over the pharmaceutical processes (44.6% of the interviewees mentioned 
this); establishment of private pharmacies and warehouses without a license from 
the MOH or obtained through an incorrect procedure, in addition, violation of 
advertising, and promotion decisions of the pharmaceutical products, is insufficient 
and 46.3% of the interviewees suggested that there is an issue with access to 
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quality, safe and efficacious medicines especially in the private sector due to 
presence of purchasing of unlicensed and counterfeited drugs in some private 
pharmacies. 
 
For these reasons,  the interviewees clearly recommended to strengthen the 
control especially over the private pharmacies to prevent any illegal trading in 
medicines and to strengthen the penalties for this trading (e.g. the purchasing of 
non-prescribed, unlicensed and counterfeiting drugs) to reduce this matter. 
 
Medicines which are considered counterfeit are also an increasing area of concern 
in Kuwait and this violation was mentioned by many of the interviewees and during 
informal visits to the Administrations. Counterfeit medicines are a worldwide 
problem, which has recently attracted a large attention from the major Drug 
Regulatory Agencies, Governments, WHO and National and International Police 
Organisations (including Interpol). Counterfeiting is a large business with known 
international criminal gangs involved.  At this time, when a NDP is likely to be 
developed in Kuwait it is a good time to include the protection against 
counterfeiting in Kuwait.  To understand the problem more clearly the definition of 
counterfeiting of drugs/medicines is given below, with some recommendations from 
with the world groups and agencies, including the WHO and an indication of where 
counterfeiting occurs, how to combat it and how the penalties for counterfeiting 
medicines can be strengthened. 
  
6.3.1 Definition of Drug Counterfeiting 
Drug counterfeiting refers to the bogus medicines, which can be polluted or may 
contain the wrong ingredient, poor quality ingredients or contains no active 
component. Counterfeit medicines may even contain the correct active ingredients 
but not in correct dosage. These drugs are hazardous to health and their marketing 
is considered as illegal (WHO, 2012).  
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According to the USA Food and Drug Administration (FDA), Counterfeit medicines 
may be contaminated, may not contain the benefits for which the drug is intended 
to be prescribed, or may be packaged in spurious packaging. Use of such improper 
medicines may not cure the disease or ailment and can even lead to dangerous 
side effects (FDA, 2009). 
Furthermore problems of drug counterfeiting is not just limited to one nation, it is a 
serious global concern as in some countries it was projected that about 30-50% of 
medicines provided to treat hazardous diseases are counterfeit. However it is 
difficult to obtain an accurate estimate of the extent of medicines counterfeiting. It 
is proposed that more efficient and more intense research is required to explore 
the basis of the problem and to gauge the harm it is causing (Margaret, 2010). 
Figure 6.1 shows examples of spurious/falsely-labelled/ falsified/counterfeit (SFFC) 
medicines (WHO, 2010). 
 
 
Figure 6.1 Examples of spurious/falsely-labeled/ falsified/counterfeit (SFFC) 
medicines. (WHO, 2010) 
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6.3.2 The WHO and International Organization’s Recommendations  
The WHO during the World Health Authorities Meeting were asked to become 
more involved in coordinating national and regional support for controlling 
medicines counterfeiting (WHO, 2010).  As a result the International Medical 
Products Anti-Counterfeiting Taskforce (IMPACT) was developed by the WHO and 
International Regulatory Authorities (and with the major pharmaceutical 
companies) to help countries in protecting against counterfeiting drugs, in 2006. 
The IMPACT initiative has worked towards involving a large number of 
stakeholders in concerted efforts for protecting the public from purchasing and 
consuming SFFC drugs. IMPACT's areas of focus particularly centred on 
preventing the manufacturing and marketing of counterfeiting medicines, through 
the development of improved legislative and regulatory infrastructures, and 
improved and monitored regulatory execution of policy measures and their 
effective enforcement, by making use of the latest available technology and 
working towards a consistent approach for information sharing and efficient 
communication through worldwide publishing (WHO, 2010).  In addition many 
Regulatory Agencies and the Pharmaceutical Companies are working together and 
with scientists to detect and stop medicines counterfeiting. 
 
These developments together with International Conferences and publications by 
the WHO are starting to have an impact through promotion prevention of 
counterfeiting and awareness creation by way of the Conferences/ Symposia and 
through documentation from the major Drug Regulatory Authorities, WHO and 
Pharmaceutical Companies. This spread of awareness among decision makers, 
health professionals and consumers, and also development of global inspection by 
the medicines inspectors of the regulatory agencies and the development of an 
alert system, the assembly and circulation of reliable and quality data has had an 
effect on reducing the level of SFFC drugs in public circulation.  
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For Kuwait, the absence of a more controlled Pharmaceutical Sector has led to a 
considerable problem in terms of circulating counterfeit medicines.  Part of the 
reason for this is the limited control on incoming medicines particularly in the 
Private Sector.  
However with a NDP in place in Kuwait and the tightening of the medicines quality 
and testing regimen in terms of decision on the requirements for testing, setting of 
standards for QA and GMP, emphasizing the need for bioequivalence checks and 
better checks on inter-changeability of medicines, there is likely to be greater 
control over the appearance of counterfeit medicines. In addition there may be 
proposals to examine the place of bio-similarity in medicines and tightening of 
certificates for medical products.  
 
As indicated above the WHO, the major Drug Regulatory Agencies, 
Pharmaceutical Companies, University Researchers and Instrument companies 
continue to provide information and more specific technical support to countries 
(specifically developing countries), helping in review of national regulatory 
authorities for making them more effective in combating medicines counterfeiting. 
As an example the WHO have publications which provide IT assistance in 
developing quality, safety and pharmacovigilance based systems, and can provide 
quality WHO standards for medicine testing in quality-control laboratories (WHO, 
2011). 
 
Based on the information presented above, it is suggested that the KMOH should 
become more aware of the international developments in preventing drug 
counterfeiting and through the presence in the future of a NDP should review the 
literature and recent publication in this area and take knowledge from the benefits 
reported from the WHO and International Organizations (particularly the USA, FDA 
and the EMA in the EU) from their recommendations, experiences and 
suggestions.  It is also considered important that more interaction is encouraged 
with the agencies and through attendance of the appropriate  worldwide 
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conferences and symposia which either concentrate on reducing medicines 
counterfeiting or have a large section of discussion on the subject (e.g. 
International Conference on Drug Regulatory Affairs [IFPMA])  and the KMOH 
could send a group of Regulatory Pharmacists from the DFC to attend these 
conferences and training courses which concentrate of reducing the impact of 
medicines counterfeiting  
 
6.3.3 Examples of successful strengthening of penalties for purchasing of 
counterfeit and unregistered drugs. 
Therefore counterfeit and unregistered drugs pose a significant threat to the health 
of the public. Patients may often be unaware that they are purchasing counterfeit 
drugs, and they can be unaware of the risks that these pose to their health. There 
are a number of reasons why a patient may inadvertently buy a counterfeit 
medication from self-medication through to cost because they may not believe that 
their condition warrants full medical attention (Shabsigh et al, 2004).  
 
An example of a commonly counterfeited drug is;  Phosphodiesterase type 5 
inhibitor (PDE5i) which is used in the treatment of erectile dysfunction, counterfeit 
sellers offer illegal access to the drug because the patient may want to avoid 
healthcare professionals due to the  shyness and misconceptions associated with 
erectile dysfunction (Dorsey and Hellstrom, 2011).  
 
The WHO estimated in 2006 that less than 1% of pharmaceutical sales were 
estimated to be counterfeit medications in developed countries that come under 
the established regulatory lists (WHO, 2006). Although this may not seem like a 
significant number, 1% roughly can equate to over 8 million packs of counterfeit 
medicines, which are worth in excess of £425 million (Clark, 2008). In addition the 
level of counterfeiting has increased since that year. 
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In the early years there was the misconception that medicines counterfeiting was a 
problem mainly confined to developing countries, because of their lower intensity of 
the regulatory confines. However this was quickly dispelled and the level of 
counterfeit medicines reaching the population across most countries is relatively 
high.  The reasons for the increase are; the market forces of access to medicines 
without a doctor’s visit, use of medicines outside the normal health related practice 
(e.g. steroids in body building and for performance enhancing athletic use).  In 
some cases where there may be inadequate access to medications within the 
healthcare system, for example in rural areas where medical centres are often 
distant from the patient.  The health effects of taking these product can be 
considerable as can be shown by  the death of a 58 year old Canadian woman 
who died after she ingested counterfeit medication in 2006 where biochemical 
analyst experts found high levels of metals in her liver, including aluminum and 
exceptionally high levels of phosphorus, titanium, tin, arsenic and others. These 
medicines were bought from an eastern European website (Solomon, 2007). 
 
There are however in recent years many examples of successful legislation being 
developed in the European Union which was aimed at improving patient safety and 
reducing counterfeit medication contamination of medicine supply chains.  One 
such section of legislation was introduced in 2011, where the EU adopted a 
directive on counterfeit drugs, and gave European Countries 18 months to 
implement the changes shown in the legislation (Taylor, 2011). Alongside this the 
packaging was changed and three additional features were added to the packs to 
ensure that they are recognized as legitimate, these includes; the addition of a 
barcode, authenticity feature and seals designed to prevent any tampering 
(European Commission, 2008).  
Alongside the packing improvements some countries introduced stiffer fines and 
penalties In the UK enhanced penalties were introduced, which were welcomed at 
a number of levels (Jackson, 2010), and for criminally counterfeiting medications in 
the UK the perpetrators  could face up to a 12 year prison sentence (Nature 
Medicine, 2010). Also the MHRA was given the capacity and ability to prosecute 
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the manufacturers and distributors of counterfeit and unregistered medications in 
the UK and therefore they are working with law enforcement to do this (MHRA, 
2010).  
In terms of overall rights to import and sell medicines in the UK, the law allows 
individuals to import pharmaceutical products for personal use provided they hold a 
license within the country of origin and this includes products which can be bought 
over the internet (Hill, 2005). 
 
As time has passed the skills of the counterfeiters has increased and the quality of 
the packaging for medicinal products can be very similar to the original package. 
Figure 6.2 below is an example of this, where the packaging can be difficult to 
distinguish from an authentic sample. The counterfeit sample in this case should 
be a growth hormone used in AIDS treatment. However the counterfeit product 
contains no active ingredient (FDA, 2009). 
 
 
 
Figure 6.2 Counterfeit Serotism 6mg (adopted from FDA, 2009).   
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As another example of how penalties were introduced and increased for medicines 
counterfeiting in this decade is the law on drug counterfeiting which was changed 
in the Ukraine (2011), where the law established a liability for the falsification of 
drugs. The changes ensured that any production, purchase, transport, storing or in 
fact possession with any intent to sell the medication or selling counterfeit drugs 
can be punishable by a prison sentence ranging between three and five years. If 
these actions would then be repeated, or would result in injury or damage to health 
of any person, the prison sentence increases from between five and eight years. If 
the actions would cause death, this would lead to serious consequences or if it 
were  performed on a massively large scale the person(s) concerned could either 
face between eight and ten years imprisonment or alternatively a life sentence 
(Mondaq, 2012). 
 
Based on the information presented above, it can be indicated that the KMOH 
should be aware and take note of the developments in trying to reduce medicines 
counterfeiting and move towards introducing clear legislation and penalties by 
studying, the successful examples of these countries and strengthening of 
penalties for purchasing of counterfeit and unregistered drugs to ensure access of 
quality, safe and efficacious drugs for the population of Kuwait. 
 
6.3.4 Spread of drug counterfeiting in State of Kuwait 
The level of possible drug counterfeiting in Private Pharmacies in Kuwait over 
recent years has been measured under the heading of (Number of irregularities for 
private sector in 2013) by the Drug Inspection Administration during the fieldwork 
for this PhD research study.  From informal discussions with the Medicines 
Inspectors, it can be indicated that there appears to have been a relatively large 
spread of counterfeited and unregistered drugs in the pharmacies which suggests 
that these may be readily available in the medicines market in Kuwait. The Table 
6.1 shows the number of large irregularities at the private pharmacies (in all 
governorates of the country) that have been monitored by Department of Private 
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Inspection during morning inspection period in 2013. Based on the information 
presented in a table below, it can be observed that the private large irregularities 
(specifically sale of unregistered and counterfeited drugs in private pharmacies in 
Kuwait) were 94 cases (KMOH, 2013 d) 
 
Table 6.1 Number of large irregularities of the private pharmacies in Kuwait 
during the morning inspection period in 2013 (KMOH, 2013 d) 
Month/ 
Governorate 
Hawali Al 
Ahmadi 
Al 
Farwaniah 
Al Asimah 
(Cabital) 
Al 
Jahra 
Total 
Irregularities 
Per Month 
January 3 2 4 3 - 12 
February 2 2 1 1 - 6 
March 1 3 3 1 - 8 
April 1 1 3 1 1 7 
May 2 - - - 1 3 
June 3 1 - - 4 8 
July 2 - 1 - - 3 
August 5 2 5 2 - 14 
September 5 2 2 - 3 12 
October 5 2 1 - - 8 
November 2 1 - 1 - 4 
December 3 2 3 1 - 9 
Total 34 18 23 10 9 94 
 
In addition, the number of large irregularities of the private pharmacies that have 
been monitored by Department of Private Inspection during night inspection period 
in 2013 reached to 114 irregularities (related to sale of unregistered and 
counterfeited drugs in private pharmacy in Kuwait), and it can be observed that 
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there is a spread of counterfeit and unregistered drugs in the market. . See table 
6.2 (KMOH, 2013 e).  
 
Table 6.2 Number of large irregularities of the private pharmacies in Kuwait 
during night inspection period in 2013 (KMOH, 2013 e) 
Month/ 
Governorate 
Hawali Al 
Ahmadi 
Al 
Farwaniah 
Al 
Asimah 
(Cabital) 
Al 
Jahra 
Total 
Irregularities 
 Per Month 
January 3 - 1 1 1 6 
February 2 - 2 - 1 5 
March - - 1 1 - 2 
April 1 1 - 2 - 4 
May 6 2 5 3 2 18 
June - 1 - - 2 3 
July 1 - 1 2 - 4 
August 1 1 1 - 1 4 
September 5 - 3 1 - 9 
October 8 2 8 2 - 20 
November 7 3 9 2 2 23 
December 5 2 7 1 1 16 
Total 39 12 38 15 10      114 
 
Based on the information presented above (Tables 6.1 and 6.2), it can be indicated 
that there is a spread of counterfeited and unlicensed drugs in private market in 
Kuwait because the total number of private irregularities in 2013 (in both morning 
and night inspection period) were 208 large irregularities and when compared that 
number with a number of private pharmacies (450 private pharmacies) in Kuwait, it 
can be observed that there is a serious issue in this aspect. 
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In addition, during the fieldwork for this PhD research study (in 2014) the author 
had several visits to the seizures store of the Drug Inspection Administration, and 
based on the figures (photos taken of the seizures during the fieldwork visit) below 
it can be observed the large number of confiscated drugs (counterfeited and 
unlicensed drugs) from the private pharmacies in 2014.  
 
 
 
Figure 6.3  
 
The figure above shows a number of confiscated drugs which includes; 
counterfeited and unregistered drugs by the inspectors of Drug Inspection 
Administration in 2014.     
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Figure 6.4 
The figure above shows, the confiscation of slimming products, which, are 
unregistered from KMOH and were purchased in the private pharmacies in Kuwait 
in 2014. 
 
 
Figure 6.5 
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The Figure above shows, the type of confiscated counterfeited drugs which 
includes; herbal, sexual, food supplement and pharmaceutical products in the 
seizures store of the Drug Inspection Administration in 2014. 
 
 
Figure 6.6 
 
The Figure above shows the comparison between confiscations of counterfeiting 
drugs and the authentic copies such as; Augmantin, Sildenafil, Plavix and Zyprexa 
(the authentic and the counterfeit drugs side by side). 
 
6.3.5 Main solutions which have been suggested to stop drug counterfeiting 
The scientists and academics/companies working in pharmaceutical analysis have 
been working on finding solutions to the identifying of counterfeit medicines for 
some years and there is some highly sophisticate instrumental methods to handle 
the problem. Some is in the form of successful technology, procedures and training 
programs.  These could be appropriate to support the KMOH in increasing and 
promoting the ability to control the spread of counterfeited drugs in the private 
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sector by providing it to the health professionals staff (inspectors).  Some of these 
include:  
 
1. The Molecular Pharmaceutical Authentication using Energy Dispersive X-Ray 
Diffraction (EDXRD) Technology: where the low quality or counterfeiting drugs can 
be detected using EDXRD even when they are inside sealed packing, without a 
technical staff requirement. In addition, the XT250 System promptly correlates 
drug’s molecular crystalline structure against its standard profile to decide its 
authenticity and quality. This test is suggested to just take a few minutes to classify 
the drug into counterfeiting or not. (Adams, 2012) 
 
2. The application of standard procedures for drug inspectors from the Drug 
Inspection Administration: by provide the specific guidelines to the inspecting 
officer about the drug documents to be investigated, sampling methods, method to 
seal the sample to ensure it remains undisturbed until it reaches the quality control 
lab, separating suspected drugs and stopping their further distribution, to 
encourage recording of actions taken and seizure and elimination of counterfeiting 
drugs (Khalen, 2012).   
 
3. The introduction of appropriate training programs related to counterfeit drugs for 
inspectors:  Special training can be provided to inspectors of the Drug Inspection 
Administration to provide support in identifying the possibility of counterfeiting in a 
particular drug. In addition, the USA, FDA has been updating the information about 
many drugs on its website. With the use of such information both the health 
professionals (pharmacists and physicians in Kuwait) and patients should be 
conscious while taking drugs of the side effects or if the drug appears or tastes 
differently or is packaged in a different way or the drugs are damaged or cracked. 
In these cases it may be found to be a counterfeit drug (Hassett, 2012). 
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The overall conclusions from the studies above suggests that it may be necessary 
for the KMOH to carry out development and improvement of control over the 
pharmaceutical process in the private market based on the information presented 
in this section.  However from experience there are problems in private pharmacies 
in Kuwait. But it can be suggested that these can be alleviated by the KMOH 
introducing legislation, inspections and testing methods.  With these it becomes 
possible to resolve the issues surrounding the purchase of unlicensed and 
counterfeited medicines in private pharmacies in Kuwait. The action which could be 
taken includes:  
 
1. Strengthening penalties (as presented in Chapter 5), in order to restrain the 
spread of counterfeit and unregistered drugs in the market and to solve weakness 
of other aspects (as mentioned below). Because the present penalties are 
insufficient and inappropriate to reduces the issues in this area. The trade penalties 
for the private sector in Kuwait could include the following punishment levels: 
 
 a). There could be punished by imprisonment for a period not exceeding two years 
or a fine not exceeding two thousands KD (7000 USD) or by both of them if: 
         -  There is a violation of drug pricing decisions. 
         -  The licensed premises are used for other purposes. 
 b). There could be punished by fine not exceeding two thousands KD (7000 USD) 
if: 
        -  There is violation of advertising and promotion decisions of the 
pharmaceutical products.   
c). There could be punished by giving a warning, suspension from working for a 
period not to  exceed one year, cancellation of the license to practice the 
profession, closure of the premises not exceeding six months if: 
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       - There is violation of the rules regulating the registration process of the 
pharmaceutical products and the medical devices. 
       - The private pharmacy sale of any pharmaceutical product is not from a 
source which is a registered local agency in Kuwait. 
       - Sale of any pharmaceutical product which is not-registered in a Kuwaiti Drug 
Control Administration for the private market. 
       - The private pharmacy, companies and stores Sale of any counterfeited 
drugs.  
 
Based on the trade penalties for the private sector in Kuwait presented above, it is 
suggested that the KMOH strengthen those penalties because of what can be 
classed as greed of some operators of private pharmacies, suppliers and 
companies taking advantages of weakness of the present penalties and they do 
not care if they have to pay modest penalties when compared with their great 
profits. The KMOH will however have to arrange the following: 
1. Provide enough technologies, procedures and training courses in 
counterfeiting drugs for inspectors of the Drug Inspection Administration. 
2. Increase cooperation with the Ministry of the Interior and Kuwait General 
Administration of Customs to ensure enough control over border crossing 
centres at Kuwait International Airport and sea and lands ports. 
3. Provide an e-link system between Drug Inspection Administration and Drug 
and Food Control Administration to ensure continuity access to all a 
necessary data (update licensed and registered drugs and approved 
advertisements) at the right time, which supports inspectors of Department 
of Private Inspection to monitor traded drugs in private pharmacies.  
4.  Increase the cooperation and gain support from agencies such as the; 
WHO, MHRA, FDA and European Commission and take the benefits from 
their recommendation, experiences and suggestions.  
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5. Increase the educational and awareness programs for the public by using 
media, leaflets and publishing to ensure raising awareness about the 
dangers of using counterfeiting drugs. 
 
Finally it is accepted that counterfeit and unregistered drugs pose a problem and 
despite this, the laws controlling these are considered to be lax. There is therefore 
a need to strengthen the legislation in Kuwait within the NDP to protect the 
population of the country and ensure that they are not subjected to any adverse 
effects that the ingestion of a counterfeit drug may cause. 
 
6.4 High price range of medications in the private sector and lack of a Drug 
Cost Effectiveness Department in State of Kuwait 
 
Another aspect for consideration in the NDP under the Drug and Food Control  
Administration is medicines pricing and according to the structured interview 
results [Chapter 4, in question 6: (Do you think that the price range of medication in 
the private sector is publically acceptable?)], it was found that 51.2% of those 
interviewed did not accept that the price range of medicines in the private sector 
was acceptable and they suggested that the range in the private sector was 
exaggerated when compared to the Kingdom of Saudi Arabia (KSA). In addition 
they suggested that the Drug Pricing Department of the Drug and Food Control 
Administration is not strict enough with the drug prices in the private sector, due to 
a lack of a Drug Cost Effectiveness Policy and having applications, experts and 
processes to measure this in the KMOH. 
 
Based on this information, it is suggested that the Pricing Department should firstly 
collect further information and discuss the results to ensure they are using the 
correct assumptions from the collected data of this study(interview and KMOH 
data), from this and the solution suggested below it becomes possible to accurately 
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identify the main issues, solutions and future action plans of resolving the 
perceived high price range of medications in the private sector in Kuwait . The 
information which will be further examined here includes: 
 Definition of drug cost effectiveness. 
 How to choose cost effectiveness of drugs, injections and medical devices. 
 Cost and price range of drugs in Kuwait. 
 
6.4.1 Definition of drug cost effectiveness 
Drug cost-effectiveness can be determined by analyzing the economic competence 
and effectiveness of one or more forms of the drugs in the medicinal form. In 
addition it involves making a decision of whether one drug against another is as 
clinically effective and has a lower cost against another. A relatively easy decision 
is taken when one drug provides more benefit at the same or lower cost, or lower 
cost for the same or larger benefit (David Parkin, 2009). 
 
Cost-effectiveness analysis normally compares the money involved alongside the 
health benefits by measuring the level to which it can be considered as delivering 
value for money. It is proposed that this helps the decision makers to efficiently and 
effectively use the often limited healthcare resources (Ceri Phillips, 2009). Also the 
decision process in a larger study with involvement of a cost-effectiveness unit 
such as National Institute for Health and Clinical Excellence,(NICE) in the UK it 
becomes an economic study design in which the results from various alternative 
drugs are deliberated by means of a single outcome generally in units like life-
years achieved, deaths avoided or cases identified. Substitute choices of drugs are 
then evaluated with cost per unit of effectiveness, NICE, (2008). 
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6.4.2 How to decide upon cost effectiveness of drugs, injections and medical 
devices 
In order to determine the cost effectiveness of one or more drugs, medical devices 
and injections, it is proposed that firstly the nature of their combination or 
comparison should be defined whether they are independent or mutually exclusive. 
They are treated as completely independent when the money involved and effects 
of one drug/device under consideration are not impacted by the introduction or 
otherwise of other drug/device. This occurs when introducing one drug/device 
leads to clinical restriction on the other drug/device implementation, or where the 
introduction of one drug/device results in variations to the costs and effects of 
another.  In these cases they are considered as mutually exclusive. 
In order to measure the effectiveness a cost-effectiveness ratio (CER) can be used 
and should be linked to the amount in the budget to find out the most cost-effective 
strategies. In a CER costs are measured in monetary terms while benefits in terms 
other than money.  For Independent programs Cost effective ratio (CER) is 
calculated as: choice is made for Lower CER (Ceri Phillips, 2009). 
 
Other factors which also should be considered for determining the most cost 
effective strategies are sensitivity analysis; issues of equity, needs and priorities. 
Accurate Interpretation of these ratios is an integral part of the decision making 
process to arrive at accurate and reliable conclusions; assumptions and 
perspective of the study should be stated clearly for effective outcomes (Ceri 
Phillips, 2009). 
 
In addition, purchasing of generic drugs instead of patented drugs help in reducing 
the cost of the drugs. Generic medicines are pharmaceutical products which have 
the characteristics of originator compound so can be replaced in place of source 
compound. These are sold once the original patent or other exclusivity rights 
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expire, then they are manufactured by a new company who obtain a Generic 
license (The World Medicines Situation, 2004).  
 
In addition, the entry of generic products and competition among them helps in 
making available the lowest priced generic medicines for the developing countries   
(WHO, 2010).  
 
6.4.3 Cost and price range of drugs in Kuwait 
During the fieldwork for this PhD research study (2012–2015), the author had 
several informal visits to Drug Pricing Department and CMS Administration and 
based on the structured discussions with staff involved (Chapter 4) and the 
collected data (mentioned below) from these areas, it can be observed that the 
price range of drugs in the private sector is considered to be very high when 
compared to KSA. This is despite the fact that the two countries are adjacent and 
the sources of imported drugs and tariffs on imported drugs are similar (5%). Table 
6.3 below shows the comparison in prices for the same drugs in private market 
between Kuwait and KSA in 2015 (KMOH, 2015 j).   
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Table 6.3 Comparison in prices of the same drugs in private market between 
Kuwait and KSA in 2015 (KMOH, 2015 j) 
 
Name of Drug 
 
Price of drug in 
Kuwait ($) per packet 
 
Price of drug in 
KSA ($) per packet 
 
Arcoxia 90 mg (28 tablets) 
 
105 
 
49 
 
Lercadip 10 mg (30 
tablets) 
 
38 
 
16 
 
Ezetrol 10 mg (28 tablets) 
 
100 
 
60 
 
Plavix 75 mg (28 tablets) 
 
82 
 
66 
 
Januvia 100 mg (28 
tablets) 
 
97 
 
37 
 
Zocor 20 mg (28 tablets) 
 
82 
 
32 
 
Clasid 500 mg (20 tablets) 
 
40 
 
24 
 
Clasid XL 500 mg (7 
tablets) 
 
18 
 
11 
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Based on the information presented in the table above, it can be observed that 
there are large differences in drug prices between the costs in the private market in 
Kuwait and KSA.  In some cases the difference is as high as double and 
sometimes triple the price in KSA. What are the reasons for these high prices?  
The investigation suggests it may be caused because of two main reasons 
includes; 
 
a). The absence of a Drug Cost Effectiveness Department in the Drug and Food 
Control Administration, and in addition, possibly poor drug cost effectiveness 
monitoring because of deficient; training programs and appropriate staff) in the 
Drug Pricing Department. It was found that the staff responsible for pricing of 
medicines may need more experience and training in this aspect to ensure that 
they have access to appropriate prices for the consumers and private suppliers, 
companies and pharmacies.  
b). Absence of an Essential Medicine List, where the current situation doesn’t help 
the public and private sectors in determining the needs of appropriate medicines 
and the selection of these medicines for supply in the long term. 
 
Based on the information above, it is suggested that the KMOH can control and 
where appropriate reduce the prices of medicines in the private sector by 
introducing: 
 
1. A medicines cost effectiveness programs and special training for the staff of 
the Drug Pricing Department of the Drug and Food Control Administration. 
2.  Formation of a multidisciplinary Pricing Committee, which can ensure a 
transparent pricing structure and the pricing system, should not distinguish 
between public and private sector. 
3.  Replacement of wholesale and retail mark-ups with a fixed professional fee. 
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4.  Formation of a price monitoring system with contrasting drug prices to 
international levels. 
5.  Regulation of the effects of inflation on drug prices, and the provision of 
priority medicines to the private sector (Loraine Hawkins, 2011). 
 
In summary, it was observed that there is an absence of a Drug Cost Effectiveness 
Department in the administrative formation of a CMS Administration, and this 
absence of this important department effects negatively on the process of 
purchasing of medicines and may not allow optimum price levels to be achieved to 
obtain the appropriate drugs at suitable prices and cause overcharging for the 
State budget, which could otherwise be used in other areas of the MOH.. 
Furthermore according to the discussions with senior staff in the CMS 
Administration (Chapter 6) it was noted that the method used in determining the 
prices of purchased medicines was only based on the experience of the senior 
staff without consulting any experts of cost effectiveness.     
Based on the information presented above, it is clear that there are problems in the 
process of pricing drugs in the CMS and it is important as part of the NDP to 
establish a Drug Cost Effectiveness Department for this Administration, to advise 
on drug pricing.  It is also suggested that the KMOH should take into account the 
need to develop the process of drug pricing.  But they should also be aware that in 
reducing medicines costs in the private sector there should be no negative effects 
on the patient's health. 
 
As an overall conclusion from these studies, it can be suggested that the KMOH 
should develop the process of purchasing drugs at suitable prices in a more 
measured way and save the national budget by carrying out the following; 
 
1. Establishing a Drug Cost Effectiveness Department in the CMS 
Administration. 
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2.  Increase the cooperation with the Gulf Cooperation Council (GCC) 
countries in the field of purchasing of medicines requirements by a 
collectively tender process to obtain lowest costs.  Such cooperation could 
lead to economies of scale.  
3. Purchasing of generic drugs where available instead of patented drugs, as 
patented drugs have a negative impact on the state's budget and this is due 
normally to their high prices and the manufacturer's monopoly. The Table 
below shows the typical difference in cost between patent drugs and generic 
drugs which the KMOH purchased in 20012-2013.  
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Table 6.4 The difference in cost between patent drugs and generic drugs 
which the KMOH purchased in 20012-2013 (KMOH, 2013 f) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical Group Patented Drugs 
( price per unit ) 
$ 
Generic Drugs 
( Price per unit ) 
$ 
Domperidone  
(10MG) Tablet 
Motilium 
(Janssen , Belgium) 
0.098 $ 
 
Pokinin 
(Jamjoom , KSA ) 
0.077 $ 
Diclofenac Potassium  
(50 MG) Tablet 
Cataflam 
(Novartis , Switzerland ) 
0.14 $ 
 
Rapidas 
(Tabuk , KSA ) 
0.071 $ 
 
Atenolol  
(100 MG) Tablet 
Tenormin 
(Astrazeneca , Sweden ) 
0.08 $ 
Apoatenol 
(Apotex INC , Canada ) 
0.0274 $ 
 Metformin  
(500MG) Tablet 
Glucophage 
(Merck Sante , Germany ) 
0.042 $ 
Metaphage 
(KSPICO , Kuwait ) 
0.0105 $ 
Amoxicillin+Ciavulanic 
(1GM) Tablet 
Augmentin 
(Glaxo Smith Kline , UK ) 
1.033 $ 
Klavox 
( SPIMACO , KSA) 
0.1693 $ 
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The overall conclusion from these studies, indicate that the high price range of 
medications in the private sector and lack of a Drug Cost Effectiveness Department 
in State of Kuwait are main issues and the KMOH could carry out the solutions for 
these aspects to ensure the availability and affordability of quality drugs in a good 
prices for the population in Kuwait.  
 
6.5 The Absence of a Quality Assurance and Service Management 
Departments in the Public Health Areas in State of Kuwait 
 
The current deficiency of the Quality Assurance (QA) Department to examine the 
information on the quality of medications reaching the population was mentioned 
by a large majority of the interviewees (121, 82.6%) (Question 3 of the interviews, 
in Chapter 4). They indicated that this is a major weakness in Kuwait over its 
control of the quality of the Administration and Access for Patients to Medicines 
which have good quality, are safe and are efficacious for the use against 
diagnosed illness.  The deficiency in checks on medicines was found across most 
public health areas (CMS Administration, Laboratories and Hospitals) in Kuwait.   
 
The absence of QA and Service Management takes a number of forms 1).The 
assessments of quality (safety and efficacy) of medicines entering Kuwait and in 
the future the quality of medicines which may be manufactured in Kuwait.  This is 
directly relevant to the developments within the NDP, 2).The second level of 
QA/Management is linked to the quality of medicines provided through 
procurement practices. 3) The quality of health service management and support 
to patients.  These 3 aspects were commented upon during the study and limitation 
on the assessment of service at different levels was observed directly during this 
study at the Drug and Food Control Administration, CMS Administration, ten public 
hospitals and two health clinics (PhD study, 2012–2015). In addition it was 
mentioned during discussions with professional health care staff and through 
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observing the nature and operation of the work in these areas that the quality of 
service during the interaction with patients and the support given to patients should 
be examined (as mentioned in Chapter 5) and this could be introduced into the 
relevant section of the NDP.   
 
From these observations on medicines quality it is recommended that the 
introduction of adherence to good QA (medicines and service quality) practices is 
featured in the NDP and that the KMOH should focus on the significance of QA 
and work together with health professionals to disseminate knowledge on this 
property in all public health areas, that work with and supply medicines and health 
support.   
In particular it is the former aspect of QA which is given most attention in this study.  
By considering and operating good QA for medicines quality it will assist in 
developing and improving the health services in the country and support the work 
which will be carried out in establishing a NDP in Kuwait. 
In this section, the following areas are discussed; 
1. Definition of QA. 
2. QA and the Drug and Food Control Administration in Kuwait. 
3. Absence of a good management practices for drug procurement in the CMS 
Administration in Kuwait. 
4. Absence of a quality of service assessments in public hospitals in Kuwait. 
5. The importance of assessing excellence in developing the Health Care 
System in Kuwait. 
 
6.5.1 Definition of Quality Assurance 
QA refers to a process which ensures that medications which reach patients are 
safe, effective and can be used for that patient. The deficiency of a QA program, 
Departments or Organization has been observed during these studies and are 
thought to effect negatively on Kuwait’s Health Services, and may be involved in 
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the risk of the government/MOH in procuring pharmaceutical products that could 
be sub-standard and may lead to product recall, wastage of money and most 
importantly health risks to individual/groups of patients that have been exposed to 
these medicines (WHO, 2007).  
 
In addition to the reducing the effect on the patient, the presence of a structured 
QA program is very important in ensuring the control and monitoring of drugs, their 
drug testing and the analytical work carried out in the laboratories. It is important 
that testing laboratories through the QA Department are able to quickly exchange 
reliable data between laboratories and the drug enforcement agency, the CMS and 
where appropriate between laboratories on a national and regional or international 
level. Having well developed QA procedures in place which, work with analytical 
precision should have the effect of stimulating GLP (Good Laboratory Practices) 
across laboratories, which should have well trained staff and have a sufficiency of 
suitable instrumentation and access to methods.  This should be under the control 
of the Food and Drug Control Administration to test for medicines entering Kuwait 
through the drug procurement program and where illegal drugs are suspected 
(United Nations, 1995).  The Drug and Food Control Administration would also 
discuss medicines quality and QA testing where appropriate with the CMS. In order 
to undertake these suggestions it is important that within the NDP there is full 
discussion of a QA Plan which is operated in a way which is linked into the 
structure of the NDP. 
 
 6.5.2 QA and the Drug and Food Control Administration in Kuwait 
From the knowledge base developed through studying the introduction of a NDP, 
knowledge from working in the Laboratories of the Drug and Food Control 
Administration for a number of years and the fieldwork visits to Kuwait (PhD study 
2012–2015) (as discussed in Chapter 5), it is clear that the operation of the QA 
Department as a section of the Drug and Food Control Administration has a 
number of areas, where further developments are needed.  
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The areas which should be considered include; management and operational 
structures, the method of operation and the management control, training and 
update training of staff and its authority alongside other Departments. Therefore it 
is proposed that for a QA structure to operate affectively, it must have authority, to 
include the power to make and take decisions, to which other Departments and 
Areas should take heed. But presently in the Drug and Food Control Administration 
and other areas where the QA has involvement it is very difficult to achieve this 
without clear lines of authority and with very limited staff (presently they only have 
2 pharmacist staff) to cover what should amount to a very large area of 
responsibility.  As an example the management decision structure of medicines 
discharge after testing operates through the Registration and Release Supervision 
(Quality Control), rather than the authority and clearance through the QA 
Department, which is the internationally accepted chain of management. 
. 
At the present time it is proposed that the QA Department are not working at the 
level which would be expected to ensure that the medicines entering Kuwait and 
stored in Kuwait in the CMS can always be said to be of the best quality, have 
been efficiently tested and that decisions have been taken which are sound on the 
basis of good quality assurance practices.  Therefore the issues mentioned above 
are suggested to be causing obstructions in the work efficiency of the QA 
Department and consequently do not support the reaching of the desired goal; 
controlling and monitoring, accepting analytical and administrative work which 
should be carried out to allow quality testing and then ‘signing off’ and registration 
from the Laboratory Supervision.  In addition to this assessment of quality and 
therefore the capability to indicate that the medicine reaches the required 
Pharmacopoeia requirements.   
 
There is also the further stage of being able in the future to use a greater degree of 
assurance that when a medicines enters the circulation chain in Kuwait it has been 
tested efficiently and then if there are later problems with Post Marketing 
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Surveillance in Kuwait, (which would be introduced as a part of the NDP), any 
issues that arise can be reported as possible adverse drug reactions and not 
based on quality concerns. 
 
Hence to develop and improve the QA Department in the Drug and Food Control 
Administration the first stage should be to ensure the structure allows enough 
management decision control and power to make decisions relating to quality (and 
where appropriate safety and efficacy) over other Supervisions and Departments of 
the Administration.  In order to achieve this, the KMOH should make clear the role 
of the QA Department in written documents relating to the NDP and provide 
statements which promote the work of this Department.  These could include; 
providing greater power of authorization to ensure that there is sufficient clear 
monitoring of the drug registration process and insisting that drug testing is carried 
out at the level appropriate in Kuwait and relate this to international testing, that 
there are the employment of a suitable number of staff and that all the staff are fully 
trained in procedures and processes appropriate for making decisions in QA. The 
QA Department should also collaborate with the CMS to ensure that medicines 
stored in the CMS and the medicines collected during inspections are tested. In 
addition, in particular the Department should be independent and divided from 
Registration and Release Supervision. 
 
Communication is also of major concern and the present communication methods 
are suggested to be inadequate to handle the needs of the Administration.  As a 
result electronic methods of communication are considered to be essential to 
ensure that the QA Department can provide the high level of support needed. 
Accordingly an e-link system between the Supervisions and Departments of Drug 
and Food Control Administration and CMS Administration to ensure provision of 
more efficient communication and faster response to decision making  to ensure 
that medicines procured for Kuwait and used in its Health Areas are of the best 
quality, safe and efficacious.  
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6.5.3 Absence of a good management practices for drug procurement in the CMS 
Administration in Kuwait 
Based on the structured discussions with pharmacists (in CMS Administration) 
(presented in Chapter 4), and information provided on the drug procurement 
system (mentioned in Chapter 5) and informal visits to the CMS Administration 
during the PhD study (2012–2015), it can be indicated that this Administration 
suffers from management limitations in areas relating to ensuring the best 
practices are operated in the procurement of medicines through the CMS. A lack of 
quality of practices in this Administration was considered by interviewees to be 
acting negatively on monitoring and evaluation on the work of CMS Administration 
relating to procurement of medicines and the Procurement Cycle which is operates 
in Kuwait and many other countries. 
 
It is proposed that the CMS should establish a section of the department which 
would support the Drug Procurement Process and ensure in an independent 
format to assess the management procedures of:   
1. Identifying the prequalification of drugs and medical devices before 
procurement. 
2. Examine the processes of purchasing of drugs. 
3. Ensure good storage and record keeping of purchased drugs. 
4. Introduce effective control of drug distribution. 
5. There should also be links with the QA Department in the Drug and Food 
Control Administration for medicines testing 
 
6.5.3.1 Identify the prequalification of drugs and medical devices before 
procurement 
According to the information obtained during field visits to the CMS, it is suggested 
that the KMOH can improve the process to identify the prequalification of drugs 
and medical devices before procurement by establishing an improved 
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management department in the CMS Administration. The procurement practice 
which is recommended, is a continuous cycle from year to year and has been 
discussed in the textbook, Management Science and Health Publications – 
Managing Drug Supply in collaboration with the WHO action programme on 
essential drugs and this text should be examined and compared with the 
procurement practices in Kuwait to ensure the best practices for medicines 
procurement in the public sector (MSH, 1997).    
 
Added to the information source above a WHO team of specialists in 2003 found 
that there was a substantial difference between the prequalification of vaccines and 
pharmaceutical products (WHO, 2003).  
 
Prequalification of drugs is a term given to a service or a system which examines 
the choice of medicines through assessing their quality, safety and efficacy. The 
first major form of prequalification was carried out as a directive from the World 
Health Assembly (1997) to the WHO to request they set out the basis for an 
Essential Medicine Programme of prequalification and every 2 years the list of 
medicines is examined closely and some are added and some are removed based 
upon their quality, cost and health value and by the end of 2012 the list contained 
more than 316 drugs (WHO, 2013).  
 
The process of prequalification as proposed by the WHO consists of five steps, 
which includes: 
1. Firstly an invitation is made to product manufacturers to submit products for 
evaluation.  (Only approved drugs on the Essential Drugs List, are 
evaluated).  The Drugs on the List having been selected on the basis of 
public health need, effectiveness in comparison to other products, their 
safety and cost. But as Kuwait does not have an Essential Drug List to work 
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with under their CMS drug procurement system, it is important that the 
KMOH work with the CMS on establishing this list.  
2.  It is proposed that the manufacturers are responsible for providing their own 
data on the quality, safety and efficacy of their product which includes data 
on the ingredients, to include the purity, and also where appropriate to 
provide data from clinical trials in healthy volunteers. 
3. This data should then be gathered together and analyzed by the health 
professional from the procurement management. 
4. It is normally the case that the MOH sends a team of inspectors to the 
manufacturing site where they can ensure that the site complies with GMP, 
and this extends onto any contractors, such as other laboratories or 
companies carrying out manufacturing of the pharmaceutical preparation or 
clinical trials, who both have to comply with either good clinical or laboratory 
practice.  
5. A decision is then made based on whether the product meets the 
requirements of prequalification, and the drug in the required 
pharmaceutical form is then added to the list of prequalified drugs. However 
at present this set of procedures can take from three months to considerably 
longer if the manufacturer does not meet the required standards. The MOH 
continues through the CMS medicines inspection team to visit and ensure 
that the product continues to meet specifications and also to account for any 
variations made to the product (WHO, 2013).  
  
In the information gathered during the study there were concerns that the different 
processes of drug procurement could be tightened and improved with a dedicated 
management team and In particular, not having and Essential Medicines List can 
be said to reduce the effectiveness of the present medicines procurement system 
and can lead to difficulties in maintaining medicines supply and in obtaining the 
best prices for the medicines required.  With a dedicated Management Team in 
place to oversee the procurement practices and to follow the other stages of 
medicines storage and management, there is likely to be a closer liaison with the 
QA in the Drug and Food Control Administration leading to the exchange of data 
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among the Supervisions which is considered very important to ensure medicines 
procurement of the best quality and provide the best financial position within the 
budget provided.   
6.5.3.2 Purchasing of Medicines. 
One of the major functions of a Procurement Management Teams in the CMS is to 
obtain medicines at the best possible cost, within the government budget and 
therefore the processes used in the purchasing of drugs by the CMS 
Administration in Kuwait, is highly important.  
 
The overall aim of purchasing is to obtain good quality, effective and safe drugs at 
the lowest cost possible. There are four main goals which ensure good purchasing 
of drugs (Managing Drug Supply, 1997) and this applies to any system which can 
be both public and private. These are the 1) ensuring the value of the drugs in an 
Essential Drugs List and selection of reliable manufacturers or suppliers, 2) 
purchasing of the most cost efficient medicines in the right amounts, 3) finding the 
time it will take for delivery and 4) ensuring the medicines total costs to include all 
aspects of the purchasing cost (e.g. packaging, shipping, storage on receipt before 
QA clearance (WHO, 1999). The QA Department in the Drug and Food Control 
Administration can support the health professionals of the Procurement 
Management Team in the CMS in these actions by provide a data base of quality 
concerns and stability information to assist in finding the best drugs/medicines for 
use in the public health system. They can also through the Laboratories provide 
medicines quality data (QA data) both initially and during medicines storage. 
 
It is proposed that there can be four main methods for purchasing of medicines 
after the processes above are handled of; selection of products and manufacturer, 
list of quantity and specifications. These include; 
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a) Restricted tender, any manufacturers considered are already preapproved 
through prequalification. This can be referred to as limited international bidding. 
This method ensures quality products are selected from reliable sources.  
b) Competitive negotiation, quotations for price are obtained from suppliers, and 
the lowest price is usually selected. This method is useful when obtaining a small 
quantity of medicines.  
c) Direct procurement, pharmaceutical products are purchased directly from a 
supplier without any applications or price comparisons. This may be used when 
there is only one supplier for a product.  
d) Open tender, all manufacturers are allowed to bid and this can be referred to as 
international competitive bidding. This can be a long process and is generally 
inadvisable as it can be uncertain whether the supplier will be able to deliver the 
specifications (Managing Drug Supply 1997).  
 
6.5.3.3 Storage of purchased drugs 
As mentioned in Chapter 5, medicines storage of purchased drugs is carried out at 
the warehouse of the CMS Administration and the company which acquired 
storage tender will be responsible for arranging the drugs storage in the warehouse 
of the CMS. Presently the overseeing of this storage is loosely carried out within 
the CMS, but the introduction of a  Procurement Management Team should have 
greater control of this storage function and ensure enough control and monitoring 
over the Companies operations by ensuring that all the stored drugs are under 
conditions set out by the KMOH and from this prepare electronic reports on the 
level and quality of their work.  
 
The Procurement Management Team will be important in ensuring that the receipt 
of medicines into storage is constantly updated by the CMS staff and the storage 
conditions are maintained in order to ensure that their quality is preserved.  The 
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CMS staff should ensure that the batches can be traced and the stock can be 
rotated and this would be overseen by the Management Team.  Another function 
would be to liaise with the Drug and Food Control  Administration Analytical 
Laboratories to ensure that samples in each batch of product are be chosen by the 
Drug and Food Control  Administration QA management and tested within the Drug 
and Food Control Administration laboratories to ensure that  meet the 
specifications, prior to supply of the product. When receiving a delivery of product, 
not only should their transfer be protected, but it should also be traceable and the 
product should be quarantined until it is cleared for use. The Procurement 
Management Team should ensure that any products deemed to be rejected should 
be marked and stored separately so that they cannot be used and their disposal 
arranged. The storage conditions should also be appropriate, and comply with 
manufacturer’s instructions, which protect the integrity and quality of the product 
(WHO, 2003) (It should be noted that stated temperatures for example may in-fact 
mean a range as demonstrated in Table 6.5).  
 
The overall conclusion of these studies shows the importance of establishment a 
Procurement Management Team in the CMS Administration to ensure enough 
control over the Procurement and Medicines Storage in the CMS store and it is 
suggested that the management structure should appear in the NDP and the 
KMOH should carry out this necessary action in the future plan. 
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Table 6.5 Manufacturer instructions and equivalent conditions (adapted from 
WHO, 2007)  
Label Conditions 
Do not store over 30oC Between +2oC and +30oC 
Do not store over 25oC Between +2oC and +25oC 
Do not store over 15oC Between +2oC and +15oC 
Do not store over 8oC Between +2oC and +8oC 
Do not store below 8oC Between +8oC and +25oC 
Protect from moisture Conditions must be below 60% humidity 
Protect from light Must be kept away from light 
 
6.5.3.4 Effective control of drug distribution 
Based on the information presented in Chapter 5, it is indicated that The CMS 
Administration is responsible for distributing medicines to the public hospitals and 
clinics. The final step within the Management Teams remit of product procurement 
is the effective control of distribution. 
 
Appropriate distribution systems should be in place to maintain a supply of drugs, 
of good quality and condition at all stages of the process, good inventory records 
should be kept, theft should be reduced and adequate forecasting by systems for 
future demand established (MHRA, 2011).  
 
It is clear that the establishment of a Procurement Management Team in the CMS 
Administration in Kuwait should improve the supply management of drug selection, 
procurement, storage and distribution within this Administration. 
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As has been indicated the reassessing the processes of Medicines Procurement 
should be continuously monitored. These include the suppliers and manufacturers 
who should continue to be re-evaluated, and it is suggested it should be at least 
every three years and any changes made by the manufacturer should be noted as 
this may have an effect on prequalification. Secondly the Quality Assurance 
System undertaken at Drug and Food Control Administration should aim to re-
evaluate products after a period of time; this is especially true if the product needs 
to be retested as a result of a change made to the product characteristics. 
Thirdly, the contractor should also be monitored, particularly with regards to 
storage and distribution of products, where all transport and storage should be 
traceable. As indicated above, one of the most important areas for QA monitoring 
is carried out by the Drug and Food Control  Administration Laboratories where the 
methods of testing, and the analytical results should be subject to quantitative and 
qualitative assessment to ensure the methods and the statistical results are 
appropriate to assess the quality of the medicines.  While carrying out this quality 
testing the quality of medicines from outside the country, there should also be 
statistical measurements of the analytical performance of the Laboratories in each 
of its areas of assessment.  The assessment of results from the laboratories is a 
continuous process to ensure that the performance does not waiver with time. 
Finally research organizations attached to the Laboratories should also be quality 
assessed to ensure they continue to deliver quality in development results and for 
clinical standards (WHO, 2007).  
 
6.5.4 Limitations of not having a Performance Assessment Team in public 
hospitals in Kuwait. 
The structured discussions with professional health care staff (Chapter 4) during 
the PhD study (2012–2015), and information gained during informal visits to 10 
public hospitals, it was indicated that there is an absence of a Performance 
Assessment Team who work with the Administration and with the Health 
Professionals.  
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Such a Team would be expected to carry out performance checks at a number of 
levels within the hospitals and could be made up of Health Administrators and 
Human Resource members.  The main function of such a team would be to 
monitor the overall performance of the different health service personnel, without 
specifically looking at individual performance, the facilities and the overall 
experience of the patients to their time as in-  and outpatients In addition to the 
assessment of the service provided of the  Pharmaceutical Administration in 
delivering the sport service.  Individual performance review would also be 
assessed (physicians, pharmacists, dentists, nurses, auxiliary staff and 
technicians) but this would normally carry out in conjunction with the Human 
Resource Department in an individual or group of hospitals and handled as a 
performance review. The area of contact with patients and the service provided for 
these assessments would be varied in many cases, with the range spanning; 
pharmacies, medical wards and clinics, biochemistry laboratories, dental clinics 
and operating rooms. 
 
The benefits of establishment of a Performance Monitoring Team in public 
hospitals in Kuwait, includes: 
1. Ensuring that all prescribing and dispensing drugs in the public hospitals are 
of high quality, safety and efficacy and cost effective for treatments and the 
patient is satisfied with the service received. 
2. Ensure that the patients and other health professionals are satisfied with the 
level of health support given in the public hospitals, which has the 
advantage that developments from these assessments are likely to increase 
the efficiency of the support to patients.  
3. Ensuring that safe guards are in place to reduce medical errors. 
4.  Ensure that the work procedure overall of health professionals meet the 
needs of the Health Care System. 
5. Increases the ability to identify medical, health, management and patient 
service problems and being able to find solutions for these problems and 
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preparing improvement plans for development of health services in the 
future.   
 
6.5.5 The importance of improved quality of service in the development of the 
Health Care System in Kuwait 
The overall conclusion from these studies across a wide range of pharmaceutical/ 
medical service delivery is firstly the need of an Essential Medicines List for 
Kuwait. In terms of the medicines dispensed there is the requirement for greater 
assessment of incoming medicines from outside the country and the quality of 
health service provision to the patient in the pharmacies, clinics and hospitals. 
These aspects are only likely to improve, if there is a degree of Management 
involvement of;  the quality of medicines through a QA Department with powers of 
decision in the Drug and Food Control Administration, in the procurement of 
medicines through a Procurement Management Team in the CMS, and in the 
service provision by greater assessment of employee and facilities performance of 
Health and Support Staff at all levels, which would normally be handled through 
performance review carried out by the Human Resources Department and the 
Service Provision to patients through Facilities Management. Each of these 
management functions should be strengthened as part of the development of the 
NDP. The main points from the proposal are that there should be improved control, 
monitoring and evaluation of work, medicines and facilities in the following areas: 
a. Drug registration and testing in Drug and Food Control 
Administration. 
 
b.  Drug selection, procurement, storage and distribution in CMS 
Administration. 
 
c. Drug prescribing, dispensing, medical and pharmaceutical services in 
the Public Hospitals. 
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6.6 The Deficiency of an Essential Medicines List in Kuwait 
 
95% of interviewees (in Chapter 4) supported the importance of the introduction of 
an Essential Medicines List for Kuwait. It was suggested that the selection of an 
essential or restricted drugs list for Kuwait is probably one of the most important 
issues of developing a national drug policy and it could be described as one of the 
principal reasons behind the efforts to design, implement and regulate a NDP.  
 
To ensure the success in establishing an Essential Medicines List (EML) in Kuwait 
and gaining the expected advantages and benefits from its introduction it is 
suggested that the KMOH should firstly study and understand the concept of an 
Essential Medicines List and identify main core elements of this policy 
development. Secondly the KMOH should analyse the process of selecting drugs 
in the CMS Administration (as described above for medicines procurement) and to 
determine if the current processes go any way to meet the appropriate needs of 
the population. Thirdly to take advice from other developing countries who have 
succeeded in introducing an EML to include; Namibia, Kenya and Oman (as 
mentioned in Chapter 3) and view the WHO Model List and recommendations, as a 
starting point for developing a List for Kuwait. Developing such a List will require 
the gathering of a large amount of medicines information both on the drugs 
themselves and on the best basis for the needs of Kuwait.  Once the collected data 
from public hospitals, health clinics, health centres, pharmacovigilance centres, 
country wide medicines regulators, e.g. Food and Drug Control (FDA) in the USA, 
European Medicines Agency (EMA) in the EU and many other Medicines 
Regulators and the WHO and  the  private sector is gathered and analysed and 
information discussed by a Committee of Health Professionals, Scientists and 
Administrators the medical value, disease state needs, cost effectiveness and 
clinical treatment guidelines, should be consulted, there should be a list of 
medicines found which are suitable for the needs of the population in Kuwait (and 
represent the most used and needed drugs in the State), and these 
Drugs/Medicines can become Kuwait’s EML.       
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In this section, the following aspects are discussed: 
  ● Definition and main importance of EML. 
  ● WHO Criteria’s of selection essential drugs. 
  ●  Process of drug selection in CMS in Kuwait 
  ●  Advantages from having an EML in Kuwait. 
 
6.6.1 Definition and importance of EML.   
Drugs that fulfil the health needs and concerns of the people are described by the 
world health community as Essential Medicines. In 1977 the WHO introduced the 
first Model List of Essential Drugs which is reviewed every 2 years by the WHO 
Expert Committee on the Selection and Use of Essential Medicines (WHO, 2007). 
According to the definition proposed by the WHO, Essential Medicines are 
considered to be “those that satisfy the needs of the majority of the population and 
therefore should be available at all times, in adequate amounts, in appropriate 
dosage forms and at a price the individual and the community can afford” (WHO, 
2001). 
 
The number of different drugs produced worldwide from many different processes 
is very large and there is no countries health organization which can provide all the 
drugs available in the global environment  and it is the case that only a limited list 
of these drugs are really necessary to provide health support to populations.  
Therefore there is an advantage in implementing a form of an EML which is based 
upon the clinical value for treating health conditions, along with guidelines 
specifying the active use of the drugs in therapy (Tetteh, 2009). 
 
The WHO 1977 list originally included approximately 200 drugs and vaccines by 
generic name (Reich, 1987). The most significant challenges that EML Selection is 
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faced with is acceptance of the limited number of drugs by the health fraternity, 
consumers, pharmacies and manufacturers. Also there has been in the past 
objections to the introduction and enforcement of the EML in the private sector and 
the control of non-essential drug donations which are required to support drug 
shortages. (WHO, 2001) 
Each nation may have their own list of drugs in the EML and the WHO EML may 
only act as a guide for choice of a nation’s individual essential drugs. This is 
understandable as the priorities in terms of disease treatment will be different in 
most countries, however for poorer developing countries there is generally some 
commonality between countries choice and the WHO List. It was the case at the 
beginning of discussions at the World Health Assembly and with the WHO that the 
main purpose of an EML was to; make available appropriate medicines for the 
countries health needs at all times, in the appropriate quantity and dose, with the 
assurance of its quality, to provide suitable health information for the individuals 
and the community, at the most affordable cost.  
Examination of the Medicines Market reveals that there are a considerable number 
of drugs available, many of which can be described as being excessively charged.  
But a country EML should provide cost effectiveness value, but still maintain the 
major aspects of quality, safety and efficacy.  An EML is generally based on clinical 
and health needs, clinical value, together with the medicines cost effectiveness, 
(Sekhar Kar et al., 2009)  
There are also other advantages and uses for a well organised National EML.  The 
most apparent is it will be the basis for the management’s public sector medicines 
procurement and distribution policy. However there are also advantages of having 
a limited list in health education and training of health professionals and a major 
advantage of having a structured list when informing the general public about their 
use. In addition, from a financial viewpoint for those who have health insurance, an 
EML is often consulted by insurance companies in order to formulate their 
insurance policies as far as coverage of drug reimbursement is concerned (WHO, 
2001).  
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6.6.2 NDP and selection of Essential Drugs 
National Drug Policies seek to establish regulatory frameworks to ensure the 
sustainable development of the pharmaceutical sector and the provision of 
pharmaceutical medicines to citizens in a country (WHO, 2003). Regardless of 
where in the world we are, this is a considerable task, with legal, medical, logistical 
and financial hurdles to overcome. Ultimately, a NDP aims to ensure people have 
safe access to high quality drugs when required, and it is safe to say that 
successful NDPs are tailored to the needs, resources and capacities of the country 
in question, and one size does not fit all. 
 
The first piece of convincing evidence that NDPs can alter the healthcare and 
pharmaceutical landscape concerns the fact that more and more countries have 
NDPs as time goes on. In short, this means that more people globally appreciate 
the need for medicines to improve the quality of life. At present, more than 70 
countries have implemented their own NDP, although vast portions of Africa and 
Asia still live with very poor access to essential medicines or medical professionals. 
Compared to 1977, when 2,100,000,000 people had access to medicines, 
3,800,000,000 were served by 1999 (WHO, 2003), and more are predicted to be 
reached today. In general, the past 50 years has seen big strides made in the 
provision of safe and affordable medicines to more impoverished areas of the 
world, although much more remains to be done. In future, established NDPs will 
make it easier to procure and distribute drugs and increase the quality of life.  
 
During the past few decades, National Drug Policies have helped increase public 
access to drugs in a major way, and given that the WHO reports that essential 
medicines are underused globally, their number needs to increase further. It 
remains unacceptable that millions of people are at risk of dying from highly 
treatable bacterial infections due to a lack of medication (WHO, 2013).  
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However, before considering the diverse issues influencing the establishment of a 
NDP, it is worth remembering the bureaucratic and financial implications such a 
move would have on a government. For example, in a developing nation with poor 
internal infrastructure, a NDP would struggle to find distribution solutions, and may 
not be their top priority. The successful implementation of a NDP, therefore, 
requires a concerted effort across different branches of government, and will 
require continual evaluation and editing to keep it in-line with best practice as new 
medicines are developed. Those responsible for the development of the NDP will 
need to employ a team focused on communications with the 
pharmaceutical/biotech industries so that solutions to supply and demand 
problems, for example, can be dealt with efficiently and in the best way possible. 
By working together, governments and pharmaceutical corporations have great 
power to shape our healthcare environment, and given their shared interests, it is 
safe to say that one influences the other, and vice-verse. Indeed, governmental 
matters affecting pharmaceutical business is not restricted to NDP development 
and implementation, but also compound registration and licencing (Carrese and 
Rhodes, 2000). 
 
Indeed, should funds be available to pursue the endeavour, a primary limitation to 
the implementation of a NDP is selecting a drugs list. There are many thousands of 
clinically-established medicines globally, and many different drugs are used to treat 
the same condition. When setting up a new NDP, drugs will need to be selected 
according to budget, population needs and availability. Accordingly, the generation 
of the NDP drug list alone will require extensive epidemiological and statistical 
analysis from basic researchers with experience of their country’s healthcare 
needs. The drugs list should also be regularly updated and benefit from the latest 
medical research knowledge and expertise to deliver maximum benefit to patients. 
In the UK and other nations, government-independent bodies are charged with 
overseeing medicines (and technology) selection and purchasing for the NHS, and 
have received repeated public criticism for drug selection policies, demonstrating 
the scale of the task at the population level (Chaplin, 2014). 
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However, selecting drugs can be viewed as the easy step. Agreeing a price with 
the pharmaceutical companies can be a drawn-out, difficult process, with private 
companies seeking to protect their ability to invest in future products (Landers, 
2017). That said, it has been reported that large-scale agreements between 
countries, such as the UK and UAE, and pharmaceutical companies have been 
reached to ensure a fair-pricing structure is in place to generate a sustainable 
industry going forward (Khoja and Bawazir, 2005; Morgan et al., 2008); after all, we 
need new drugs and companies need to sell them. Importantly, aging populations 
worldwide (driven by our increasing access to modern clinical medicine) will lead to 
increased drug requirements in the long-term, necessitating countries to plan for 
the occurrence in advance so that they are able to develop sustainable financial 
policies.  
 
Despite collective buying power, and pricing frameworks, many drugs under patent 
are prohibitively expensive even for the wealthiest national healthcare systems and 
are only available to wealthy individuals with private medical coverage (Ghinea et 
al., 2016). For example, some new anti-cancer monoclonal antibody treatments 
cost hundreds of thousands of dollars per year of treatment, with top selling 
medicines raking in billions in annual sales (Siddiqui and Rajkumar, 2012). 
Accordingly, poorer countries with smaller health budgets are unable to acquire the 
medicines they need in sufficient quantities. Again, countries working more closely 
with the pharmaceutical sector seem to be the way to go to improve relations and 
agree pricing structures that benefit both parties. Although recent years have seen 
large biotech companies increasing their participation in charity endeavours – 
including donating/selling at reduced price essential medicines to the developing 
world – these examples are the exception rather than the norm (Gottlieb, 2000), 
and western pharmaceutical companies should increasingly look to be more 
flexible in the global marketplace to increase the quality of life worldwide.  
 
 
 
280 
 
As touched upon previously, a successful NDP requires the means for drugs to be 
purchased, distributed and securely stored, something which is more easily 
achieved in different parts of the world (Strang et al., 2012). Medicines requiring a 
cold-chain, for example, are difficult to provide to very remote populations with 
intermittent access to electricity. Therefore, infrastructure is vitally important, and 
could represent a considerable investment if greater numbers of people are to be 
reached by a NDP.   
 
Aside from the challenges faced before we reach the bedside, the introduction of a 
new NDP will also require additional training on legal and medical topics for 
doctors and nurses in the healthcare system concerned (Leung et al., 2013). A 
new NDP may bring with it several new medicines that were previously 
unavailable, and new types of paperwork to control drug use, all of which will bring 
their own learning curves. The application of new medicines will also require 
additional follow-up studies depending on the population, as different drugs can 
have very different effects in different ethnic groups (Xie and Frueh, 2005).  
 
Further down the line, and during the implementation phase, litigation and 
legislation are likely to feature prominently and will consume much effort, not only 
in the establishment of new deals with private corporations, but also from civil right 
groups wanting to ensure appropriate checks and balances are in place in the 
policy to protect the public (Harpwood, 2016). Government work and law making 
cannot be understated as time-consuming requirements for the implementation of 
any NDP. New NDP frameworks will also need to control for corruption and 
advertising which influences a doctor’s decision to administer any particular 
treatment. 
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6.6.3 WHO Criteria for selection of Essential Drugs 
A criteria has been suggested which can give guidance to MOH Departments for 
selection of drugs which could be included in an EML.  Initially it is proposed that a 
committee of knowledgeable experts in their fields of pharmacy, pharmacology, 
and clinical medicines can be set out and the information taken by this committee 
can be in the form of consultations with pharmaceutical companies, professional 
associations and organisations linked to patient groups.  For the drugs to be 
considered they should have positive proof of their clinical efficiency and benefit. 
These drugs should have been shown to be safe under adverse drug reaction 
monitoring in the short and long term and in the presence of different types of 
health disease. Another major consideration would be the cost effectiveness, 
where medicines can be compared not just on the unit cost of the medicine but 
when comparing two medicines the total cost of treatment can be given importance 
over unit costs but also  the total cost of the full treatment alongside the efficacy of 
the drug(s) could be considered. Additional factors which can be studied are 
pharmacokinetic properties or any special storage or manufacturing facilities. Drug 
should be available in an adequate form to confirm its quality, bioavailability and 
stability. Generally a medicine should be a single compound or in a fixed ratio of 
compounds where it can be shown there is advantage over a single drug medicine 
when taking into consideration drug safety, patient adherence and their clinical 
effect. (Sekhar Kar et al., 2009) 
It is suggested that the need for specific diagnostic facilities and treatment 
requirements can also be a factor in some in medicines choice for a List. 
Comparison should normally be made within a therapeutic group and not among a 
therapeutic category (For example, the treatment of HIV and the treatment of 
malaria). On occasions there may be an absence of scientific evidence for priority 
disease treatment, and in this event the expert committee may decide to postpone 
selection until further information becomes available. (WHO, 2002) 
In addition to the general EML, specialist areas of health problems have regularly 
been considered over recent years by the medicines regulators, such as the Drug 
and Food Control Administration in the USA and the EMA in the EU and the WHO 
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in recent years. Typically work programmes on areas such as paediatric 
medicines, for the elderly and orphan medicines which have found their way into 
EML.  
 
The case for introduction of an Essential Medicines List in Kuwait is convincing, 
particularly when the number of different medicines brought into Kuwait each year 
and the very high cost of procuring these medicines is taken into consideration. 
The criteria that are recommended can be used to establish an EML is persuasive.  
The KMOH can use the reasonable large information base and take information 
from other similarly sized developing countries experiences in setting up an EML.  
In doing this the KMOH should also take into consideration the individual 
differences between countries on disease prevalence, demographic and financial 
conditions, healthcare service quality and availability of appropriate healthcare 
facilities. These differences the health professionals in Kuwait can determine and 
set out a programme to find the best mix of medicines in the EML for Kuwait, 
according to their experience. 
 
6.6.4 Process of drug selection in CMS in Kuwait 
It is clear that (as mentioned in Chapter 5) the CMS Administration is responsible 
to purchasing drugs for the public sector in Kuwait. The current process of drug 
selection for purchasing in the CMS Administration however suffers from a lack of 
an EML and is only based on the decisions of the committees between the CMS 
and the Council Medical Departments (consisting of physicians from several 
medical specialities), where physicians suggested the appropriate needs of drugs 
for the population based on their experience and sometimes from outside 
advertising and seminars.  
 
Based on the structured discussions with health professionals of the CMS (Chapter 
4) and the collected data from the KMOH (Chapter 5), it can be observed that the 
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process of drug selection suffers from many issues (See below) and may not 
effective because it is not based on clinical studies and treatment guidelines, which 
related to a number of prescribed and dispensed drugs in all the public hospitals 
and health clinics.  In addition the Council Medical Departments have regularly not 
enough information about medicines (clinical study, stability study, bioequivalence 
studies and cost effectiveness) and they have not recent information about 
updated drugs. According to the information presented the researcher was alerted 
to the existence of some problems that don’t help in the development of drugs 
selection and purchasing and the results found ensure the importance of 
establishing an Essential Drug List in Kuwait. From the PhD studies it was found 
that: 
1. There was a large wastage of medicines and it was found that the total 
amount of the expired drugs in the CMS from 01/01/2013 to 31/12/2013 was 
estimated to have reached 5,75 million $ (See Chapter 5). 
2. Physicians and consultants in the public hospitals ordered products and 
after short time they changed their order and asking for different drugs. 
3. Many of purchased drugs are not meet needs of population or purchased 
from non-qualified manufacturers especially from GCC countries. 
 
Therefore it can be suggested that it may be necessary to carry out establishment 
of an EML in Kuwait to solve the issues mentioned above, in addition the KMOH 
should also considered that, clinical guidelines and the EML should be reviewed 
regularly (a likely interval would be every 2 years) in order to ensure adherence to 
the policy standards and assess the impact of these compounds on the population 
(WHO, 2001). 
 
6.6.5 Advantages from having an Essential Medicines List in Kuwait 
The EML is therefore a very important factor for the development of the Health 
Care System. It is possible that the State of Kuwait could begin to start thinking 
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about establishing a list at an early time to overcome the issues resulting from lack 
of an EML and to satisfy the health care needs of the majority of the population. 
 
The establishment of an EML in the State of Kuwait can be developed and improve 
the Health Care System through: 
1. Savings for the national budget. 
2. Reducing the expired drugs in CMS warehouse. 
3. Ensuring the availability of the appropriate needs of drugs in a long term. 
4. Supporting to have a vision for a long term program for the specific needs of 
Kuwait. 
5. Ensuring the availability of drugs for sustainability of the health system. 
6. Purchasing of most cost efficient medicines in the right amount. 
 
 
6.7 Insufficient training programmes for health professionals in Kuwait 
 
The majority of the interviewees (64.5%) suggested that the training/update 
training programmes for health professionals were not sufficient, especially for the 
senior pharmacists, as there are a lack of an effective training programmes to 
support them in understanding how to develop and improve their pharmaceutical 
knowledge. 
They also suggested that the lack of training programmes in new areas of 
pharmaceutical services limits pharmacists’ knowledge and means they cannot 
update their pharmaceutical information for patients. Most interviewers suggested 
that increasing the amount of participation in international scientific conferences 
(and providing funding for attendance) is one a way to develop new knowledge in 
the profession.  
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It is clear that human resources form the backbone of a Health Care System and 
therefore a sufficiency of staff is an essential component. In Kuwait the 
Government and MOH cannot function efficiently, manage, oversee and finance 
programmes if the workforce is insufficient to be able to carry out the tasks, which 
can often be specialized (Rockefeller Foundation, 2003).  
 
In that respect even with a full workforce, training programmes are a very important 
aspect and directly affect the work of health professionals and they can determine 
the degree of success of the work of the Health Care System. 
Thus the importance of human resource development and training programmes for 
health professionals cannot be overstated. It is important that the MOH introduces 
the appropriate type of training programmes for the pharmaceutical sector in 
Kuwait, and within these needs there is the requirement of training programmes 
that support the implementation of a NDP in Kuwait.  
 
6.7.1 Human resource development 
Human resource development has often been thought of as organizing courses for 
workforce training, and whilst this is a part of human resource development, it 
should incorporate a wider field to include vocational education, training and 
management of professional development. Often education has been seen as 
separate from training because it involves undertaking academic learning in the 
pursuit of a qualification, which would then lead to employment (Gibb, 2011). Here 
the role and duty of the Kuwait University (School of Medical, Pharmacy, Dentistry 
and Nursing) is to provide appropriate educational courses for students, endeavour 
to use suitable and the latest educational curricula and contract with a qualified 
educational team. It is also suggested that the KMOH could cooperate more with 
Kuwait University and contribute to improving health education by allowing an 
increase in the number of student visits to public health areas (hospitals, health 
clinics, labs and administrations), which would help the health students to 
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recognize and practice the nature of the work before graduation. Training, on the 
other hand, comprises learning to develop skills for work whilst in or out of work, 
which would enable good performance within the work place setting. Development 
is seen as separate from education and training, but is also associated with both. 
Development can occur during the person’s growth through their education and 
training and then in their job, and normally involves on-the-job experience (Gibb, 
2011). 
 
Development can also be about a change of the whole person, and so it is an 
integral part of the working life of an employee. Human resource development is a 
process that includes dealing with the process of facilitating, guiding and even 
coordinating learning of individuals so that the individual, team or even 
organization can perform in the way that is desired by the system. It is important to 
note that human resource development as a whole should identify the needs of the 
individual. This is because a new junior doctor may have different developmental 
needs to an experienced consultant, and this presents distinct challenges. It can be 
summarized that work-related development is a combination of three elements. 1) 
Cognitive capacity, which is the ability to process learnt and memorized 
information. 2) Cognitive capability, comprising the many abilities involved in the 
employment; these may be innate or learnt. Finally, 3) Desired behaviour of the 
individual, can be summarized as the attitudes, values and emotional intelligence 
of the individual (Gibb, 2011). 
 
Cognitive capacity can be divided into two views, modular and unidimensional.  
The modular view takes into account degrees of complexity, specifically with 
regards to memory skills, language skills, analysis, reasoning, and hypothesis 
testing like thinking, decision making, problem solving and creative thinking 
(Halpern, 2002). On the other hand, a unidimensional view of cognitive capacity 
includes the ability to remember and understand, apply and analyse, create and 
evaluate (Anderson and Krathwohl, 2001). 
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There are a number of ways in which the human resources department within the 
University/KMOH can facilitate development; this may be via on job training, 
mentoring, formal education, training facilities, conferences, internet- and intranet-
based and non-electronic open learning (Gibbs, 2011). 
 
According to the information presented above it can be suggested that it may be 
necessary for the KMOH to carry out support development in the types and views 
of the human resource development (mentioned above) to ensure that the 
training/support programs for health professionals are based upon solid 
foundations. 
 
6.7.2 Training programmes for health professionals in Kuwait 
As mentioned at the beginning of this section, the majority of the interviewees 
indicated that there was insufficiency and defects in the KMOH training system, 
and specifically there was no training programme for pharmacists to develop their 
work or to update their clinical and scientific knowledge (except one programme for 
pharmacists who were recent graduates). This is whether they are working in 
hospitals, health clinics, health centres or pharmaceutical administrations. 
 
In some pharmaceutical administrations, there is also a lack of training 
programmes in some aspects of the process that can be considered to be at the 
core of the work (e.g. a lack of GMP and inspection training programmes for health 
staff in the Drug Inspection Administration). 
 
Therefore as a conclusion to the discussions at the interviews with health 
professionals (especially pharmacists) and through several visits to the various 
health care environments to observe the nature of the work of these areas, it is 
suggested that KMOH should provide a number of training programmes for the 
 
 
288 
 
health care team to develop their work and ensure quality performance of the 
working staff. Based on the results obtained, it is recommended that the KMOH 
organize training systems for health professionals according to the needs of both 
the health care workplace and its staff. 
 
From the research studies it is possible to suggest that the KMOH organize training 
programmes for each health area (public pharmaceutical administrations, hospitals 
and health clinics) to include:   
1. Giving a greater role to the Human Resource Development Department and 
giving them more power and authority to play a primary role in supervising 
the training of health professionals by providing the necessary training 
courses, and supporting health professionals in attending local and global 
conferences. Also giving them responsibility for following-up training 
programmes and up-skilling of the scientific aspect of courses and to 
increase the knowledge of health staff cadres able to give training to the rest 
of the staff.    
 
2. Development of a specific plan of action in cooperation with Kuwait 
University to help the KMOH to provide the necessary training courses. 
From observation and discussion with the Vice Dean of the Kuwaiti Faculty 
of Pharmacy and the Head of the QA Department, during the Research 
Interviews for this study, in 2013, it was suggested that the Faculty of 
Pharmacy could provide specific courses for training KMOH pharmacists 
(e.g.; in QA, Quality Control, Drug Inspection, GMP, GLP and Supply 
Management) and these courses were unlikely to be charged for, by the 
University, but would be provided in order to support the KMOH’s 
development and to improve Kuwait’s health services. 
 
3. Providing training programmes for pharmacists who work in public 
pharmacies, including programmes in: 
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a) Communication skills with patients. 
b) Communication skills with other health professionals, within a health care 
system, where groups of health professionals work together in teams. These 
could include doctors, nurses, pharmacists and other health related groups. 
It would be expected that there would be a coordination of their activities 
and discussion of cooperation to make patient care a priority. Overall, it is 
suggested that teams are susceptible to less error than individuals working 
on their own; this is because a team member may not only know their role, 
but also the responsibilities of other individuals (Sims et al., 2004); this is 
likely to be the case if the KMOH provides a training programme system to 
ensure that everyone in the team gets adequate training. 
c) Pharmacy practice. 
d) Clinical pharmacy, to ensure that the pharmacists renew and update their 
information and knowledge.   
e) Medical errors, to reduce the errors in prescriptions and maintain patient 
safety. 
 
4. Improving the work of Drug Inspection Administration by provide training 
programmes in: 
a) GMP (Good Manufacturing Practice) Courses. It was reported from the 
study that most medicines inspectors who are responsible for inspecting the 
local and international drug industries through the GCC inspection 
committee had not attended GMP courses and did not have a GMP licence. 
b) Drug Inspection Course. New medicines inspectors depend on the 
experience of their colleagues to learn from and understand the ways and 
methods of inspection in Kuwait, The main reason for this is because there 
is a shortage of guidelines and a lack of training courses for drug inspection. 
c) Drug Counterfeiting Course, to learn more about the problems of having 
counterfeit medicines enter Kuwait and to discuss ways of reducing the 
entrance and production of these medicines into the country. 
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5. Organizing a number of training programmes for the health care staff of the 
Drug and Food Control Administration, where there is a lack of training 
programmes in: 
a) GMP studies. 
b) GLP studies. 
c) Clinical studies. 
d) Stability studies. 
e) Bioequivalence studies. 
All of these studies are important and necessary for the health staff who works 
in Drug Registration Departments and Laboratories, and it is suggested that 
they should undertake these studies to ensure that all the registered drugs are 
safe, of good quality and efficacious. 
 
6. Provision of annual educational courses on pharmaceutical legislations and 
regulations that are applicable in the KMOH, to ensure that all pharmacists 
understand the rules and know their rights and duties. 
 
7. To develop and improve the work of CMS by providing a training programme 
for the health care staff working in: 
a) Drug Procurement. 
b) Supply Management. 
c) GMP. 
 
It is accepted that training for health professionals has an impact on the attitudes, 
knowledge and skills of trainees, which in turn serves to develop their skills, which 
translates directly to the care given to patients and is reflected in improving health 
care services (Boonyasai et al., 2007). Nevertheless, researchers conclude that 
training should be a part of a curriculum for health care students, as well as being 
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available to professionals to ensure efficacious professional development (Ongrinc 
et al., 2003).  
Overall, it can be summarized that a successful human resource development, 
which includes training opportunities for health care professionals, is critical in 
providing quality critical care. Effective training strategies and perhaps more 
research are required to enable development that is most successful and shows 
highest efficacy (Kabene et al., 2006).  
Human resource development can lead to development of the Health Care System 
if the innate human resources are also developed, resulting in increased 
productivity, eradication of errors and overall change in the working and social life 
of health care professionals as they would be able to progress within their careers, 
allowing others to take over their old roles and continue to develop themselves. 
This would allow a system that maintains a highly trained workforce (Tailal, 2008). 
 
Finally, the organization of the training process and increase in the provision of 
training courses is likely to develop and improve the professional work of health 
staff.  This should then be reflected positively in the work in health care services 
through an increase the level of competence of health professionals and especially 
the senior staff, a reduction in the need for more staff for health areas, a reduction 
in medical and administrative errors. Having quality training guidelines will enable 
the training of health professionals and can be develop their efficiency in the future, 
where it will support the implementation of a NDP in Kuwait. 
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6.8 Weakness in control over the medical outcomes and adverse effects of 
medicines administration in both public and private sectors and a lack of a 
Pharmacovigilance Centre in the State of Kuwait  
 
Some 44.6% of the interviewees suggested that the control over the medical 
effects of the pharmaceutical administration process in patients is insufficient. They 
suggested that the main reason for the weakness in control is the lack of a 
Pharmacovigilance Centre in the country. Therefore there is a lack of specialized 
organization to monitor and follow up the effects of drugs after the completion of 
registration and the licensing process and a lack of continuing control to examine if 
a drug has any adverse effects on the patients. Therefore it was proposed that the 
establishment of a Pharmacovigilance Centre in Kuwait is needed to improve the 
control over drugs, especially in the private sector. 
6.8.1 Definition of pharmacovigilance 
It is the case that even though drugs are extensively tested on animals and other 
clinical trials on humans are carried out, unfavourable reactions may not be noticed 
unless they are experienced by many people during the use of the drug over time. 
Therefore it is very important that the safety of all drugs is examined all through 
their marketed life – this is known as pharmacovigilance (MHRA, 2010). 
 
Pharmacovigilance is therefore the process of determining the risks and benefits 
associated with drugs so as to access the required action to use them safely and 
effectively. This process normally involves continuous examination of drugs to 
recognize any adverse effects or changes in previously identified effects of the 
drugs, and also the resultant outcome of any action taken on the drug. This branch 
of pharmacy can educate health professionals and consumers of the drugs, about 
their nature and effective usage, and this information about the drug helps ensure 
the safe and efficient use of drugs (WHO, 2002). 
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Pharmacovigilance with a larger population is also needed because although drugs 
undergo clinical trials, they are often tested only on small population sizes relative 
to the population size they are prescribed to during the medicines lifetime. 
This means that previously undetected side effects may emerge. Drugs that cause 
severe adverse drug reactions must not only be identified but they must also be 
removed from the Health Care System and the market (Executive Agency for 
Health and Consumers, 2009). The surveillance of the safety of a medicinal 
product during its life on the market is extensively regulated by the major health 
groups across the world, such as the FDA in the USA, WHO in Sweden and the 
EU who have in place detailed directives and regulations (MHRA, 2010). 
 
There are many sources of information which can be introduced within a 
Pharmacovigilance System, and these include reporting from healthcare 
professionals, which is usually specific to checking for adverse drug reactions. 
Other sources of information which are monitored, include clinical trials and 
epidemiological studies; other published medical literature, medical information 
from companies who manufacture the medicines, statistics on populations, 
information from within Health Care Systems and information on pharmaceutical 
consumption (SUKL, 2010). 
 
6.8.2 Risk and benefits of Medicines 
The clinical and side effects of medicines can be good as well as bad. When drugs 
are suggested by doctors, they should prescribe them after assessing the changes 
it causes in terms of adverse actions compared to the cure it provides. Any drug 
should be consumed only when the expected benefits override the possible risks 
from it. Consideration should also be given to the possible effects the drug will 
have on the patient after its consumption is stopped. However there is no accurate 
determination in the form of quantitative analysis of the severity of the potential 
risks and the benefits from drugs (MHRA, 2010). 
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Drugs are considered safe and secure only when harmful reactions are minimal 
compared to the cure associated with the medicine. However drugs by their very 
nature always carry the possibility of adverse reactions but still, it should not be 
neglected that the majority of individuals do not experience serious side effects. 
Medicine labels or the associated information sheets list the possible side effects 
for the medicine for its informed usage by consumers (WHO, 2002). 
 
While prescribing the drug, health professionals should take into account its effect 
on a person’s quality of life compared to risks from the drug, typical minor disorders 
include coughs, headache and muscle strains; these are often considered 
acceptable but if they are providing discomfort the symptoms it can be treated 
using effective over-the-counter (OTC drugs). OTC drugs can have wide safety 
margins when taken as prescribed. But serious or life-threatening disorders like 
heart attack, stroke, cancer, or organ transplant rejection are obviously considered 
highly important safety concerns and should be noted for their benefit–risk 
outcomes (Tarloff, 2007). 
 
General risks associated with drugs include the possibility of not working as well as 
they should, problems that occur alongside the accepted cure, and chances of 
adverse reactions between the drug and a food, beverage or dietary supplement 
(FDA, 2011). 
 
These are some of the reasons why a Pharmacovigilance Centre is needed for 
Kuwait – the Centre should focus on the assessment of benefit, harm, 
effectiveness and risk involved in the use of drugs, and promote their safe, rational 
and cost-effective use. A Pharmacovigilance Centre should aim to support 
information dispersal of information about drugs, educating the public about them, 
training the health care workforce to provide efficient services by providing clinical 
knowledge and practical experience.  Also most importantly a Kuwait Centre would 
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expect to feed information into worldwide Centres such as the Uppsala Monitoring 
Centre in Sweden. However to join such a Centre would require the Kuwait Centre 
to have in place a standard set of procedures which are internationally accepted.  It 
is for these reasons that within a NDP, there should be the capability of the KMOH 
to ensure control over side effects of drugs on the market (WHO, 2002). 
 
Although the State of Kuwait is a small part of this world it has been affected by a 
number of difficulties which affect many other countries in world trade.  However, 
for more than twenty years now, globalization, free trade increase, communication 
across borders, and the Internet have all caused a change in access to medicinal 
products and information reported about their use.  Included in this are problems of 
the illegal sale of drugs by non-professionals, and abuse of these drugs through 
access over the Internet. 
 
Difficulties that have increased are self-medication by the public, who although 
they may not be able to interpret or find accurate information, they sometimes self-
medicate anyway. Irrational drug prescribing and use, although it may be 
dangerous, can be quite wide-spread and the manufacture, sale and delivery of 
counterfeit medicines are increasing.  In addition the use of traditional drugs, 
outside their traditional use or in combination with other drugs, including herbal 
drugs, can cause a potential for adverse drug interactions. It has been suggested 
that pharmacovigilance should be applied to these situations; however these 
occurrences are normally beyond the confines of detecting new safety concerns 
(Meyboom et al., 1999). It is suggested however that under the structures 
developed in the NDP, these should allow the development of a 
Pharmacovigilance Centre which given some development time could become a 
partner in a wider international Centre in the future. 
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Apart from helping to monitor the adverse drug reactions in Kuwait, the benefits of 
pharmacovigilance also include its use in drug regulation, clinical practice and 
international health.  
 
With regards to drug regulation, arrangements to monitor drugs provide a basis on 
which national drug safety can be established, and this in turn can lead to an 
increase the confidence of the public in the medicine. The place of 
pharmacovigilance and drug control is linked into earlier clinical trials, during drug 
development, the safety of synthetic and complementary drugs including traditional 
drugs, vaccines and other biological drugs such as herbal, and overall is part of the 
lifetime monitoring of medicines as long as they are prescribed (WHO, 2002). 
Currently the Drug and Food Control Administration of Kuwait is responsible for the 
process of monitoring drug safety in Kuwait, but because of limited structure and 
trained and full-time health professionals for this work, they often follow the reports 
of the USA Food and Drug Administration (FDA) without relying on their own 
studies.  It is suggested that this could be dangerous because sometimes there are 
epidemics and diseases present in Kuwait that do not exist in the USA, or vice 
versa. In the future the setting up and operation of an efficient Pharmacovigilence 
Centre is likely to require the cooperation between the Drug Control and 
Pharmacovigilance Departments where it is likely to be for each Department to 
support the other by provision of the required expertise and data, so strengthening 
the control over pharmaceutical products and leading to the success of the 
monitoring process.  
   
It is proposed that the Health Professionals in Kuwait should understand that drug 
monitoring is an important skill for a pharmaceutical professional in pharmacy 
practice.  Therefore the degree to which pharmacists are informed about 
pharmacovigilance, and therefore they need to study the practice accordingly, as it 
can have an impact on the overall quality of health care delivery. Education in drug 
safety and a successful exchange of information between national centres, their 
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coordination, and linking pharmacovigilance to research and health policy are likely 
to have an important place in increasing and enhancing health care delivery (WHO, 
2002). 
 
6.8.3 How to monitor the safety of licensed drugs 
Licensed drugs are evaluated for their safe and secure nature through using 
various information sources including clinical and epidemiological studies, WHO 
publishing, spontaneous Adverse Drug Reaction (ADR) reporting schemes, global 
medical literature, regulatory organizations, morbidity and mortality databases. 
Information then obtained is evaluated to determine the  side effects from the drug, 
any possible reactions in certain individuals, probable adverse behaviour expected 
in certain situations, frequency of bad effects and their severity. Information when 
analysed should help to determine the safety of the drug and specify the control 
over the drug’s use, like the changes required in providing marketing authorization 
or applying certain dosage changes, restricted usage and warning indications 
(MHRA, 2010).  
 
From the information found during this research study, it has been possible to 
extract suggestions which can help in minimizing the risk of licensed drugs, and 
solving this issue in the State of Kuwait includes:  
a) To continuous update of the product information or information label, 
specifically mentioning the warnings regarding the drug.  
b) Removing the drugs that have questionable side effects from the 
OTC drug list, or making variations to the legal status of the drug, or 
making the drug prescription-only. 
                c)  Limiting the indications for usage; in the case of a drug being of a 
hazardous nature, or the risks being greater than the benefits it provides, it can 
even be removed from the market, but only in exceptional circumstances (MHRA, 
2010).  
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There are various ways in which Adverse Drug Reactions can be reported. One 
example of these systems is the yellow card scheme in the United Kingdom (UK) 
operated by the MHRA and Commission on Human Medicines. It receives reports 
of adverse drug reactions, or events that may be suspected to be adverse drug 
reactions, not only from health professionals such as doctors and nurses, but also 
from patients. In turn this can provide early warning to these groups of any adverse 
effects that drugs are found to have (MHRA, 2013). Countries such as the United 
Kingdom, New Zealand and the United States of America also have active 
surveillance programmes that use records and prescription event monitoring 
systems to collect data on drugs (Coulter, 2000). 
 
Returning to Kuwait, from observation and discussions with the health professional 
interviewees during the PhD study (2012–2015), it is suggested as a result of this 
research; that the KMOH should support the establishment of a pharmacovigilance 
centre in Kuwait by taking necessary steps such as: 
1. The KMOH could coordinate with the Kuwaiti Government (Civil Services 
Commission) to issue a law for establishing this centre in the country. 
2. The question arises, where could the provision of an adequate and appropriate 
place for the centre, be located?. Academic Departments in universities and 
university hospitals are ideal for pharmacovigilance because it can easily be linked 
with the clinical, pharmacology and epidemiology departments. Such a location for 
the centre would be ideal for peer review of any adverse drug reactions that may 
occur, as there is access to experts, and this could improve the efficiency of the 
process. However any access to information on medicines would have to be kept 
confidential and agreements reached that this information would only be used 
through correct channels.  This could mean that an advisory panel could be 
created. Any general educational information obtained in these centres could be 
incorporated into undergraduate and post graduate education programmes, but 
again specific information would only be available through agreement, but it would 
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lead to establishing a good knowledge base among new health care professionals 
(WHO, 2002).  
 
National pharmacovigilance centres have played major roles in promoting drug 
safety and this is possible because many of these centres are based within 
hospitals, medical schools, poison information centres and also drug information 
centres, as opposed to being confined to a separate regulatory authority (Coulter, 
2000). 
Furthermore, health professionals are more likely to feel comfortable in reporting 
any adverse drug reactions to their academies or hospitals as they may feel that 
the familiar environment would be more likely to analyse any reports.  
Finally, feedback on cases, support for experts and academic detailing can be 
better achieved under circumstances where pharmacovigilance centres are 
established in academia or hospitals (Soumerai et al., 1990) (Davis et al., 1995).  
3. The provision of all the necessary requirements for the pharmacovigilance 
centre, such as a trained and qualified health professional team, powers and 
authority to practice their work, participation, electronic links (not presently 
available in Kuwait) with the necessary health areas and the cooperation of other 
public health areas (e.g. Hospitals, Health Clinics, Food and Drug Control 
Administration, Drug Inspection Administration, Dasman Diabetic Institute and 
Kuwait University) to support this centre in providing the necessary data, research 
and information relating to the registered drugs and morbidity due to adverse 
effects. The establishment of committees comprising these health bodies is also 
needed to ensure continued control over drugs on the market. 
4. The provision of governmental financial support for this centre to make savings 
in the national budget – in 1999, pharmaco-economic studies found that 
governments can spend considerable portions of their health care budgets on 
covering the costs of adverse drug reactions (White et al., 1999). 
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5. In the larger scheme of development in the future Kuwait can consider working 
towards joining the Uppsala Monitoring Centre (mentioned above), as Kuwait is not 
a member of this centre at the moment. The Uppsala Monitoring Centre (run by the 
University of Uppsala) in conjunction with the WHO manages an international 
database of adverse drug reactions, based on reports received from national 
centres. It has been instrumental in establishing standardized forms of reporting by 
all centres involved, and has allowed good communication internationally to 
promote identification of signs, symptoms and signals (Olsson, 1998). The Uppsala 
centre also has created and provides training courses for health professionals 
about pharmacovigilance and provides suggestions and recommendations to the 
countries involved to improve their work, which may be an option for Kuwait in the 
future. 
6. To communicate with health care professionals and patients to collect relevant 
and vital information about the drug, its effects, possible harm and other queries – 
with accuracy, in a timely manner and in suitable settings for both patients and 
health care professionals.  
As an indicator of how there can be successful interaction between the medicines 
regulators and the health professionals, the MHRA in the UK use various ways; to 
include, specific drug hazards are sent to all doctors and pharmacists by post or 
electronic mail describing the urgent warnings; Patient Information Leaflets (PILs) 
and Summaries of Product Characteristics (SPCs) for medicines are continuously 
updated; safety alerts are published through the MHRA website, and a drug safety 
bulletin is published for the latest information on drugs (MHRA, 2010). 
7. To make contact with a number of organizations involved in worldwide drug 
safety monitoring, such as the WHO, to gain the benefit from its experiences.  
 
6.8.4 The WHO suggested some of the basic steps which should be taken when 
setting up a Pharmacovigilance Centre  
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Within the WHO, the quality assurance and safety team recommends that 
countries aims to close gaps between the beneficial potential that essential drugs 
may have, and the actual real world reality of people for whom drugs may be 
unavailable due to them being unaffordable, or they are unsafe or not correctly 
used (WHO, 2010).  
 
The WHO outlines some of the basic steps which are generally needed when 
setting up a pharmacovigilance centre. Firstly, contacts should be established with 
health authorities and other institutions on a local, regional and national level. 
Furthermore, contacts need to be established with groups that work in clinical 
medicine, pharmacology and toxicology departments and they need to be made 
aware of the importance of pharmacovigilance. Once this has been established, 
there needs to be a system, potentially through a standard form, which can be 
distributed to medical departments so that data can be collected, along with 
information material for health care professionals which highlights the aims and 
methods of the new pharmacovigilance system.  
 
Therefore the evidence suggests a Pharmacovigilance Centre should be created in 
Kuwait, and this means that there is a need for trained staff, development of 
database capability, a bibliography through a library and other aspects of 
developing a Centre of Information, in order that the Centre could provide 
information for health professionals on a continuous basis.  
Staff involved within the centre should be of a certain educational level and trained 
with regard to attaining knowledge on pharmacovigilance. This would be 
particularly relevant to data collection, verification of data received, being able to; 
code any adverse drug reactions data received, to code drugs/medicines, to 
assess each case individually with regard to cause, the detection of signals and 
symptoms, and finally to assess the management of risks.  Within the 
Pharmacovigilance Centre there must be an established database that is able to 
process all of the information collected.  
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In order to disseminate the information it is important that a system of 
communication is established, which can take a number of forms from written 
notification of findings on a regular basis, to holding or contributing to meetings 
with health professionals in medical organizations. In addition information on the 
principles of pharmacovigilance can be openly discussed, to provide knowledge for 
those new to the principles and can give assistance in their understanding and the 
demands that operating as Centre can make. The advantages for Kuwait in 
reporting of adverse drug reactions should also be promoted; which can take a 
direct form, or can be done through medical journals, professional publications and 
other forms of communication.  
 
In addition, a countries centre should maintain contacts with other Centres and 
Institutions that work in pharmacovigilance, especially the WHO Department of 
Essential Drugs and Medicines Policy, and also the Uppsala Monitoring Centre 
(WHO, 2000).  
 
Although ideally all adverse drug reactions would be reported, there are often 
problems when running a Pharmacovigilance Centre. One of the major points is 
the level of reporting, which tends to start off successfully in terms of reporting 
numbers, but with time tends to reduce considerably. One reason given for why 
professionals may not report all adverse drug reactions may be apathy and an 
overall lack of awareness among prescribing professionals, and when the Centre is 
in place under the NDP structures, the KMOH should be aware that this is likely to 
happen. Furthermore, although adverse drug reactions seem to be reported in a 
spontaneous manner – the level of reporting does drop off with time and it is 
usually the case that following reminders, meetings or advertising programmes the 
level of reporting can increase considerably (Dikshit, 2008).  
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In conclusion the establishment of a Pharmacovigilance Centre in the State of 
Kuwait is likely to develop and improve the health care system through: 
1. Promoting control and monitoring adverse drug reactions, medical 
errors and counterfeit drugs across the public and private sectors. 
2. Developing a national disease control programme and increasing the 
monitoring of ADRs. 
3. Undertaking the assessment of risk and options for risk management. 
4. Identifying and classify any issues relating to patients taking drugs in 
Kuwait. 
5. Helping to improve supply management and supporting the CMS and 
private companies in the selection and purchase of drugs. 
6. Improving the Essential Drug List (when one is developed) by 
determining the quality, safety and efficacy of drugs for Kuwait. 
7. Saving the national budget by reducing the expense of covering the 
costs of adverse drug reactions, and promoting the KMOH’s choice of 
drugs. 
 
 
6.9 Spread of irrational use of drug in the State of Kuwait 
 
Some 86% of interviewees strongly advised that irrational drug use is a serious 
issue in Kuwait, especially the irrational usage of antibiotics, hormones used for the 
sport such as for body-building and the use of sexual medicines. In terms of the 
State of Kuwait, a large part of the problem revolves around self-medication. This 
leads to irrational use (sometimes abuse) of antibiotics, psychotropic, slimming, 
sexually related drugs and herbal drugs, and this area should be addressed under 
the guidelines of pharmaceutical therapy and focused on in the NDP. As a result, 
the KMOH should consider, as part of the NDP, increasing the education to the 
public by increasing access to health education programmes for the media, in 
schools and in public areas. In addition they could encourage the establishment of 
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health education conferences and seminars that warn the population and health 
professionals of the irrational use of certain medicines and describe the health 
disadvantages of this practice. 
 
Overall it is suggested that the KMOH as part of the changes which are likely to be 
envisaged in the NDP, should re-examine the legislation related to the control of 
prescribing and dispensing medicines in both the public and private sectors. 
 
6.9.1 The irrational use of drugs 
As part of the many areas which make up a NDP, the examination of rational 
prescribing dispensing and use are essential when establishing the NDP. The 
essence of rational drug use is that patients receive medications appropriate to 
their clinical needs, at an appropriate individual dose, for an appropriate time 
period and at the lowest cost to themselves and the community (WHO, 1987). It is, 
however, estimated that over 50% of all medicines worldwide are prescribed, 
dispensed or sold inappropriately, while at least half of all patients fail to take their 
drugs correctly (Hogerziel, 1995). These were very worrying figures and added to 
this, it is estimated that only one third of the world's population has access to 
Essential Medicines, which contributes greatly to this problem (Ford, 2003). 
 
It has been proposed during the research for this study that the Health Care 
System in Kuwait suffers from many issues that cause and increase the irrational 
use of drugs, such as; there is a considerable lack of knowledge among 
prescribers and patients, lack of guidelines and standardized treatment regimens, 
and weakness of control regulation over the private pharmaceutical agents, 
companies and pharmacies, all of which contribute to this problem, which is 
considered to be a problem particularly in Developing Countries. The 
consequences of irrational use are often devastating and not only jeopardize the 
health of patients, but also increase the level of resource waste and financial 
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burden placed on a Health Care System. As a result, support groups such as the 
International Network for the Rational Use of Drugs (INRUD) (established 1989) 
were set up to design, test and disseminate effective strategies to improve the way 
drugs are prescribed, dispensed and used, with particular emphasis on resource-
poor countries (INRUD, 2003). 
 
These policies are applicable to every nation, although the developing world is a 
key target for the future. The aim of this section is to discuss the causes and 
consequences of irrational drug use in some detail, to focus on the strategies in 
use to resolve the problems and relate this information to the handling and solving 
this problem in Kuwait. 
 
6.9.2 Examples of irrational drug use in Kuwait 
Irrational drug use can be found in a number of circumstances and can stem from 
the manufacturing process, consultation and use by the individual patient (Contact, 
2006). One of the most common examples of irrational use in Kuwait is antibiotics 
(Antibacterial), which are often prescribed unnecessarily and this is suggested to 
be due to the lack of a clear antibiotics prescribing system. It has been proposed 
that there is also no control over and monitoring of the number of antibiotics 
prescriptions for each public clinic or linked to individual physicians.  
 
As an example of where this can cause medical problems and is effectively linked 
into medical negligence is where a viral illness is present, and many of the 
physicians in Kuwait and especially those working in health clinics prescribe 
antibiotics for infected patients without taking a sample for a laboratory to run a 
culture test to ensure if the infection is bacterial or viral, or where they may 
prescribe at a dose that is too low to be effective (Chandy, 2008).  
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On the other side a Patient may be poorly educated in the importance of 
completing a course of the antibiotic in question, and so may not take the required 
dosage (WHO, 2000). These problems can lead to under-treatment of the initial 
infection and the development of resistant organisms, which can be a major 
problem, particularly where alternative agents are unavailable. The use of 
antibiotics which have a known resistance pattern in the population is also an 
example of irrational drug use (Lancet, 2010); but may occur where resources are 
poor or education is low (Barah et al., 2009). Anti-motility agents prescribed for 
diarrhoeal illness are another example of irrational drug use in the developing 
world. (See Figure below) 
 
 
 
Figure 6.7 Percentage of patients receiving antibiotics (adopted from WHO, 
2004) 
 
Figure 6.7 shows data from a range of countries on antibiotic prescribing. On 
average, about 45% of the patients were prescribed antibiotics. However, in 
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Indonesia (1990), Pakistan (1998) and West Bengal, India, (1999) rates in excess 
of 70% were observed, and the prescribing patterns should have been questioned. 
It is proposed that the clinical needs of the patient must be considered when 
prescribing drugs and their rational use, which often only occurs following a lack of 
adherence to available clinical guidelines or a lack of guidelines in the first instance 
(Chandy, 2008). 
 
Another reason proposed in this study for the spread of irrational drug use in 
Kuwait is the non-compliance of some private pharmacies to the KMOH regulations 
and legislations, where they may dispense prescribed drugs (Antibiotics, 
Antihistamines, Sildenafil (Viagra) and Testosterone hormone) without 
prescriptions. Also it was proposed that some private pharmacists dispensed drugs 
which were not suitable for the particular condition or at an incorrect dose for the 
patient which can lead to serious consequences or health concerns.  
 
Many countries have introduced a system of poly-pharmacy, but this form of 
dispensing can lead to problems, where too many drugs are prescribed at the 
same time for one patient. Often these medicines are prescribed without thinking 
about introducing the risk of drug interactions and increasing the chances of side 
effects in the patient. Often this reflects an uneconomical approach to prescribing 
and a lack of review of patient medications (some prescriptions may have been 
renewed continuously for years, without reference back to checking on the medical 
condition and despite the advice of the doctor and the consequences to the patient 
of inappropriate use, drug interactions and drug resistance). This can be a major 
issue in the developed world, particularly among elderly patients (Barah et al., 
2009). Based on the information presented above, it is suggested that the KMOH 
should consider introducing a better structured adverse drug reaction monitoring 
system within the overall development of the NDP.  
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As indicated above self-medication by patients is a factor in irrational drug use, 
with individuals often taking medication that is out of date or not suitable for a 
particular condition. In some cases the patients had found the medication at home, 
either following an earlier prescription for a previous condition or had taken 
medication given to another individual (Barah et al., 2009).  
 
During the structured discussions with the physician interviewees as part of the 
PhD study, self-medication was mentioned as one of the major causes of irrational 
drug use in Kuwait –  it is indicated that many patients, especially elderly people, 
use self-medication, (due to lack of education) and uneducated parents. For 
example, some parents are reported to have used Non-Steroidal Anti-Inflammatory 
Drugs (NSAIDs) such as ibuprofen for their children without consulting a doctor, to 
reduce a high temperature, even if the temperature was mild.  Another important 
example of parents using self-medications, is the case of a child with asthma, and 
the parent had given an inhaled bronchodilator drug (Ventolin – an asthma 
treatment) for a child suffering from a cough because they thought that this 
medication would be useful for the treatment of coughing, even if the child did not 
suffer from asthma (Hutin et al., 2003).    
 
As a result, a number of studies have proposed that rational drug use should also 
extend into patient education and monitoring of drug treatments in order to prevent 
such occurrences. An associated issue in rational use is the medical device in 
which medication is delivered to the patient clinically – which raises another topic 
worth considering as the part of a NDP which would deal with education of health 
professionals and the public. This example is the over-use of injections, which is 
rife in many developing nations. While injections may have a perceived placebo 
effect compared with a tablet in some populations, the risk of needle 
contamination, infection and ineffective drug delivery is increased and therefore 
alternative means of delivery should be prioritized where appropriate (Hutin et al., 
2003). 
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Based on the examples provide by the interviewees and the literature, above, it is 
suggested that the KMOH should consider a programme which can provide advice 
to feed into the NDP which can help to solve the issue of irrational use of drugs 
and ensure public safety and support in develop and improving the Health Care 
System in Kuwait, as part of development and implementation of the NDP. 
 
6.10 The lack of a pharmaceutical industry in the State of Kuwait 
 
Some 83% of the interviewees (in Chapter 4) were in favour of developing a 
Kuwaiti Pharmaceutical Industry, because it can secure the country’s medical 
resources by providing the availability of the medicines during emergency cases, 
epidemics and war, where a rapid influx of the required medicines may not be 
readily available from outside the country.  It also increases and improves national 
sources of income and develops pharmaceutical technologies.  
 
However Kuwait has a poor experience in the field of developing pharmaceutical 
industries; there is only one modest industry (KSPICO-Pharmaceutical Industry) 
and it is unambitious, where the medicines manufactured in this industry are 
generally only based on simple generic medicines (e.g. ointments, creams and 
tablets) and this industry receives most of its raw materials from India and China.  
 
Kuwait is essentially like many developing countries and has a similar health status 
to many of them; for that reason it is necessary to study and review the 
importance, need, advantages and benefits of pharmaceutical industries for 
developing countries to understand the importance of this aspect, and how is it 
possible to realise benefits for the State of Kuwait.   
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According to recent statistics, developed countries contribute to their 
pharmaceutical industries more than they do to the development of defence and 
aerospace industries, and the research-based pharmaceutical industry is 
consistently financed, even during the periods of financial crisis and economic 
turmoil; however, the situation is the opposite in developing countries, thus 
underlining the importance of future investments in this area (IFPMA, 2014). Based 
on the estimations of the EU industrial scoreboard 2010, the majority of 
pharmaceutical companies are based in the US, Europe and Japan, with daughter 
companies having sprung up in developing countries (Spilsbury, 2014). 
 
However many factors contribute to the presence of a pharmaceutical industry in 
developing countries and the existence of such an industry is associated with 
considerable financial investment into the economy.  But the rewards in terms of 
better provision for the people of Kuwait and the views of the Health Professionals 
interviewed suggests that the development of its own industry, should be a priority 
in the not too distant future and the Kuwaiti Government should give attention to 
increasing investment in this area, and also encourage local and foreign investors 
to invest in the industry and  for the government to provide all necessary 
assistance for them and create a basis for a suitable grounding for such projects. 
 
6.10.1 How to ensure compliance between the pharmaceutical industry and NDPs? 
NDPs set-out important guidelines for the use of drugs, they do not provide legally-
binding commitments to the country, and therefore, have little legal power to ask 
companies to cooperate with them. NDPs have likely been drafted in this way as it 
allows a government pursuing a NDP increased flexibility to deal with 
implementation problems along the way, or to modify the approach.  
 
After a NDP is completed, a country will have a better idea of what it requires from 
the pharmaceutical industry to achieve its aims, which may be to get essential 
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medicines to more than 90% of its population. However, knowing what is required 
is not the same as getting what is required, for which a country must talk to large 
medicine buying groups or the pharmaceutical companies themselves. Given that 
many countries have very large populations and very small public finances, 
expectations on both sides of the negotiating table could be widely disparate. Here, 
negotiation on a case-by-case basis has led to deals being reached between 
private companies and governments sourcing medicines, although in many cases 
agreements are not reached (Morgan et al., 2008). 
 
As touched upon earlier, agreements between governments of developed 
countries, such as the UK and EU members, have been drawn up to establish fair 
pricing frameworks (UK Government, 2010). Such agreements could be replicated 
by other countries as they implement their own NDPs, and often groups of 
countries negotiate together for a better deal. Further good news for poorer 
countries is the rapid development of the generic drug market (i.e. in India) over 
the past 20 years, making off-patent drugs (many on the WHOs list of essential 
medicines) readily available at minimal cost (Morgan et al., 2008). 
 
Given that governments are the largest purchasers of drugs, it is in the interest of 
the pharmaceutical industry to work with them to increase revenue and profits 
(Zadeh, 2013). However, drug pricing remains a highly controversial topic 
(Moynihan et al., 2002), and many senior politicians in the UK have called for the 
pharmaceutical industry to be nationalised so that the best treatments can be 
made available to all regardless of the cost. In reality, however, the development of 
new drugs costs many billions of dollars, and the fact that private corporation buy 
those products reduces the incentive to immediately drop prices to more affordable 
levels. The cost of investment in new medicines is also the most commonly cited 
reasons as to why drugs cannot be given away to the developing world. The deals 
between third world governments and pharmaceutical companies should be 
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considered on a case-by-case basis with the aim of getting medicines to the 
greatest number of people possible.  
 
In future, it is possible that the cost of drugs will be fixed and related to other 
economic measures in a country -such as capping maximum drug expenditure by a 
country to a nominal percentage of GDP(Good Drug Practice), with the company 
fulfilling the rest of the cost (Shajarizadeh and Hollis, 2015). In this way, countries 
will be more likely to invest in the healthcare of the citizens knowing that its budget 
is protected for other requirements and that the international community is trying to 
help. 
Long-term business confidence is greatly aided by stability and predictable 
outcomes. In this light, the effective execution of a NDP – which orders and pays 
for drugs periodically – ensures pharmaceutical companies are treated fairly, 
helping them work together with government representatives professionally and 
routinely. Indeed, it must be noted that both parties should be looking to make a 
deal and work together, which in the long-term will help establish standard 
worldwide networks for drug manufacture, purchase, distribution and use.  
 
6.10.2 The importance of pharmaceutical industries for developing countries 
The importance of pharmaceutical industries to a country like Kuwait is a 
highlighted by the effects of this sector of the economy on the health of the 
country’s population and also on global health. A pharmaceutical industry is 
capable of substantially improving people’s lives – through small and large 
discoveries in the pharmaceutical arena and contribute to considerably elevating 
life expectancy as well as contributing to better life quality of the population of the 
country (Jacobsen & Wertheimer, 2009). For instance, with the aid of vaccines it 
became possible to eradicate smallpox at both regional and global levels and 
eliminate measles and polio at the regional level. Presently, with vaccines, it is 
projected that overall the lives of approximately 2 million children are saved 
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annually. In Africa, recent success of pharmaceutical industry development has 
been reported by the WHO which it is estimated will prevent approximately 3 
million malaria deaths and reduce the number of disability cases by one million 
(WHO, 2005). 
 
In addition, immunization campaigns have reduced measles deaths by 91%. 
Among other factors highlighting the importance of drug industries, it can be stated 
that since the beginning of the 20th century scientists have been able to discover 
and further develop nineteen antibiotic classes, resulting in the possibility of 
treating thousands of infections and saving millions of lives. The pharmaceutical 
industry, through a series of medical discoveries, was able to discover 20 varied 
antiretroviral techniques for treating HIV/AIDS – essential for epidemic control in 
developing countries. With the introduction of national drug industries, developing 
countries will be able to produce their own drugs against diabetes, cancer, 
HIV/AIDS and malaria (Jacobsen & Wertheimer, 2009).  
 
At present all the medicines mentioned above (vaccines and antibiotics) and other 
drugs are imported to Kuwait, which does not manufacture any of these within the 
country. If it were the case that an Industry could be developed, in the first instance 
it would most likely be based around the production of generic medicines and 
possibly also producing medicines as a national subsidiary of one of the 
multinational pharmaceutical companies. But with time it may be possible to 
expand into the development and production of novel drugs. In first case, the 
development of a pharmaceutical industry would support the State at least in terms 
of self-reliance in the supply of necessary common medicines, ensuring the 
provision of these medicines at all periods and especially in emergency situations. 
 
When looking at the state of health of the population in developing countries and its 
effects on the economy, it can be indicated that the introduction of a 
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pharmaceutical industry in these countries manifests two types of social benefits. 
First of all, it becomes possible to improve both mental and physical wellbeing of 
every member of society. Additionally, it lowers the costs of medicines and possibly 
hospitalization and other types of health care (WHO, 2005).  
 
The likely future prosperity of this sector in Kuwait should result in savings in the 
national health budget. As mentioned in Chapter 4, in 2014–2015 the KMOH spent 
700 Million USD on the purchase of drugs from abroad, so it is certain that the 
presence of pharmaceutical industry If an industry does develop in Kuwait it is 
likely it would reduce the proportion of the budget spent on high-cost, 
internationally shipped and insured medicines, and instead use inexpensive 
manpower within the country.     
6.10.3 Why the State of Kuwait needs the pharmaceutical industry 
The State of Kuwait should invest in its own pharmaceutical industry for a number 
of reasons; one of the primary reasons is the necessity of removing drug 
monopolies, which are a fundamental issue in accessing drugs and draining the 
budgets of developing countries. The Kuwaiti Government can act on reducing 
costs of medicines by developing and improving investment in this field.  
 
The effects of drug monopolies on developing countries were explored in a recent 
publication by R. Hellerstein. The paper focused on the assessment of 
antiretroviral drug (ARV) prices in Africa, where the pharmaceuticals market 
financing is greatly affected by foreign pharmaceutical companies. Two types of 
data were obtained; the first group included countries with no widespread 
availability of antiretroviral drugs and for this reason prices were dictated by 
monopolistic companies. These countries included Uganda, Tanzania, Rwanda, 
Kenya and Ethiopia. In contrast, the second group was formed by developing 
countries with availability of ARV drugs, and this group comprised Cameroon, 
Thailand, India and Brazil. Due to the presence of a national pharmaceutical 
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industry as well as foreign companies, prices were able to be set, based on the 
result of competition among companies (Hellerstein, 2011). 
 
Therefore for these countries where a monopoly exists (which is also likely to 
include Kuwait) the need is both financial and to access drugs appropriate for the 
countries needs. This problem is connected with the presence of monopolies in the 
corresponding markets. As a result, expenditure on drugs was determined as a 
considerable proportion of the total health costs recorded in developing countries. 
Consequently, access to the required treatment is in considerable correlation with 
affordability and availability of medicines.  
 
According to the estimations of the WHO, 1/3 of the population in developing 
countries is not able to regularly obtain essential medicines (WHO, 2005). The 
WHO also stated that introduction of pharmaceutical industries in developing 
countries should promote distribution of medicines in the following ways: 
1. Rational selection and employment of medicines. 
2. Acceptable prices for medicines. 
3. Sustainable involvement of financial resources from abroad. 
4. Formation of reliable health systems. 
 
In terms of the factors outlined above, it can be stated that reduction of drugs 
prices should be the most important issue addressed by the implementation of 
pharmaceutical industries. Thus, the WHO determined that investment in such 
industries in developing countries should reduce margins, taxes, and tariffs, along 
with the development of pricing policies. Competition among pharmaceutical 
companies should also increase what will lead to multi-source product availability 
(WHO, 2002). 
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Finally, it is clear that Kuwait should invest in its pharmaceutical industries and 
companies to become independent from the foreign pharmaceutical companies 
that dominate the market. 
 
6.10.4 The advantages and benefits of the pharmaceutical industries for the State 
of Kuwait 
In addition to becoming independent from foreign companies, reduction of prices 
for the most important drugs and an increase in the life expectancy of the country’s 
population, the introduction of a pharmaceutical industry is also associated with a 
range of other advantages and benefits for Kuwait. The most important of these 
are associated with the economic impact of pharmaceutical industries. This sector 
is robust and was proved to be a highly important aspect of the economies of 
industrialized countries. It also is increasingly manifesting itself as an intrinsic part 
of the economies in the developing world (Cook, 2015). 
 
Looking at the current investments in developing countries, it can be stated that the 
pharmaceutical industry research and development sectors of the economy in 
China and Brazil were estimated to be 74 billion USD and 134 million USD 
respectively in 2008 (Shadlen, et al., 2013). 
 
The pharmaceutical sector can also have a considerable positive impact in 
developing countries which sometimes exhibit a lack of innovative production 
capabilities, via the diffusion of technology allowing substantial improvements in 
the manufacturing of original drugs and generics (Shadlen et al., 2013). 
The activity of pharmaceutical industries can also have a considerable positive 
impact on a country’s economy. In the majority of cases, the economic impact is 
observed in the form of financial investments in the research and development of 
new drugs as well as their manufacturing. Additional positive effects include 
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improvement of conducted academic research and support for the formation of 
companies that conduct the development of new drugs and the production of 
existing ones. The research-based drug industry is highly active in developed 
countries. Thus, in countries such as the US, UK, France and Japan, billions of US 
dollars are invested in pharmaceutical companies. These investments give a 
considerable boost to the economies of the corresponding countries. Nevertheless, 
development of drugs is not only connected with their production. For instance, a 
country may have low research and development activity, compared with the 
production of drugs, while the activity of other countries may be focused on drug 
development rather than on their production. Consequently, State of Kuwait should 
establish the activity that contributes the most to their economies and attract the 
required financial resources (Schweitzer, 2006). 
As outlined above, the pharmaceutical industry substantially contributes to the 
formation of new work places for health care professionals in Kuwait, encouraging 
them to work in the private sector and reducing pressure on the Kuwaiti 
Government to provide jobs for new graduate health care professionals in the 
public sector.  
 
This beneficial contribution was observed in both developing and developed 
countries to differing extents. In 2006, it was estimated that pharmaceutical 
industries in China employed 1.3 million people. Additionally, 92K and 25K of 
people were employed in Brazil and Turkey respectively, and 4.2 million were 
employed in India, highlighting the intensive development of this region (Kuanpoth, 
2010). 
 
The pharmaceutical industry is able to provide high-skilled job opportunities via 
direct employment and also promote the creation of workplaces not directly 
connected with the production of drugs. Knowledge dissemination throughout the 
economy presents another beneficial consequence of pharmaceutical industry 
development. For instance, people employed in the pharmaceutical industry in the 
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majority of cases are exposed to new processes and techniques as well as 
receiving additional qualified training. These trends substantially contribute to the 
formation of a trained workforce with the possibility of employees changing their 
workplace or starting a new company, something that would help foster the 
economic development of the whole country (Kuanpoth, 2010). 
In the discussion above it was indicated that pharmaceutical industries were highly 
important for Kuwait and the most important advantages and benefits are 
summarized here: 
a. Increase and make savings in the national budget. 
b. Reduce the proportion of high-cost drugs. 
c. Ensure the availability of necessary drugs and secure access to 
essential drugs during wars and emergency cases. 
d. Improve availability of statistical studies and future planning for health 
care services. 
e. Develop the national investment and economy. 
f. Improve the quality of life of the population, and increase the life 
expectancy of the country’s population. 
g. Reduce the effects of monopolies imposed by international 
companies. 
h. Contribute to increasing new work places and providing job 
opportunities for health care professionals. 
i. Participate in the transfer of technology to the country; recent studies 
suggest that advanced technology transfer is of paramount 
importance to the economic development of all countries. 
j. Increase the acquisition of information, equipment, experience and 
innovative processes.    
 
Based on the advantages and benefits mentioned above, it is suggested that the 
Kuwaiti Government should support the development of this sector and follow the 
successful examples of the Gulf States (Saudi Arabia, Oman and United Arab 
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Emirates) that have preceded Kuwait in this area, and that they take several 
measures contributing to the implementation of the pharmaceutical industry, by: 
 
1. Encouraging and urging of private companies and investors to invest in this 
economic action plan and provide all necessary facilities for them. 
2. Participation of the Kuwaiti government to invest in this area by allowing the 
Kuwait Investment Authority (KIA) (which is considered the fifth-largest 
sovereign investment fund in the world with assets equal to 592 billion US 
dollars) to invest in the pharmaceutical industry, to diversify the income 
sources of the State and ensure health security. 
3. Establishment of an official website dedicated to this aspect, which provides 
all the necessary information, regulations and legislations, data and 
requirements for this plan. It should be a source and reference for local and 
international investors, companies and agencies interested in identifying and 
viewing such investments in the country. 
 
 
6.11 The lack of a Linked Electronic System in the public health sector 
 
During the PhD Research Program visits were carried out to the Public Health 
Areas of the; Drug and Food Control Administration, CMS Administration, Drug 
Inspection Administration, Drug Release Department in Kuwait International 
Airport, 10 public hospitals and 2 health clinics (Period of visits, 2012–2015), where 
informal ans structured discussions with professional health care staff were carried 
out and in addition observation of the nature of the work and its operation in each 
of the Administrations and Health Care Centres, was carried out.  This research 
was approved by the Ministry of Health in Kuwait.   
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Throughout these discussions and particularly through observations it was clear 
that the, communication, method of working, collection of data, recording visits and 
medicines inspector visits in the public sector suffers from a lack of an electronic 
system to link different areas together, and that receipt of medicines at the airport 
and port would greatly benefit from electronic recording of all stages of medicines 
management within the KMOH, whether by an internal e-link inside the 
Administration, hospital or health clinic itself or external e-link between theses 
health areas. In spite of the provision and presence of computers in each 
department and supervision of these health areas, the KMOH has not provided an 
e-link system (until now).  
 
The equipping of a e-link system should include all the pharmaceutical 
administrations of the KMOH and the pharmacies in public hospitals and health 
clinics –not having an e-link can cause many issues (mentioned later) that impact 
negatively on the development of health services and this would not support the 
implementation of a NDP in Kuwait. 
 
In this section, the difficulties created by the lack of an e-link system in the KMOH 
health areas was observed during a visit to the health areas as part of the PhD 
study.  The visit was designed in order to try to understand the limitations relating 
to the work of the KMOH, the possible solutions, and the advantages and benefits 
that can be obtained from establishing an e-link system in Kuwait. 
 
The public health areas that most require the presence of an e-link system in their 
work process include: 
1. Drug and Food Control Administration. 
2. Drug Inspection Administration. 
3. The CMS Administration and Pharmacies in public hospitals 
and health clinics. 
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6.11.1 The Absence of an Electronic Link System in Drug and Food Control 
Administration 
It was found during the visits and in discussions with staff that the system of work 
in this Administration suffers from the lack of an e-link between the different 
supervisions and the departments, which is thought to cause hindrances in the 
following areas: 
1. An increase in the time taken to complete routine tasks and delays in work 
practices, where the work is not completed as quickly as required  
2. The accumulation of hardcopy files and papers and the difficulties of 
cataloguing with the possibility of loss or damage to their content. 
3. Increasing need for porters to manually transfer the results of the analysis 
samples from the Laboratories Supervisions to the Registration and Release 
Supervisions. 
4. The need for internal committees to enable the exchange of data between 
the supervisions. 
5. Unavailability of additional electronic copies of drug registration files to use 
in case of loss or damage, specifically in the case of fire. 
6. The availability to access and exploit information easily because all drug 
registration files since the establishment of the Administration have only 
been saved in paper form. 
7. Limitations in the ability of the senior staff to follow, check and control work. 
8. An increase in complaints from drug companies, agencies and suppliers 
because work is delayed, because the production of results and decisions is 
longer than it would be with electronic recording. 
9. As above the limitations of using only paper copy has reasonably regularly 
prevented drugs suppliers obtaining early release for medicine shipments 
from the Drug Release Office in Kuwait International Airport because of the 
slow delivery of clearance from data supplied on licensed drugs.  This 
occurs even though this office belongs to the same administration. Suppliers 
instead have often to gain clearance/ approval from the main Administration 
Offices, which are located far from the airport site.    
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The introduction of an e-link system would clearly lead to much faster, generally 
safer, and better communication between the Supervisions and Departments of the 
Drug and Food Control Administration and would therefore resolve the difficulties 
mentioned above. In particular the main areas to benefit from an e-link system 
would be between the Laboratories Supervision, Registration and Release 
Supervision and the Drug Release Office in Kuwait International Airport, which is 
likely to ensure sharing of all the necessary data and information between them 
(See Figure 6.8 below). 
 
 
  
Figure 6.8 The establishment of an e-link system between the supervisions 
and department of the Drug and Food Control Administration.   
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The major advantages and benefits of improved efficiency and time saving from an 
e-link system between the Laboratories Supervision and Registration and Release 
Supervision would result from reducing the drug registration time; by providing data 
in the fastest time possible; helping senior staff (Supervisor and Head of 
Departments in both Supervisions) to follow, control and monitor the drug 
registration process and provide a more efficient file record system.  The overall 
advantage would result from earlier decisions and release of the results from the 
registration process to companies.  
 
As indicated above, one of the bottle necks is the communication on the initial 
receipt of medicines at the Drug Release Office in Kuwait International Airport and 
the main Release Supervision. An e-link system would improve the provision of all 
the necessary data (for all the registered drugs in Kuwait) at the Central 
Administration, and give a positive effect on the work involved in drugs release.  As 
a result, pharmaceutical companies, representative agents and suppliers should 
not need to visit the distant main building of the Administration to get approval 
release for their shipments. In additions to time saving there would be a reduction 
in the cost of storage of shipments at the airport until clearance is agreed, and also 
there would be a reduction in the workload for Central Administration staff. 
 
In addition to the need for an e-link system for this Administration, it is suggested 
that better communication with health professionals could be achieved if an official 
website for the Drug and Food Control Administration be set up. This could provide 
many benefits, including: 
1. Being a reference for the pharmaceutical companies, investors, suppliers 
and local agencies by providing all the information relating to: 
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a) The registration requirements for pharmaceuticals, herbal medicines, 
veterinary drugs, cosmetics and food supplements drugs and medical 
devices. 
b) The registration requirements for a pharmaceutical company’s licences in 
Kuwait. 
c) The necessary requirements for pharmaceutical advertisements. 
d) Identifying and explaining the registration process. 
e) The information related to drug pricing. 
f) Enabling drug companies to submit the details for registration of drugs 
electronically (by email) and follow the registration process through the 
Administration’s website without the need to visit the area. 
g) Using the website for announcements of the latest Ministerial Decrees and 
new requirements relating to drug registration, licensing and advertising. 
h) Using the website for announcements of the cancellation of drug licences in 
case of adverse effects of the drug being found. 
i)  Being a reference for health care professionals and the public, enabling 
them to access information about the traded and available drugs in Kuwait. 
 
 
6.11.2 The Absence of an Electronic link System in Drug Inspection Administration 
As mentioned in Chapter 5, the absence of an electronic system in the Drug 
Inspection Administration caused difficulties and has had a negative effect on the 
control of drugs in the Kuwait health system. Presently there is only a limited link 
between this Administration and the Drug and Food Control Administration. The 
process of data transfer (new registered drugs, latest drugs pricing and approved 
drug advertisement) from the Drug and Food Control Administration to this 
Administration is presently carried out manually, and this basic method does not 
help the inspectors in updating the existing data and identifying any irregularities in 
an accurate manner. 
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To resolve these issues and improve the work of drug inspection in Kuwait, and 
specifically the inspection of traded drugs in private pharmacies, it is suggested 
that an e-link system between the Drug Inspection Administration, the Registration 
and Release Supervision, the Drug Pricing Department and the Committee for 
Drugs Advertisements (which belongs to the Drug and Food Control Administration 
– see Figure 6.9 below) is set up as one of the important links within the NDP to 
ensure: 
 
a. Continuity access to all a necessary data at the right time. 
b. Reduction in the sale of unregistered drugs and drugs that need a 
renewed license.  
c. The drugs in the private sector are sold according to the prices set by 
the KMOH.   
d. All drug advertisements are controlled, by identifying if the product is 
licensed and the content of the advertisement matches what is 
approved in the licence.   
e. All private pharmaceutical companies are registered with the KMOH. 
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Figure 6.9 The establishment of an e-link system between the Drug 
Inspection Administration and the pharmaceutical parts of the Drug and 
Food Control Administration.   
 
6.11.3 The Absence of an Electronic Link System in the Central Medical Store 
Administration and in pharmacies in public hospitals and clinics 
One of the main functions of the CMS Administration is distribution of drugs to all 
pharmacies in public hospitals, health clinics and health centres (6 general 
hospitals, 9 specialized hospital, 13 specialized health clinics and 93 general 
medical clinics) in the State of Kuwait (see Chapter 5). 
 
The process of drug distribution from the CMS to the public pharmacies is based 
on contact between the CMS and the Central Pharmacies of the KMOH, where in 
each Health Area there is a Central Pharmacy supervised and responsible for the 
work of public pharmacies affiliated to its area of work. When a public pharmacy 
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needs a new drug order, they ask the Central Pharmacy to supply the required 
quantities of drugs, and then the Central Pharmacy sends the request to the CMS 
to prepare the required medicines and distribute them to the pharmacy. 
 
The present communication is between the CMS and Central Pharmacies and is 
done through committees, KMOH postal mail and phone. This can be a 
unsophisticated method which is slow and therefore causes delays in the drug 
distribution process, negatively affecting access by the pharmacies to the required 
medicines in a timely manner, and often leading to problems in availability (e.g. of 
Vitamin D, some brands of antibiotics and statins) for the patients.  
 
During the PhD study and through interviews and discussions, many pharmacists 
working in public pharmacies and CMS emphasized that this communication 
system doesn’t help the CMS to effectively distribute drugs to all the public 
pharmacies in the required time. 
 
It was again emphasised that the e-link system between the CMS, Central 
Pharmacies and pharmacies in public hospitals and clinics should provide the 
support to solve these problems and regulate the process of drugs distribution and 
ordering. 
 
The advantages and benefits that could be obtained from an e-link between these 
Health Areas are: 
1. Providing information on stored drugs (amounts and use by dates) (through 
an electronic database) in the public pharmacies in Kuwait to the CMS, 
which helps the CMS to determine the priority of drug distribution for 
pharmacies according to the needs. 
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2. Supporting the CMS to control and monitor drug consumption in each public 
pharmacy. 
3. Reducing the delay in drug distribution to the pharmacies. 
4. Ensuring access to the required drugs for each public pharmacy. 
5. Supporting the CMS in identifying and providing the appropriate medicines 
by analysing the electronic database from the e-link system.   
 
In addition, the e-link system would help to develop and improve the work of drug 
dispensing and storage of prescriptions and patient files in public pharmacies, 
where the lack of this system causes concerns such as: 
1. After completion of dispensing in the pharmacy (e.g. in Alsabah Hospital), 
hard copies of all the medical prescriptions and patient files are sent to be 
stored in the Archive Department. This Department is located outside the 
hospital, because of lack of space to keep them on site, and also the lack of 
an e-link system. This requires a daily effort to transfer patient files and 
prescriptions manually from the Alsabah Hospital pharmacies to the Archive 
Department, and causing delay in access to the necessary information if it is 
required again. In the case of any emergency (e.g. a fire) all the stored data 
could be damaged or lost, and there are no additional copies to replace 
them. 
2. Lack of annual statistical studies for the number, quantities and types of 
dispensed prescriptions, due to unavailability of electronic data. 
3. Because there are no formalised records, some patients may take the same 
drugs from different hospitals or health clinics at the same time, which can 
be dangerous for their health and life as they make take over doses or give 
the additional medication to someone else (self-medication) and causes 
wastage in the KMOH budget. 
 
To alleviate the problem above it is suggested that the KMOH resolve these issues 
and develops the access to additional information in their pharmacies by setting up 
an e-link system between: 
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a) The pharmacies in public hospitals and health clinics, to prevent patients 
(especially patients with chronic diseases) from acquiring the same drug from 
different public pharmacies in the hospital itself or from different hospitals and 
health clinics at the same time. This is safer for the patient and makes savings in 
the KMOH budget. 
b) The pharmacies in the same hospital, to share and exchange the dispensed 
drugs and other data between them. 
c) The pharmacies and medical clinic (physicians) in the hospital, to reduce 
medical errors and to ensure that physicians have enough information (types, 
brands and amounts of drugs) about the available stored drugs in the pharmacies, 
and to ensure a good prescription.  
d) The pharmacies and the Central Pharmacy in each Health Area, to save the 
time in ordering drugs and increase the control over dispensed drugs. 
e) The Central Pharmacies and CMS Administration, as presented above.  
 
In summary the discussion in this Chapter concentrated on the interview results 
and the information and data collected from the KMOH during the PhD study and 
highlighted the main concerns that reflect negatively on the development of Health 
Care System in Kuwait.  Most of these concerns and the administrative solutions 
discussed can be partially or fully resolved, through the development and 
introduction of the main stages of a NDP.  The beneficiaries will be the KMOH and 
participants (Kuwaiti Government, Kuwait University, Pharmaceutical Association, 
Medical Association, researchers and private sector)  and of course the population 
of Kuwait.  
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Chapter 7.0: Recommendations 
 
During the Research Study, a number of areas of the Public and Private 
Pharmaceutical Sector have been investigated and explored through collection of 
the information on the structures and from personal visits to the facilities and 
interviews and discussions with health professionals who are working in all 
disciplines and areas of the health services. From this work a number of 
recommendations can be made and these areas are discussed in more detail 
below. 
  
The overall conclusion from these studies is that there are a number of issues in 
the Health Care System in Kuwait, which could benefit from closer examination 
and decisions taken on whether changes are needed in the future  
 
However one area of legislation which has been strongly supported throughout 
these PhD studies is that the introduction of a National Drug Policy (NPD) which it 
is suggested should be a priority to support the efficient development and working 
of the Pharmaceutical Sector in Kuwait.  
 
In Chapter 5, the basis of the Pharmaceutical Administrations in the Public and 
Private Sector are described. This Chapter also discusses some of the Ministerial 
/Ministry of Health decisions; Decrees; and the function of the Health 
Administrations and the interaction between the Administrations.   
 
Following on from this information, at the beginning of the PhD study, the 
structured interviews which were undertaken during visits to the public and private 
health facilities in Kuwait provided the responses of 121 health professionals to the 
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current position and their views across many levels of the Pharmaceutical Sector 
(Chapter 4).  
 
In Chapter 7 is an in depth review carried out during the study by the author of this 
work where in addition to the Interview data generated and analysed in Chapter 5 a 
number of informal visits were carried out to the facilities of the Pharmaceutical 
Sector to include the Central Medical Stores, the primary receipt of Pharmaceutical 
Products at the Airport and the Seaport, the MOH Laboratories, discussions at 
Kuwait University on Pharmacy/ Health Education programmes, Pharmaceutical 
Administration, Pharmaceutical Association, Dasman Diabetic Institute, Islamic 
Herbal Medicine Centre, Drug Control Registration Departments, ten Public 
Hospitals, two Public Health Clinics, ten Private Pharmaceutical Companies, 
Private Hospital and the Medicines Inspectorate Offices.   
 
By combining the interview data, discussions at ministerial level, observations 
during visits and on operational visits, to Laboratories, CMS, warehouses, major 
receipt areas for medicines and medical devices, it is possible to provide 
recommendations which could be considered to assist in resolving some of the 
issues highlighted during this study of the Kuwaiti Health Care System. 
 
Based on the study results two main sets of recommendations (mentioned below) 
can be proposed:  
-  Main recommendations, revolving around the introduction of a NDP which can be 
utilized as a primary source of adjustment in reforming the Health Care System.   
- The second set of ‘recommendations’ for the Health Care System can be taken 
from the results of the qualitative and quantitative data analysis that have been 
presented in the previous chapters to include: 
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7.1 Main Recommendations 
 
The main ‘recommendations’ is to address the development of a National Drug 
Policy.  However this is not simply a matter of following a suggestion of the 
different steps associated with a NDP, as described by the WHO (WHO, 2001), as 
the structure and development varies from country to country and are dependent 
on the country’s priorities and economy (as discussed in detail in following Chapter 
8). Nevertheless there are some main structural points which are considered from 
this work to be very important in creating the basis for an introduction of a NDP (as 
discussed in chapter 6): 
1. To form a cross-party forum on the introduction of a NPD, which, is aimed at 
increasing the level of policy discussion and engagement needed to make 
members of the public aware of the probability of the introduction of a NPD.  
This recommendation is based on the fact that the nature of drug policy issues (as 
discussed in chapter 7):  inhibits the assessment of possible changes in the policy. 
For this reason, it is necessary to produce a discussion space and agreement on 
the most important aspects of the drug policy as well as possible actions resulting 
in the enhancement of the existing NDP.  
2. There should be clear responsibility for the implementation of the NDP and it 
should lie with the MOH and not directly with the Government. 
In stating this, the author is taking into consideration past examples of introducing 
a NDP in developing countries, where Government involvement may have been 
restrictive for reasonably rapid, successful development of their NDP (Normad & 
Weber, 1998). For this reason it is recommended to shift the responsibilities to the 
MOH, which could result in formation of new perspectives and forms of leadership, 
from within the MOH. 
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3. Once in place the Government should appoint an external body of health 
professionals, government officials and academics to periodically review the 
developed NDP policy and determine which sections are working efficiently 
and which sections need improvement 
4. The adopted drug strategies (such as Essential Drug List and Drug 
Procurement Policy) must presume a commitment to their execution from 
the initial stages of the policy development. 
An NDP should incorporate an aspect of evaluation and learning, which will make it 
more effective and ensure that they can deliver the claims that will be made when it 
is proposed and introduced. By ensuring this is part of the Policy, it should result in 
the ability to address any failed aspects of the policy. Thus, if a particular aspect is 
not working there should be an opportunity to re-evaluate that aspect. 
5. An independent organization from within MOH should be appointed to 
coordinate and supervise development and implementation of the drug 
policy.  
 
The organization should be chosen by the Government to coordinate research 
in the area as well as carry out regular assessments and monitoring of the 
implemented policy. It is expected that the organization will be partly financed 
by the money provided by the Kuwaiti Government to the KMOH. 
 
7.2 Recommendations for the health care situation in the State of Kuwait 
 
The Health Care System in Kuwait has many areas to commend it and the support 
given by the Government is done very well. However, like any major system in 
operation, its function should be monitored regularly for the good of the public and 
private sector stakeholders and to ensure that it is financially efficient.  
The Health Care System in Kuwait has served the people well, but there are some 
issues that impede its future development; further to this it suggested that one 
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major solution would be for the KMOH to consider bringing together all aspects of 
health delivery under the structure of a NDP. By doing this it is likely it would 
improve the success factors and solve many of the issues by: 
1. Developing the present guidelines for the Legislations and Regulations that 
relate to medicines. 
2. Developing guidelines to ensure that all manufactured or imported medicines in 
the State of Kuwait are of high quality, safety and efficacy and that they are 
registered under the Kuwaiti Drug and Food Control Administration and are 
suitable for human use. 
3. Proposing an electronic system linking all the administrative sections of the 
Ministry of Health, which could lead to improved and increased collaboration within 
the Ministry of Health framework. 
4. Supporting health investment in the State of Kuwait by providing information and 
distribution about the official legislation, regulations and data concerning the health 
services to all stakeholders.  
5. Suggesting the basis to strengthen the Legislation and Regulations of the health 
care system, which will better protect the patients.  
6. Establishing an Essential Drug List that will promote increased rational use of 
medicines and ensure that the procured drugs meet the needs of the health care 
system. 
7. Improving the procurement system and supply management. 
8. Encouraging personnel development and training and developing increased 
professionalism and efficiency of the workforce.    
9. Establishing quality assurance to ensure control, monitoring and evaluation of 
work in the public sector. 
10. Establishing a pharmacovigilance centre in the country (These points have 
been discussed in details in Chapter 6). 
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In order to handle, regulate and organize all of these areas, it has been indicated 
there is need to establish a NDP in Kuwait that will act as a guide in developing 
and improving the Health Care System and increase the level of quality and 
efficiency in health services.  
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Chapter 8.0: Proposal for Introduction of the Kuwaiti NDP 
 
Based upon the recommendations presented in the previous Chapter and the work 
of this study, it can be suggested that development of the Health Care System and 
access to problem solving of issues in the health sector in Kuwait are linked to the 
lack of a NDP and all the work of this PhD is based upon proposing how this could 
be developed and carried out. However before introducing a NDP, there should be 
an information document which can explain the basis of a NDP and it would then 
be the responsibility of the KMOH through the NDP group to educate both senior 
and junior health professionals in order for them to accommodate and understand 
the importance of establishing a NDP for developing the health sector.  This could 
be carried out by providing a range of initiatives, such as an information 
leaflet/booklet, short seminars, and/or a conference related to the NDP. 
Secondly, the KMOH could create a future action plan to introduce a basis for this 
project by studying key points such as: 
1. How to start working on the establishment of a NDP in the State of Kuwait. 
2. The best procedure to regulate and control the work of this national programme, 
giving an outline of a time period for development of the NDP and setting up its 
structure.  
3. The factors affecting the establishment of the NDP. 
4. Steps and stages of NDP establishment. 
5. The importance of NDP indicators. 
6. Implementation of NDP indicators. 
7. The monitoring results during the proposal.  
8. NDP implementation. 
9. Assessment and monitoring of the NDP. 
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8.1 Establishment of a National Drug Policy in the State of Kuwait 
 
The development of a NDP can be a highly complex process that would normally 
involve a combination of policy developments and implementation. In addition there 
should be a monitoring process for the Policy at a suitable time point after it is 
introduced and then at regular time intervals in the future.  
a) In the first steps of the development process it would be helpful to have a 
National Drug Policy draft. 
b)  With the second stage the developed activities and strategies, depend on 
the main objectives of the policy.  
c) The final stage would involve the implementation of monitoring activities and 
any adjustments of the developed NDP from the initial format which was 
introduced at the outset.  
 
It is proposed that to obtain a successful NDP, there is a need for careful planning 
combined with an active involvement of all parties. Additionally, it is suggested that 
as the NDP is in a dynamic state and therefore it should monitored on regular 
occasions. In introducing and maintaining full operation of a NDP, it does require 
considerable involvement and checking, however despite many difficulties in the 
development/operation, over 100 developing countries had a working NDP by the 
end of 1990s (WHO, 2005). 
 
As a result it is important that the health staff of the KMOH is made aware of the 
concepts related to the establishment process through awareness of the important 
combination of procedures which make up this process – development, 
implementation and monitoring. Therefore effective planning is paramount 
during the first part of the NDP establishment. It is clear from other countries 
reporting that without this; recently developed NDP’s have suffered from very low 
effectiveness (Babor.et al., 2009). 
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However to produce a successful outcome of the process, it is also dependant on 
the implementation actions and activities and therefore the KMOH must also 
consider carefully these aspects.   
Thus at the planning stage the Kuwait KMOH should produce a range of plans and 
possible alternatives: 
a) Initially a strategic plan should be developed that describes the main 
aspects of the Kuwaiti NDP and the various stages of the policy 
development, as well as the actions which should be taken to attract as 
many financial resources as possible from the government.  
b) A master or implementation plan should be produced; in order to help the 
KMOH set a timetable to complete this process. Such a plan would normally 
cover a period of three to five years and would describe the main activities 
of the master plan. The master plan should clearly describe the actions that 
should be taken and the people responsible for the successful outcome of 
these possible actions. Additionally, this type of plan would estimate a time 
frame for the policy development and implementation, as well as proposing 
a rough outline budget. If it was the case that resources are not available 
and there is no external input, the KMOH would have to consider setting out 
a range of priorities and goals which they would expect could be 
accomplishable with the available financial resources. The discussion 
around the available finance shows that there will be importance in 
convincing the Kuwaiti Government to support the project if the KMOH are 
to achieve the desired results.  
       [ Note: It is also possible to break down the master plan into several annual 
plans for implementation in various departments or organizations (Babor et al., 
2009)]. 
 
c) Interaction with external organizations is also of paramount importance to 
the establishment of the Kuwaiti NDP, such as the WHO, Executive Office of 
the Council of Health Ministers of the Gulf Cooperation Council, the MOH of 
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developing countries and other health organizations. This aspect of the 
policy development presumes that during both the development and 
implementation stages, negotiations, dialogue and consultations must be 
carried out between all the stakeholders and interested groups. Thus, 
interested groups which are expected to participate in the policy 
development and implementation process are likely to include consumer 
groups, professional associations, NGOs (Non-governmental organizations), 
academia, drug sellers, international and local pharmaceutical companies, 
nurses, pharmacists, doctors and the Kuwaiti Ministries. In this way there 
would be a strong framework of interested groups in the State of Kuwait. It is 
also considered very important to consider all the distinct and provincial 
administrative and medical personnel, and additionally making the 
necessary effort to take into consideration the place of herbal and traditional 
medicines and the associated practitioners. In addition to the parties 
described above, it is considered very important to involve the Kuwait 
Government drug regulatory agencies/ groups in making contributions in the 
Health Care System and also representatives of health insurance 
companies. It is expected that the involvement of the media as well as the 
support of international organizations will add considerably to the success of 
the NDP.  
It is expected that the above-mentioned committee who would cover the 
development of the NDP in Kuwait would meet regularly to review and 
discuss policy implementation with the parties described above in a forum 
addressing NDP issues (Brienen et al, 2015). 
 
However disagreements are expected within the involved stakeholders. For 
instance, it may be suggested that commercial interests of the drug producers may 
be threatened, or doctors may suggest that they could lose their clinical freedoms 
and some senior staff may be concerned that the reregulation of legislations and 
regulations or guidelines could reduce their responsibilities and powers. 
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It is clear that all parties thriving on the existing situation will feel themselves in 
danger from the forthcoming changes, so the KMOH and those in charge in this 
project will need to be careful that there is not major disruption caused by those 
who fear that they will be affected by the development of the Health Care System 
in Kuwait. Thus the development and implementation of a process that is able to 
sustain the broad consensus is highly desirable in the policy implementation.  
In general, it can be concluded that with the increase in the needs in introducing 
with time a pharmaceutical industry and elevation in the number of sectors that 
require improvement, it is expected that more parties will be involved in the 
decision-making process (Reich, 1994). 
 
Finally, the political dynamics in the views of government present another essential 
aspect of a successful establishment of the NDP. Formation and the subsequent 
implementation of the produced NDP both present highly important political 
processes. This observation is associated with the fact that in the majority of cases 
the employed policy is aimed at achieving equity of health care to the population 
through the increase in the efficiency of the pharmaceutical sector, as well as being 
responsive to existing health requirements and being cost-effective. The described 
response may be associated with redistribution of power and priorities, resulting in 
an elevated level of competition among the present interested organizations 
affected by the reforms, which will be required.  
Considering the diversity of the interests involved, as well as the economic 
importance of the NDP, there may be substantial opposition to the suggested 
implementations, similar to that experienced in the Philippines and Bangladesh 
(Lee et al., 1994). Consequently, it is of major importance to identify the main 
political allies and if possible to sustain their support during the Development 
Process. Additionally, strategies to confront political opponents should be 
considered and if possible to put in place approaches which would allow the 
capability to work with them. Both priorities and decisions which relate to the 
stakeholders’ interests should be considered and balanced on the basis of possible 
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expected gains and losses. Considerable political leadership combined with 
sustained development are of particular importance when considering the 
development and implementation of a successful NDP (Lee et al., 1994). 
 
8.2 Setting up the structure of the Kuwaiti NDP    
 
Before thinking about the proposal for introduction of the Kuwaiti NDP and setting 
up the structure of the policy, it is reported in many research projects and 
publications that in order to obtain the best outcomes, the project should follow a 
number of logical steps, with each step subject to critical analysis and assessment. 
These would include researching the definition, goal, objectives, structure, 
formulation, process of the NDP, including the WHO recommendations and the 
successful examples of a NDP in developing countries (WHO, 2001); it also 
includes finding suitable overall references on development and introduction 
through sources in the library and on the Internet. 
 
This and the importance of a NDP for the State of Kuwait was discussed with the 
supervisor(s) – including the External Supervisor Dr Omar, the Assistant Under 
Secretary for Drug and Medical Supplies of KMOH. From these discussions it was 
proposed that the development of a NDP would lend support to the possibility of 
updating and reregulating of legislation and regulations of the KMOH, and the 
Kuwaiti NDP would act as a guideline for health professionals and help the KMOH 
to set future plans for the Health Care System in Kuwait. This is especially 
important as currently this is lacking in Kuwait, and for that reason the chosen topic 
was the establishment of a NDP in the State of Kuwait. 
 
Through discussions with Dr Omar during the course of this study about the 
mechanism of action, how to manage and follow-up this project on establishing a 
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NDP, and around the team that would engage and help to work towards 
establishing and development a NDP, the creation of a Steering Committee and 
Internal Department in charge of establishing a NDP was proposed, both of which 
would be affiliated to KMOH. 
 
Many countries have introduced similar NDPs to the one here proposed in recent 
decades (Laing, 1991; Ministry of Health, 1994, 2000), and a wealth of information 
from the WHO and other sources suggests that planning and communication are 
central to reaching the correct agreements for a NDP (Ratanawijitrasin et al., 
2001). In this respect, the researcher suggested to having a number of committees 
and sub-committees to deal with different aspects of the process (mentioned later).  
 
In the majority of cases of recently established NDPs, various committees 
composed of public and private sector health workers and legal experts have been 
established to set-up the systems (Chowdhury et al., 2006). This is true across the 
world, and established NDPs are continually monitored for best practice by 
different committees.  
 
An example of NDP creation by committee is provided by Namibia, where the 
permanent secretary of the MOH established the National Drug Policy committee 
in 1995 (Ministry of Health and Social Services, 1998). Similarly, in neighbouring 
South Africa, the National Drug Policy Committee was established in 1994 to set-
up their NDP (Laing, 1991). In all cases, the overarching drug policy committee 
was reported to by several smaller committees focusing on specific issues, such as 
the essential drugs list or drug pricing. In addition, the laws of Civil services 
Commission (responsible for all ministries and governmental agencies in Kuwait) 
obliges the governmental ministries and agencies in the case of on the 
establishment of any department, administration and organization to be through 
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working in committees, in order to discuss all views and arguments and ensure 
achievement to the appropriate results (KMOH, 2000).   
 
The Steering Committee could consist of five members; all of them would be senior 
staff and the Head of the steering committee would be expected to be Dr Omar. 
The other members are expected to be: 
1. Director of Drug Control Administration. 
2. Director of CMS Administration.  
3. Director of Drug Inspection Administration. 
4. Director of Pharmaceutical Services Administration.  
Reporting to this committee would be three sub-committees, which could be the 
primary means of providing all the necessary information and the required data for 
the steering committee (See Figure 8.1).                                                                                           
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Figure 8.1. The Steering committee and the three sub-committees of KMOH  
 
 
a) The first sub-committee (as indicated in the diagram above) would work within 
the pharmaceutical administrations, hospitals and health clinics related to the 
KMOH and create a link between these areas. It is likely to consist of six 
pharmacists; four of them would work in each of the different MOH pharmaceutical 
administrations (there are four pharmaceutical administrations in Kuwait), one 
pharmacist would work in a hospital and one pharmacist would work in a health 
clinic.  
 
The duty of the first sub-committee would be to talk with and interview their 
colleagues working in the public pharmaceutical administrations, hospitals and 
The Steering 
Committee 
 
The 1st Sub-Committee 
 
-Consist of 6 pharmacists. 
It works within the 
pharmaceutical administrations, 
hospitals and health clinics 
relating to KMOH and creates a 
link between these areas. 
The 2nd Sub-Committee 
-Consist of 4 
pharmacists. 
It works to create a link 
between the KMOH and 
other local health areas, 
whether in the public or 
private sector in Kuwait. 
The 3rd Sub-Committee 
 
 
 
-Consist of 2 
pharmacists. 
It works to create a link 
between the KMOH and 
the international health 
organizations and MOH 
of some developing 
countries. 
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health clinics in much greater depth to the initial interviews carried out in this study, 
to: 
 Collect more detailed data from administrations, hospitals and health clinics 
where they work. 
 To examine for areas of concern and find any issues relating to the work 
status of those working in these areas, and relate these to the NDP 
 Analyse and suggest solutions to these issues. 
 Discuss solutions to try to resolve any problem areas found and relate these 
to the structures within the NDP, by suggesting development strategies and 
how these strategies can be incorporated in future planning associated with 
the NDP. By developing and therefore improving the work in these health 
areas. 
  To bring forward and discuss ideas, advice and recommendations from 
other health staff to ensure that the setting out of the requirements in the 
NDP will be suitable specifically for the Kuwaiti Health Care System and the 
pharmaceutical field. 
 
b) The second sub-committee could consist of four pharmacists working with a 
remit to create greater links between the KMOH and other health-related 
organizations in Kuwait. One of their major responsibilities would be to visit all the 
local organizations, whether in the public or private sector. These include Kuwait 
University, Medical Associations, Pharmaceutical Associations, Military Hospitals, 
Dasman Diabetes Institute, the private health care sector (hospitals and health 
clinics, pharmaceutical companies, pharmacies, drug industries and drug 
distributors) and other local health organizations. The aim of this committee would 
be to examine the link between these institutions, the Health System and the NDP 
and also identify any further concerns, difficulties, possible problems, requested 
requirements, needs, possible barriers and their potential solutions, and to discuss 
these within the wider requirements of the Health System and the NDP.  It could 
also discuss the value of their scientific and practical expertise to ensure that this 
NDP project has a structural framework which includes the interests of all the 
 
 
346 
 
health professionals and covers the main points and fields of the health care 
system in Kuwait 
 
c) The third sub-committee could consist of two health staff and could work 
towards creating a link between the KMOH and the international health agencies to 
discuss medicines policy developments and to gain advice on the introduction of a 
NDP (WHO, Executive Office of the Council of Health Ministers of the Gulf 
Cooperation Council, Uppsala Monitoring Centre (Sweden) and other international 
health organizations).  Of importance would be the setting up of dialogue and 
possible links with the MOH of other developing countries, especially those which 
have had successful experiences in developing a NDP. This committee could after 
establishing its working knowledge and remit have a meeting(s) with the WHO 
regarding Kuwait’s proposals for a NDP, with specific reference to the general 
guideline proposed by the WHO in 2003.   
 
In these contacts it is also likely to be important that Kuwait’s links with other 
developing countries, who have introduced a NDP like Oman, Jordan, Nigeria, and 
Ghana by using official correspondence through the KMOH, emails and official 
visits to these countries which are likely to be particularly beneficial. The reason for 
contacting them would be to gain advice on their experiences, to study their 
successful and not so successful experiences in establishing and developing their 
NDP.  This interaction could go further, by opening dialogue with some of these 
countries and taking advantage of their successful operations and asking them if 
they would be willing to provide helpful support to the KMOH in completing the 
NDP project. However it is important to note that although all possible help and 
support will be appreciated, the members of this committee should always take into 
account the specificity of Kuwait’s needs and the differences of the factors, nature 
of work and the needs of each country. 
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An essential section of the NDP management team will be The Working Party or 
Committee for the development in implementation of the NDP, who should carry 
out: 
1. Developing the work of the Sub-committees and coordination between them and 
the NDP Group and the Development/Steering Committee. 
2. Arranging the Training and rehabilitation of the chosen staff to work in this field, 
especially those working in the sub-committees, explaining the importance of a 
NDP and the benefits that can be gained from it. The department will also inform 
them about the work plan of this project and how to implement it professionally, 
providing for all requirements and supporting the teamwork to ensure a quality 
performance. 
3. Follow the work of each sub-committee separately and map the work of each. 
4. Evaluating the work of each sub-committee and submitting reports to the 
Steering Committee and informing it of the progress of the NDP development. 
5. Ensuring completion of the NDP by the pre-established time and ensuring the 
efficiency of the work. 
 
Throughout the process of development the Working should report to the Steering 
Committee on a regular basis, and the Chair of the Steering Committee should 
attend the Steering Group Meetings. By having in place a clear structure and an 
overall independent monitoring committee it is likely to ensure the development 
and introduction will be successful. With agreed choice of decisions, there should 
be insight into possible errors before they occur and that no important aspects are 
neglected 
 
e) The Coordination and Monitoring Department for the NDP. One of the most 
important operations during and after a NDP is introduced is to continuously 
monitor its development and operation and it has been proposed to establish an 
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Internal Department (The Coordination and Monitoring Department for the NDP) to 
be responsible for monitoring the development of the first draft of the policy. This 
Department, should be introduced as the process of creation of the NDP which 
could take considerable time and the Department could through its monitoring 
induce a certain degree of urgency and insistence of direction when/if the 
development of the NDP slows down and the time period is excessive. An 
extended time period could arise due to the complexity of the government work 
cycle and the presence of established routines. Therefore in order to save time and 
not to delay this important national project it is proposed to establish the Internal 
Monitoring Department to keep the process moving. 
 
The main functions of this Department would be that they were responsible for:  
 Selecting the appropriate health professional staff for the Sub-Committees 
and train/supervise them in the introduction of the importance, of the aims 
and goals of a NDP for Kuwait. 
 Supervising their work and making sure they take responsibility for the 
required actions and incorporate these actions, methods, processes and 
steps into the future action plan.  
 Providing support for the selected staff in terms of any training needs before 
they start action on this national project. 
 Setting up the draft structure of the Kuwait NDP and establishment process 
through awareness of the important combination of procedures which make 
up this process – including development, implementation and monitoring. 
 Ensuring that all the collected and analysed data by the working group (Sub-
Committees) is accurate, appropriate and effective during the process of 
development and implementation, in addition to ensure access of accurate 
structures, policy development outcome and results are available for 
discussion to the Steering Committee before final decisions are made.   
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It is proposed that in the future, after completing the implementation of the NDP, 
the KMOH could establish a Drug Administration Unit for the established NDP, 
which would be responsible for: 
1. Continuous development of the NDP. 
2. Ensuring the continuous updating of the NDP. 
3. Regular monitoring and evaluation of the NDP. 
The health professionals working in this administration should be highly skilled in 
managing, improving and developing proposals and legislation which they can 
transfer to the development and functions of the NDP, which should reflect 
positively on the Health Care System in Kuwait. 
 
8.2.1 Examples of NDP implementation in Developing Countries 
As has been mentioned earlier in the Thesis, the development of a NDP in different 
countries of the world has continued for many years and although the majority of 
countries have a working NDP, there are still countries who have to consider its 
introduction. However in the last 15yr a number of Developing Countries have 
moved forward with the successful implementation of a NDP and as indicated 
above these include Oman, Jordan and Nigeria, who generally have some 
similarity to Kuwait. 
However of these, Oman as a developing country has many similarities to Kuwait 
in terms of population size, proportion and types of common diseases, health 
services and health care system, and is likely to have come across many of the 
areas which Kuwait will have to address. It was the forerunner in the Gulf States in 
the establishment of a NDP, in deciding to improve its Health Care System and to 
resolve difficulties in its health system through the establishment of this Policy. It 
was understood from published text (Omani MOH, 2000) that the NDP in Oman 
has provided a solution for many difficulties and structural issues, and helped 
organise and structure the work of the MOH and its health system. Oman started 
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working on establishing its NDP and the organization of the work required over a 
period of five years, from 1996 to 2000. It was finally introduced and proposed on 
the 4th of July 2000 (Omani MOH, 2000).  
 
The Omani MOH wanted, through the establishment of a NDP, to achieve key 
objectives that included:   
● Developing the legislation and regulations and following the development of up-
to-date   
    drug registration, licensing, prescribing and dispensing systems;  
● To strengthen the rules concerned with drug inspections in the public and private 
sector; 
● Control of imported and exported drugs;  
● Ensuring that all the local drug industries in Oman met the GMP conditions and a 
GPP exists in the pharmacies;  
● To improve supply management and drug procurement,  
● To develop the human resources (Omani MOH, 2000).     
 
The MOH of Oman has therefore gained expertise in these areas and in 
developing a working NDP and it would be beneficial if Kuwait can link with Oman 
and take some advantage from these experiences to help the KMOH to avoid 
some of the difficulties it may have had in developing their NDP. This is likely to be 
beneficial in being aware of difficulties they found which may be appropriate in the 
Kuwait NDP.  In addition advice from Oman and other countries could assist in 
advising on the methods needed to solve some of the organisational and 
introductory difficulties and ensure the best results are achieved. For this, it 
therefore may be possible for the KMOH to make arrangements with the Omani 
MOH for assistance, and be possible to discuss the possibility of sending a work 
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team to learn about the steps, plans and the methods used by Omani MOH, in 
order to take advantage of them.   
It is also possible to suggest that a similar interaction may be entered into with 
Jordan. The National Drug Policy in Jordan was formed as the result of 
cooperation between the Jordanian Ministry of Health and PHRplus (Partners for 
Health Reformplus) and was introduced in 2002. The premise which was 
suggested at the time of development was that the formed NDP would act as a 
framework for subsequent employment in both private and public sectors of the 
health economy in Jordan. The primary goals of Jordan’s NDP were to provide 
safe, high-quality and effective medical devices to the population of the country as 
well as to ensure the regular availability of the most important medicines and 
medical consumables. It was proposed that the development of the pharmaceutical 
sector would be established as one of the top priorities of the Jordanian reforms. In 
addition to the actions of Jordanian MOH and PHRplus, they brought in an 
additional agency, the USAID (US Agency for International Development) to 
provide an oversight of the developments within the country. The policy was 
therefore developed as the result of cooperation between the different 
organizations and Jordanian Hospitals and the Health Ministry (Al-Halawani & 
Qawwas, 2006). 
The specific purpose of the PHRplus involvement was to help the Jordanian 
Government produce within the National Drug Policy, a National Formulary and a 
Rational Drug List which would lead to better rational distribution and management 
of pharmaceuticals, as well as the reduction of expenses in both public sectors and 
households for pharmaceutical products. In detail the PHRplus were involved in: 
1. Promoting and periodically updating the JRDL (Jordan Rational Drug List). 
2. Promoting and periodically updating the National Drug Formulary of Jordan. 
3. Facilitating the developing and adopting the National Drug Formulary and 
Rational Drug List by the Jordanian Government.  
 These activities required the: 
a) Promotion of the organizational reforms: Formation of the National Advisory 
Board, the National Drug Policy Unit and National Technical Committees. 
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b) Promotion of the mechanisms aimed at rational selection and use of the 
most important medicines (Hashemite Kingdom of Jordan, 2002). 
 
Based on the information described above and on the discussion of analysed 
interview data and the collected data from the KMOH (In Chapter 6), it is indicated 
that a large part of the goals of implementation of a NDP in Kuwait are close and 
similar to the goals of Jordan’s NDP, these include;  
 Ensuring the access of safe, high quality and efficacious drugs to the 
population. 
 Ensuring availability and affordability of appropriate needs of drugs in the 
country. 
 Providing an Essential Drug List. 
 Developing the process of drug supply management and distribution. 
 
It is however suggested that it is necessary to benefit from the Jordanian 
experience in the area of establishment a NDP, where it could support the staff of 
KMOH in this national action plan.    
Nigeria is also reported to have introduced and implemented a successful NDP in a 
developing country. Like Jordan, the NDP in Nigeria was produced and 
implemented as the result of collaboration with the WHO. The strategies employed 
in the implementation of the NDP focused on the effective management of the 
available resources at that time, proposing appropriate quantification of countries 
medicines requirements and addressing the problem of rational selection of drugs.  
 
Their main requirement in the structuring of the NDP was to establish an effective 
Drug Registration Department and organize registration of all medicinal products 
and ensure adequate drug legislation. In addition as Nigeria had an active 
manufacturing base the NDP attempted to promote manufacturing of local 
medicines and to try to ensure the quality of drugs was consistently high at all 
levels. However in practice this aspect was not as robust as it could be and the 
quality of some of the manufactured products was below the level normally 
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expected. But the strategies associated with addressing rational drug use and 
proper accountability for the consumers and health workers, was to a certain extent 
successful (Federal Ministry of Health, 2003). In establishing a NDP the Nigerian 
MOH were very aware of the insistence that proper selection of drugs is of major 
importance to produce a successful operational NDP.  
 
Thus, the Nigerian Ministry of Health established an Essential Drugs List where the 
medicines selection was generally based around clinical effectiveness and rational 
selection to satisfy the requirements of the majority of the population. The Drugs 
List is regularly revised and used to inform the annual procurement selection of 
drugs by the Ministry in Nigeria. The Essential Drugs List is reasonably regularly 
updated and made available to health institutions, local governments and health 
professionals. The drugs included in the list are considered safe because they are 
chosen based upon international standards and receive a registration number from 
the Nigerian National Regulatory Organizations (Federal Ministry of Health, 2003). 
It is reported that when assembling the Essential List of approved drugs, every 
effort is taken to avoid formulations represented by more than one active 
compound. In cases where a range of therapeutically equivalent drugs was 
assessed, preference is given to the formulation manifesting the lowest price but it 
still has to be supported by significant clinical data and scientific research. This list 
formed a major part of their NDP policy and is periodically updated at roughly 4 
year intervals (Federal Ministry of Health, 2003). 
 
Based on the information presented above (Examples of a NDP implementation in 
Developing Countries), it can be indicated that the mission of the third sub-
committee is very important; where it would work in creating a link with the MOH of 
these countries to share and collect all the required data, information and 
recommendations from them, where it would support the steering committee to 
take the right decisions in implementation a NDP in Kuwait. 
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8.3 Factors affecting the establishment of the NDP 
 
It is clear that an effective policy implementation is a particularly important aspect 
of the NDP establishment. As indicated above, regardless of the targeted country 
in every case a Master Plan and an Implementation Plan must be developed. In 
this respect each policy component should possess a clear plan of action with the 
corresponding detailed strategy. However it is important to bear in mind that the 
establishment of the NDP is affected by factors such as financial resources, 
regional cooperation among countries as well as with the WHO, and 
regulation/legislation aspects (WHO, 2005). 
 
Considering financial resources, it is of high importance to match the developed 
NDP establishment strategies with the financial resources available. In the majority 
of cases, financial resources are allocated from the revenue generated as the 
result of drug registrations and from central governmental funds and taxes. The 
corresponding responsible agencies should be able to quickly and efficiently 
process applications from the organizations looking for funding and be able to 
provide governmental funding on the regular basis. But additionally, specialized 
mechanisms may need to be set up to eliminate conflicts of interest arising as the 
result of donations. These situations are possible in cases when donors would like 
to support activities that are considered of low priority for the establishment of the 
NDP (Turner, 2012). The Kuwaiti Drug and Food Control Administration is in 
charge of registration, licensing and releasing of imported drugs through the Drug 
Release Department in Kuwait International Airport; when the KMOH develop the 
work in this field it is likely to increase income, especially when the Administrations 
become more experienced and efficient in ensuring the continued availability of 
income. But as the Kuwaiti Government is considered the largest financial resource 
for the KMOH, it is important that there is agreement that it should continue to 
support and assist in the financing of the NDP because it is unlikely that the 
present income from registration, licensing and release fees is not enough to 
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support this new initiative, particularly in the development stage. Thus it is likely 
that the Government/KMOH will play a very important role in supporting and 
financing the establishment of the Kuwaiti NDP.     
 
In addition to the allocation of the necessary financial resources, technical 
cooperation with other agencies, countries and the WHO also represents factors 
affecting successful establishment of the NDP. The WHO through its many 
discussion, symposia and on-line information materials is likely to be able to offer 
the basis of a forum for information exchange and it also has available with other 
agencies the support particularly to Developing Countries to promote cooperation 
via international and national training courses, as well as providing information on 
research projects which are currently operating within countries. The Centres 
which are presently supported by the WHO can take an active part in the 
development of professional networks, promotion of information exchange among 
countries and research/training of the professionals involved in the development of 
projects such as a NDP.  
 
In addition with the information technologies and current means of communication 
it becomes possible to provide a range of opportunities for low-cost but efficient 
exchange of information, technical cooperation, collaboration and consultations. A 
typical example is the Medicine WHO website which provides some of the most 
recent information regarding technical data, and some documents covering the 
development and implementation of a NDP. In addition to this website, a 
considerable amount of relevant information is provided by the Management 
Sciences for Health (MSH) who is working in cooperation with the WHO. 
 
In addition there are a number of international meetings and symposia, such as the 
Federation of International Pharmacists (FIP), which is every year and is attended 
by many health regulators and representatives of Ministries of Health, and WHO 
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representatives where communication at this major symposium and at other 
symposia, where there is opportunities to meet with organizations responsible for 
NDP development (WHO, 2015). It is proposed that it would be the responsibility of 
the 3rd Sub-Committee to become involved with such developments and 
international meetings and would further instigate contact with international health 
organizations and agencies to take advice and suggestions from them to support to 
development and completion of the process of establishing a NDP for Kuwait. This 
sub-committee is likely therefore to be the focal point between the KMOH and 
these organizations. 
 
Based on the information presented above, it can be stated that regional 
cooperation is as important as cooperation with other countries, agencies and the 
groups associated with the WHO. As stated above, regional cooperation with 
Oman and Jordan is likely to manifest very good outcomes in the initial stages of 
development and implementation of the new drug policy. It is hoped that links with 
individual organizations, institutions and government health departments both 
internally and with other countries, can be established where there could be access 
to experience, facilities, skills, expertise and information between them and the 
KMOH. Expertise exchange could ensure that the pitfalls are explained and only 
best practice is promoted and carried out, with a view to try to eliminate the 
possibility of errors and to introduce the principle of effectively using limited 
resources. It can be stated that cooperation in the Health Areas already exists at 
many levels from the regional to International cooperation, covering a number of 
both health policy and economic issues. Examples of regional partnerships include 
the; Organisation of African Unity (OAU), European Union (EU), Uppsala 
Monitoring Centre and the Association of South-East Asian Nations (ASEAN). 
 
In some cases the strategies employed and policies can result in mutual interest, 
and in these cases the sharing of information as well as technical expertise can be 
highly effective. Additionally, similar drug regulatory standards are expected to be a 
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possible outcome of effective regulatory and technical cooperation. Harmonization 
in these areas can result in the formation of international and regional standards 
across countries as well as more effective use of materials and human resources. 
However, in addition to the formation of similar drug standards, sovereignty issues 
and specific differences from country to country must also be taken into 
consideration. Consequently, during the harmonization process it should be 
investigated that every country involved does make sure that harmonized areas 
are relevant to the corresponding national interests (IPC Group, 1999). In the case 
of Kuwait it is proposed that the KMOH Drug Department (The Coordination and 
Monitoring Department for the NDP) which is charged with bringing forward the 
NDP should be allowed to control such technical matters until the completion of the 
NDP project.  At that point it is probable that the KMOH will establish an individual 
Drug Administration for the NDP which will have competent to continue all work 
related to a NDP. 
 
8.4 Steps and stages of NDP establishment in Kuwait 
 
In the case of the majority of developed countries who have newly established, or 
have made alterations to their existing NDP, it has normally (or will be) been 
adjusted once every 10 years. In many cases these changes to a NDP are 
promoted from highly important changes in the political profile of the country or 
sudden emergency situations which can create windows of opportunity for starting 
the establishment of a new NDP or updating an existing Policy.  
Whether a country is up-dating a NDP or introducing a new NDP, there are a 
number of stages which it is suggested they undertake which can lead to 
developing a NDP or improvement and harmonisation of the present system.  In 
adjusting the majority of a pharmaceutical system NDP, it is important that the 
MOH makes itself fully aware of the requirements, factors and specificity relating to 
the country’s needs. In some developing countries there are problems with drug 
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distribution, while other countries may suffer from the lack of an Essential 
Medicines List or shortcomings in controlling the pharmaceutical market. 
In the case of Kuwait the circumstances facing the KMOH are based upon it being 
a relatively rich country, but one where the Health System, although it has 
successfully served the country, it is currently being held back by organisational, 
communication and limited control over its procurement of new medicines.  
However within a NDP there are expectations that the KMOH will be able to have 
more control over procurement of medicines and the structures under which the 
medicines are chosen and dispensed For these reasons, before the establishment 
and development of a NDP the country should pass through a number of steps and 
stages to determine the main aims, objectives, needs, and concerns in the Health 
System. In the next stage of development an action plan can be proposed with 
possible, solutions added to the action plan, in order to create an integrated and 
appropriate NDP for future implementation (WHO, 2004). 
 
The main steps and stages of establishing an outline NDP in Kuwait are 
summarized below: 
Stage I: Organization of the Policy process 
The KMOH represents the most important national authority responsible for the 
formulation and implementation of the NDP in Kuwait. The first stage (after 
deciding that a NDP is required) should be the effective organization of the 
development process with the identification of the policy structure, main objectives 
of the policy, formulation, process of the NDP and primary components. In the first 
stage it is of major importance to establish the main parties who should be involved 
and to set out an indication of the required financial resources needed as well as 
possible approaches to securing them. The necessity of consultations with country 
officials and donors should be considered at this initial stage. It however suggested 
that it is possible to carry out this stage within the KMOH with the additional 
support from a group/committee who can be formed with a small number of the 
required experts (Chatwin, 2011). 
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Stage II: Examination the current operational procedures within Kuwait in the 
health care system  
An investigation should be completed into providing a thorough understanding and 
analysis of the most important operating points existing in the pharmaceutical and 
medical fields in Kuwait. This is necessary in order to form a realistic set of 
objectives. A range of approaches can then be used to conduct a situational 
analysis. To carry this through the approach suggests that there would be 
involvement of a small ‘group of experts’ with the necessary policy development 
experience.  
It is however suggested that these ‘experts’ would be based on the Ministry of 
Health representatives and can be involved from another local or international 
health agencies, to possess the necessary training in the relevant pharmaceutical 
background. The experts should perform the functions of advisers, making the 
corresponding recommendations to the government of the country. The resulting 
reports are usually collected and analysed by the MOH (by the steering committee) 
and discussed later with the WHO. The organization is also responsible for making 
them publicly available (WHO, 2005).  
 
Stage III: Carrying out a detailed analysis of the Health Care System 
It may be necessary to carry out a detailed analysis of the organisation and 
working of the existing Health Care System and the components of the public and 
private sectors, as they affect the Pharmaceutical Services. This stage can be 
considered highly important for revealing whether there are organisational 
requirements, to establish appropriate strategies, to deal with the findings and to 
develop the first outline for the NDP. In addition it could deal with any, formation of 
priorities and provide a baseline for the possible evaluation and monitoring of the 
systems (Executive Office of the President of the United States, 2015). In order to 
fully understand the topic and the results from the initial period of study and 
searches, further detailed research should be carried out to look more closely at 
the causes of any difficulties, organisational and operating points that are revealed. 
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To more closely examine their basis and how these can be tackled within the 
stages of introduction and implementation of the NPD. In this respect from the 
information above which suggested the introduction of sub-committees in the 
development phases for the NDP they would look at aspects of the development of 
knowledge for the NDP, the duty of the three sub-committees in KMOH would be to 
cover all these functions by interviewing health professionals, researching if there 
are needs and issues and providing data for further discussion in the appropriate 
Sub-Committee discussions.  Then to propose both the points associated with the 
findings and possible solutions which can be taken forward by the Working Party 
Head to the Steering Committee. 
 
Stage IV: Form objectives and goals for the future NDP 
This stage proposes that there is a need to define the main issues, to set goals and 
identify the main priorities resulting from the previous stages finding. For instance, 
in cases where one of the problems indicated may result from the lack of an 
Essential Medicines programme in Kuwait, it may be necessary to increase the 
assessment of the therapeutic value of the most important drugs as well as 
improve distribution, affordability and selection. Strategies involving selection and 
procurement are complex processes due to the fact that there may need to be 
specific organisational structural changes to selection and procurement of specific 
drugs which is difficult to carry out rapidly. As a result individual approaches may 
be required to address each situation. Additionally, it may be necessary to carry 
out a meeting with participating primary health/policy professionals.  
Thus in carrying through the main strategies for handling the choice and 
procurement of drugs it will be necessary to agree objectives and to discuss them 
with the interested organizations and individuals. In the early stages a well-
structured situational analysis can provide the basis for the decision-making 
process and justify the choices made. 
Once the primary strategies and objectives have been determined, the necessary 
consultations with all the interested parties would be carried out. The discussions 
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and outcomes will require careful consideration and broad consultation, with 
corresponding acknowledgement of possible conflicts of interest as well as 
structural constraints, but the outcome from discussions will be required to produce 
working decisions, objectives and to develop possible strategies which can be 
carried forward into the draft of a working NDP (WHO, 2005). 
 
Stage V: Produce the initial draft of the NDP 
It is necessary to produce the policy draft at the point when the situation existing in 
the country has been thoroughly analysed and the main goals, approaches and 
objectives established. The initial draft should include the main objectives of the 
developed policy. In the majority of cases, the main objectives presume the 
availability of the most important drugs, safe use of drugs by the total population of 
the country, and their good quality and rational prescription by health professionals. 
Additionally, specific objectives must also be described along with the 
corresponding strategy that should be adopted. Formation of the policy draft can 
be carried out by a team of experts, employed in the previous stages of the 
development process. During the draft development stage it is also highly 
important to consider successful examples from other countries (Fresle & 
Wolfheim, 1997). The steering committee (consisting of senior staff) is in charge of 
producing the initial draft of the Kuwaiti NDP after they get the required data from 
the sub-committees and the internal department for the NDP. 
 
Stage VI: Revision of the initial draft policy 
In order to revise and refine the developed NDP it is important to circulate the 
document, initially within the MOH and subsequently within other Ministries and 
Departments of the Government and finally, within relevant organizations, private 
institutions and academia. At this stage it would be expected to receive 
endorsements from the Government, because the Government is responsible for 
education, finance and planning operations within the Health Ministry. Circulation 
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of the document within the institutions and organizations would be expected to lead 
to remarks and comments being made through representatives of these 
organizations. Consequently, at the point when the consultation stage is 
completed, all the received comments must be considered and the policy draft 
finalized (Normad & Weber, 1998). 
 
Stage VII: To secure Governmental endorsement of the developed NDP  
In a range of countries it is possible that the developed document would be sent to 
the parliament or cabinet of ministers for the necessary endorsement. It is also 
possible that the document will be employed as the administrative basis for the 
introduction of changes and plans for the existing regulations and law. In clearing 
the introduction of a NDP it is likely that a substantial political commitment is 
required through the Government and the MOH, because agreeing changes to 
existing procedures and Laws (Decrees) should be well checked as any further 
major adjustments in the future may be difficult. In a number of countries the 
developed NDP has been fully accepted by their governments and has led to a 
series of decrees or statement which are now legal requirements (WHO, 2005).  
 
Based on the information presented above, it is suggestion that the KMOH could 
follow the process mentioned by presenting an official request (with attachment of 
the main goals, benefits and advantages of this National Plan) to the Kuwaiti 
Council of Ministries (Kuwaiti Cabinet) and the Kuwait National Assembly (Kuwaiti 
Parliament) to get the endorsement for establishment a NDP in Kuwait. But as 
potential adjustments are commonly needed it is usually recommended that only a 
range of aspects from the developed Policy are implemented as law and the 
remaining points considered as recommendations (WHO, 2005).  
 
How will this aspect be handled in Kuwait?  During a number of discussions with 
the Assistant Undersecretary of Drugs and Medical Supply Affairs in the Kuwaiti 
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MOH (Dr Omar) and the author of this Thesis, it was agreed that he would submit 
an official request to the Prime Minister of Kuwait to meet with him in the presence 
of the Minister of Health.  Such a meeting would allow Dr Omar to explain the 
importance of this NDP project and the extent of the benefits that Kuwait may be 
obtained from it, and to ask him, with the Minister of Health to consider supporting 
the principle of a NDP and to consider bolstering the KMOH in order to complete 
the establishment of the NDP. In addition Dr Omar submitted an official request (in 
2013) to the Minister of Health and the Undersecretary of MOH, where he 
suggested a proposal for establishment of a NDP in Kuwait to keep abreast of 
developments in the health care field. 
 
Stage VIII: Introduction of the developed NDP 
In addition to a series of challenging technical tasks, the introduction of a NDP 
includes a series of communication issues that must be resolved. Thus, it can be 
stated that to a considerable extent the success of the policy will depend on the 
understanding among various society sectors and organizations as well as their 
support of the introduced policy. Consequently, it is highly important in gaining 
these groups support to establish clearly the probable benefits for the participating 
organizations. It is also necessary to promote the implemented policy via a well-
designed and clear informational campaign. At this stage, endorsement from the 
public as well as political leaders and experts in the field can be highly 
advantageous. However this aspect will need to he handled sympathetically as the 
public are often suspicious of changes (Babor et al., 2009).  
 In order to reach the necessary target groups, various means of communication 
and information distribution should be used.  In this respect it will be important to 
use the strength of the media who can play a significant role in the distribution of 
information and ensure public support and understanding of the intended drug 
policy. As an example of how this can operate, literature reports are available for a 
range of countries, where high profile drug policy introductions were organized 
(Babor et al., 2009). Therefore it is considered essential that one of the KMOH sub-
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committees (possibly No 3) takes steps towards publicising that the NDP has/will 
be establishment in Kuwaiti NDP to the public and associated groups and 
agencies.  Particularly to indicate that the NDP will be a qualitative leap for Kuwait 
and the KMOH in the reform and development of Health Care System, where there 
will be considerable advantages in supplying the Pharmaceutical Services to the 
population of Kuwait. 
 
8.5 The importance of NDP indicators 
 
Both evaluation and monitoring are highly important and extremely challenging 
aspects during the development and implementation of the NDP. Factors which will 
come under these indicators will be; to consider time restraints, the lack of 
necessary budget, human resources and ensuring full understanding of the value 
of monitoring.  There is also the expectation that there may be resistance to 
introduction of close monitoring.  However it will be essential to critically and 
objectively assess the outcome of activities outlined and implemented in the NDP 
Master Plan. In order to assist in introducing such an important assessment of the 
developed and implemented NDP the establishment of a Drug Administration for 
the NDP has been proposed, and it is suggested it should consist of a trained and 
qualified team who can work to avoid the difficulties above.  
After completion of the development of the Kuwaiti NDP, it is proposed that the 
Administration should follow the implementation, evaluation and monitoring of the 
NDP, because to not to pursue these aspects is likely to reduce the benefits and 
privileges of a NDP in Kuwait.  
Overall monitoring can be described as a continuous review, the purpose of which 
is to present a clear picture of the activities carried out and establish whether the 
objectives initially set were/are being met. Monitoring can take various forms from 
physical monitoring to structural procedures.  In this latter respect it is possible to 
carry out monitoring operations with the aid of a series of structured methods, such 
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as a combination of ‘sentinel reporting’ and ‘periodic supervisory visits’. In turn, 
evaluation represents a form of progress analysis that presumes regular 
assessment of the progress made towards the previously established goals and 
objectives. 
At the initial stages of the programme evaluation, methods can be based on the 
monitoring carried out and employed to establish the main needs of the country in 
the area of drug distribution. At the next stage, the purpose of a mid-term 
evaluation would be to provide the necessary information showing whether the 
implemented programme works. The final evaluation would provide a total 
assessment of the progress made and the achievements of the programme, which 
are employed to draw the corresponding lessons for the future programmes. A 
monitoring and evaluation system can be a sophisticated management tool that 
makes it possible to carry out a continuous process of assessment and make from 
the information generated the required decisions. The system also provides the 
required evidence of progress, which results in the support of the introduced policy 
in the dialogue with policy makers and interested organizations (Brudon-
Jakobowicz et al., 1999). It is proposed however that the KMOH and senior staff of 
the Steering Committee should bear in mind the importance of these indicators to 
ensure the continued success the NDP project.   
 
Taking into consideration the information outlined above, it is clear that the choice 
of NDP indicators is highly important for the successful implementation and 
continued success of the drug policy. Thus, in order to establish if the expected 
progress is attained, it can be very helpful to define performance standards and 
produce realistic targets. In this case NDP indicators can be introduced to compare 
sets of results, detect changes and establish whether the expected targets were 
met. The indicators employed are expected to be valid, reliable, measurable, useful 
and clear.  
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Some of the most important NDP indicators were developed and subsequently 
refined by the WHO (Trap et al., 2006). Thus, the main indicators currently 
employed by a number of countries often consist of; outcome indicators, process 
indicators, structural indicators and background indicators. These indicators can be 
employed individually or in a combination, to meet the needs and requirements of a 
particular country. It is proposed that the administrative committees for the NDP in 
Kuwait can establish a standard complex of core indicators to include both sentinel 
reporting and routine use., as discussed in the WHO documents (Trap et al., 
2006). It is important that the indicators chosen are standardized, making the 
observed trends easy to identify. Additionally, collection of data can be easier, 
resulting in efficient and regular monitoring.  
 
Core indicators which can be employed to cover the following aspects of the NDP: 
1. Access to the most important drugs and their supply to the general public. 
The indicator is employed to address the availability and affordability of 
Essential Drugs. 
2. Efficiency and functions of the organisations regulating drug distribution, 
handling of the drugs and the work in the laboratories, providing drug quality 
control. This indicator can be used to address drug quality issues. 
3. Description of drugs and the use of Clinical Guidelines and an Essential 
Drugs List. This indicator can be employed to address patterns of drug use 
(MSH, 2005).   
Both the Sentinel and Routine Reporting are likely to be of major importance as 
part of the different types of indicators used. A routine system of reporting should 
also be introduced to give some consistency in the drug management system, and 
will aid the provision of information necessary to monitor the development and 
implementation of the drug policy. However, in the actual data collection 
environment the main bulk of the information may not be obtained by systematic 
methods and in these cases a system which is consistent will need to be 
introduced. In cases when the sentinel system of reporting is employed, it is likely 
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to be necessary to regularly survey the most important health facilities. Looking at 
recent examples, the value of this type of data collection, for the corresponding 
NDP indicators, was employed in Zimbabwe, where over a period of two years it 
was possible to establish weaknesses and strengths of the most important facilities 
of the country’s Health Care System. As a result of these studies, it was possible to 
develop a highly effective managing mechanism (Trap et al., 2006). 
It is possible that the indicators outlined above, as well as management systems 
applied in the pharmaceutical sector, can be employed by a range of parties 
working in the pharmaceutical area. To include managers, policy-implementers and 
policy-makers who can use the NDP indicators to investigate the problems existing 
within the country, develop the primary strategies and set priorities. The results 
obtained can also be employed to improve the existing procedures, aiming for 
maximum impact.  
 
In addition the results can be employed by both Health Ministries and 
Governments to synchronize their policies. For instance, if the indicators point out 
low levels of affordability and availability of the most important drugs, policy makers 
can conclude that current directions on drug and health financing should be 
reviewed. This scenario is possible due to the fact that the majority of countries are 
looking to join the global economy, but with no particular consideration of the 
implications of the actions carried out on drug pricing, medicines and their cost and 
quality can be major issues to include consequently on their availability and 
affordability.  
 
The existence of substandard drugs on the market of a country may result in the 
need to review the implications of the existing free market, associated with the 
existence of foreign drugs in quantities that the drug regulatory organizations 
cannot efficiently control. Both donors and international agencies can employ the 
results on medicines to establish the priorities in the sectors that require the most 
support and assess the viability of resource investment in areas where maximum 
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impact is expected. Additionally, results from NDP indicators can be applied by the 
professional groups to establish the areas which require information on the existing 
drug policy and create advocacy campaigns promoting the use of new techniques 
or drugs (WHO, 2005). 
 
In addition to within-country assessments, NDP indicator results can also be 
employed in multi-country cooperation programmes. Thus, multi-country 
investigations implementing standard approaches can be used to establish 
innovative techniques that can subsequently be employed in other countries. Multi-
country evaluations can also be used to promote international collaboration and 
exchange of information covering drug policy (WHO, 2003).  Despite the fact that 
the organization is able to inspect drug retailers and manufacturers as well as 
register new drugs, the enforcement abilities of the organization are limited. The 
most important indicators outlined above are recorded by the WHO for the 
subsequent international comparison and are employed by the organization to 
make reports covering the world pharmaceutical industry and drug distribution 
(WHO, 2003). 
 
Finally it can be suggested that the indicators presented above can be used to 
carry out periodic assessment of an existing NDP. In this respect it is advised that 
the implemented NDP is evaluated at least once every four years. In order to 
accomplish this task, it may be that independent professionals and consultants 
could be attracted from either international agencies or other countries to work 
together with the national team of experts. Monitoring and evaluations methods 
should be listed in the previously described master plan, with the expectation of 
allocation of the corresponding resources at the planning stage (Chatwin, 2011). 
From the information given above, the proposal to the KMOH is that they should 
accommodate the importance of NDP indicators and not neglect this aspect.  
 
 
 
369 
 
8.6 Implementation of NDP indicators 
 
As established in the previous sections, in order to assess the performance of the 
implemented NDP it is necessary to consider the use of outcome, process, 
structural and background indicators. The indicators presented can be employed 
individually or in a combination. It is suggested that initially background indicators 
are applied. The purpose of this type of indicator is to provide data covering the 
existing demographics, pharmaceutical, health and economic situation of the 
country in which the developed drug policy is applied. The information can be 
collected in quantitative form, describing a certain single point in time. In the 
majority of countries this information is immediately available at the start of the 
indicator implementation (Buse, 2009). In Kuwait there is no concern about the 
availability of background indicators because the KMOH would normally provide 
data for the working committees, whether on ministerial decisions, charts, 
statistical tables or other information.  
 
Also the private sector is likely to cooperate, to provide the required information 
and will support this project if they believe that the results will be positive for their 
work. The Kuwait University (Faculty of Medicine and School of Pharmacy) as well 
as medical and pharmacy associations would be expected to provide help; as they 
have indicated their support during the interviews with them during the course of 
this research, where they showed interest and asked to participate in the work of 
this project, and especially after they were involved in discussions and explanation 
of the importance of a NDP, and how it will positively affect the health system in 
Kuwait.     
 
In addition to background indicators, it is advised that structural indicators should 
also be used to assess the outcome of the application indicators’. The purpose of 
this set of indicators would be to produce qualitative data assessing the capability 
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of the pharmaceutical system and to achieve the objectives of the implemented 
policy in the country. Structural indicators are aimed at establishing whether the 
most important mechanisms, systems and structures required by the NDP 
implementation are fully developed and introduced. Based on the information 
obtained at the central level, the structural indicators used can provide “yes” or “no” 
answers. The WHO suggests that structural indicators can be used to assess the 
presence of the necessary elements, highlighted initially in developing the NDP 
(WHO, 1999).  
 
Process indicators should be applied after the application of background and 
structural indicators. Their purpose is to provide quantitative information describing 
the processes through which the NDP is implemented. Process indicators can 
describe the magnitude of the activities required to achieve the necessary 
objectives and the progress that is made over time. Like the structural indicators, 
monitoring of the main activities is conducted from the perspective of the 
implemented NDP. Also, as in the previous cases, information obtained at the 
governmental level or via the use of surveys is used to collect information for the 
process indicators. 
Currently, the process indicators that are documented are used to assess NDP 
performance, with the final set of indicators aimed at measuring the results 
achieved and assessing the observed changes in policy associated with the 
implemented NDP. The WHO has developed 10 outcome indicators and, as in the 
case of the previous types of indicators, the data can be collected through the use 
of surveys or official, governmental sources. In particular, the purpose of outcome 
indicators is to measure the effects of the employed policy on the objectives 
outlined in the NDP. For instance, possible objectives can include rational selection 
and use of drugs as well as affordability and availability of the most important 
pharmaceuticals (WHO, 1999). 
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Overall the main purpose of the NDP is the improvement of the health of the total 
population of the country (Smith & Hanson, 2011). To achieve this, the place of the 
indicators in the implementation of the NDP should be carefully considered for a 
number of reasons. First of all, the complex nature of the existing health status 
should be taken into consideration. Additionally, highly complicated causality 
issues connected with the drug policy should be considered. Finally, highly 
complex methodological difficulties associated with the selection of health 
indicators should be resolved. It should also be assumed that the findings obtained 
as the result of applying the indicators should have an impact on the accessibility 
and availability of the most important drugs and their quality, and consequently, 
should improve the health level of the total population of the country. In a range of 
circumstances managers responsible for the application of indicators may want to 
apply only certain indicators selected from the ones outlined above. It is suggested 
however that the number of the applied indicators should only be reduced when 
the parts of the NDP assessed are relatively simple, but the collected data should 
be analysed with greater care (Smith & Hanson, 2011). 
 
Considering the application of the indicators, it can be stated that according to the 
WHO statements and the many publications in the area, the developed indicators 
should be employed in their current state, with only minor alterations addressing 
individual circumstances of the country in which they are applied. It should also be 
ensured that their application results in the formation of a comprehensive 
assessment of the applied NDP. This effectiveness of the indicator application was 
supported by recent assessments carried out in 12 countries, where the 
assessment of the pharmaceutical policies implemented was carried out in a range 
of socioeconomic contexts. Nevertheless, in any country it is expected that the 
responsible managers will alter the indicators to correspond to national 
circumstances (Drummond et al., 2005). 
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It is possible to apply a range of techniques to alter the NDP indicators. First of all, 
it is possible that in addition to improvement of the Health Care System, the 
assessed country may have its own set of objectives, such as implementation of 
traditional medicine or development of its own pharmaceutical industry. In this 
case, introduction of supplementary indicators at the country level can be 
suggested. This example is similar and applies to the health situation in Kuwait, 
where one of the objectives of this project is the implementation of traditional 
medicines, because there is only one specialized centre (Islamic Herbal Medicine 
Centre) for Traditional Medicine in Kuwait. During this PhD Study there was a visit 
to this centre and the visit showed that the centre may not be at the required level 
of efficiency – as it appears there are not enough employees, a lack of 
laboratories, equipment, training courses for the staff, and the existing library is 
small and lacking in adequate reference books. So they are likely to need to 
develop this centre and build more centres to improve the traditional medicine field.  
 
In Kuwait there is only one commercial pharmaceutical industry and it is obviously 
not enough to provide for the needs of the population; for these reasons the 
implementation of traditional medicines and the development of pharmaceutical 
industries in Kuwait should be set as an important area for expansion. This type of 
introduction should be accompanied with careful identification of the main 
objectives and primary strategies, resulting in the selection of indicators that may 
afford highly important information regarding the usefulness of the development of 
this area in the NDP.  
 
Additionally, it is also possible that managers operating at the national level may 
decide to employ normative standards for the indicators, taking into consideration 
specific priorities of the country (Jackson, 2012). It is clear that all countries are 
different, they manifest different socioeconomic development, political structures 
and consequently, possess individual priorities. Alternatively, the use of provisional 
standards complementing outcome and process indicators can be suggested. 
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Nevertheless, the managers responsible for the implementation of these standards 
should review them carefully, in order to ensure that they meet the goals and 
targets of the NDP.  
In addition to the cases described above, it is also possible that managers at the 
national level will require more detailed information regarding the most important 
aspects of the implemented drug policy. In this case the employed indicators 
should be subdivided. Thus, the indicators referring to prescribers in a general 
sense can be converted into more specific ones through their adaptation to various 
types of prescribers. It is very important to consider that the primary objective is to 
monitor and evaluate progress of the policy implementation and not to carry out all 
the activities presumed by the indicator.  
 
In addition to the potential alterations outlined above, it should be mentioned that 
due to substantial differences between countries, some indicators may be more 
important than others. In this case it is possible to exclude the indicators that are 
not relevant from the assessment, and based on the WHO assessments, in the 
majority of cases inapplicable indicators are removed or altered in the context of 
developing countries (Glied & Smith, 2013). 
 
It is possible to successfully apply the NDP indicators described above only in 
cases when the assessed country has the necessary infrastructure for monitoring 
their existing drug policy. In such instances the WHO recommendations could be 
applied to collect the necessary data, carry out the indicator-based analysis and 
produce the corresponding reports. In countries with reduced organizational 
activities, WHO recommendations could be followed initially to establish the basis 
for an adequate industrialized monitoring system as well as development and 
introduction of the NDP. The purpose of the recommended monitoring system is 
the supply of the required information with no need for specialized ad hoc 
investigations. While introducing the system supporting implementation of NDP 
indicators, it should be presumed that during the first years some data will be 
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collected via specific surveys, because of the reduced efficiency of the employed 
systems. In this type of situation it is advised to develop a method that would 
presume a balance between logistical simplicity of the model and collection of 
accurate data. In a range of countries, it is also possible to start applying the 
indicators with a minimal number of possible activities and expand the process with 
the development of the monitoring system (Briggs et al., 2006). 
 
The Organizational Department responsible for drug policy implementation, as well 
as the corresponding indicators assessing the performance of the system, could 
represent a MOH subdivision, working either in the Planning or Pharmaceutical 
Department. Even in cases of extremely decentralized health systems, possibly 
with minimal activity by a MOH, a degree of central capacity for implementation of 
a developed NDP and monitoring of the corresponding results is highly desirable 
(Morris et al., 2012).  
 
Once the necessary data collection systems are introduced, the process of using 
the NDP indicators would normally require the steps outlined below to: 
1. Determine the targets in each of the assessed objectives and policy. It is 
advised that this step should be carried out at the planning and policy 
formation stages. 
2. Establish the required indicators and the data that should be used. 
3. Assist in data collection. 
4. Analyse and subsequently interpret the data. 
5. Propose changes based on the results obtained. 
 
Based on the information above, it can be stated that the outlined institution-based 
process of using NDP indicators in Kuwait may require involvement of external 
parties as well as the commitment of the corresponding policy makers. Thus, it will 
be possible to ensure the effective use of the NDP indicators, which should result 
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in effective improvement of the existing NDP, once introduced. For this reason it 
was suggested that the use of the NDP indicators should form an intrinsic part of 
the national health system (Buse et al., 2012). It is also suggested that it should be 
possible to choose required and important indicators in Kuwait successfully, as 
members of the steering committee, its sub-committees and an individual 
department for NDP should come from all categories of health professionals, and 
in particular from the most experienced in Kuwait. Among them should be senior 
and junior staff, and a range of pharmaceutical administrations, hospitals and 
health clinics. This should mean that all the health areas are covered and that the 
search process for good practice, structural developments, finding any issues, 
analysis of results and finding solutions and defining strategies could be through 
their experience all-encompassing, and thus ensuring that the impact of indicators 
on the development and implementation of a NDP is highly efficient and effective. 
 
8.7 The use of monitoring results 
 
The indicators outlined above can only be considered useful if their results are 
employed to support the development of Kuwait’s NDP or to suggest necessary 
alterations, once it is in place. It is important to note that data collected should 
always be analysed fully as recent publications have indicated that in a 
considerable number of cases the collected data has not been fully analysed, or is 
analysed but the results are not used to modify or improve the existing policy or 
practice. For this reason, the WHO and other authors have indicated that the 
monitoring results should generally always be used to elevate drug policy 
effectiveness (Guinness, 2011, p. 85). 
 
First of all, the indicators outlined above can be employed to monitor the success 
of the implementation of various components of the developed NDP. For instance, 
typical problematic areas can include lack of basic structural components and 
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adequate functioning of the most important components. Additionally, with the aid 
of the generated results it is possible to establish the components that require 
improvement. In cases where the indicators were used during a certain time frame, 
it could be possible to establish whether the assessed components of the policy 
declined or improved in performance (Wonderling et al., 2005). 
 
Secondly, the results of the indicators could be employed to establish the current 
priorities of the pharmaceutical sector as well as to determine the effectiveness of 
the implemented drug policy approaches. Thus, in cases when one drug policy 
component provides poor results compared with other components, the allocation 
of increased financial and human resources and commitment could be considered, 
and consequently, a reassessment of the priorities of the implemented drug policy 
components. In a range of cases, alteration of the existing strategy may be 
suggested. It is possible that this goal can be achieved by introducing the 
corresponding schemes promoting the use of an Essential Drugs List. Additionally, 
development of a new pricing policy could be suggested, which should result in the 
encouragement of private distribution of the most important drugs (Guest et al., 
2013). 
 
Thirdly, the results manifested by the indicators can be employed by both 
international and national companies to compare the performance of various drug 
policies employed by different countries. Thus, by comparing structural indicators it 
will be possible to establish relative strengths and weaknesses in the ability of the 
country to employ the developed NDP, while process indicators could be used to 
establish the progress in the completion of the drug policy goals. Cross-national 
modes of comparison can also be used by policy makers at the national level, to 
learn of new innovative methods applicable in their particular countries (e.g. for the 
Kuwaiti cabinet and parliament). Additionally, the country data collection carried out 
by the Essential Drugs Departments could be used to support the development of 
the corresponding international database describing the formation and use of a 
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NDP, but because the KMOH does not have this department, it proposed to 
convey this work to the committees and a temporary department. This type of 
database could be distributed worldwide to support policy-makers in all 
participating countries in assessing the performance of the pharmaceutical sector 
of their country and the developed NDP (Lewis et al., 2008). 
 
Finally, the collected results can be used during negotiations covering changes in 
drug policies among interested organizations within Kuwait, as well as discussions 
with international agencies and external donors regarding reforms in the Kuwait 
health system. The employment of the indicators over a prolonged period of time 
could be used to manifest the impact of various changes in the macro-economic 
policy on the pharmaceutical and health care system. The NDP indicators can be 
employed to collect data that would enable Kuwait policy makers working in the 
health sector to put forward more coherent and persuasive arguments during their 
discussions, which should result in the protection of the interests of vulnerable 
groups within Kuwait and during periods of economic and organisational change 
(Donaldson & Scally, 2009). The health team working on the establishment of a 
NDP in Kuwait should be aware of the necessity of using the monitoring results 
because it is a very important step – all the decisions, recommendations, solutions, 
planning and strategies will be based on the collected data, and the results of this 
outcome could determine the success or failure of the work. However all staff at all 
levels should undertake educational and training courses about the steps of 
establishment of the NDP, the indicators, development, implementation and 
monitoring before starting to discuss the NDP for Kuwait. 
 
8.8 NDP implementation 
 
Based on the information presented in this Chapter, it can be indicated that the 
success of NDP implementation is dependent on the evaluation of the country and 
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its health needs, as well as the formation of effective Master and Work plans 
covering which could cover a period of around three to five years and address the 
health priorities of Kuwait. Additionally, appointment of governmental officials 
responsible for the implementation of the NDP plan may be required (Babor et al., 
2009). 
 
Each country has its own set of priorities. For instance, in the case of a country 
with a well-developed Health Care System and access to a variety of drugs, 
rational drug usage, control of drug cost is unlikely to be one of the main NDP 
priorities. It is expected that in this case the NDP employed should be focused on 
marketing control and actions which in turn will result in control of drug costs with 
no reduction in their quality. However in developing countries, overall spending on 
pharmaceuticals/health will generally be low and the private sector will not be able 
to meet the needs of a considerable proportion of the population. In this case the 
NDP should be focused on the supply of Essential Drugs. Where a NDP is to be 
introduced certain priorities should be set out and included in the Master and Work 
Plans. Development of a NDP presumes the formation of an implementation plan, 
which should be part of the Master Plan, covering a period of three to five years 
(Guest et al., 2013). 
 
All these aspects should be studied in general but decision-makers in the KMOH 
will understand that although these issues may be found in some developing 
countries it does not mean that the Health Care System in Kuwait is suffering from 
limitations in all the areas. As was said in the early part of this Chapter, the 
Pharmaceutical Services in Kuwait have served the country well. For example, in 
Kuwait there is no issue with drug distribution (more develop is needed), access 
and affordability of drugs and lack of financial sources. Therefore these aspects 
should not be included in the master plan, to save time, effort, and financial 
resources.   
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In developing the Master Plan it should outline the most important components of 
the developed NDP, the required actions and the budget necessary for successful 
NDP implementation. If financial and human resources are insufficient with no 
external input, a range of the most important activities should be produced that can 
be carried out with the available resources. Nevertheless, it is also very important 
to determine the gaps in resources for consideration of future support. One of the 
purposes of the Master Plan is to facilitate the follow-up and for monitoring. 
Consequently, it is very important that it is distributed to all the involved parties. To 
clarify the details the Master Plan should be broken into a series of action/work 
plans. These plans could cover a period of one year and describe actions carried 
out by individual organizations. In particular, it is necessary to estimate time frames 
and required budgets, describe the expected output all of which is likely to be 
scrutinised during the monitoring indicator process and detail the most important 
tasks and individuals responsible for success (Normad & Weber, 1998). 
 
The implementation of the plans outlined above should be supervised by the 
Working Party of the NDP and coordinated by the Steering Committee and KMOH. 
In many countries this role is performed by a specialized subdivision of the MOH 
and it has been indicated earlier in the Chapter that the responsibility for 
implementation should lie with the working party (The Coordination and Monitoring 
Department for the NDP and Sub-Committees) who would report regularly to the 
Steering Committee. It performs coordinating functions with its own personnel and 
budget. In addition to coordinating groups, it is also essential for overseeing the 
implementation of the policy through national consultative forums. This type of 
action is vital to create and subsequently to maintain the implemented policy 
countrywide as well as ensure that the most important stakeholders are well 
informed and remain involved. Similar types of supervision can be introduced for 
highly specific components of the policy, such as rational drugs use and quality 
assurance (WHO, 1999).  
The KMOH Steering Committee-Sub-Committees and the Coordination and 
Monitoring Department for the NDP would have an interest in setting up 
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conferences specialized in the establishment of a NDP with the participation of the 
WHO, KMOH health professionals, MOH staff from developing countries, GCC 
Ministries of Health, international and local agencies, Kuwait University, health 
associations, local agencies, international drug companies, the private sector and 
foreign experts in this field. If these conferences are repeated more than once 
during the period of work of the master plan, they ensure the contribution of 
experts to this project and the correction of mistakes in the work if found.    
 
In addition to the KMOH, other key parties in the implementation of a NDP in 
Kuwait are provincial and district health services, CMS and drug regulatory 
agencies. Successful implementation is also dependent on the actions taken by 
other agencies involved in education, planning, trade and finance. Finally, taking 
into consideration the magnitude of possible pharmaceutical issues, it is essential 
to both obtain and sustain the consensus formed on the primary objectives of the 
policy. 
8.9 Assessment and monitoring of the NDP   
In the previous sections it was indicated that assessment and monitoring of the 
NDP is a very important aspect of Health Care System development. The NDP 
assessment should be determined by the methodology employed to calculate the 
indicators described above (Carr et al., 2007). 
 
The methodology used in calculations should be based on the following aspects: 
1. Organization of the data collection. 
2. Data collection procedure. 
3. Analysis and reporting of the obtained findings. 
4. Survey implementation. 
5. Determination of the cost of the most important drugs. 
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During the assessment and monitoring of the implemented NDP, establishing 
adequate indicators and sources of data, determination of the approaches to the 
data collection and analysis of results should be carefully considered, such as 
careful identification of adequate indicators combined with the quality of the 
collected information should provide the most significant effect on validity of results 
and the necessity for proposed changes. In order to make sure that the results 
assessment obtained accurately represents the performance of the NDP, it is 
suggested to be necessary to follow the steps outlined above (Carr et al., 2007). 
 
As indicated above, organization of the data collection represents the first step of a 
successful assessment and monitoring of the NDP. In order to accomplish this task 
a team of the Steering Committee – Sub-Committees must be formed at central 
level, working in the national drug authority or the KMOH.  
 
In addition the team of the Steering Committee – Sub-Committees and the 
Coordination and Monitoring Department for the NDP described above must 
establish the indicators to be used in the assessment, identify primary sources of 
data, and determine the techniques employed in the data collection, plan the data 
collection time frame and estimate the required budget as well as main resources. 
Estimation of the budget and necessary resources represents one of the most 
important aspects of the initial stage of NDP assessment. Thus, the appointed 
team of the Steering Committee – Sub-Committees and the Coordination and 
Monitoring Department for the NDP could prepare a detailed report addressing the 
time necessary to collect as well as carry out data processing and analysis 
operations at both peripheral and central levels. The budget must take into 
consideration costs of supplies, transportation, and personnel as well as monitoring 
units (Wilson & Mabhala, 2008). 
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The following stages of assessment and monitoring of NDP should be focused on 
the data collection operations. At this stage two highly important aspects must be 
addressed: development of the data collection methods and their successful 
implementation. 
It is advised that data should be collected through the use of specialized forms, 
designed, tested and approved by the MOH or another agency such as the WHO. 
The described forms should subsequently be employed to collect data from 
interviews and surveys. It is also highly important that the data collection 
operations are carried out by selected and trained staff. Thus, two groups of 
collectors can be established (within the Sub-Committees): the purpose of the first 
group is to perform the surveys while the second collects information based on 
interviews and records. It is of paramount importance to ensure a high quality of 
collected data. The data should be valid, reliable and accurate. In order to address 
this issue both evaluation and supervision operations should be carried out by a 
specialized monitoring unit, formed by properly selected and trained data collectors 
(Baggott, 2010). 
 
Calculation of the indicators employed and the analysis of findings should be 
suitable for presenting one of the most important aspects of the assessment and 
monitoring of the NDP. It is proposed that the operations to be employed in data 
analyses should be finalized before the data collection methods are carried out. 
Using suitable data collection methods will considerably ease the processing 
aspects.  
 
It is proposed that the processing operations would be carried out by the 
specialized monitoring unit (The Coordination and Monitoring Department for the 
NDP) working at the national level, who would receive the results of the surveys, 
reviews and any interviews. Although it is possible to manually perform the 
required calculations; the implementation of computer-based techniques can 
substantially increase the speed of the assessment and accuracy of the findings. In 
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the data collection stage a check on the authenticity of the data and the processing 
is required. To these figures a level of quality control should be implemented during 
the analysis. The checks would include assessment for internal consistency and 
completeness (Douglas et al., 2009).  
I addition to ensure that the results obtained from the Sub-Committees are under 
quality standards, it should be checked by the separate Monitoring Department or 
section to validate and ensure that all the results are a valid assessment of the 
reality of the health status in Kuwait. 
 
It is proposed that the results obtained should be reported and employed in 
improving the existing health system. A corresponding report can then be 
presented by the Coordination and Monitoring Department for the NDP [Monitoring 
Department] to outline the information collected, and to define the main results and 
the most important conclusions. Subsequently, the report can then be used to form 
a basis for the majority of new decisions on the development of drug policy. 
Additionally, along with official reports, information could be presented using 
printed and on-line articles and presentations. Particularly during the introduction of 
the NDP it will be important to address specific problems and tailor the information 
presented to possible solutions and then further specific actions. Thus, it is 
expected that the resulting actions will take place on three levels: 1) the level of the 
health facility, 2) the specialists’ audience and 3) the Governmental level. At these 
levels three types of action are expected: a) those which are recognized as the 
most effective actions and encourage them, b) change are proposed for the 
aspects that do not work and c) altering of the policy in areas where poor results 
were recorded (Mckee, 2011). 
 
The implementation of specialized surveys is another highly important aspect of 
the assessment and monitoring operations. Thus, despite the fact that all the data 
required for the indicator calculation can be collected using existing systems of 
monitoring as well as interviews of the government officials and document reviews, 
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at a central level, the calculation of a range of outcomes and process indicators 
may require the individual completion of surveys carried out in medicines outlets 
and health facilities. As it is possible to organize surveys in a fashion that can 
simultaneously collect information required for a range of indicators it is expected 
that the main bulk of the data would be collected by cross-sectional surveys 
conducted though these health facilities and drug outlets. The data should be 
collected either from drug dispensers/prescribers or patients at drug outlets. It is 
also very important to consider the procedures that should be followed in order to 
obtain an adequate sample. However the exact procedures will depend on the data 
availability and the context of the country. However when assessing sample 
selection methods it should be presumed that every sample should have an equal 
possibility of being included into the survey.  
 
By using this approach it will be possible to avoid selection bias and ensure 
adequate representation of the total population. Nevertheless, in certain cases 
substantial logistic drawbacks, such as the need for specific skilled workers, 
budget, time or transportation, may need to be considered when designing the 
described surveys. Consequently, the best approach for the design of surveys 
represents a combination of effective statistical methods and data collection 
techniques (Peacock & Peacock, 2010). 
 
Estimation of the selection of the most important drugs represents the final aspect 
of assessment and monitoring for the NDP. A range of methods can be employed 
to monitor trends in prices of drugs. However, a range of principles should be taken 
into consideration in order to obtain accurate representation of actual consumption 
of drugs at the national level. Thus, it is necessary to consider the nature of the 
consumed drugs and their volume. The drugs that should be introduced into the 
drug list should be selected from the list of the most important, widely used drugs 
in the country. In the ideal case a National Essential Drugs List would be used to 
establish the required drugs selection, but unfortunately Kuwait does not have an 
 
 
385 
 
Essential Medicines List at present. It is also not possible to obtain a list and 
volume of the essential drugs at the global level, because in the majority of cases 
country-specific variables have to be taken into consideration. In an ideal scenario, 
the prices and the list of all drugs available worldwide should be recorded and 
assessed; however getting the results would require substantial financial 
investment. For this reason, it is proposed by the WHO that monitoring is limited to 
three types: (1) Drugs presented in the National Essential Drug List, (2) 
Therapeutically important drugs, (3) Most widely used drugs (WHO, 2005). 
 
The information above further strengthens the reasons for establishing a NDP for 
the State of Kuwait because it is an effective solution to the concerns facing the 
Health Care System; where with the presence of these issues it will be difficult to 
develop the health sector for the future because they are considered a major 
obstacle to improving the work of the KMOH. The major health issue in Kuwait at 
present is a management issue, and specifically the lack of guidelines or a 
reference for health professionals, and weakness in determining future action 
plans, which are in line with future needs and requirements. But on the other hand, 
there are many success factors available for the KMOH to help in developing the 
Health Care System, such as financial resources, human resources and provision 
of infrastructure for the establishment of the NDP. 
 
It is proposed through this study that the KMOH can successfully complete this 
project and avoid obstacles through following the steps mentioned in this Thesis 
and specifically in this  Chapter to; 
 
1. Select a trained qualified staff for the task, where they would work full-time on 
the project and the KMOH should chose them according to their efficiency, 
knowledge and training, because the working team will be the foundation stone of 
the project.     
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2. Provide the required laws/decrees for establishment of the NDP by presenting 
an official request to the Kuwaiti Cabinet and Parliament to endorse the 
establishment of a NDP in Kuwait, and approve the establishment of the Steering 
Committee – Sub-Committees and a full-time Drug Department to develop, monitor 
and evaluate the action plan. 
3. Carefully follow all the steps relevant to the development of a NDP and don’t 
neglect any stage. 
4. Invite all the consumer groups, professional associations, NGOs (Non-
governmental organizations), academia, drug sellers, international and local 
pharmaceutical companies, nurses, pharmacists, doctors and the appropriate 
Kuwaiti Ministerial members to participate in this National Action. 
5. Thoroughly analyse the collected data by local specialists (Steering Committee – 
Sub-Committees - the Coordination and Monitoring Department for the NDP) and 
outsourcing foreign experts (if necessary) to verify the results obtained before 
making decisions on the development of the future plan and strategy for the NDP.   
6. Pay attention to efficient implementation and monitoring of the NDP to ensure 
the success of the project and that it does not falter in the future. 
 
As mentioned earlier, the development of the NDP is the first step of the National 
Action Plan and the KMOH should not stop at this stage, but maintain continued 
interest in the implementation and monitoring of the NDP. It is not only important to 
establish a NDP in Kuwait but also critical that this organization is effective, 
productive and useful for the Health Care System. The KMOH and the Kuwaiti 
Government should take benefit from the recommendations, advice and 
suggestions of the committees and working team, and it is hoped  they would 
support the NDP organisations work financially, administratively and through the 
media. For example, if the team recommends the establishment of Quality 
Assurance Departments in Administrations and Hospitals, an Essential Drug List, 
pharmacovigilance and an individual Drug Administration for the NDP organisation 
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to manage this organization, and act as the decision-maker and should apply the 
ideas and developments suggested above on the grounds. 
 
The establishment of a Kuwaiti NDP would lead to the existence of official 
reference healthcare structure for the KMOH, which can also be useful for other 
health professionals, local health agencies, researchers, students and persons 
interested in the Health Care System in Kuwait. The most important benefits from 
the establishment of the NDP in Kuwait would be the development of professional 
beneficial structures in pharmaceutical and medical health services, and the 
reregulating of legislation and regulations (especially as these areas were 
introduced some time ago); the NDP is also likely to lead into the establishment of 
several new health projects (such as; Quality Assurance Departments,  a 
Pharmacovigilance Centre, an Essential Drug List and an Electronic Link System 
between the health areas of the KMOH), which the KMOH needs in order to 
complete the development and improvement of the Health Care System. 
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Chapter 9.0: Conclusion 
 
It is evident from the information provided in the Thesis that the development and 
implementation of a NDP for every country is very important to promote safe, 
effective and regulated drug use, and to ensure that quality and appropriate 
medicines reach the country’s population. This is particularly important for nations 
of the developing world where resources are scarce and access to valuable 
information is limited and therefore the risks and dangers of irrational drug use are 
greater. However, such policies are also proven to be extremely useful in countries 
of the developed world where they can be concerned with combating additional 
phenomena such as poor quality medicines, counterfeit products, and recreational 
substance abuse alongside irrational drug use.  
 
Regardless of the particular focus, implementation of National Drug Policies on a 
global basis with the help of international organizations is of major importance in 
order to improve the quality of healthcare and consequently improve the health and 
welfare of millions of people around the world. In carrying this through the 
international agencies can provide advice and recommendations to a country and 
especially for the developing countries to establish their NDP.   
 
Establishing a regulated policy for Medicines and Healthcare in a country is 
fundamental and at present although the Ministry of Health in Kuwait has provided 
a good support to health for many years, it has been shown in this study that there 
are a number of areas where there can be improvements in the operation and 
control of the regulations and processes and the rapid rise in the medicines cost 
statement each year is of concern. The main method used to keep control of 
quality, safety and efficacy and the outlay on medicines and the resultant 
improvements in healthcare in the majority of countries is to have a national policy 
in place and presently Kuwait does not have such a National Drug Policy (NDP) 
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and the early part of this Thesis has promoted the importance of development and 
introduction of a NDP. 
 
The basis of a NDP is promoted by the WHO in conjunction with the World Health 
Authority and the WHO provides both literature and advice to assist countries who 
wish to develop a NDP.  In addition the support of other countries which have a 
similar structure, outlook and financial basis can and should be used in providing 
their experiences in the development, implementation and operation of a NDP in 
Kuwait. 
The research discussed here has justified the need for a NDP, by showing results 
and information from the interviews with a wide range of health professionals and a 
number of visits to the Central Medical Stores (CMS), discussions with medicines 
inspectors, examination of pricing policy, visits to the main receipt points for 
medicines and the analytical laboratories and discussions with senior officials in 
the Ministry of Health. Then the research work compared this information with that 
proposed for a country which is operating a fully functioning NDP. 
 
Once the need for a NDP was demonstrated in the work the next stage was to 
discuss how the many facets of a NDP could be assembled and reported and the 
structure of management of development of a NDP and its implementations could 
be undertaken. 
 
It was found that a number of fundamental issues needed to be addressed, with 
one of the first being the development and introduction of an Essential Medicines 
List (EML) as presently Kuwait does not have a priority list of medicines which are 
both appropriate to the needs of the people, but also provide some control of the 
number of drugs in different forms and origin which are brought into Kuwait each 
year. In order to tackle the development of an EML a number of ground rules would 
be required and a committee established who would examine the needs, clinical 
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benefits and clinical guidelines, side effects, range of application and cost 
effectiveness of drug/medicines which could be provided as a priority for public 
health in the EML.   As basic guidance the WHO publishes its own model list of 
essential medicines, which are specifically limited in number to assist with cost 
control.  The EML committee of the KMOH could start by considering these 
drugs/medicines and then move forward with a list which is appropriate to its health 
needs.  Putting together an EML will be a major development and will require a 
number of decisions to be taken which may cause discussion within the health 
professional groups, however if a NDP is to be successful there needs to be 
increased control of medicines in Kuwait both in the public and private sector. 
 
By supporting the introduction of a controlled List of medicines it was determined in 
the studies that in providing health and drug support to the population in Kuwait 
there are a number of areas where there are problems of direction of the 
operations and the legislation and regulations presently in place. In operational 
control terms it was indicated that there are shortages or weakness in the areas of; 
communication between sections of the KMOH, authority and power of decision 
making, lack of a well-designed Quality Assurance process in the public 
pharmaceutical administrations and hospitals in Kuwait, and the absence of Quality 
Assurance and Service Management Departments in the Laboratories of the Drug 
and Food Control Administration that test medicines, and investigates suspected 
illicit drugs.  Also testing of medicines as appropriate from the Central Medical 
Stores, for storage problems and controlling the risk of distributing medicines which 
are sub-standard, which are then subject to product recall, wastage of money and 
health risks to the patients in Kuwait.  
 
In establishing a well-structured NDP, the knowledge levels of the staff are very 
important and the employees involved particularly those in management, those 
with direct contact with the public and in technical positions have indicated that 
there is an absence of clear further development programmes in training and 
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update training for public health professionals in Kuwait.  In particular the 
interviewees indicated that there was an insufficiency and defects in the KMOH 
training system, and specifically there was no programme for pharmacists to 
develop their work or to update their clinical and scientific knowledge, this is 
whether they are working in hospitals, health clinics, health centres or 
pharmaceutical administrations. It is therefore necessary to development this 
aspect in Kuwait by carrying out fully structured training programmes for each 
health area. 
 
It is suggested that the implementation of a NDP in Kuwait could support 
development of the level of Human Resources (HR) and this can then be reflected 
positively in a HR Department’s work in health care services through supporting an 
increase in the level of competence of health professionals and especially the 
senior staff and could lead to a reduction in the need for more staff for health areas 
and a reduction in medical and administrative errors.  It is proposed that there 
should be a greater role for a Human Resource Development Department and 
giving them more power and authority to play a primary role in supervising the 
training of health professionals by providing the necessary training courses, and 
supporting health professionals in attending local and global conferences.  
 
In order to develop the basis for a NDP, this research provides an outline structure 
to the issues, how these can be challenged and what can be done to resolve them 
if a NDP for Kuwait can be agreed .  However the process if undertaken will take 
some time and the organisation of the structures and committees to develop, 
implement and test the NDP for Kuwait will require much discussion and 
agreement.  The Thesis proposes which committees could be introduced and how 
these committees could be organised. 
Once this section is accepted then the major operation is implementation.  It is 
indicated that there are primary factors affecting the outcome of the NDP 
implementation.  These include the level of financial resources, cooperation 
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between regional organisations, international organisation and organisations such 
as the WHO as well as regulation/legislation aspects.  
 
In order to assess the successful introduction of the NDP the requirement of quality 
indicators is proposed and the Thesis focuses on the use of four main NDP 
indicators: background assessment, structural, process and outcome indicators. It 
was suggested that each indicator should be applied in turn and the most important 
aspects associated with their use are discussed and described. It was also 
concluded that NDP indicators are highly important for the assessment of the 
results and alteration of the policy elements, and to reduce the effects of poor 
results. Thus, based on the data obtained, conclusions could be drawn regarding 
the effects of the implemented policy and comparisons of the results of the areas of 
success of implementation of the National Drug Policies in Kuwait.  In addition, the 
monitoring results can also be evaluated and employed by the suggested 
Coordination and Monitoring Department for the NDP and the Sub-Committees in 
Kuwait. Thus, it should be possible to form new priorities and make alterations in 
the drug policy aimed at removing the gaps and difficulties highlighted in the 
strategy used. Exact NDP development recommendations are expected to vary 
from country to country, however in the majority of cases it is expected that the 
appointment of external monitoring organisation may be necessary. It is expected 
that 3 to 5 years will be necessary to produce and realise an effective National 
Drug Policy in Kuwait.  
 
This study has shown through the interviews with managers and health 
professionals that there is an awareness of the issues which need to be addressed 
if a NDP is to be successful to include the strengthen of the Legislation and 
Regulations of the drug registration process, stronger penalties to restrain the 
spread of rule breaking, which should include  developments for the reduction of 
numbers of counterfeit and unregistered drugs in the market and a major reduction 
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in the  high price range and cost variability of medications in the private sector in 
the State of Kuwait. 
 
In addition the non-existence of a Pharmacovigilance Center in Kuwait causes 
deficiency of presence of a specialized organization to monitor and follow up the 
effects of drugs after the completion of registration and the licensing process and a 
lack of continuing control to examine if a drug has any adverse effects on the 
patients.  
From the studies there was considerable enthusiasm among senior managers 
(officials in KMOH) to take forward the establishment of a NDP to provide a more 
efficient and better organized Health System in Kuwait. There are a large number 
of physicians, pharmacists and specialists in the medical field that have contributed 
to the study and can have a positive role in the establishment of NDP and help to 
develop the Health Care System which can contribute so much in improving the 
human health in Kuwait. 
It has been shown that this policy is necessary for the State of Kuwait for several 
reasons; one of these reasons is to regulate and organize sections of the health 
system, which have been shown to require updating by re-examining the issues 
associated with this system and should give the State of Kuwait a health system to 
support its population. Using interview information revealed through the survey and 
review of literature, this research project offers proposals and suggestions, which 
can help find answers to understanding the importance of the National Drug Policy 
for the State of Kuwait. 
In final conclusion it can be stated that the implementation of an effective National 
Drug Policy in Kuwait is of major importance to the successful development of the 
country. The information presented in this Thesis indicates that the main purposes 
of the National Drug Policy are to establish the most important aims, values, 
aspirations, to outline both medium and long term policy of the government, 
establish national goals/objectives specifically in the pharmaceutical sector as well 
as to form primary strategies, by addressing the primary objectives. Therefore it 
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can be said that the Establishment of a NDP could be one of the most important 
aspects of future health development in Kuwait.  
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